{
  "id": 112,
  "name": "Gyne Cancer - Oncogenic Variants",
  "type": "SOMATIC",
  "genomeBuild": "GRCh37.p13",
  "molecularVariants": [
    {
      "id": 12190,
      "chromosome": "1",
      "start": 16256061,
      "stop": 16256061,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "SPEN is a transcriptional repressor involved in regulating ESR1, cell migration, development, and beta-catenin pathway activity (PMID: 11331609, 26297734, 28877752, 17234755). SPEN alterations have been observed in breast cancer (PMID: 26297734).<br />\nThe SPEN p.Ser1109* nonsense variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in SPEN are likely oncogenic (PMID: 26297734).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:27",
      "evidences": [],
      "reference": "C",
      "alternative": "G",
      "gene": "SPEN",
      "transcript": "NM_015001.2",
      "cNomen": "c.3326C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 11,
      "effect": "stopgain",
      "pNomen": "p.S1109*"
    },
    {
      "id": 12146,
      "chromosome": "1",
      "start": 27023354,
      "stop": 27023354,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\nThe ARID1A p.Tyr154Thrfs*78 frameshift variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\nA clinical study in ovarian cancer suggests this variant is predicted sensitive to Aurora kinase A and FLT3 inhibitors (PMID: 30108107).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:31",
      "evidences": [],
      "reference": "T",
      "alternative": ".",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.460delT",
      "type": "deletion",
      "location": "exonic",
      "exon": 1,
      "effect": "frameshift",
      "pNomen": "p.Y154Tfs*78"
    },
    {
      "id": 11058,
      "chromosome": "1",
      "start": 27023796,
      "stop": 27023796,
      "classification": "Very high",
      "variantInfo": " <br />\n <br />\nThe p.Ser301* nonsense variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ARID1A p.Ser301* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of BRD or PARP inhibitors.<br />\n ",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/18 02:21:22",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.902C>A",
      "type": "snp",
      "location": "exonic",
      "exon": 1,
      "effect": "stopgain",
      "pNomen": "p.S301*"
    },
    {
      "id": 11757,
      "chromosome": "1",
      "start": 27057713,
      "stop": 27057713,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\nThe ARID1A p.Ser475Valfs*144 frameshift variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ARID1A p.Ser475Valfs*144 variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:31:45",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.1423delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 3,
      "effect": "frameshift",
      "pNomen": "p.S475Vfs*144"
    },
    {
      "id": 11638,
      "chromosome": "1",
      "start": 27087458,
      "stop": 27087458,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\nThe p.Gln678* nonsense variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ARID1A p.Gln678* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of BRD or PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/14 16:58:21",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.2032C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "stopgain",
      "pNomen": "p.Q678*"
    },
    {
      "id": 11926,
      "chromosome": "1",
      "start": 27087932,
      "stop": 27087953,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\nThe ARID1A p.Met741Lysfs*85 frameshift variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ARID1A p.Met741Lysfs*85 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PARP and BRD4 inhibitors.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/14 19:32:07",
      "evidences": [],
      "reference": "CCATGAACCAATCAAGCATTGC",
      "alternative": ".",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.2222_2243delTGAACCAATCAAGCATTGCCCA",
      "type": "deletion",
      "location": "exonic",
      "exon": 6,
      "effect": "frameshift",
      "pNomen": "p.M741Kfs*85"
    },
    {
      "id": 11712,
      "chromosome": "1",
      "start": 27089462,
      "stop": 27089462,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\nThe c.2420-2A&gt;G splice site variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ARID1A c.2420-2A&gt;G variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of BRD or PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/05 18:20:50",
      "evidences": [],
      "reference": "A",
      "alternative": "G",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.2420-2A>G",
      "type": "snp",
      "location": "intronic",
      "exon": 8,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 12357,
      "chromosome": "1",
      "start": 27092770,
      "stop": 27092770,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\nThe ARID1A p.Gly931* nonsense variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\nA clinical study in endometrial cancer suggests ARID1A loss is predicted sensitive to immunotherapy targeting PD-L1 (PMID: 32111729).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/06/01 20:55:17",
      "evidences": [],
      "reference": "G",
      "alternative": "T",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.2791G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 9,
      "effect": "stopgain",
      "pNomen": "p.G931*"
    },
    {
      "id": 11577,
      "chromosome": "1",
      "start": 27092814,
      "stop": 27092814,
      "classification": "Very high",
      "variantInfo": "<br />\nTwo deleterious variants were detected in ARID1A: p.Tyr948Ilefs*59 frameshift and p.Gln1306* nonsense variant. Both variants are predicted to result in an absent or disrupted protein product. While these variants have not been reported in the literature, loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ARID1A p.Tyr948Ilefs*59 and p.Gln1306* variants currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of BRD or PARP inhibitors.<br />\n ",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/27 21:23:03",
      "evidences": [],
      "reference": ".",
      "alternative": "C",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.2840dupC",
      "type": "insertion",
      "location": "exonic",
      "exon": 9,
      "effect": "frameshift",
      "pNomen": "p.Y948Ifs*59"
    },
    {
      "id": 12159,
      "chromosome": "1",
      "start": 27092950,
      "stop": 27092950,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\nThe ARID1A p.Met961Trpfs*7 frameshift variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\nA clinical study in ovarian cancer suggests this variant is predicted sensitive to Aurora kinase A and FLT3 inhibitors (PMID: 30108107).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:31",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.2881delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 10,
      "effect": "frameshift",
      "pNomen": "p.M961Wfs*7"
    },
    {
      "id": 11639,
      "chromosome": "1",
      "start": 27093059,
      "stop": 27093059,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\nThe c.2988&#43;2del splice site variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ARID1A c.2988&#43;2del variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of BRD or PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/14 16:58:35",
      "evidences": [],
      "reference": "T",
      "alternative": ".",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.2988+2delT",
      "type": "deletion",
      "location": "intronic",
      "exon": 10,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 12388,
      "chromosome": "1",
      "start": 27097645,
      "stop": 27097645,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764). The ARID1A p.Asn1079Lysfs*26 frameshift variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625). A clinical study in endometrial cancer suggests ARID1A loss is predicted sensitive to immunotherapy targeting PD-L1 (PMID: 32111729).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/06/25 18:26:16",
      "evidences": [],
      "reference": ".",
      "alternative": "A",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.3236dupA",
      "type": "insertion",
      "location": "exonic",
      "exon": 12,
      "effect": "frameshift",
      "pNomen": "p.N1079Kfs*26"
    },
    {
      "id": 11711,
      "chromosome": "1",
      "start": 27099947,
      "stop": 27099947,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\nLoss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625). The p.Arg1276* nonsense variant is a hotspot variant (cancerhotspots.org) and is predicted to result in an absent or disrupted protein product.  <br />\nA search by the Watson for Genomics platform indicates in this disease site, the ARID1A p.Tyr948Ilefs*59 and p.Gln1306* variants currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of BRD or PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/05 18:16:54",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.3826C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 15,
      "effect": "stopgain",
      "pNomen": "p.R1276*"
    },
    {
      "id": 12154,
      "chromosome": "1",
      "start": 27100107,
      "stop": 27100107,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\nThe ARID1A p.Ser1301Argfs*180 frameshift variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\nA clinical study in ovarian cancer suggests ARID1A loss is predicted sensitive to Aurora kinase A and FLT3 inhibitors (PMID: 30108107). Preclinical evidence suggests ARID1A mutations are predicted sensitive to EZH2 inhibitors, ATR inhibitor, and immunotherapy targeting PD-L1 (PMID: 25686104, 27958275, 32111729, 29736026).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:31",
      "evidences": [],
      "reference": "C",
      "alternative": ".",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.3903delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 16,
      "effect": "frameshift",
      "pNomen": "p.S1301Rfs*180"
    },
    {
      "id": 11576,
      "chromosome": "1",
      "start": 27100120,
      "stop": 27100120,
      "classification": "Very high",
      "variantInfo": "<br />\nTwo deleterious variants were detected in ARID1A: p.Tyr948Ilefs*59 frameshift and p.Gln1306* nonsense variant. Both variants are predicted to result in an absent or disrupted protein product. While these variants have not been reported in the literature, loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ARID1A p.Tyr948Ilefs*59 and p.Gln1306* variants currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of BRD or PARP inhibitors.<br />\n ",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/27 21:22:41",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.3916C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 16,
      "effect": "stopgain",
      "pNomen": "p.Q1306*"
    },
    {
      "id": 11696,
      "chromosome": "1",
      "start": 27100181,
      "stop": 27100181,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\n<br />\n<br />\nThe ARID1A p.Gln1334dup variant results in an in-frame insertion of one amino acid in the glutamine-rich region of the ARID1A protein. Functional assays suggest this variant results in loss of tumor suppressor function as shown by reduced binding activity and increased cell growth in vitro (PMID: 23097632). Loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\n<br />\n<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ARID1A p.Gln1334dup variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/28 17:22:12",
      "evidences": [],
      "reference": ".",
      "alternative": "GCA",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.3999_4001dupGCA",
      "type": "insertion",
      "location": "exonic",
      "exon": 16,
      "effect": "inframe",
      "pNomen": "p.Q1334dup"
    },
    {
      "id": 11168,
      "chromosome": "1",
      "start": 27100183,
      "stop": 27100183,
      "classification": "Very high",
      "variantInfo": "The p.Gln1327* nonsense variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ARID1A p.Ser301* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of BRD or PARP inhibitors.<br />\n ",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/04/16 02:41:44",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.3979C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 16,
      "effect": "stopgain",
      "pNomen": "p.Q1327*"
    },
    {
      "id": 12135,
      "chromosome": "1",
      "start": 27100207,
      "stop": 27100207,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764). Loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625). The ARID1A p.Arg1335* nonsense variant is predicted to result in an absent or disrupted protein product (PMID: 29736026). In other disease sites, this variant is predicted to be responsive to Aurora kinase A and FLT3 inhibitors (PMID: 30108107).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/02/22 21:15:01",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.4003C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 16,
      "effect": "stopgain",
      "pNomen": "p.R1335*"
    },
    {
      "id": 11965,
      "chromosome": "1",
      "start": 27100908,
      "stop": 27100908,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\nLoss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625). Two deleterious variants were detected in ARID1A: p.Gln1399Alafs*46 and p.Lys1905Asnfs*18 frameshift variants. Both variants are predicted to result in an absent or disrupted protein product (PMID: 29736026).<br />\nA clinical study in ovarian cancer suggest these variants are predicted sensitive to Aurora kinase A and FLT3 inhibitors (PMID: 30108107).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/14 20:33:17",
      "evidences": [],
      "reference": ".",
      "alternative": "G",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.4194dupG",
      "type": "insertion",
      "location": "exonic",
      "exon": 18,
      "effect": "frameshift",
      "pNomen": "p.Q1399Afs*46"
    },
    {
      "id": 11749,
      "chromosome": "1",
      "start": 27101252,
      "stop": 27101252,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\nThe ARID1A p.Gln1512* nonsense variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ARID1A p.Gln1512* variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:23:27",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.4534C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 18,
      "effect": "stopgain",
      "pNomen": "p.Q1512*"
    },
    {
      "id": 11390,
      "chromosome": "1",
      "start": 27101265,
      "stop": 27101265,
      "classification": "Very high",
      "variantInfo": "<br />\nThe p.Ala1517Cysfs*15 frameshift variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ARID1A p.Ala1517Cysfs*15 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of BRD or PARP inhibitors.<br />\n ",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/07/09 12:05:45",
      "evidences": [],
      "reference": ".",
      "alternative": "T",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.4548dupT",
      "type": "insertion",
      "location": "exonic",
      "exon": 18,
      "effect": "frameshift",
      "pNomen": "p.A1517Cfs*15"
    },
    {
      "id": 12147,
      "chromosome": "1",
      "start": 27101300,
      "stop": 27101300,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\nThe ARID1A p.Arg1528* nonsense variant is predicted to result in an absent or disrupted protein product. This variant has been reported in endometrial cancers (COSMIC). Loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\nA clinical study in ovarian cancer suggests this variant is predicted sensitive to Aurora kinase A and FLT3 inhibitors (PMID: 30108107).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:31",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.4582C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 18,
      "effect": "stopgain",
      "pNomen": "p.R1528*"
    },
    {
      "id": 11744,
      "chromosome": "1",
      "start": 27105805,
      "stop": 27105805,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\nThe ARID1A p.Ser1807Glnfs*2 frameshift variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ARID1A p.Ser1807Glnfs*2 variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:17:27",
      "evidences": [],
      "reference": ".",
      "alternative": "T",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.5417dupT",
      "type": "insertion",
      "location": "exonic",
      "exon": 20,
      "effect": "frameshift",
      "pNomen": "p.S1807Qfs*2"
    },
    {
      "id": 11651,
      "chromosome": "1",
      "start": 27105930,
      "stop": 27105930,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\nThe ARID1A p.Asp1850Glyfs*4 frameshift variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ARID1A p.Asp1850Glyfs*4 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of BRD or PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/20 19:00:53",
      "evidences": [],
      "reference": ".",
      "alternative": "G",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.5548dupG",
      "type": "insertion",
      "location": "exonic",
      "exon": 20,
      "effect": "frameshift",
      "pNomen": "p.D1850Gfs*4"
    },
    {
      "id": 11966,
      "chromosome": "1",
      "start": 27106100,
      "stop": 27106100,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\nLoss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625). Two deleterious variants were detected in ARID1A: p.Gln1399Alafs*46 and p.Lys1905Asnfs*18 frameshift variants. Both variants are predicted to result in an absent or disrupted protein product (PMID: 29736026).<br />\nA clinical study in ovarian cancer suggest these variants are predicted sensitive to Aurora kinase A and FLT3 inhibitors (PMID: 30108107).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/14 20:33:27",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.5715delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 20,
      "effect": "frameshift",
      "pNomen": "p.K1905Nfs*18"
    },
    {
      "id": 11795,
      "chromosome": "1",
      "start": 27106199,
      "stop": 27106199,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\nThe ARID1A p.Lys1938Glnfs*7 frameshift variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ARID1A p.Lys1938Glnfs*7 variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:23",
      "evidences": [],
      "reference": ".",
      "alternative": "C",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.5811dupC",
      "type": "insertion",
      "location": "exonic",
      "exon": 20,
      "effect": "frameshift",
      "pNomen": "p.K1938Qfs*7"
    },
    {
      "id": 11867,
      "chromosome": "1",
      "start": 27106354,
      "stop": 27106354,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764).<br />\nThe ARID1A p.Arg1989* nonsense variant is predicted to result in an absent or disrupted protein product. An in vitro study suggests the p.Arg1989* variant results in loss of ARID1A protein expression (PMID: 29736026). This variant has been reported to be associated with endometroid carcinoma (PMID: 20942669, 22653804, 27159395). Loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ARID1A p.Arg1989* variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:23",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.5965C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 20,
      "effect": "stopgain",
      "pNomen": "p.R1989*"
    },
    {
      "id": 12264,
      "chromosome": "1",
      "start": 27106872,
      "stop": 27106872,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID1A is a tumor suppressing helicase and ATPase involved in cell fate through activation of chromatin modification (PMID: 26473533, 26384299) and is inactivated in gynecologic cancers, ovarian clear cell carcinomas and endometrial cancers (PMID: 21900401, 21590771, 20826764). The ARID1A p.Val2162Cysfs*38 frameshift variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in ARID1A are known to be oncogenic (PMID: 21900401, 24899687, 25625625). A clinical study in ovarian cancer suggests this variant is predicted sensitive to Aurora kinase A and FLT3 inhibitors (PMID: 30108107).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/04/27 19:23:59",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "ARID1A",
      "transcript": "NM_006015.4",
      "cNomen": "c.6484delG",
      "type": "deletion",
      "location": "exonic",
      "exon": 20,
      "effect": "frameshift",
      "pNomen": "p.V2162Cfs*38"
    },
    {
      "id": 10997,
      "chromosome": "1",
      "start": 45797372,
      "stop": 45797372,
      "classification": "Very high",
      "variantInfo": "The MUTYH p.Ala385Profs*23 variant is a frameshift variant predicted to result in an altered protein product or nonsense mediated decay due to the introduction of a premature stop codon. The MUTYH p.Ala385Profs*23 variant has been reported in the germline context by 12 clinical laboratories as pathogenic or likely pathogenic (ClinVar); this variant has been reported in population studies (MAF &#61; 0.006%; 18/281328 alleles; gnomAD).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the MUTYH p.Ala385Profs*23 variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "MUTYH is a DNA repair protein involved in genome maintenance (PMID: 21235684, 12915454). Germline mutations in MUTYH lead to colorectal polyposis and adenomas that are inherited in a recessive fashion and an increased risk of gliomas and breast cancer (PMID: 12606733, 26902849, 26824983, 26296701).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/09 20:27:20",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "MUTYH",
      "transcript": "NM_001128425.1",
      "cNomen": "c.1147delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 12,
      "effect": "frameshift",
      "pNomen": "p.A385Pfs*23"
    },
    {
      "id": 11689,
      "chromosome": "1",
      "start": 45799124,
      "stop": 45799124,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "MUTYH is a DNA repair protein involved in genome maintenance (PMID: 21235684, 12915454). Germline mutations in MUTYH lead to colorectal polyposis and adenomas that are inherited in a recessive fashion and an increased risk of gliomas and breast cancer (PMID: 12606733, 26902849, 26824983, 26296701).<br />\n<br />\n<br />\nThe MUTYH p.Trp103* nonsense variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in MUTYH are known to be oncogenic (PMID: 19032956, 26109431, 24834277, 18534194, 20663686). The MUTYH p.Trp103* variant has been reported in the germline context (ClinVar).<br />\n<br />\n<br />\nA search by the Watson for Genomics platform indicates in this disease site, the MUTYH p.Trp103* variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/28 16:49:26",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "MUTYH",
      "transcript": "NM_001128425.1",
      "cNomen": "c.309G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 3,
      "effect": "stopgain",
      "pNomen": "p.W103*"
    },
    {
      "id": 11970,
      "chromosome": "1",
      "start": 65306997,
      "stop": 65306997,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "JAK1 is a non-receptor protein tyrosine kinase involved in the interferon-alpha/beta/gamma pathway and is a member of the JAK/STAT signaling pathway (PMID: 15575979, 25057888, 9096349).<br />\nThe JAK1 p.Lys860Asnfs*16 frameshift variant is predicted to result in an absent or disrupted protein product. Loss-of-function variants in JAK1 are known to be oncogenic (PMID: 29121062, 12576323, 24154688) and are associated with high mutational burden and microsatellite instability (PMID: 29121062). In case reports of other disease sites, loss of function variants in JAK1 have been associated with resistance to immune checkpoint inhibitor (PMID: 27903500, 27433843), however the impact of this variant in this disease context is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/14 20:53:09",
      "evidences": [],
      "reference": "T",
      "alternative": ".",
      "gene": "JAK1",
      "transcript": "NM_002227.3",
      "cNomen": "c.2580delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 19,
      "effect": "frameshift",
      "pNomen": "p.K860Nfs*16"
    },
    {
      "id": 12219,
      "chromosome": "1",
      "start": 65339111,
      "stop": 65339111,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "JAK1 is a non-receptor protein tyrosine kinase involved in the interferon-alpha/beta/gamma pathway and is a member of the JAK/STAT signaling pathway (PMID: 15575979, 25057888, 9096349).<br />\nThe JAK1 p.Lys860Asnfs*16 and p.Lys142Argfs*26 frameshift variant are predicted to result in an absent or disrupted protein product. Loss-of-function variants in JAK1 are known to be oncogenic (PMID: 29121062, 12576323, 24154688) and are associated with high mutational burden and microsatellite instability (PMID: 29121062). In case reports of other disease sites, loss of function variants in JAK1 have been associated with resistance to immune checkpoint inhibitor (PMID: 27903500, 27433843), however the impact of this variant in this disease context is currently unknown.<br />\nA search by the Qiagen Clinical Insight platform indicates in this disease site, these variants currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of JAK inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/25 01:32:05",
      "evidences": [],
      "reference": "T",
      "alternative": ".",
      "gene": "JAK1",
      "transcript": "NM_002227.3",
      "cNomen": "c.425delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 5,
      "effect": "frameshift",
      "pNomen": "p.K142Rfs*26"
    },
    {
      "id": 11525,
      "chromosome": "1",
      "start": 115256529,
      "stop": 115256529,
      "classification": "Very high",
      "variantInfo": "<br />\nThe NRAS p.Gln61Arg is a hotspot mutation that lies within a GTP-binding region of the Nras protein (UniProt.org). This variant results in a loss of NRAS GTPase function as indicated by increased GTP-bound NRAS, which leads to activation of MAPK signaling in culture (PMID: 16818621, 25277205, 21993244, 20194776, 23515407, 24651010, 19492075)<br />\n <br />\nA search by the Watson for Genomics platform indicates in this disease site, the NRAS p.Gln61Arg variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MAPK inhibitors.<br />\n ",
      "reportAbstract": "The NRAS gene encodes a membrane-associated GTPase that controls intracellular oncogenic MAPK and PI3K signaling pathways. Activating NRAS mutations lock the enzyme in an active state causing increased cellular proliferation via hyperactivating these downstream pathways (PMID: 20194776, 21993244). NRAS mutations are common in thyroid cancer, ovarian cancers, melanoma and hematological cancers (PMID: 21993244, 22589270, 24651010). NRAS mutations may contribute to resistance to anti-EGFR therapies (PMID: 20619739, 25110411, 24024839).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/09 19:19:01",
      "evidences": [],
      "reference": "T",
      "alternative": "C",
      "gene": "NRAS",
      "transcript": "NM_002524.3",
      "cNomen": "c.182A>G",
      "type": "snp",
      "location": "exonic",
      "exon": 3,
      "effect": "nonsynonymous",
      "pNomen": "p.Q61R"
    },
    {
      "id": 11716,
      "chromosome": "1",
      "start": 115256530,
      "stop": 115256530,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "The NRAS gene encodes a membrane-associated GTPase that controls intracellular oncogenic MAPK and PI3K signaling pathways. Activating NRAS mutations lock the enzyme in an active state causing increased cellular proliferation via hyperactivating these downstream pathways (PMID: 20194776, 21993244). NRAS mutations are common in thyroid cancer, ovarian cancers, melanoma and hematological cancers (PMID: 21993244, 22589270, 24651010). NRAS mutations may contribute to resistance to anti-EGFR therapies (PMID: 20619739, 25110411, 24024839).<br />\nThe NRAS p.Gln61Lys is a hotspot mutation that lies within a GTP-binding region of the Nras protein (UniProt.org). This variant results in a loss of NRAS GTPase function as indicated by increased GTP-bound NRAS, which leads to activation of MAPK signaling in culture (PMID: 25277205, 21993244, 20194776, 23515407, 24651010, 19492075)<br />\nA search by the Watson for Genomics platform indicates in this disease site, the NRAS p.Gln61Lys variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MAPK inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/05 21:24:29",
      "evidences": [],
      "reference": "G",
      "alternative": "T",
      "gene": "NRAS",
      "transcript": "NM_002524.3",
      "cNomen": "c.181C>A",
      "type": "snp",
      "location": "exonic",
      "exon": 3,
      "effect": "nonsynonymous",
      "pNomen": "p.Q61K"
    },
    {
      "id": 12039,
      "chromosome": "1",
      "start": 226568817,
      "stop": 226568817,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PARP1 encodes a nuclear protein modifier enzyme involved in the DNA repair pathway (PMID: 15743666, 9315851, 26184161, 32722408). PARP1 dysregulation has been identified in acute myeloid leukemia, breast and colorectal cancers (PMID: 25483710, 25528020, 16809031), and mutations may confer resistance to PARP inhibitors (PMID: 32722408).<br />\nThe p.Lys418Glufs*24 frameshift variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in PARP1 are likely oncogenic (PMID: 9285557, 24916104). The impact of this variant is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/30 00:30:53",
      "evidences": [],
      "reference": ".",
      "alternative": "C",
      "gene": "PARP1",
      "transcript": "NM_001618.3",
      "cNomen": "c.1251dupG",
      "type": "insertion",
      "location": "exonic",
      "exon": 9,
      "effect": "frameshift",
      "pNomen": "p.K418Efs*24"
    },
    {
      "id": 11909,
      "chromosome": "1",
      "start": 241661227,
      "stop": 241661227,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "FH encodes for an enzyme that converts fumurate to malate (PMID: 23643539, 14708972). Pathogenic germline variants in the FH gene are associated with both autosomal dominant hereditary leiomyomatosis and renal cell cancer (HLRCC) (PMID: 11865300, 15937070) and autosomal recessive fumarase deficiency (PMID: 21560188).<br />\nLoss-of-function variants in FH are known to be oncogenic (PMID: 11865300, 25985877, 16639410, 23612258, 24441663, 9635293). The FH p.Lys477dup variant (also referred to in the literature as c.1433_1434insAAA, c.1431insAAA, c.1433_1434dupAAA, AAAins435, 435insK, InsK477, 435insAAA) is predicted to result in an absent or disrupted protein product. Experimental studies suggest this variant results in reduced enzymatic activity (PMID: 9300800, 15987702, 18313410). This variant has been reported in the germline of individuals with cancers other than renal cancer or leiomyoma (PMID: 29909963, 31444830, 30426508, 29506128, 28825054) as well as reported in multiple families associated with fumarase deficiency (PMID: 24182348, 20549362, 9300800, 9635293).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the FH p.Lys477dup variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/21 17:38:22",
      "evidences": [],
      "reference": ".",
      "alternative": "TTT",
      "gene": "FH",
      "transcript": "NM_000143.3",
      "cNomen": "c.1431_1433dupAAA",
      "type": "insertion",
      "location": "exonic",
      "exon": 10,
      "effect": "inframe",
      "pNomen": "p.K477dup"
    },
    {
      "id": 12194,
      "chromosome": "1",
      "start": 241665852,
      "stop": 241665852,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "FH encodes for an enzyme that converts fumurate to malate (PMID: 23643539, 14708972). Pathogenic germline variants in the FH gene are associated with both autosomal dominant hereditary leiomyomatosis and renal cell cancer (HLRCC) (PMID: 11865300, 15937070) and autosomal recessive fumarase deficiency (PMID: 21560188).<br />\nLoss-of-function variants in FH are known to be oncogenic (PMID: 11865300, 25985877, 16639410, 23612258, 24441663, 9635293). The FH p.Gln376Pro missense variant (also referred to in the literature as p.Gln333Pro) is suggested to disrupt FH activity (PMID: 17182618, 18313410). In other disease sites, mutations in FH may be predicted sensitive to VEGF and mTOR inhibitor therapy (PMID: 32975815). This variant has been reported in the germline of individuals with fumarase deficiency (ClinVar).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:39",
      "evidences": [],
      "reference": "T",
      "alternative": "G",
      "gene": "FH",
      "transcript": "NM_000143.3",
      "cNomen": "c.1127A>C",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "nonsynonymous",
      "pNomen": "p.Q376P"
    },
    {
      "id": 11645,
      "chromosome": "2",
      "start": 25457259,
      "stop": 25457267,
      "classification": "Very high",
      "variantInfo": "The Y874_D876del variant has not been functionally characterized, however another variant that affects the same residue has been shown to disrupt DNMT3A tetramer formation and decreased activity in vitro (PMID: 22722925).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the DNMT3A Y874_D876del variant currently serves as an inclusion eligibility criterion for Phase 1 clinical trials of HDAC inhibitors.",
      "reportAbstract": "DNMT3A is a methyltransferase involved in cell fate determination through chromatin modification (PMID: 28286768, 25693834). Mutations in DNMT3A have been associated with hematological malignancies (PMID: 22722925, 24283755).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/19 18:06:54",
      "evidences": [],
      "reference": "GTCAGTATA",
      "alternative": ".",
      "gene": "DNMT3A",
      "transcript": "NM_022552.4",
      "cNomen": "c.2620_2628delTATACTGAC",
      "type": "deletion",
      "location": "exonic",
      "exon": 23,
      "effect": "inframe",
      "pNomen": "p.Y874_D876del"
    },
    {
      "id": 11584,
      "chromosome": "2",
      "start": 48026361,
      "stop": 48026361,
      "classification": "Very high",
      "variantInfo": "<br />\nTwo deleterious variants were detected in MSH6: the p.Trp413* nonsense and the c.3646&#43;2T&gt;G splice site variant. MSH6 truncating mutations found in individuals with inherited Lynch syndrome or sporadic tumors with microsatellite instability are considered oncogenic due to the loss of normal mismatch repair function (PMID: 1651234, 9111312, 9822680, 9564049, 18790734). Germline MSH6 mutations are associated with Lynch (Hereditary Nonpolyposis Colorectal Cancer) syndrome (PMID: 15528792). The p.Trp413* variant has been previously reported in the germline context (ClinVar). Another variant (c.3646&#43;2T&gt;C) at the same position as the c.3646&#43;2T&gt;G variant has been previously reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, both MSH6 variants currently serves as an inclusion eligibility criterion for FDA approved therapies (PMID: 30787022) and Phase 3 clinical trials.<br />\n ",
      "reportAbstract": "MSH6 is a tumor suppressor involved in genome maintenance through regulation of the DNA damage control pathway (PMID: 23391514, 30121009). Mutations in MSH6 are associated with colorectal and endometrial cancer (PMID: 20028993, 11153917, 20142816).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/27 22:26:02",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "MSH6",
      "transcript": "NM_000179.2",
      "cNomen": "c.1239G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 4,
      "effect": "stopgain",
      "pNomen": "p.W413*"
    },
    {
      "id": 10918,
      "chromosome": "2",
      "start": 48026731,
      "stop": 48026731,
      "classification": "Very high",
      "variantInfo": "MSH6 truncating mutations found in individuals with inherited Lynch syndrome or sporadic tumors with microsatellite instability are considered oncogenic due to the loss of normal mismatch repair function (PMID: 1651234, 9111312, 9822680, 9564049, 18790734).Germline MSH6 mutations are associated with Lynch (Hereditary Nonpolyposis Colorectal Cancer) syndrome (PMID: 15528792). The K537fs variant has not been previously reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the MSH6 K537fs variant currently serves as an inclusion eligibility criterion for FDA approved therapies (PMID: 30787022) and Phase 3 clinical trials.",
      "reportAbstract": "MSH6 is a tumor suppressor involved in genome maintenance through regulation of the DNA damage control pathway (PMID: 23391514, 30121009). Mutations in MSH6 are associated with colorectal and endometrial cancer (PMID: 20028993, 11153917, 20142816).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/02/24 20:33:11",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "MSH6",
      "transcript": "NM_000179.2",
      "cNomen": "c.1610delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 4,
      "effect": "frameshift",
      "pNomen": "p.K537Sfs*34"
    },
    {
      "id": 11978,
      "chromosome": "2",
      "start": 48030640,
      "stop": 48030640,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "MSH6 is a tumor suppressor involved in genome maintenance through regulation of the DNA damage control pathway (PMID: 23391514, 30121009). Mutations in MSH6 are associated with colorectal and endometrial cancer (PMID: 20028993, 11153917, 20142816).<br />\nMSH6 truncating mutations found in individuals with inherited Lynch syndrome or sporadic tumors with microsatellite instability are considered oncogenic due to the loss of normal mismatch repair function (PMID: 1651234, 9111312, 9822680, 9564049, 18790734). The MSH6 p.Phe1088Serfs*2 frameshift variant is predicted to result in a truncated or absent protein. In ovarian cancer, loss of MSH6 is predicted sensitive to immune checkpoint inhibitor (NCCN), however the impact of this variant in this disease context is currently unknown.<br />\nGermline MSH6 mutations are associated with Lynch (Hereditary Nonpolyposis Colorectal Cancer) syndrome (PMID: 15528792). The p.Phe1088Serfs*2 variant has been previously reported in the germline context (ClinVar).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/15 02:00:03",
      "evidences": [],
      "reference": "C",
      "alternative": ".",
      "gene": "MSH6",
      "transcript": "NM_000179.2",
      "cNomen": "c.3261delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 5,
      "effect": "frameshift",
      "pNomen": "p.F1088Sfs*2"
    },
    {
      "id": 11585,
      "chromosome": "2",
      "start": 48032848,
      "stop": 48032848,
      "classification": "Very high",
      "variantInfo": "<br />\nTwo deleterious variants were detected in MSH6: the p.Trp413* nonsense and the c.3646&#43;2T&gt;G splice site variant. MSH6 truncating mutations found in individuals with inherited Lynch syndrome or sporadic tumors with microsatellite instability are considered oncogenic due to the loss of normal mismatch repair function (PMID: 1651234, 9111312, 9822680, 9564049, 18790734). Germline MSH6 mutations are associated with Lynch (Hereditary Nonpolyposis Colorectal Cancer) syndrome (PMID: 15528792). The p.Trp413* variant has been previously reported in the germline context (ClinVar). Another variant (c.3646&#43;2T&gt;C) at the same position as the c.3646&#43;2T&gt;G variant has been previously reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, both MSH6 variants currently serves as an inclusion eligibility criterion for FDA approved therapies (PMID: 30787022) and Phase 3 clinical trials.<br />\n ",
      "reportAbstract": "MSH6 is a tumor suppressor involved in genome maintenance through regulation of the DNA damage control pathway (PMID: 23391514, 30121009). Mutations in MSH6 are associated with colorectal and endometrial cancer (PMID: 20028993, 11153917, 20142816).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/27 22:26:17",
      "evidences": [],
      "reference": "T",
      "alternative": "G",
      "gene": "MSH6",
      "transcript": "NM_000179.2",
      "cNomen": "c.3646+2T>G",
      "type": "snp",
      "location": "intronic",
      "exon": 7,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11751,
      "chromosome": "2",
      "start": 128050332,
      "stop": 128050332,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ERCC3 is a DNA helicase involved in the nucleotide excision repair (NER) pathway (PMID: 21571596, 8465201, 8157004).<br />\n <br />\nThe ERCC3 p.Arg109* nonsense variant is expected to result in an absent or disrupted protein product. This variant is a loss of function alteration as indicated by reduced DNA repair and decreased cell viability in vitro (PMID: 27655433). Germline mutations of ERCC3 are associated with Cockayne&#39;s syndrome, xeroderma pigmentosum and trichothiodystrophy, and associated with an increased risk of breast cancer (PMID: 10064601, 24508195, 27655433, 8304337,16947863, 9012405). The ERCC3 p.Arg109* variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ERCC3 p.Arg109* variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:24:40",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "ERCC3",
      "transcript": "NM_000122.1",
      "cNomen": "c.325C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 3,
      "effect": "stopgain",
      "pNomen": "p.R109*"
    },
    {
      "id": 11630,
      "chromosome": "2",
      "start": 141108364,
      "stop": 141108364,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "LRP1B encodes for an endocytic LDL-family receptor (PMID: 12194987). Mutations in LRP1B are frequently observed in melanoma, lung cancer, esophageal squamous-cell carcinoma, head and neck squamous cancer, and gastric cancer and may be associated with high tumor mutational burden (PMID: 31164891, 31493933, 31054778).<br />\nThe LRP1B c.11892&#43;2T&gt;C splice site variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in LRP1B are known to be oncogenic and may be associated with acquired chemotherapy resistance (PMID: 22896685, 20095042, 31442444, 27626682, 21057533).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the LRP1B c.11892&#43;2T&gt;C variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/13 18:19:04",
      "evidences": [],
      "reference": "A",
      "alternative": "G",
      "gene": "LRP1B",
      "transcript": "NM_018557.2",
      "cNomen": "c.11892+2T>C",
      "type": "snp",
      "location": "intronic",
      "exon": 77,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11574,
      "chromosome": "2",
      "start": 148657041,
      "stop": 148657041,
      "classification": "Very high",
      "variantInfo": "<br />\nACVR2 is commonly mutated in microsatellite unstable (MSI) colon cancers, leading to protein loss, signaling disruption, and larger tumors (PMIDs: 14988818, 20011542, 26497569, 25225355, 30310521, 16636301, 17258738). Two frameshift variants were detected in ACVR2A: p.Lys437Argfs*5 and p.Asp96Thrfs*54. Both variants result in a truncated protein product and are associated with MSI-high gastric cancer (PMID: 32440149).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ACVR2A p.Lys437Argfs*5 and p.Asp96Thrfs*54 variants do not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "Activin A receptor type 2A (ACVR2A) is a membrane receptor in the transforming growth factor- beta (TGF-) signaling pathway, which is involved in the regulation of cell proliferation, migration, and apoptosis.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/27 21:17:55",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "ACVR2A",
      "transcript": "NM_001616.4",
      "cNomen": "c.285delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 3,
      "effect": "frameshift",
      "pNomen": "p.D96Tfs*54"
    },
    {
      "id": 11575,
      "chromosome": "2",
      "start": 148683686,
      "stop": 148683686,
      "classification": "Very high",
      "variantInfo": "<br />\nACVR2 is commonly mutated in microsatellite unstable (MSI) colon cancers, leading to protein loss, signaling disruption, and larger tumors (PMIDs: 14988818, 20011542, 26497569, 25225355, 30310521, 16636301, 17258738). Two frameshift variants were detected in ACVR2A: p.Lys437Argfs*5 and p.Asp96Thrfs*54. Both variants result in a truncated protein product and are associated with MSI-high gastric cancer (PMID: 32440149).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ACVR2A p.Lys437Argfs*5 and p.Asp96Thrfs*54 variants do not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "Activin A receptor type 2A (ACVR2A) is a membrane receptor in the transforming growth factor- beta (TGF-) signaling pathway, which is involved in the regulation of cell proliferation, migration, and apoptosis.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/27 21:18:24",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "ACVR2A",
      "transcript": "NM_001616.4",
      "cNomen": "c.1310delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 10,
      "effect": "frameshift",
      "pNomen": "p.K437Rfs*5"
    },
    {
      "id": 11563,
      "chromosome": "2",
      "start": 178098945,
      "stop": 178098945,
      "classification": "Very high",
      "variantInfo": "<br />\nThe NFE2L2 p.Arg34Gly missense variant occurs within conserved amino-terminal regulatory domain. This variant has been previously reported in endometrial carcinomas (COSMIC). Experimental studies suggest variants in this region inhibit KEAP1-mediated degradation of NFE2L2, resulting in stabilization and nuclear accumulation of NFE2L2 and activation of downstream oxidative stress response genes (PMID:15581590).<br />\nA search by the Watson for Genomics platform indicates in this disease site, NFE2L2 p.Arg34Gly variant currently serves as an inclusion eligibility criterion for Phase 1/2 clinical trials of NFE2L2 inhibitors.<br />\n ",
      "reportAbstract": "NFE2L2 (also known as NRF2) encodes a transcription factor that regulates critical antioxidant and stress-responsive genes. Aberrant activation of NFE2L2 results in increased proliferation, apoptosis resistance, and resistance to drugs and radiotherapy. Recurrent mutations have been identified in squamous cell carcinoma, hepatocellular carcinoma, and esophageal squamous cell carcinoma (PMID: 21798893, 22561517, 25839328, 20421815).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/24 02:09:26",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "NFE2L2",
      "transcript": "NM_006164.4",
      "cNomen": "c.100C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "nonsynonymous",
      "pNomen": "p.R34G"
    },
    {
      "id": 11176,
      "chromosome": "2",
      "start": 190728500,
      "stop": 190728500,
      "classification": "Very high",
      "variantInfo": "The PMS1 p.Arg630* nonsense variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in PMS1 are known to be oncogenic (PMID: 28687356, 8072530). Germline pathogenic mutations in PMS1 are associated with Lynch syndrome (PMID: 19466295, 15528792). This variant has not been reported in the germline context (ClinVar).<br />\nA search by the Clinical Insight (Qiagen) platform indicates in this disease site, the PMS1 p.Arg630* variant serves as an inclusion eligibility criterion for FDA approved therapies of PD1 inhibitors and Phase 2 clinical trials of CTLA-4 and PD-1 inhibitors.<br />\n ",
      "reportAbstract": "PMS1 is a component involved in the DNA mismatch repair (MMR) system (PMID: 11920679, 24614649). Somatic mutations in PMS1 have been identified in multiple myeloma, colorectal cancer, and ovarian cancer (PMID: 30809292, 24614649, 24333356).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/04/16 04:13:13",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "PMS1",
      "transcript": "NM_000534.4",
      "cNomen": "c.1888C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 10,
      "effect": "stopgain",
      "pNomen": "p.R630*"
    },
    {
      "id": 12141,
      "chromosome": "2",
      "start": 202137388,
      "stop": 202137388,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "CASP8 is a tumor suppressor involved in cell survival through activation of the apoptosis pathway (PMID: 25617598, 18073771, 16894031, 27544395).<br />\nInactivating somatic mutations as well as gene silencing by promoter hypermethylation of CASP8 have been observed in different cancers including hepatocellular, gastric, colorectal, central nervous system malignancies and head and neck cancers (PMID: 12384554, 14688019, 23619168, 21798893).The CASP8 p.Glu179* variant is a nonsense variant that leads to a premature termination codon, which is predicted to result in a truncated or absent protein.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:36",
      "evidences": [],
      "reference": "G",
      "alternative": "T",
      "gene": "CASP8",
      "transcript": "NM_001228.4",
      "cNomen": "c.535G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 6,
      "effect": "stopgain",
      "pNomen": "p.E179*"
    },
    {
      "id": 10922,
      "chromosome": "2",
      "start": 202149808,
      "stop": 202149808,
      "classification": "Very high",
      "variantInfo": "Inactivating somatic mutations as well as gene silencing by promoter hypermethylation of CASP8 have been observed in different cancers including hepatocellular, gastric, colorectal, central nervous system malignancies and head and neck cancers (PMID: 12384554, 14688019, 23619168, 21798893).The CASP8 Q375* variant is a nonsense variant that leads to a premature termination codon, which is predicted to result in a truncated or absent protein.",
      "reportAbstract": "CASP8 is a tumor suppressor involved in cell survival through activation of the apoptosis pathway (PMID: 25617598, 18073771, 16894031, 27544395).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/02/24 21:22:45",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "CASP8",
      "transcript": "NM_001228.4",
      "cNomen": "c.1123C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 9,
      "effect": "stopgain",
      "pNomen": "p.Q375*"
    },
    {
      "id": 12324,
      "chromosome": "2",
      "start": 209113113,
      "stop": 209113113,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "IDH1 plays a role in cellular metabolism and in protection against oxidative stress and apoptosis. The IDH1 p.Arg132Cys missense variant result in downstream effects that are associated with tumorigenesis (PMID: 20142433, 21598255). Experimental studies suggest this variant confers a gain-of-function, resulting in conversion of -KG to the oncometabolite D-2-hydroxyglutarate (2-HG) (PMID: 20142433, 20171147, 22442146). A search by the Qiagen QCI platform indicates in this disease site, this variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PARP inhibitor.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/05/17 20:35:53",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "IDH1",
      "transcript": "NM_005896.3",
      "cNomen": "c.394C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 4,
      "effect": "nonsynonymous",
      "pNomen": "p.R132C"
    },
    {
      "id": 11119,
      "chromosome": "2",
      "start": 215645382,
      "stop": 215645382,
      "classification": "Very high",
      "variantInfo": "The BARD1 p.Arg406* nonsense variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in BARD1 are known to be oncogenic (PMID: 25994375, 29292755, 20029420, 8944023). Pathogenic germline variants in BARD1 have been associated with breast and ovarian cancer (PMID: 15342711, 28649662, 28418444, 20077502). The p.Arg406* variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the BARD1 p.Arg406* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PARP inhibitors.",
      "reportAbstract": "BARD1 is a tumour suppressor and encodes for a ubiquitin ligase and DNA repair protein involved in genome maintenance (PMID: 28624371, 28032817). BARD1 forms a stable core complex with BRCA-1 (PMID: 8944023) and loss-of-function variants of BARD1 are considered oncogenic (PMID: 29292755, 20029420, 8944023).<br />\n<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/24 17:53:40",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "BARD1",
      "transcript": "NM_000465.2",
      "cNomen": "c.1216C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 4,
      "effect": "stopgain",
      "pNomen": "p.R406*"
    },
    {
      "id": 11871,
      "chromosome": "3",
      "start": 3209337,
      "stop": 3209337,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "CRBN is a ubiquitin ligase that is involved in ubiquitination and degradation of protein substrates (PMID: 16964240). Somatic CRBN loss-of-function mutations and reduced expression of CRBN have been reported in refractory multiple myeloma (PMID: 23480694, 27458004).<br />\nThe CRBN p.Trp223* nonsense variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in CRBN are likely oncogenic (PMID: 29370161, 24993823, 24166296).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the CRBN p.Trp223* variant does not currently serve as an inclusion eligibility criterion for clinical trials.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:23",
      "evidences": [],
      "reference": ".",
      "alternative": "ATTT",
      "gene": "CRBN",
      "transcript": "NM_016302.3",
      "cNomen": "c.664_667dupAAAT",
      "type": "insertion",
      "location": "exonic",
      "exon": 5,
      "effect": "stopgain",
      "pNomen": "p.W223*"
    },
    {
      "id": 11760,
      "chromosome": "3",
      "start": 3216915,
      "stop": 3216915,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "CRBN is a ubiquitin ligase that is involved in ubiquitination and degradation of protein substrates (PMID: 16964240). Somatic CRBN loss-of-function mutations and reduced expression of CRBN have been reported in refractory multiple myeloma (PMID: 23480694, 27458004).<br />\nThe CRBN p.Gln36* nonsense variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in CRBN are likely oncogenic (PMID: 29370161, 24993823, 24166296).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the CRBN p.Gln36* variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:33:11",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "CRBN",
      "transcript": "NM_016302.3",
      "cNomen": "c.106C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "stopgain",
      "pNomen": "p.Q36*"
    },
    {
      "id": 11126,
      "chromosome": "3",
      "start": 10115047,
      "stop": 10115047,
      "classification": "Very high",
      "variantInfo": "<br />\nThe FANCD2 c.2715&#43;1G&gt;A variant is located within 2bp of the intron-exon boundary and is predicted to result in aberrant splicing and disrupted protein product. Germline FANCD2 mutations have been reported in individuals with Fanconi anemia, a condition associated with congenital defects, bone marrow failure, and increased risk of cancer (PMID: 23653579). The FANCD2 c.2715&#43;1G&gt;A variant has been reported in the germline context (PMID: 17436244, 28678401, 24448499, 28386063, 25703294).<br />\nA search by the Clinical Insight (QCI) platform indicates in this disease site, the FANCD2 c.2715&#43;1G&gt;A variant currently serves as an inclusion eligibility criterion for Phase 1 clinical trials of PARP inhibitors.",
      "reportAbstract": "FANCD2 is a tumor suppressor and DNA repair protein involved in genome maintenance by regulating the DNA damage control pathway (PMID: 23934222, 29376519, 27145721). Loss of FANCD2 has been associated with sporadic as well as hereditary breast cancer (PMID: 17333336, 20363922).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/24 20:02:27",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "FANCD2",
      "transcript": "NM_033084.3",
      "cNomen": "c.2715+1G>A",
      "type": "snp",
      "location": "intronic",
      "exon": 28,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 10928,
      "chromosome": "3",
      "start": 12629100,
      "stop": 12629100,
      "classification": "Very high",
      "variantInfo": "CRAF-activated MAPK signaling has been associated with resistance to the BRAF inhibitor vermurafenib in melanoma (PMID: 23737487, 27327499). The RAF1 M469I variant is a missense variant and may be resistant to RAF inhibition as suggested by in vitro studies (PMID: 23737487).<br />\nA search by the Clinical Insight (Qiagen) platform indicates in this disease site, the RAF1 M469I variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials.<br />\n ",
      "reportAbstract": "RAF1 (CRAF) is an oncogenic serine/threonine protein kinase involved in cell growth, proliferation, and survival through activation of the RAS/RAF/MAPK pathway (PMID: 17555829, 21779496, 26399658).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/02/24 22:01:56",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "RAF1",
      "transcript": "NM_002880.3",
      "cNomen": "c.1407G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 13,
      "effect": "nonsynonymous",
      "pNomen": "p.M469I"
    },
    {
      "id": 12189,
      "chromosome": "3",
      "start": 12632388,
      "stop": 12632388,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "RAF1 (also referred to as CRAF), is a serine/threonine protein kinase involved in cell proliferation, metabolism, and differentiation through activation of the RAS/RAF/MAPK pathway (PMID: 17555829, 28978120). RAF1 alterations have been reported in various cancers, including melanoma, lung, and breast cancers (PMID: 27273450, 31285551, 32123303, 29203461).<br />\nThe RAF1 p.Ser427Gly missense variant is a gain-of-function variant that lies within the protein kinase domain. Functional assays suggest this variant results in increased kinase activity (PMID: 16585161). Preclinical studies suggest RAF1 mutations are predicted sensitive to MEK inhibitors (PMID: 30867592, 24569458).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:36",
      "evidences": [],
      "reference": "T",
      "alternative": "C",
      "gene": "RAF1",
      "transcript": "NM_002880.3",
      "cNomen": "c.1279A>G",
      "type": "snp",
      "location": "exonic",
      "exon": 12,
      "effect": "nonsynonymous",
      "pNomen": "p.S427G"
    },
    {
      "id": 12322,
      "chromosome": "3",
      "start": 12645699,
      "stop": 12645699,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "RAF1 (also referred to as CRAF), is a serine/threonine protein kinase involved in cell proliferation, metabolism, and differentiation through activation of the RAS/RAF/MAPK pathway (PMID: 17555829, 28978120). RAF1 alterations have been reported in various cancers, including melanoma, lung, and breast cancers (PMID: 27273450, 31285551, 32123303, 29203461). The RAF1 p.Ser257Leu missense variant is a gain-of-function variant that lies within the CR2 domain. Functional assays suggest this variant results in increased MEK/ERK phosphorylation and impairs binding of 14-3-3 proteins (PMID: 12077328, 24569458, 20679480, 20052757). Preclinical studies suggest RAF1 mutations are predicted sensitive to MEK inhibitors (PMID: 30867592, 24569458).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/05/17 20:25:24",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "RAF1",
      "transcript": "NM_002880.3",
      "cNomen": "c.770C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "nonsynonymous",
      "pNomen": "p.S257L"
    },
    {
      "id": 11721,
      "chromosome": "3",
      "start": 30691871,
      "stop": 30691871,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TGFRB2 is a serine/threonine protein kinase involved in multiple biological processes including cellular proliferation, differentiation and tissue homeostasis (PMID: 22992590, 11057902). TGFBR2 loss-of-function variants have been reported in pancreatic cancers and gastrointestinal cancers with microsatellite instability (PMID: 22992590, 11057902, 7585632, 9927040, 17985359).<br />\nThe TGFBR2 p.Pro154Alafs*3 frameshift variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in TGFBR2 are known to be oncogenic (PMID: 16310402, 17456004, 17985359, 9927040, 7585632, 15256431). Pathogenic germline variants in TGFBR2 have been associated with Marfan syndrome and Loeys-Dietz syndrome (PMID: 15731757, 15235604). This variant has not been reported in the germline context (ClinVar).<br />\n <br />\nA search by the Watson for Genomics platform indicates in this disease site, the TGFBR2 p.Pro154Alafs*3 variant does not currently serves as an inclusion eligibility criterion for clinical trials.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/06 16:04:14",
      "evidences": [],
      "reference": ".",
      "alternative": "A",
      "gene": "TGFBR2",
      "transcript": "NM_001024847.2",
      "cNomen": "c.458dupA",
      "type": "insertion",
      "location": "exonic",
      "exon": 4,
      "effect": "frameshift",
      "pNomen": "p.P154Afs*3"
    },
    {
      "id": 10927,
      "chromosome": "3",
      "start": 30715596,
      "stop": 30715596,
      "classification": "Very high",
      "variantInfo": "Loss of TFBR2 occurs most frequently in MSI (&#43;) cancers of the biliary, colon (HNPCC), gastric, brain and lung tissues (PMID: 11057902). The TGFBR2 c.1330-1G&gt;A variant occurs within 2bp of the intron-exon boundary and may induce aberrant splicing resulting in a truncated protein and loss of function.<br />\n ",
      "reportAbstract": "TGFBR2 is a cytokine receptor and serine/threonine protein kinase involved in cellular proliferation, differentiation and tissue homeostasis through activation of the TGFb pathway (PMID: 22992590, 11057902). Following TGFb-family ligand activation, TGFBR2 phosphorylates its dimerization partner and induces phosphorylation of downstream effectors such as the SMAD proteins, which control gene regulation (PMID: 18662538).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/02/24 21:56:40",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "TGFBR2",
      "transcript": "NM_001024847.2",
      "cNomen": "c.1330-1G>A",
      "type": "snp",
      "location": "intronic",
      "exon": 6,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11169,
      "chromosome": "3",
      "start": 37048556,
      "stop": 37048556,
      "classification": "Very high",
      "variantInfo": "The MLH1 c.453&#43;2T&gt;G is a splice site variant and is predicted to result in an altered protein product or absence of protein due to nonsense mediated decay. Truncating mutations found in individuals with inherited Lynch syndrome or sporadic tumors with microsatellite instability are considered oncogenic through the loss of normal mismatch repair function (PMID: 7892206, 11781295). Pathogenic germline variants in MLH1 have been associated with Lynch syndrome (PMID: 8128251, 8145827, 7584997, 15937084, 19419416). The c.453&#43;2T&gt;G variant has not been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the MLH1 c.453&#43;2T&gt;G variant currently serves as an inclusion eligibility criterion for FDA approved therapies of PD1 inhibitors and Phase 3 clinical trials of PD-L1 inhibitors.<br />\n<br />\n ",
      "reportAbstract": "MLH1 encodes a tumor suppressor involved in DNA mismatch repair. Select mutations of MLH1 are associated with Lynch syndrome and can lead to genomic instability via microsatellite instability in tumors (PMID:19659756, 22714864, 25328415, 28772289, 31337882).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/04/16 02:59:32",
      "evidences": [],
      "reference": "T",
      "alternative": "G",
      "gene": "MLH1",
      "transcript": "NM_000249.3",
      "cNomen": "c.453+2T>G",
      "type": "snp",
      "location": "intronic",
      "exon": 5,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 12187,
      "chromosome": "3",
      "start": 37056036,
      "stop": 37056036,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "MLH1 encodes a tumor suppressor involved in DNA mismatch repair. Select mutations of MLH1 are associated with Lynch syndrome and can lead to genomic instability via microsatellite instability in tumors (PMID:19659756, 22714864, 25328415, 28772289, 31337882).<br />\nThe MLH1 c.790&#43;1G&gt;A is a splice site variant that results in exon skipping and may result in impaired protein activity (PMID: 16395668, 11781295). Truncating mutations found in individuals with inherited Lynch syndrome or sporadic tumors with microsatellite instability are considered oncogenic through the loss of normal mismatch repair function (PMID: 7892206, 11781295). In other gynecologic diseases, PD1 inhibitors are recommended for mismatch repair-deficiency (NCCN).<br />\nPathogenic germline variants in MLH1 have been associated with Lynch syndrome (PMID: 8128251, 8145827, 7584997, 15937084, 19419416). The c.790&#43;1G&gt;A variant has been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:39",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "MLH1",
      "transcript": "NM_000249.3",
      "cNomen": "c.790+1G>A",
      "type": "snp",
      "location": "intronic",
      "exon": 9,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 12394,
      "chromosome": "3",
      "start": 41266097,
      "stop": 41266097,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "CTNNB1 (also referred to as -catenin) is a transcriptional activator involved in the WNT signaling pathway (PMID: 22682243, 22617422). Gain-of-function alterations in CTNNB1 are recurrently reported in various cancers including uterine/endometrial carcinoma (PMID: 9721853, 23636398, 19349352). The CTNNB1 p.Asp32Asn missense variant has been previously reported in endometrial cancer (COSMIC). This variant occurs in the ubiquitination recognition motif, and results in a gain-of-function of activity (PMID: 15064718, 11955436). Small cohort studies suggest patients with endometrioid cancer and CTNNB1 mutations may be responsive to everolimus and letrozole (NCT01068249; PMID: 25624430).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/06/25 19:13:53",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "CTNNB1",
      "transcript": "NM_001098209.1",
      "cNomen": "c.94G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 3,
      "effect": "nonsynonymous",
      "pNomen": "p.D32N"
    },
    {
      "id": 12225,
      "chromosome": "3",
      "start": 41266098,
      "stop": 41266098,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "CTNNB1 (also referred to as -catenin) is a transcriptional activator involved in the WNT signaling pathway (PMID: 22682243, 22617422). Gain-of-function alterations in CTNNB1 are recurrently reported in various cancers including uterine/endometrial carcinoma (PMID: 9721853, 23636398, 19349352).<br />\nThe CTNNB1 p.Asp32Gly missense variant has been previously reported in endometrial cancer (COSMIC). This variant occurs in the ubiquitination recognition motif, and results in a gain-of-function of activity (PMID: 15064718, 22298898). Small cohort studies suggest patients with endometrioid cancer and CTNNB1 mutations may be responsive to everolimus and letrozole (NCT01068249; PMID: 25624430).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/04/23 14:51:19",
      "evidences": [],
      "reference": "A",
      "alternative": "G",
      "gene": "CTNNB1",
      "transcript": "NM_001098209.1",
      "cNomen": "c.95A>G",
      "type": "snp",
      "location": "exonic",
      "exon": 3,
      "effect": "nonsynonymous",
      "pNomen": "p.D32G"
    },
    {
      "id": 11634,
      "chromosome": "3",
      "start": 41266101,
      "stop": 41266101,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "CTNNB1 (also referred to as -catenin) is a transcriptional activator involved in the WNT signaling pathway (PMID: 22682243, 22617422). Gain-of-function alterations in CTNNB1 are recurrently reported in various cancers including uterine/endometrial carcinoma, ovarian, hepatocellular cancers, and colorectal carcinoma (PMID: 9721853, 23636398, 19349352, 20942669, 22634756, 23788652, 22810696).<br />\nThe CTNNB1 p.Ser33Tyr missense variant has been previously reported in a variety of cancer types (PMID: 22722839, 22653804, 22832583). This variant occurs in a GSK3B phosphorylation site which results in nuclear accumulation of CTNNB1 and thus a gain-of-function of activity (PMID: 20307497, 9065403, 11943721). Small cohort studies suggests patients with endometrioid endometrial cancer and CTNNB1 mutations may be responsive to everolimus and letrozole (PMID: 25624430).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the CTNNB1 p.Ser33Tyr variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/14 02:16:50",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "CTNNB1",
      "transcript": "NM_001098209.1",
      "cNomen": "c.98C>A",
      "type": "snp",
      "location": "exonic",
      "exon": 3,
      "effect": "nonsynonymous",
      "pNomen": "p.S33Y"
    },
    {
      "id": 11688,
      "chromosome": "3",
      "start": 41266109,
      "stop": 41266123,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "CTNNB1 (also referred to as -catenin) is a transcriptional activator involved in the WNT signaling pathway (PMID: 22682243, 22617422). Gain-of-function alterations in CTNNB1 are recurrently reported in various cancers including uterine/endometrial carcinoma, ovarian, hepatocellular cancers, and colorectal carcinoma (PMID: 9721853, 23636398, 19349352, 20942669, 22634756, 23788652, 22810696).<br />\n<br />\n<br />\nThe CTNNB1 p.His36_Thr40del variant has not been functionally characterized, however another variant that affects the same residue has been shown to be likely pathogenic (PMID: 9065402, 9635572, 18282277).<br />\n<br />\n<br />\nA search by the Watson for Genomics platform indicates in this disease site, the CTNNB1 p.His36_Thr40del variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/28 16:48:54",
      "evidences": [],
      "reference": "CATTCTGGTGCCACT",
      "alternative": ".",
      "gene": "CTNNB1",
      "transcript": "NM_001098209.1",
      "cNomen": "c.106_120delCATTCTGGTGCCACT",
      "type": "deletion",
      "location": "exonic",
      "exon": 3,
      "effect": "inframe",
      "pNomen": "p.H36_T40del"
    },
    {
      "id": 11025,
      "chromosome": "3",
      "start": 41266113,
      "stop": 41266113,
      "classification": "Very high",
      "variantInfo": "The CTNNB1 p.Ser37Phe missense variant has been previously reported in endometrial cancer (COSMIC). This variant occurs in a GSK3B phosphorylation site which results in nuclear accumulation of CTNNB1 and thus a gain-of-function of activity (PMID: 20307497, 9065403, 11943721). Small cohort studies suggests patients with endometrioid endometrial cancer and CTNNB1 mutations may be responsive to everolimus and letrozole (NCT01068249; PMID: 25624430).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the CTNNB1 p.Ser37Phe variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "CTNNB1 (also referred to as -catenin) is a transcriptional activator involved in the WNT signaling pathway (PMID: 22682243, 22617422). Gain-of-function alterations in CTNNB1 are recurrently reported in various cancers including uterine/endometrial carcinoma (PMID: 9721853, 23636398, 19349352).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/10 21:35:57",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "CTNNB1",
      "transcript": "NM_001098209.1",
      "cNomen": "c.110C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 3,
      "effect": "nonsynonymous",
      "pNomen": "p.S37F"
    },
    {
      "id": 11640,
      "chromosome": "3",
      "start": 41266113,
      "stop": 41266113,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "CTNNB1 (also referred to as -catenin) is a transcriptional activator involved in the WNT signaling pathway (PMID: 22682243, 22617422). Gain-of-function alterations in CTNNB1 are recurrently reported in various cancers including uterine/endometrial carcinoma, ovarian, hepatocellular cancers, and colorectal carcinoma (PMID: 9721853, 23636398, 19349352, 20942669, 22634756, 23788652, 22810696).<br />\nThe CTNNB1 p.Ser37Tyr missense variant occurs in a GSK3B phosphorylation site and results in nuclear accumulation of CTNNB1 and thus a gain-of-function of activity (PMID: 20606007, 9065402, 9635572). Small cohort studies suggests patients with endometrioid endometrial cancer and CTNNB1 mutations may be responsive to everolimus and letrozole (PMID: 25624430).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the CTNNB1 p.Ser37Tyr variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/14 16:58:50",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "CTNNB1",
      "transcript": "NM_001098209.1",
      "cNomen": "c.110C>A",
      "type": "snp",
      "location": "exonic",
      "exon": 3,
      "effect": "nonsynonymous",
      "pNomen": "p.S37Y"
    },
    {
      "id": 12031,
      "chromosome": "3",
      "start": 41266113,
      "stop": 41266113,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "CTNNB1 (also referred to as -catenin) is a transcriptional activator involved in the WNT signaling pathway (PMID: 22682243, 22617422). Gain-of-function alterations in CTNNB1 are recurrently reported in various cancers including uterine/endometrial carcinoma (PMID: 9721853, 23636398, 19349352). The CTNNB1 p.Ser37Cys missense variant has been previously reported in endometrial cancer (COSMIC). This variant occurs in a GSK3B phosphorylation site, and another variant at this position results in a gain-of-function of activity (PMID: 20307497, 9065403, 11943721). Small cohort studies suggests patients with endometrioid endometrial cancer and CTNNB1 mutations may be responsive to everolimus and letrozole (NCT01068249; PMID: 25624430).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/27 20:50:52",
      "evidences": [],
      "reference": "C",
      "alternative": "G",
      "gene": "CTNNB1",
      "transcript": "NM_001098209.1",
      "cNomen": "c.110C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 3,
      "effect": "nonsynonymous",
      "pNomen": "p.S37C"
    },
    {
      "id": 12148,
      "chromosome": "3",
      "start": 41266137,
      "stop": 41266137,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "CTNNB1 (also referred to as -catenin) is a transcriptional activator involved in the WNT signaling pathway (PMID: 22682243, 22617422). Gain-of-function alterations in CTNNB1 are recurrently reported in various cancers including uterine/endometrial carcinoma (PMID: 9721853, 23636398, 19349352).<br />\nThe CTNNB1 p.Ser45Phe missense variant has been previously reported in endometrial cancer (COSMIC). This variant occurs in a GSK3B phosphorylation site which results in nuclear accumulation of CTNNB1 and thus a gain-of-function of activity (PMID: 18282277, 20307497). Small cohort studies suggest patients with endometrioid endometrial cancer and CTNNB1 mutations may be responsive to everolimus and letrozole (NCT01068249; PMID: 25624430).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:36",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "CTNNB1",
      "transcript": "NM_001098209.1",
      "cNomen": "c.134C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 3,
      "effect": "nonsynonymous",
      "pNomen": "p.S45F"
    },
    {
      "id": 12215,
      "chromosome": "3",
      "start": 47162780,
      "stop": 47162780,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "SETD2 regulates chromatin structure by site specific trimethylation of histone H3K36 (PMID: 28159833, 28386724) and plays a role in genomic stability (PMID: 31747945).<br />\nThe SETD2 p.Lys1116* nonsense variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in SETD2 are likely oncogenic (PMID: 24509477, 25728682, 23417712). The impact of this variant in this disease context is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/25 00:35:02",
      "evidences": [],
      "reference": "T",
      "alternative": "A",
      "gene": "SETD2",
      "transcript": "NM_014159.6",
      "cNomen": "c.3346A>T",
      "type": "snp",
      "location": "exonic",
      "exon": 3,
      "effect": "stopgain",
      "pNomen": "p.K1116*"
    },
    {
      "id": 11727,
      "chromosome": "3",
      "start": 52643841,
      "stop": 52643841,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PBRM1 encodes a tumor suppressing DNA binding protein which is a component of the switching defective/sucrose non-fermenting (SWI/SNF) complex involved in chromatin remodeling to modulate gene expression (PMID: 23867514). PBRM1 is mutated in clear cell renal cell carcinoma (PMID: 19084573, 31861590) and intrahepatic cholangiocarcinomas (PMID: 24185509).<br />\n<br />\nThe PBRM1 p.Arg686Glyfs*13 frameshift variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in PBRM1 are known to be oncogenic (PMID: 21248752, 18339845, 24613357, 22949125, 21654818, 24613357).<br />\n<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PBRM1 p.Arg686Glyfs*13 variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of immunotherapy.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:23",
      "evidences": [],
      "reference": "C",
      "alternative": ".",
      "gene": "PBRM1",
      "transcript": "NM_018313.4",
      "cNomen": "c.2055delG",
      "type": "deletion",
      "location": "exonic",
      "exon": 17,
      "effect": "frameshift",
      "pNomen": "p.R686Gfs*13"
    },
    {
      "id": 11969,
      "chromosome": "3",
      "start": 71101751,
      "stop": 71101751,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "FOXP1 encodes for a transcriptional repressor regulating genes involved in several cellular processes, including cell proliferation, migration, and differentiation (PMID: 17614763, 26654944, 10702024, 23792361).<br />\nThe FOXP1 p.Lys149Asnfs*57 is predicted to result in an absent or disrupted protein product. Loss-of-function variants in FOXP1 may be oncogenic (PMID: 25329375). The impact of this variant in this disease context is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/14 20:46:37",
      "evidences": [],
      "reference": "T",
      "alternative": ".",
      "gene": "FOXP1",
      "transcript": "NM_032682.5",
      "cNomen": "c.447delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 9,
      "effect": "frameshift",
      "pNomen": "p.K149Nfs*57"
    },
    {
      "id": 11887,
      "chromosome": "3",
      "start": 89499354,
      "stop": 89499354,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "EPHA3 encodes for a receptor tyrosine kinase that results in activation of downstream signaling pathways that control cell adhesion, cell migration, cells spreading and proliferation (PMID: 11870224). EPHA3 is overexpressed in various cancer types, including sarcoma, leukemia, glioblastoma and hepatocellular cancer (PMID: 25391995, 23410976, 28415715, 2792259 ). EPHA3 loss-of-function mutations have been identified in various cancer types including lung cancer, melanoma and non-melanoma skin cancers resulting in decreased EPHA3 signaling and enhanced cellular proliferation (PMID: 22829656, 22242939).<br />\nThe p.Arg842* nonsense variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in EPHA3 are known to be oncogenic (PMID: 21135139, 22144690, 25125683, 28169277).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the EPHA3 p.Arg842* variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 19:55:21",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "EPHA3",
      "transcript": "NM_005233.5",
      "cNomen": "c.2524C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 15,
      "effect": "stopgain",
      "pNomen": "p.R842*"
    },
    {
      "id": 11567,
      "chromosome": "3",
      "start": 134977891,
      "stop": 134977891,
      "classification": "Very high",
      "variantInfo": "<br />\nThe EPHB1 p.Gln962* nonsense variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in EPHB1 are known to be oncogenic (PMID: 12408869). Reduced expression of EPHB1 has also been detected in a variety of cancers including colorectal, gastric, and ovarian cancer (PMID: 18931529, 18424888).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the EPHB1 p.Gln962* variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "EPHB1 is a receptor tyrosine kinase that is a member of the ephrin (EPH) protein family (PMID: 31297055). EPHB signaling has been implicated in a variety of other cellular processes including immune regulation, epithelial integrity, invasion, cell shape, cellular proliferation and axon guidance (PMID: 12408869, 18424888, 31297055, 26790531, 23669443, 21514363). Somatic mutations in EPHB1 are found in patients with metastatic colorectal cancer (PMID: 12408869).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/24 02:53:56",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "EPHB1",
      "transcript": "NM_004441.4",
      "cNomen": "c.2884C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 16,
      "effect": "stopgain",
      "pNomen": "p.Q962*"
    },
    {
      "id": 12155,
      "chromosome": "3",
      "start": 138374293,
      "stop": 138374293,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3CB, a catalytic subunit of PI3-kinase, is an oncogene involved in cell proliferation, growth and metabolism through activation of the PI3K/AKT/MTOR pathway (PMID: 23411347, 18594509, 18780892). PIK3CB also plays a role in tumorigenesis driven by loss of PTEN (PMID: 18755892, 18594509).<br />\nThe PIK3CB p.Glu1051Lys missense variant lies within the PI3K/PI4K kinase domain (Uniprot). In vitro assays suggest this variant is activating (PMID: 29533785, 29279775).<br />\nPreclinical studies suggest mutations in PIK3CB in breast cancer cells are predicted sensitive to AKT and mTOR inhibitors and are associated with resistance to PI3K inhibitors (PMID: 26759240). However, the impact of this variant in patient care is currently unknown.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:31",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "PIK3CB",
      "transcript": "NM_006219.2",
      "cNomen": "c.3151G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 22,
      "effect": "nonsynonymous",
      "pNomen": "p.E1051K"
    },
    {
      "id": 11643,
      "chromosome": "3",
      "start": 138665163,
      "stop": 138665163,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "FOXL2 encodes for a transcription factor that is a member of the forked-winged helix family and plays a role in ovary development (PMID: 21640373). FOXL2 is commonly mutated in granulosa-cell tumors (PMID: 19956657, PMID: 31162286), including of the ovary (PMID: 32064045).<br />\n <br />\nThe FOXL2 p.Cys134Trp variant is highly recurrent (~94-97%) in adult-type granulosa cell tumors of the ovary (COSMIC, PMID: 27297428, 28276867, 20693978, 26033501). This variant is suggested to have diagnostic utility in adult-type granulosa cell tumors due to its high prevalence in this tumor type, and its absence/low prevalence in other tumor types (present in 3/14 thecomas and 1/10 juvenile granulosa cell tumors but absent in 49 other sex cord stromal tumors and in 329 unrelated ovarian or breast tumors; PMID: 19516027, 27297428, 27446412).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the FOXL2 p.Cys134Trp variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/14 17:09:10",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "FOXL2",
      "transcript": "NM_023067.3",
      "cNomen": "c.402C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 1,
      "effect": "nonsynonymous",
      "pNomen": "p.C134W"
    },
    {
      "id": 11981,
      "chromosome": "3",
      "start": 142241667,
      "stop": 142241667,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ATR s a serine/threonine kinase involved in the DNA damage response. ATR responds to DNA damage and single-strand DNA by activating cell-cycle checkpoint and DNA repair pathways (PMID: 25512053, 12791985, 20818375, 17157788). The ATR p.Ser1390* nonsense variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in ATR are known to be oncogenic (PMID: 10691732, 15282542). In other disease sites, preclinical studies suggest loss of function variants in ATR are associated with sensitivity to mTOR/ATR inhibitors (PMID: 25630452, 25010037, 25468710), however the impact of this variant in this disease context is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/15 02:24:33",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "ATR",
      "transcript": "NM_001184.3",
      "cNomen": "c.4169C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 23,
      "effect": "stopgain",
      "pNomen": "p.S1390*"
    },
    {
      "id": 12218,
      "chromosome": "3",
      "start": 142274739,
      "stop": 142274739,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ATR is a serine/threonine kinase involved in the DNA damage response. ATR responds to DNA damage and single-strand DNA by activating cell-cycle checkpoint and DNA repair pathways (PMID: 25512053, 12791985, 20818375, 17157788).<br />\n <br />\nThe ATR p.Ile774Asnfs*3 frameshift variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in ATR are known to be oncogenic (PMID: 10691732, 15282542). Preclinical data has shown that kinase inhibitors of ATR may enhance chemotherapy response and treatment of DNA repair-pathway-deficient cancers (PMID: 26517239, 21552262, 26312880, 25630452, 25010037, 25468710).<br />\n <br />\nA search by the Qiagen Clinical Insight platform indicates in this disease site, the ATR p.Ile774Asnfs*3 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/25 01:28:45",
      "evidences": [],
      "reference": ".",
      "alternative": "T",
      "gene": "ATR",
      "transcript": "NM_001184.3",
      "cNomen": "c.2320dupA",
      "type": "insertion",
      "location": "exonic",
      "exon": 10,
      "effect": "frameshift",
      "pNomen": "p.I774Nfs*3"
    },
    {
      "id": 12358,
      "chromosome": "3",
      "start": 142274740,
      "stop": 142274740,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ATR is a serine/threonine kinase involved in the DNA damage response. ATR responds to DNA damage and single-strand DNA by activating cell-cycle checkpoint and DNA repair pathways (PMID: 25512053, 12791985, 20818375, 17157788).<br />\nThe ATR p.Ile774Tyrfs*5 frameshift variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in ATR are known to be oncogenic (PMID: 10691732, 15282542). Preclinical data has shown that kinase inhibitors of ATR may enhance chemotherapy response and treatment of DNA repair-pathway-deficient cancers (PMID: 26517239, 21552262, 26312880, 25630452, 25010037, 25468710).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/06/01 20:56:49",
      "evidences": [],
      "reference": "T",
      "alternative": ".",
      "gene": "ATR",
      "transcript": "NM_001184.3",
      "cNomen": "c.2320delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 10,
      "effect": "frameshift",
      "pNomen": "p.I774Yfs*5"
    },
    {
      "id": 11901,
      "chromosome": "3",
      "start": 178916726,
      "stop": 178916726,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).<br />\nThe PIK3CA p.Arg38His missense variant lies within the PI3K-ABD domain of the PIK3CA protein (UniProt.org). Experimental studies suggest the p.Arg38His variant is a gain-of-function alteration as indicated by a moderate increase in kinase activity and transformation ability in vitro (PMID: 15930273, 29533785, 17376864).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PIK3CA p.Arg38His variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/21 16:31:00",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.113G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "nonsynonymous",
      "pNomen": "p.R38H"
    },
    {
      "id": 11171,
      "chromosome": "3",
      "start": 178916876,
      "stop": 178916876,
      "classification": "Very high",
      "variantInfo": "The PIK3CA p.Arg88Gln missense variant lies within the PI3K-ABD domain of the PIK3CA protein (UniProt.org). The p.Arg88Gln variant is a gain of function alteration as indicated by increased kinase activity and transformation ability in vitro (PMID: 29533785, 18829572, 21266528).<br />\nA search by the Clinical Insight (Qiagen) platform indicates in this disease site, the PIK3CA p.Val344Gly variant currently serves as an inclusion eligibility criterion for Phase 4 clinical trials of MTOR inhibitors.<br />\n ",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/04/16 03:18:07",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.263G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "nonsynonymous",
      "pNomen": "p.R88Q"
    },
    {
      "id": 12223,
      "chromosome": "3",
      "start": 178916890,
      "stop": 178916890,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).<br />\n <br />\nThe PIK3CA p.Arg93Trp is a missense alteration located within the adapter binding domain (ABD) of the p110-alpha protein (UniProt), which mediates the interaction between p110-alpha and p85-alpha. This variant has been reported to result in increased lipid kinase activity and Akt phosphorylation, as compared with wild-type p110-alpha, in vitro (PMID:18079394, 21266528, 22949682).<br />\n<br />\nIn this disease site, these variants currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of mTOR inhibitors (NCT03297606).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/25 01:39:20",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.277C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "nonsynonymous",
      "pNomen": "p.R93W"
    },
    {
      "id": 11172,
      "chromosome": "3",
      "start": 178916936,
      "stop": 178916936,
      "classification": "Very high",
      "variantInfo": "The PIK3CA p.Arg108His missense variant lies within the p85 domain of the PIK3CA protein (PMID: 15016963). The p.Arg108His variant is a gain of function alteration as indicated by increased kinase activity and transformation ability in vitro (PMID: 18829572, 29533785).<br />\nA search by the Clinical Insight (Qiagen) platform indicates in this disease site, the PIK3CA p.Arg108His variant currently serves as an inclusion eligibility criterion for Phase 4 clinical trials of MTOR inhibitors.<br />\n ",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/04/16 03:18:34",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.323G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "nonsynonymous",
      "pNomen": "p.R108H"
    },
    {
      "id": 11767,
      "chromosome": "3",
      "start": 178916946,
      "stop": 178916946,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).<br />\nThe PIK3CA p.Lys111Asn missense variant is a gain of function alteration as indicated by increased kinase activity and transformation ability in vitro (PMID: 17376864, 29533785).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PIK3CA p.Lys111Asn variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of mTOR inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:45:43",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.333G>C",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "nonsynonymous",
      "pNomen": "p.K111N"
    },
    {
      "id": 12178,
      "chromosome": "3",
      "start": 178917478,
      "stop": 178917478,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).<br />\nThe PIK3CA p.Gly118Asp missense variant is a gain-of-function variant that lies within the ABD-RBD linker. In vitro studies suggest this variant results in increased lipid kinase activity, Akt phosphorylation, and transformation (PMID: 22949682, 23246288, 29533785). PIK3CA mutations serve as an inclusion criteria for ongoing clinical trials of targeted therapy (e.g. NCT03297606).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:31",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.353G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 3,
      "effect": "nonsynonymous",
      "pNomen": "p.G118D"
    },
    {
      "id": 11037,
      "chromosome": "3",
      "start": 178921549,
      "stop": 178921549,
      "classification": "Very high",
      "variantInfo": "The PIK3CA p.Val344Gly missense variant is a gain-of-function variant that lies within the C2 domain. Limited functional studies suggest this variant may result in increased cellular growth in vitro (PMID: 29533785).<br />\nA search by the Clinical Insight (Qiagen) platform indicates in this disease site, the PIK3CA p.Val344Gly variant currently serves as an inclusion eligibility criterion for Phase 4 clinical trials of MTOR inhibitors.<br />\n ",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/12 20:33:40",
      "evidences": [],
      "reference": "T",
      "alternative": "G",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.1031T>G",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.V344G"
    },
    {
      "id": 11059,
      "chromosome": "3",
      "start": 178921552,
      "stop": 178921552,
      "classification": "Very high",
      "variantInfo": "<br />\nThe PIK3CA p.Asn345Ile missense variant occurs within the C2 PI3K-type domain (UniProt). Limited in vitro studies predicts this variant results in a gain-of-function alteration (PMID: 20593314, 29533785, 29636477, 26627007).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PIK3CA p.Asn345Ile variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR inhibitors.<br />\n ",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/18 02:21:46",
      "evidences": [],
      "reference": "A",
      "alternative": "T",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.1034A>T",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.N345I"
    },
    {
      "id": 11564,
      "chromosome": "3",
      "start": 178921553,
      "stop": 178921553,
      "classification": "Very high",
      "variantInfo": "<br />\nThe PIK3CA p.Asn345Lys missense variant occurs within the C2 PI3K-type domain (UniProt). Experimental studies predicts this variant results in a gain-of-function alteration increasing AKT phosphorylation and cell transformation in vitro (PMID: 17376864).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PIK3CA p.Asn345Lys variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR inhibitors.<br />\n ",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/24 02:12:53",
      "evidences": [],
      "reference": "T",
      "alternative": "A",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.1035T>A",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.N345K"
    },
    {
      "id": 11756,
      "chromosome": "3",
      "start": 178922328,
      "stop": 178922328,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).<br />\n <br />\nThe PIK3CA p.Pro366Arg missense variant lies within the C2 domain. Limited in vitro assays suggest this variant is activating (PMID: 29533785).<br />\n <br />\nA search by the Watson for Genomics platform indicates in this disease site, the PIK3CA p.Pro366Arg variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:30:28",
      "evidences": [],
      "reference": "C",
      "alternative": "G",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.1097C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 6,
      "effect": "nonsynonymous",
      "pNomen": "p.P366R"
    },
    {
      "id": 11850,
      "chromosome": "3",
      "start": 178922364,
      "stop": 178922364,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).<br />\nThe PIK3CA p.Cys378Tyr missense variant lies within the C2 PI3K-type domain of the PIK3CA protein (UniProt.org). Limited in vitro studies suggest the p.Cys378Tyr variant results in increased proliferation (PMID: 28528867, 29533785). This variant has been reported in the mosaic state in individuals with PIK3CA-related overgrowth syndrome (PMID: 28502725, 22729224, 28151489, 2763102, ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PIK3CA p.Cys378Tyr variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of mTOR inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/02 18:10:04",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.1133G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 6,
      "effect": "nonsynonymous",
      "pNomen": "p.C378Y"
    },
    {
      "id": 12195,
      "chromosome": "3",
      "start": 178927980,
      "stop": 178927980,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).<br />\nThe PIK3CA p.Cys420Arg missense variant is a hotspot gain-of-function variant. Functional studies suggest this variant results in increased AKT phosphorylation and transformation ability in vitro (PMID: 17376864, 29533785, 18074223). PIK3CA mutations serve as an inclusion criterion for ongoing clinical trials of targeted therapy (e.g. NCT03297606).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:31",
      "evidences": [],
      "reference": "T",
      "alternative": "C",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.1258T>C",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "nonsynonymous",
      "pNomen": "p.C420R"
    },
    {
      "id": 11868,
      "chromosome": "3",
      "start": 178928226,
      "stop": 178928226,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).<br />\nThe PIK3CA p.Pro471Leu missense variant lies within the C2 PI3K-type domain of the PIK3CA protein (UniProt.org). Limited in vitro assays suggest this variant is activating (PMID: 29533785).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PIK3CA p.Pro471Leu variant does not currently serve as an inclusion eligibility criterion for clinical trials.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:23",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.1412C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 9,
      "effect": "nonsynonymous",
      "pNomen": "p.P471L"
    },
    {
      "id": 12040,
      "chromosome": "3",
      "start": 178936082,
      "stop": 178936082,
      "classification": "Very high",
      "variantInfo": "<ul><li>Case studies of endometrial cancer suggest this variant is associated with stable disease when treated with PIK3CA/D inhibitors (PMID: 31934607).</li><li>In another early phase trial, a patient with cervical squamous cell carcinoma harboring PIK3CA E542K demonstrated a partial response when treated with a combination of LY2780301 and gemcitabine (PMID: 28750271).</li></ul>\n",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).<br />\nThe PIK3CA p.Glu542Lys missense variant is a hotspot gain-of-function variant. Functional studies suggest this variant results in increased PI3K activity and tumorigenic properties in vitro and in vivo (PMID: 30206110, 20593314, 16432179, 26627007, 17376864, 30093452). ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/30 00:48:11",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.1624G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 10,
      "effect": "nonsynonymous",
      "pNomen": "p.E542K"
    },
    {
      "id": 12222,
      "chromosome": "3",
      "start": 178936091,
      "stop": 178936091,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).<br />\n <br />\nThe PIK3CA p.Glu545Gln missense variant in the helical domain of the p110-alpha protein, at a mutational hotspot. Preclinical studies suggest this variant result in increased growth factor independent cell growth and phosphorylation of the downstream target Akt, as compared with wild-type protein (PMID: 15647370, 16432179, 22363598, 17376864).<br />\n <br />\nIn this disease site, PIK3CA p.Glu545Gln variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of mTOR inhibitors (NCT03297606).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/25 01:37:03",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.1633G>C",
      "type": "snp",
      "location": "exonic",
      "exon": 10,
      "effect": "nonsynonymous",
      "pNomen": "p.E545Q"
    },
    {
      "id": 12270,
      "chromosome": "3",
      "start": 178936091,
      "stop": 178936091,
      "classification": "Very high",
      "variantInfo": "Preclinical studies of cervical cancer suggest this variant predicts sensitivity to PI3K inhibitor (PMID: 22391131).<br />\nPreclinical studies of ovarian cancer suggest this variant predicts sensitivity to PI3K inhibitor (PMID: 21558396) and AKT inhibitor (PMID: 33723724)",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC). The PIK3CA p.Glu545Lys missense variant is a hotspot gain-of-function variant that lies within the PIK helical domain. Functional studies suggest this variant results in increased PI3K activity and tumorigenic properties in vitro and in vivo (PMID: 26627007, 29533785, 15647370, 16432179, 18317450).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/04/27 20:18:47",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.1633G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 10,
      "effect": "nonsynonymous",
      "pNomen": "p.E545K"
    },
    {
      "id": 12393,
      "chromosome": "3",
      "start": 178936093,
      "stop": 178936093,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC). The PIK3CA p.Glu545Asp missense variant in the helical domain of the p110-alpha protein, at a mutational hotspot. Preclinical studies suggest this variant result in increased transformation ability in vitro (PMID: 29533785). In this disease site, PIK3CA p.Glu545Asp variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of mTOR inhibitors (NCT03297606).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/06/25 19:03:57",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.1635G>C",
      "type": "snp",
      "location": "exonic",
      "exon": 10,
      "effect": "nonsynonymous",
      "pNomen": "p.E545D"
    },
    {
      "id": 11964,
      "chromosome": "3",
      "start": 178936095,
      "stop": 178936095,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).<br />\nThe PIK3CA p.Glu546Arg missense variant lies within the PIK helical domain (PMID: 24559118). Functional studies suggest this variant results in increased cell survival and transforming ability in vitro (PMID: 26627007, 29533785).<br />\nLate phase clinical studies suggest variant is predicted sensitive to combined PIK3CA inhibitor and hormone therapy in breast cancer (PMID: 31091374). However, the impact of this variant in this disease context remains unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/14 20:05:11",
      "evidences": [],
      "reference": "A",
      "alternative": "G",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.1637A>G",
      "type": "snp",
      "location": "exonic",
      "exon": 10,
      "effect": "nonsynonymous",
      "pNomen": "p.Q546R"
    },
    {
      "id": 12281,
      "chromosome": "3",
      "start": 178947827,
      "stop": 178947827,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).<br />\nThe PIK3CA p.Cys901Phe missense variant lies within the PI3K/PI4K domain of the PIK3CA protein (UniProt.org). Limited in vitro assays suggest this variant is activating (PMID: 29533785). PIK3CA mutations serve as an inclusion criteria for ongoing clinical trials of targeted therapy (e.g. NCT03297606). Preclinical studies suggest that activating PIK3CA variants may be associated with sensitivity to targeted inhibitors (PMID: 29401002, 24608574, 21558396, 23674493).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/05/17 20:25:24",
      "evidences": [],
      "reference": "G",
      "alternative": "T",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.2702G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 19,
      "effect": "nonsynonymous",
      "pNomen": "p.C901F"
    },
    {
      "id": 12247,
      "chromosome": "3",
      "start": 178947865,
      "stop": 178947865,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).<br />\nThe PIK3CA p.Gly914Arg missense variant lies within the PI3K/PI4K domain of the PIK3CA protein (UniProt.org). This variant has been reported in association with Megalencephaly Capillary Malformation Syndrome (MCAP) (PMID: 24939587, 28502725, 22729224), and likely affects PIK3CA protein function. A cell line derived from an MCAP patient carrying this mutation displays elevated PIP3 levels compared to controls, further suggesting that this mutation results in activation of PIK3CA (PMID: 22729224).<br />\nPIK3CA mutations serve as an inclusion criteria for ongoing clinical trials of targeted therapy (e.g. NCT03297606). Preclinical studies suggest that activating PIK3CA variants may be associated with sensitivity to targeted inhibitors (PMID: 29401002, 24608574, 21558396, 23674493).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/04/23 14:51:19",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.2740G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 19,
      "effect": "nonsynonymous",
      "pNomen": "p.G914R"
    },
    {
      "id": 11385,
      "chromosome": "3",
      "start": 178952074,
      "stop": 178952074,
      "classification": "Very high",
      "variantInfo": "<br />\nThe PIK3CA p.Met1043Ile missense variant is a gain of function alteration as indicated by increased kinase activity and transformation ability in vitro (PMID: 17376864, 29533785).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PIK3CA p.Met1043Ile variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR inhibitors.<br />\n ",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/07/09 04:12:13",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.3129G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 21,
      "effect": "nonsynonymous",
      "pNomen": "p.M1043I"
    },
    {
      "id": 11698,
      "chromosome": "3",
      "start": 178952077,
      "stop": 178952077,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).<br />\n<br />\nThe PIK3CA p.Asn1044Lys missense variant is a gain-of-function variant that lies within the kinase domain. Functional studies suggest this variant results in a moderate increase in tumorigenic properties in vitro (PMID: 26627007).<br />\n<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PIK3CA p.Asn1044Lys variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR inhibitors.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/28 17:22:46",
      "evidences": [],
      "reference": "T",
      "alternative": "A",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.3132T>A",
      "type": "snp",
      "location": "exonic",
      "exon": 21,
      "effect": "nonsynonymous",
      "pNomen": "p.N1044K"
    },
    {
      "id": 12030,
      "chromosome": "3",
      "start": 178952085,
      "stop": 178952085,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).<br />\nThe PIK3CA p.His1047Arg missense variant is a hotspot gain-of-function variant. Functional studies suggest this variant results in increased PI3K activity and tumorigenic properties in vitro and in vivo (PMID: 15647370, 16432179). Preclinical studies are inconclusive as to whether this variant is predicted sensitive to PI3K/mTOR/AKT inhibitors (PMID: 27016228, 31714586, 31934607, 21216929, 29401002, 21558396, 23674493).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/27 20:38:45",
      "evidences": [],
      "reference": "A",
      "alternative": "G",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.3140A>G",
      "type": "snp",
      "location": "exonic",
      "exon": 21,
      "effect": "nonsynonymous",
      "pNomen": "p.H1047R"
    },
    {
      "id": 11878,
      "chromosome": "3",
      "start": 178952090,
      "stop": 178952090,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3CA is an oncogene involved in cell growth, apoptosis, transformation, motility, and adhesion through activation of the PI3K/AKT/MTOR pathway (PMID: 12040186, 9759495, 15647370). PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers (COSMIC).<br />\nThe PIK3CA p.Gly1049Arg missense variant is a hotspot gain-of-function variant. Functional studies suggest this variant results in increased PI3K activity and tumorigenic properties in vitro and in vivo (PMID: 26627007, 29533785).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PIK3CA p.Gly1049Arg variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:08",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "PIK3CA",
      "transcript": "NM_006218.2",
      "cNomen": "c.3145G>C",
      "type": "snp",
      "location": "exonic",
      "exon": 21,
      "effect": "nonsynonymous",
      "pNomen": "p.G1049R"
    },
    {
      "id": 12184,
      "chromosome": "4",
      "start": 1806119,
      "stop": 1806119,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "FGFR3, fibroblast growth factor receptor 3, is a receptor tyrosine kinase and upon binding of the FGF ligand, activates signaling pathways that include the PI3K/AKT and MAPK pathways (PMID: 20094046, 22388515). FGFR3 is frequently activated by gene alterations in urothelial carcinoma (PMID: 17668422, 23175443).<br />\nThe FGFR3 p.Gly380Arg variant occurs in the transmembrane domain of the receptor and results in ligand-independent phosphorylation and activation (PMID: 20624921, 9136983, 10611230). FGFR3 mutations serve as an inclusion criterion for ongoing clinical trials of targeted therapy (e.g. NCT03297606).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:43",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "FGFR3",
      "transcript": "NM_000142.4",
      "cNomen": "c.1138G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 9,
      "effect": "nonsynonymous",
      "pNomen": "p.G380R"
    },
    {
      "id": 12128,
      "chromosome": "4",
      "start": 84406225,
      "stop": 84406225,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ABRAXAS1 (FAM175A) is a BRCA1-binding protein that plays a role in DNA repair and regulation of the G2/M cell cycle phase checkpoint (PMID: 17525340, 29497033). The ABRAXAS1 c.1A&gt;C (p.Met1?) is a missense variant affecting the translation initiation codon however the consequence of this change is currently unknown. While this particular variant has not been reported in the literature, loss-of-function variants in ABRAXAS1 are known to be likely oncogenic (PMID: 25066119).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/02/22 20:18:31",
      "evidences": [],
      "reference": "T",
      "alternative": "G",
      "gene": "FAM175A",
      "transcript": "NM_139076.2",
      "cNomen": "c.1A>C",
      "type": "snp",
      "location": "exonic",
      "exon": 1,
      "effect": "startloss",
      "pNomen": "p.M1?"
    },
    {
      "id": 12139,
      "chromosome": "4",
      "start": 106157548,
      "stop": 106157548,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TET2 is a member of the ten-eleven-translocation family of genes that plays a role in DNA methylation and is involved in hematopoesis (PMID: 25510268, 27848178). The TET2 p.Tyr819Leufs*2 frameshift variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in TET2 are known to be likely oncogenic (PMID: 24315485, 21057493). Preclinical studies in other disease sites suggest this variant is predicted to be responsive to DNMT inhibitor (PMID: 21494260, 25224413).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/02/22 21:56:29",
      "evidences": [],
      "reference": ".",
      "alternative": "C",
      "gene": "TET2",
      "transcript": "NM_001127208.2",
      "cNomen": "c.2453dupC",
      "type": "insertion",
      "location": "exonic",
      "exon": 3,
      "effect": "frameshift",
      "pNomen": "p.Y819Lfs*2"
    },
    {
      "id": 11391,
      "chromosome": "4",
      "start": 153247288,
      "stop": 153247288,
      "classification": "Very high",
      "variantInfo": "The FBXW7 p.Arg505Leu missense variant occurs at a conserved arginine residue in the WD40 domain of the Fbxw7 protein, a region responsible for substrate recognition (PMID: 17909001). This variant has been previously reported in endometrial cancer (COSMIC). Experimental studies suggest this variant is a loss-of-function alteration that results in a dominant-negative effect and lack the ability to bind substrates (PMID: 28522751).<br />\nA search by the Watson for Genomics platform indicates in this disease site, FBXW7 p.Arg505Leu variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR inhibitors.<br />\n ",
      "reportAbstract": "FBXW7 is part of the SCF E3 ubiquitin-protein ligase complex, which plays a role in the degradation of proteins including proto-oncogene substrates (PMID: 17909001, 18094723, 22673505). Inactivation of FBXW7 is frequently observed in endometrial and colorectal cancers (PMID: 27399335, 28424412, 17909001).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/07/09 12:29:33",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "FBXW7",
      "transcript": "NM_033632.3",
      "cNomen": "c.1514G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 10,
      "effect": "nonsynonymous",
      "pNomen": "p.R505L"
    },
    {
      "id": 12118,
      "chromosome": "4",
      "start": 153247289,
      "stop": 153247289,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "FBXW7 is part of the SCF E3 ubiquitin-protein ligase complex, which plays a role in the degradation of proteins including proto-oncogene substrates (PMID: 17909001, 18094723, 22673505). Inactivation of FBXW7 is frequently observed in endometrial and colorectal cancers (PMID: 27399335, 28424412, 17909001).<br />\nThe FBXW7 p.Arg505Cys missense variant occurs at a conserved arginine residue in the WD40 domain of the Fbxw7 protein, a region responsible for substrate recognition (PMID: 17909001). This variant has been previously reported in cervical cancer (COSMIC). Experimental studies suggest this variant is a loss-of-function alteration that results in impaired substrate degradation (PMID: 17646408, 17646409, 30510140, 28963353). Preclinical evidence in other disease sites suggest this variant may be resistant to PD-1 antibody (PMID: 32371478) and may be sensitive to HDAC inhibitors (PMID: 23274910).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/02/18 20:14:21",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "FBXW7",
      "transcript": "NM_033632.3",
      "cNomen": "c.1513C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 10,
      "effect": "nonsynonymous",
      "pNomen": "p.R505C"
    },
    {
      "id": 12321,
      "chromosome": "4",
      "start": 153247289,
      "stop": 153247289,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "FBXW7 is part of the SCF E3 ubiquitin-protein ligase complex, which plays a role in the degradation of proteins including proto-oncogene substrates (PMID: 17909001, 18094723, 22673505). Inactivation of FBXW7 is frequently observed in endometrial and colorectal cancers (PMID: 27399335, 28424412, 17909001). <br />\nThe FBXW7 p.Arg505Gly missense variant occurs at a conserved arginine residue in the WD40 domain of the Fbxw7 protein, a region responsible for substrate recognition (PMID: 17909001). This variant has been previously reported in endometrial cancer (COSMIC). In vitro assays suggest this variant is a loss-of-function alteration as shown by increased cell proliferation and colony formation (PMID: 31161818). <br />\nPreclinical studies in other cancer types suggest that variants at Arg505 in FBXW7 may be resistant to immunotherapy, multiple receptor tyrosine kinase (RTK) inhibitors, and -secretase inhibitors (PMID: 27399335, 17646409, 32371478). However, the impact of this variant on patient care in this disease site is currently unclear. ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/05/17 20:25:24",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "FBXW7",
      "transcript": "NM_033632.3",
      "cNomen": "c.1513C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 10,
      "effect": "nonsynonymous",
      "pNomen": "p.R505G"
    },
    {
      "id": 12261,
      "chromosome": "4",
      "start": 153247366,
      "stop": 153247366,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "FBXW7 is part of the SCF E3 ubiquitin-protein ligase complex, which plays a role in the degradation of proteins including proto-oncogene substrates (PMID: 17909001, 18094723, 22673505). Inactivation of FBXW7 is frequently observed in endometrial and colorectal cancers (PMID: 27399335, 28424412, 17909001).<br />\nThe FBXW7 p.Arg479Gln missense variant lies within WD repeat 3 protein domain (UniProt). Experimental studies suggest this variant impairs substrate degradation and resulting in sustained Notch signaling (PMID: 17646409, 25450649, 30510140). Preclinical studies in other disease sites suggest inactivating mutations in FBXW7 may be predicted sensitive to mTOR and HDAC inhibitors (PMID: 18787170, 23274910).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/04/23 14:51:07",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "FBXW7",
      "transcript": "NM_033632.3",
      "cNomen": "c.1436G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 10,
      "effect": "nonsynonymous",
      "pNomen": "p.R479Q"
    },
    {
      "id": 11561,
      "chromosome": "4",
      "start": 153249384,
      "stop": 153249384,
      "classification": "Very high",
      "variantInfo": "<br />\nThe FBXW7 p.Arg465His missense variant occurs within the WD repeat domain of the Fbxw7 protein, a region responsible for substrate recognition (PMID: 17909001). This variant has been previously reported in T-ALL and CRC (COSMIC, PMID:17646408, 19420964). Experimental studies suggest this variant is a loss-of-function alteration that results in a dominant-negative effect of the wild-type protein (PMID: 17909001, 17646409).<br />\nA search by the Watson for Genomics platform indicates in this disease site, FBXW7 p.Arg465His variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR inhibitors.<br />\n ",
      "reportAbstract": "FBXW7 is part of the SCF E3 ubiquitin-protein ligase complex, which plays a role in the degradation of proteins including proto-oncogene substrates (PMID: 17909001, 18094723, 22673505). Inactivation of FBXW7 is frequently observed in endometrial and colorectal cancers (PMID: 27399335, 28424412, 17909001).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/24 01:53:33",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "FBXW7",
      "transcript": "NM_033632.3",
      "cNomen": "c.1394G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 9,
      "effect": "nonsynonymous",
      "pNomen": "p.R465H"
    },
    {
      "id": 11579,
      "chromosome": "4",
      "start": 153249385,
      "stop": 153249385,
      "classification": "Very high",
      "variantInfo": "<br />\nThe FBXW7 p.Arg465Cys missense variant occurs within the WD repeat domain of the Fbxw7 protein, a region responsible for substrate recognition (PMID: 17909001). This variant has been previously reported in T-ALL and CRC (COSMIC, PMID:17646408, 19420964). Experimental studies suggest this variant is a loss-of-function alteration that results in a dominant-negative effect of the wild-type protein (PMID: 17909001, 17646409).<br />\nA search by the Watson for Genomics platform indicates in this disease site, FBXW7 p.Arg465Cys variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR inhibitors.<br />\n ",
      "reportAbstract": "FBXW7 is part of the SCF E3 ubiquitin-protein ligase complex, which plays a role in the degradation of proteins including proto-oncogene substrates (PMID: 17909001, 18094723, 22673505). Inactivation of FBXW7 is frequently observed in endometrial and colorectal cancers (PMID: 27399335, 28424412, 17909001).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/27 22:06:07",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "FBXW7",
      "transcript": "NM_033632.3",
      "cNomen": "c.1393C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 9,
      "effect": "nonsynonymous",
      "pNomen": "p.R465C"
    },
    {
      "id": 12165,
      "chromosome": "4",
      "start": 153253749,
      "stop": 153253750,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "FBXW7 is part of the SCF E3 ubiquitin-protein ligase complex, which plays a role in the degradation of proteins including proto-oncogene substrates (PMID: 17909001, 18094723, 22673505). Inactivation of FBXW7 is frequently observed in endometrial and colorectal cancers (PMID: 27399335, 28424412, 17909001).<br />\nThe FBXW7 p.Glu328Glyfs*3 frameshift variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in FBXW7 are likely oncogenic (PMID: 17646409, 18094723, 31772025, 24390348, 33234509).<br />\nPreclinical studies in other disease sites suggest inactivating mutations in FBXW7 may be predicted sensitive to mTOR and HDAC inhibitors (PMID: 18787170, 23274910).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:27",
      "evidences": [],
      "reference": "CT",
      "alternative": ".",
      "gene": "FBXW7",
      "transcript": "NM_033632.3",
      "cNomen": "c.983_984delAG",
      "type": "deletion",
      "location": "exonic",
      "exon": 6,
      "effect": "frameshift",
      "pNomen": "p.E328Gfs*3"
    },
    {
      "id": 11637,
      "chromosome": "5",
      "start": 56183234,
      "stop": 56183234,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "MAP3K1 is an E3 ubiquitin protein ligase and serine/threonine kinase that regulates JNK and ERK signaling and plays a role in cell migration, cell survival, apoptosis (PMID: 24386504). MAP3K1 mutations have been identified in breast and endometrial cancer (PMID: 31620934, 31552290, 29765551, 23636398).<br />\nThe MAP3K1 p.Gln1382* nonsense variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in MAP3K1 are known to be oncogenic (PMID: 24135036, 11971970, 10373563, 24003131, 24386504, 25899310, 25613373).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the MAP3K1 p.Gln1382* variant currently does not serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/14 15:57:40",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "MAP3K1",
      "transcript": "NM_005921.1",
      "cNomen": "c.4144C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 18,
      "effect": "stopgain",
      "pNomen": "p.Q1382*"
    },
    {
      "id": 12150,
      "chromosome": "5",
      "start": 67589138,
      "stop": 67589138,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3R1 is an adaptor protein involved in cell growth, proliferation, and survival through regulation of the PI3K/AKT/MTOR pathway (PMID:19629070, 26807692). PIK3R1 loss-of-function variants frequently occur in the iSH2 domain (PMID: 21984976, 19962665) and have been reported in glioblastoma, endometrial, breast and colorectal cancers (PMID: 23636398, 24120142, 17932254, 22810696).<br />\nThe PIK3R1 p.Gly376Arg missense variant occurs in the nSH2 domain of the PIK3R1 protein, which is involved in interactions with the helical domain of the p110-alpha and inhibition of its catalytic activity (PMID: 28915558, 9804776). Mutations within this domain have been shown to be oncogenic (PMID: 20713702, 25314071, 29533785, 25284480). Experimental studies suggest this variant results in disruption of PIK3R1 protein function (PMID: 20713702, 28528867, 29533785, 28143957).<br />\nA clinical study suggests that mutation status of PIK3R1 is not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with temsirolimus (PMID: 27016228). However, the impact of this variant on patient care is currently unknown.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:27",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "PIK3R1",
      "transcript": "NM_181523.2",
      "cNomen": "c.1126G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 10,
      "effect": "nonsynonymous",
      "pNomen": "p.G376R"
    },
    {
      "id": 11790,
      "chromosome": "5",
      "start": 67589149,
      "stop": 67589151,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3R1 is an adaptor protein involved in cell growth, proliferation, and survival through regulation of the PI3K/AKT/MTOR pathway (PMID:19629070, 26807692). PIK3R1 loss-of-function variants frequently occur in the iSH2 domain (PMID: 21984976, 19962665) and have been reported in glioblastoma, endometrial, breast and colorectal cancers (PMID: 23636398, 24120142, 17932254, 22810696).<br />\nThe PIK3R1 p.Leu380del results in an in-frame deletion of one amino acid within the nSH2 domain of the p85alpha protein, which is involved in interactions with the helical domain of the p110-alpha and inhibition of its catalytic activity (PMID: 28915558, 9804776). Mutations within this domain have been shown to be oncogenic (PMID: 20713702, 25314071, 29533785, 25284480). Limited in vitro studies show that the p.Leu380del variant results in increased cell viability and transformation (PMID: 28528867, 29533785).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PIK3R1 p.Leu380del variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PI3K and MTOR inhibitors.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:23",
      "evidences": [],
      "reference": "ATT",
      "alternative": ".",
      "gene": "PIK3R1",
      "transcript": "NM_181523.2",
      "cNomen": "c.1138_1140delTTA",
      "type": "deletion",
      "location": "exonic",
      "exon": 10,
      "effect": "inframe",
      "pNomen": "p.L380del"
    },
    {
      "id": 11888,
      "chromosome": "5",
      "start": 67589555,
      "stop": 67589557,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3R1 is an adaptor protein involved in cell growth, proliferation, and survival through regulation of the PI3K/AKT/MTOR pathway (PMID:19629070, 26807692). PIK3R1 loss-of-function variants frequently occur in the iSH2 domain (PMID: 21984976, 19962665) and have been reported in glioblastoma, endometrial, breast and colorectal cancers (PMID: 23636398, 24120142, 17932254, 22810696).<br />\nThe PIK3R1 p.Asp440del results in an in-frame deletion of one amino acid within the iSH2 domain of the p85 alpha protein, which is involved in the interaction with the adapter-binding region of the p110-alpha and inhibition of its catalytic activity. The inter-SH2 domain has been found to be a mutational hotspot in endometrial cancer and deletions within this region, including H450_E451del and R574_T576del, have been shown to lead to increased Akt activation and to be oncogenic. Therefore, although this alteration has not been functionally characterized, it is predicted to result in inactivation of p85-alpha and activation of the PI3K/Akt/mTOR pathway. (PMID: 20713702, 19915146, 21984976, 21478295).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PIK3R1 p.Asp440del variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PI3K and MTOR inhibitors.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/16 02:54:49",
      "evidences": [],
      "reference": "GAT",
      "alternative": ".",
      "gene": "PIK3R1",
      "transcript": "NM_181523.2",
      "cNomen": "c.1318_1320delGAT",
      "type": "deletion",
      "location": "exonic",
      "exon": 11,
      "effect": "inframe",
      "pNomen": "p.D440del"
    },
    {
      "id": 12156,
      "chromosome": "5",
      "start": 67589588,
      "stop": 67589590,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3R1 is an adaptor protein involved in cell growth, proliferation, and survival through regulation of the PI3K/AKT/MTOR pathway (PMID:19629070, 26807692). PIK3R1 loss-of-function variants frequently occur in the iSH2 domain (PMID: 21984976, 19962665) and have been reported in glioblastoma, endometrial, breast and colorectal cancers (PMID: 23636398, 24120142, 17932254, 22810696).<br />\nThe PIK3R1 p.Glu451_Tyr452delinsHis variant is an in-frame deletion-insertion within the iSH2 domain of the p85 alpha protein, which is involved in the interaction with the adapter-binding region of the p110-alpha and inhibition of its catalytic activity. The inter-SH2 domain has been found to be a mutational hotspot in endometrial cancer and deletions within this region, including H450_E451del and R574_T576del, have been shown to lead to increased Akt activation and to be oncogenic. Therefore, although this alteration has not been functionally characterized, it is predicted to result in inactivation of p85-alpha and activation of the PI3K/Akt/mTOR pathway. (PMID: 20713702, 19915146, 21984976, 21478295).<br />\nA clinical study suggests that mutation status of PIK3R1 is not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with temsirolimus (PMID: 27016228). However, the impact of this variant on patient care is currently unknown.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:27",
      "evidences": [],
      "reference": "GAA",
      "alternative": ".",
      "gene": "PIK3R1",
      "transcript": "NM_181523.2",
      "cNomen": "c.1351_1353delGAA",
      "type": "deletion",
      "location": "exonic",
      "exon": 11,
      "effect": "inframe",
      "pNomen": "p.E451del"
    },
    {
      "id": 12267,
      "chromosome": "5",
      "start": 67591075,
      "stop": 67591075,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3R1 is an adaptor protein involved in cell growth, proliferation, and survival through regulation of the PI3K/AKT/MTOR pathway (PMID:19629070, 26807692). PIK3R1 loss-of-function variants frequently occur in the iSH2 domain (PMID: 21984976, 19962665) and have been reported in glioblastoma, endometrial, breast and colorectal cancers (PMID: 23636398, 24120142, 17932254, 22810696). The PIK3R1 p.Glu558_Arg562dup is an in-frame duplication variant that affects the iSH2 domain of the p85 alpha protein, which is involved in the interaction with the adapter-binding region of the p110-alpha and inhibition of its catalytic activity. The inter-SH2 domain has been found to be a mutational hotspot in endometrial cancer and have been shown to lead to increased Akt activation and to be oncogenic. Therefore, although this alteration has not been functionally characterized, it is predicted to result in inactivation of p85-alpha and activation of the PI3K/Akt/mTOR pathway (PMID: 20713702, 19915146, 21984976, 21478295). This variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials MTOR inhibitor (CAPTUR; NCT03297606). <br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/04/27 19:57:57",
      "evidences": [],
      "reference": ".",
      "alternative": "CGAGAAATTGACAAA",
      "gene": "PIK3R1",
      "transcript": "NM_181523.2",
      "cNomen": "c.1671_1685dupAGAAATTGACAAACG",
      "type": "insertion",
      "location": "exonic",
      "exon": 13,
      "effect": "inframe",
      "pNomen": "p.E558_R562dup"
    },
    {
      "id": 11770,
      "chromosome": "5",
      "start": 67591085,
      "stop": 67591085,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3R1 is an adaptor protein involved in cell growth, proliferation, and survival through regulation of the PI3K/AKT/MTOR pathway (PMID:19629070, 26807692). PIK3R1 loss-of-function variants frequently occur in the iSH2 domain (PMID: 21984976, 19962665) and have been reported in glioblastoma, endometrial, breast and colorectal cancers (PMID: 23636398, 24120142, 17932254, 22810696). The PIK3R1 p.Asp560His missense variant occurs in the iSH2 domain of the PIK3R1 protein (PMID: 20713702). Although this variant has not been functionally characterized in the literature, other variants that affect the same codon have been reported and suggest this variant results in a loss-of-function (PMID: 20713702, 19962665, 29636477).<br />\nClinical study suggests that mutation status of PIK3R1 is not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with temsirolimus (PMID: 27016228).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 19:38:52",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "PIK3R1",
      "transcript": "NM_181523.2",
      "cNomen": "c.1678G>C",
      "type": "snp",
      "location": "exonic",
      "exon": 13,
      "effect": "nonsynonymous",
      "pNomen": "p.D560H"
    },
    {
      "id": 12268,
      "chromosome": "5",
      "start": 67591113,
      "stop": 67591118,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3R1 is an adaptor protein involved in cell growth, proliferation, and survival through regulation of the PI3K/AKT/MTOR pathway (PMID:19629070, 26807692). PIK3R1 loss-of-function variants frequently occur in the iSH2 domain (PMID: 21984976, 19962665) and have been reported in glioblastoma, endometrial, breast and colorectal cancers (PMID: 23636398, 24120142, 17932254, 22810696). The PIK3R1 p.Asp569_Ile571delinsVal is an in-frame deletion-insertion variant that affects the iSH2 domain of the p85 alpha protein, which is involved in the interaction with the adapter-binding region of the p110-alpha and inhibition of its catalytic activity. The inter-SH2 domain has been found to be a mutational hotspot in endometrial cancer and have been shown to lead to increased Akt activation and to be oncogenic. Therefore, although this alteration has not been functionally characterized, it is predicted to result in inactivation of p85-alpha and activation of the PI3K/Akt/mTOR pathway (PMID: 20713702, 19915146, 21984976, 21478295). This variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials MTOR inhibitor (CAPTUR; NCT03297606). <br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/04/27 20:00:02",
      "evidences": [],
      "reference": "ACCTTA",
      "alternative": ".",
      "gene": "PIK3R1",
      "transcript": "NM_181523.2",
      "cNomen": "c.1706_1711delACCTTA",
      "type": "deletion",
      "location": "exonic",
      "exon": 13,
      "effect": "inframe",
      "pNomen": "p.D569_I571delinsV"
    },
    {
      "id": 12144,
      "chromosome": "5",
      "start": 67591135,
      "stop": 67591149,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3R1 is an adaptor protein involved in cell growth, proliferation, and survival through regulation of the PI3K/AKT/MTOR pathway (PMID:19629070, 26807692). PIK3R1 loss-of-function variants frequently occur in the iSH2 domain (PMID: 21984976, 19962665) and have been reported in glioblastoma, endometrial, breast and colorectal cancers (PMID: 23636398, 24120142, 17932254, 22810696).<br />\nThe PIK3R1 p.Arg577_Leu581del results in an in-frame deletion of five amino acids within the iSH2 domain of the p85 alpha protein, which is involved in the interaction with the adapter-binding region of the p110-alpha and inhibition of its catalytic activity. The inter-SH2 domain has been found to be a mutational hotspot in endometrial cancer and deletions within this region, including H450_E451del and R574_T576del, have been shown to lead to increased Akt activation and to be oncogenic. Therefore, although this alteration has not been functionally characterized, it is predicted to result in inactivation of p85-alpha and activation of the PI3K/Akt/mTOR pathway. (PMID: 20713702, 19915146, 21984976, 21478295).<br />\nClinical and preclinical studies suggest mutations in PIK3R1 are predicted sensitive to PI3K/mTOR and AKT inhibitors in endometrial cancer (PMID: 29636360, 26469692, 28119489). PIK3R1 mutations serve as an inclusion criterion for ongoing clinical trials of targeted therapy (e.g. NCT03297606).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:27",
      "evidences": [],
      "reference": "GAGAGACCAATACTT",
      "alternative": ".",
      "gene": "PIK3R1",
      "transcript": "NM_181523.2",
      "cNomen": "c.1730_1744delGAGACCAATACTTGA",
      "type": "deletion",
      "location": "exonic",
      "exon": 13,
      "effect": "inframe",
      "pNomen": "p.R577_L581del"
    },
    {
      "id": 12391,
      "chromosome": "5",
      "start": 67591140,
      "stop": 67591140,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3R1 is an adaptor protein involved in cell growth, proliferation, and survival through regulation of the PI3K/AKT/MTOR pathway (PMID:19629070, 26807692). PIK3R1 loss-of-function variants frequently occur in the iSH2 domain (PMID: 21984976, 19962665) and have been reported in glioblastoma, endometrial, breast and colorectal cancers (PMID: 23636398, 24120142, 17932254, 22810696). The PIK3R1 p.Gln579Profs*23 frameshift variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants within the inter-SH2 (iSH2) domain of the p85 alpha protein, which is involved in the interaction with the adapter-binding region of the p110-alpha and inhibition of its catalytic activity, have been reported (PMID: 24367658, 26807692). The iSH2 domain has been found to be a mutational hotspot in endometrial cancer and deletions, nonsense, and frameshift variants within this region have been shown to lead to increased Akt activation and to be oncogenic. Therefore, although this alteration has not been functionally characterized, it is predicted to result in inactivation of p85-alpha and activation of the PI3K/Akt/mTOR pathway (PMID: 20713702, 19915146, 21984976, 21478295). This variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials MTOR inhibitor (CAPTUR; NCT03297606).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/06/25 18:43:36",
      "evidences": [],
      "reference": ".",
      "alternative": "C",
      "gene": "PIK3R1",
      "transcript": "NM_181523.2",
      "cNomen": "c.1735dupC",
      "type": "insertion",
      "location": "exonic",
      "exon": 13,
      "effect": "frameshift",
      "pNomen": "p.Q579Pfs*23"
    },
    {
      "id": 11125,
      "chromosome": "5",
      "start": 67591153,
      "stop": 67591153,
      "classification": "Very high",
      "variantInfo": "<br />\nThe PIK3R1 c.1745&#43;2dup variant is located within 2bp of the intron-exon boundary and is predicted to result in aberrant splicing and disrupted protein product. This variant is predicted to be oncogenic (PMID: 19915146, 19962665, 20713702, 26807692).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PIK3R1 c.1745&#43;2dup variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PI3K and MTOR inhibitors.<br />\n ",
      "reportAbstract": "PIK3R1 is an adaptor protein involved in cell growth, proliferation, and survival through regulation of the PI3K/AKT/MTOR pathway (PMID:19629070, 26807692). PIK3R1 loss-of-function variants frequently occur in the iSH2 domain (PMID: 21984976, 19962665) and have been reported in glioblastoma, endometrial, breast and colorectal cancers (PMID: 23636398, 24120142, 17932254, 22810696).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/24 20:02:05",
      "evidences": [],
      "reference": ".",
      "alternative": "T",
      "gene": "PIK3R1",
      "transcript": "NM_181523.2",
      "cNomen": "c.1745+2dupT",
      "type": "insertion",
      "location": "intronic",
      "exon": 13,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11690,
      "chromosome": "5",
      "start": 67591247,
      "stop": 67591249,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3R1 is an adaptor protein involved in cell growth, proliferation, and survival through regulation of the PI3K/AKT/MTOR pathway (PMID:19629070, 26807692). PIK3R1 loss-of-function variants frequently occur in the iSH2 domain (PMID: 21984976, 19962665) and have been reported in glioblastoma, endometrial, breast and colorectal cancers (PMID: 23636398, 24120142, 17932254, 22810696).<br />\nThe PIK3R1 p.Trp583del results in an in-frame deletion of one amino acid within the inter-SH2 (iSH2) domain of the p85 alpha protein, which is involved in the interaction with the adapter-binding region of the p110-alpha and inhibition of its catalytic activity (PMID: 24367658). The iSH2 domain has been found to be a mutational hotspot in endometrial cancer and deletions within this region have been shown to lead to increased Akt activation and to be oncogenic. Therefore, although this alteration has not been functionally characterized, it is predicted to result in inactivation of p85-alpha and activation of the PI3K/Akt/mTOR pathway (PMID: 20713702, 19915146, 21984976, 21478295).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PIK3R1 p.Trp583del variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PI3K and MTOR inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/28 16:51:22",
      "evidences": [],
      "reference": "GGT",
      "alternative": ".",
      "gene": "PIK3R1",
      "transcript": "NM_181523.2",
      "cNomen": "c.1746-1_1747delGGT",
      "type": "deletion",
      "location": "exonic",
      "exon": 14,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11720,
      "chromosome": "5",
      "start": 67591258,
      "stop": 67591258,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3R1 is an adaptor protein involved in cell growth, proliferation, and survival through regulation of the PI3K/AKT/MTOR pathway (PMID:19629070, 26807692). PIK3R1 loss-of-function variants frequently occur in the iSH2 domain (PMID: 21984976, 19962665) and have been reported in glioblastoma, endometrial, breast and colorectal cancers (PMID: 23636398, 24120142, 17932254, 22810696).<br />\nThe PIK3R1 p.Gln586* nonsense variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants within the inter-SH2 (iSH2) domain of the p85 alpha protein, which is involved in the interaction with the adapter-binding region of the p110-alpha and inhibition of its catalytic activity, have been reported (PMID: 24367658, 26807692). The iSH2 domain has been found to be a mutational hotspot in endometrial cancer and deletions, nonsense, and frameshift variants within this region have been shown to lead to increased Akt activation and to be oncogenic. Therefore, although this alteration has not been functionally characterized, it is predicted to result in inactivation of p85-alpha and activation of the PI3K/Akt/mTOR pathway (PMID: 20713702, 19915146, 21984976, 21478295).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PIK3R1 p.Gln586* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PI3K and mTOR inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/06 15:52:47",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "PIK3R1",
      "transcript": "NM_181523.2",
      "cNomen": "c.1756C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 14,
      "effect": "stopgain",
      "pNomen": "p.Q586*"
    },
    {
      "id": 11394,
      "chromosome": "5",
      "start": 67591259,
      "stop": 67591261,
      "classification": "Very high",
      "variantInfo": "<br />\nThe PIK3R1 p.Lys587del results in an in-frame deletion of one amino acid within the iSH2 domain of the p85 alpha protein, which is involved in the interaction with the adapter-binding region of the p110-alpha and inhibition of its catalytic activity. The inter-SH2 domain has been found to be a mutational hotspot in endometrial cancer and deletions within this region, including H450_E451del and R574_T576del, have been shown to lead to increased Akt activation and to be oncogenic. Therefore, although this alteration has not been functionally characterized, it is predicted to result in inactivation of p85-alpha and activation of the PI3K/Akt/mTOR pathway. (PMID: 20713702, 19915146, 21984976, 21478295).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PIK3R1 p.Lys587del variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PI3K and MTOR inhibitors.<br />\n ",
      "reportAbstract": "PIK3R1 is an adaptor protein involved in cell growth, proliferation, and survival through regulation of the PI3K/AKT/MTOR pathway (PMID:19629070, 26807692). PIK3R1 loss-of-function variants frequently occur in the iSH2 domain (PMID: 21984976, 19962665) and have been reported in glioblastoma, endometrial, breast and colorectal cancers (PMID: 23636398, 24120142, 17932254, 22810696).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/07/16 14:25:39",
      "evidences": [],
      "reference": "AAA",
      "alternative": ".",
      "gene": "PIK3R1",
      "transcript": "NM_181523.2",
      "cNomen": "c.1759_1761delAAA",
      "type": "deletion",
      "location": "exonic",
      "exon": 14,
      "effect": "inframe",
      "pNomen": "p.K587del"
    },
    {
      "id": 12137,
      "chromosome": "5",
      "start": 67592075,
      "stop": 67592075,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PIK3R1 is an adaptor protein involved in cell growth, proliferation, and survival through regulation of the PI3K/AKT/MTOR pathway (PMID: 19629070, 26807692). PIK3R1 loss-of-function variants frequently occur in the iSH2 domain (PMID: 21984976, 19962665) and have been reported in glioblastoma, endometrial, breast and colorectal cancers (PMID: 23636398, 24120142, 17932254, 22810696). The PIK3R1 p.Arg631* nonsense variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants within the inter-SH2 (iSH2) domain of the p85 alpha protein, which is involved in the interaction with the adapter-binding region of the p110-alpha and inhibition of its catalytic activity, have been reported (PMID: 24367658, 26807692). The iSH2 domain has been found to be a mutational hotspot in endometrial cancer and deletions, nonsense, and frameshift variants within this region have been shown to lead to increased Akt activation and to be oncogenic. Therefore, although this alteration has not been functionally characterized, it is predicted to result in inactivation of p85-alpha and activation of the PI3K/Akt/mTOR pathway (PMID: 20713702, 19915146, 21984976, 21478295). In other disease sites, this variant is predicted to respond to MTOR inhibitor (PMID: 29636360).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/02/22 21:33:43",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "PIK3R1",
      "transcript": "NM_181523.2",
      "cNomen": "c.1891C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 15,
      "effect": "stopgain",
      "pNomen": "p.R631*"
    },
    {
      "id": 12220,
      "chromosome": "5",
      "start": 79970915,
      "stop": 79970915,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "MSH3, MutS Homolog 3, is a component involved in DNA mismatch repair (MMR) (PMID: 8942985). MSH3 mutations have been frequently reported in MMR-deficient colorectal cancers and tumors with microsatellite instability (PMID: 14871813, 23724141,18922920, 9331106, 11470537).<br />\nMSH3 loss-of-function mutations are considered oncogenic through loss of normal mismatch repair function (PMID: 10706084, 28528517, 27476653, 9331106). The MSH3 p.Lys383Argfs*32 frameshift variant has been shown to result in shortened protein length in vitro (PMID: 27476653). This variant lies within the MutsII domain and represents a microsatellite indel hotspot (PMID: 28892075). In preclinical studies of other disease sites, loss of function variants in MSH3 are predicted sensitive to DNA protein kinase inhibitor (PMID: 28224663).<br />\nA search by the Qiagen Clinical Insight platform indicates in this disease site, this variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of ipilimumab and nivolumab.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/25 01:35:07",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "MSH3",
      "transcript": "NM_002439.4",
      "cNomen": "c.1148delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 7,
      "effect": "frameshift",
      "pNomen": "p.K383Rfs*32"
    },
    {
      "id": 11976,
      "chromosome": "5",
      "start": 131931452,
      "stop": 131931452,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "RAD50 forms a complex with Mre11 and Nbs1 to repair double strand breaks, mediate DNA recombination, and maintain telomeres (PMID: 21035407, 2659437, 15309560).<br />\nThe RAD50 p.Lys722Argfs*14 frameshift variant is predicted to result in an absent or disrupted protein product. Loss-of-function variants in RAD50 are known to be oncogenic (PMID: 12208847, 16288216, 21892167, 14684699). Preclinical studies of ovarian cancer suggest loss of RAD50 is predicts sensitivity to PARP inhibitors (PMID: 27016230), however the impact of this variant in this disease context is currently unknown.<br />\nGermline pathogenic variants in RAD50 increase tumor susceptibility (PMID: 19409520, 16385572). The RAD50 p.Lys722Argfs*14 variant has been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/15 01:46:54",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "RAD50",
      "transcript": "NM_005732.3",
      "cNomen": "c.2165delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 13,
      "effect": "frameshift",
      "pNomen": "p.K722Rfs*14"
    },
    {
      "id": 11814,
      "chromosome": "5",
      "start": 176517532,
      "stop": 176517532,
      "classification": "Uncertain",
      "variantInfo": "",
      "reportAbstract": "FGFR4 is a receptor tyrosine kinase and upon binding of the FGF19 ligand, results in the activation of downstream signaling pathways including the PI3K/AKT, MAPK pathways (PMID: 22508544, 20094046, 16597617, 32154250). Gain-of-function alterations in FGFR genes result in increased tumorigenic properties in vitro and in vivo (PMID: 22508544, 23175443) and are responsive to FGFR inhibitors in patients with advanced solid tumours (PMID: 31340094, 26324363, 29848605, 31088831, 28341788).<br />\n <br />\nThe p.Arg78His missense variant lies within the Ig-like C2-type domain (UniProt.org). Limited in vitro studies suggest this variant results in increased ligand-stimulated Erk phosphorylation in culture (PMID: 30761385), and therefore, is predicted to lead to a gain of FGFR4 protein function.<br />\n <br />\nIn this disease site, the FGFR4 p.Arg78His variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/26 18:40:23",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "FGFR4",
      "transcript": "NM_002011.4",
      "cNomen": "c.233G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 3,
      "effect": "nonsynonymous",
      "pNomen": "p.R78H"
    },
    {
      "id": 12221,
      "chromosome": "5",
      "start": 176562807,
      "stop": 176562808,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "NSD1 is a histone methyltransferase and has a unique role as a bifunctional cofactor that can both positively and negatively regulate transcription (PMID: 21196496, 31727171, 12805229, 9628876, 11733144). NSD1 is also a coregulator of steroid receptors (PMID: 11733144, 11509567).<br />\n <br />\nThe NSD1 p.Gln236Glufs*3 frameshift variant is predicted to result in an absent or disrupted protein product. Loss-of-function variants in NSD1 are known to be oncogenic (PMID: 29176703, 20018718). The impact of this variant in this disease context is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/25 01:36:41",
      "evidences": [],
      "reference": "AC",
      "alternative": ".",
      "gene": "NSD1",
      "transcript": "NM_022455.4",
      "cNomen": "c.706_707delCA",
      "type": "deletion",
      "location": "exonic",
      "exon": 2,
      "effect": "frameshift",
      "pNomen": "p.Q236Efs*3"
    },
    {
      "id": 11974,
      "chromosome": "5",
      "start": 176675269,
      "stop": 176675269,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "NSD1 is a histone methyltransferase and has a unique role as a bifunctional cofactor that can both positively and negatively regulate transcription (PMID: 21196496, 31727171, 12805229, 9628876, 11733144). NSD1 is also a coregulator of steroid receptors (PMID: 11733144, 11509567).<br />\nThe NSD1 p.Met1531Cysfs*43 frameshift variant is predicted to result in an absent or disrupted protein product. Loss-of-function variants in NSD1 are known to be oncogenic (PMID: 29176703, 20018718). The impact of this variant in this disease context is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/15 01:04:32",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "NSD1",
      "transcript": "NM_022455.4",
      "cNomen": "c.4591delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 11,
      "effect": "frameshift",
      "pNomen": "p.M1531Cfs*43"
    },
    {
      "id": 11803,
      "chromosome": "6",
      "start": 32163608,
      "stop": 32163608,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "NOTCH4 is a transmembrane receptor involved in cell differentiation, growth, proliferation, survival, and metabolism (PMID: 27507209). Altered expression of NOTCH4 has been reported in several cancers (PMID: 24403446, 29805613, 27197026, 29693251, 11344305, 10797286, 25511451).<br />\nThe NOTCH4 p.Gly1873Alafs*12 frameshift variant is predicted to result in a truncated or absent protein. While this variant has not been reported in the literature, loss-of-function variants in NOTCH4 are likely oncogenic (PMID: 15187023, 28154375, 26960398).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the NOTCH4 p.Gly1873Alafs*12 variant does not currently serve as an inclusion eligibility criterion for clinical trials.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:27",
      "evidences": [],
      "reference": "C",
      "alternative": ".",
      "gene": "NOTCH4",
      "transcript": "NM_004557.3",
      "cNomen": "c.5618delG",
      "type": "deletion",
      "location": "exonic",
      "exon": 30,
      "effect": "frameshift",
      "pNomen": "p.G1873Afs*12"
    },
    {
      "id": 11894,
      "chromosome": "6",
      "start": 33288634,
      "stop": 33288634,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "DAXX is an adapter protein involved in transcription regulation and apoptosis (PMID: 23539629, 31350900, 16406523, 9215629). Loss of DAXX expression has been reported in pancreatic neuroendocrine tumors, while overexpression has been observed in oral squamous cell carcinoma and prostate cancer (PMID: 26205068, 27162024, 23954140, 23642739).<br />\nThe DAXX p.Gln319Profs*40 frameshift variant is predicted to result in a truncated or absent protein. While this variant has not been reported in the literature, loss-of-function variants have been reported in neuroendocrine pancreatic tumors and adrenocortical carcinoma and are likely oncogenic (PMID: 21252315, 24747642, 31819132, 29092957).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the DAXX p.Gln319Profs*40 variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/16 02:54:49",
      "evidences": [],
      "reference": ".",
      "alternative": "CGGGGGAGGC",
      "gene": "DAXX",
      "transcript": "NM_001141970.1",
      "cNomen": "c.944_953dupGCCTCCCCCG",
      "type": "insertion",
      "location": "exonic",
      "exon": 3,
      "effect": "frameshift",
      "pNomen": "p.Q319Pfs*40"
    },
    {
      "id": 11062,
      "chromosome": "6",
      "start": 94120525,
      "stop": 94120546,
      "classification": "Very high",
      "variantInfo": "The EPHA7 p.Thr169Leufs*14 frameshift variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, truncating variants in EPHA7 are known to be oncogenic (PMID: 18821581, 22094251, 25968442, 29022918).<br />\nA search by the Clinical Insight (Qiagen) platform indicates in this disease site, the EPHA7 p.Thr169Leufs*14 variant currently serves as an inclusion eligibility criterion for Phase 1/Phase 2 clinical trials of RTK inhibitors.<br />\n ",
      "reportAbstract": "EPHA7 encodes for a receptor tyrosine kinase which upon interaction with cell surface bound ephrin ligands, reduces Akt signaling, increases apoptotic signaling, and plays a role in cell-cell repulsion and adhesion (PMID: 24003208, 15928710, 29022918). Downregulation of EPHA7 (i.e. via deletion or hypermethylation) have been reported in multiple tumour types and associated with tumour progression (PMID: 22941188, 18948947, 23676193, 22036564).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/18 03:24:24",
      "evidences": [],
      "reference": "GTCCAATCTCTCTCACCTCAGT",
      "alternative": ".",
      "gene": "EPHA7",
      "transcript": "NM_004440.3",
      "cNomen": "c.505_526delACTGAGGTGAGAGAGATTGGAC",
      "type": "deletion",
      "location": "exonic",
      "exon": 3,
      "effect": "frameshift",
      "pNomen": "p.T169Lfs*14"
    },
    {
      "id": 11752,
      "chromosome": "6",
      "start": 152419923,
      "stop": 152419923,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ESR1 is an estrogen receptor involved in sexual reproductive development and maintenance (PMID: 21779010). Somatic mutations within the ligand-binding domain of ESR1 have been identified in metastatic breast cancer where they have been associated with decreased response to endocrine therapy (PMID: 24398047, 24185512, 24185510, 31795152, 26183887).<br />\nThe ESR1 p.Tyr537Cys variant is a hotspot mutation that lies within the ligand binding domain of the ESR1 protein (Uniprot.org). Variants at this codon are gain-of-function alterations as indicated by a constitutively active receptor with elevated ligand-independent transcriptional activity that are associated with resistance to estrogen-deprivation therapies (PMID: 9500442, 11322512, 24398047, 24185510, 24055055).<br />\n<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ESR1 p.Tyr537Cys variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of aromatase inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:25:34",
      "evidences": [],
      "reference": "A",
      "alternative": "G",
      "gene": "ESR1",
      "transcript": "NM_000125.3",
      "cNomen": "c.1610A>G",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "nonsynonymous",
      "pNomen": "p.Y537C"
    },
    {
      "id": 11769,
      "chromosome": "7",
      "start": 50459425,
      "stop": 50459449,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "IKZF1 encodes a transcription factor involved in lymphocyte development. As a transcription factor, IKZF1 alters chromatin and regulates gene expression by recruiting histone deacetylases and chromatin remodeling ATPases to target genes (PMID: 10204490). IKZF1 is the target of lenalidomide-induced degradation in multiple myeloma and its degradation is a key component of the drug&#39;s activity in myeloma (PMID: 24292625). Loss-of-function alterations of IKZF1 are frequently found in B-cell acute lymphocytic leukemia.<br />\nThe IKZF1 p.Ile240Lysfs*9 frameshift variant is predicted to result in an altered protein product or absence of protein due to nonsense mediated decay. While this particular variant has not been reported in the literature, loss-of-function variants in IKZF1 are known to be oncogenic (PMID: 27067989, 27815723, 26202931, 19129520).<br />\nMutations in IKZF1 in acute lymphoblastic leukemia are associated with poor outcome (PMID: 25335741, 26194343, 27067989). IKZF1 has been also implicated in the response or multiple myeloma cells to Lenalidomide treatment (PMID: (PMID: 24292625). The impact of this variant in this disease site is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 17:35:35",
      "evidences": [],
      "reference": "AGTCATTAAAGAAGAAACTAATCAC",
      "alternative": ".",
      "gene": "IKZF1",
      "transcript": "NM_006060.5",
      "cNomen": "c.716-2_738delAGTCATTAAAGAAGAAACTAATCAC",
      "type": "deletion",
      "location": "exonic",
      "exon": 7,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11535,
      "chromosome": "7",
      "start": 50459426,
      "stop": 50459426,
      "classification": "Very high",
      "variantInfo": "<br />\nThe IKZF1 c.716-1G&gt;A is a splice site variant and is predicted to result in an altered protein product or absence of protein due to nonsense mediated decay. While this particular variant has not been reported in the literature, loss-of-function variants in IKZF1 are known to be oncogenic (PMID: 27067989, 27815723, 26202931, 19129520).<br />\nA search by the Watson for Genomics platform indicates in this disease site, IKZF1 c.716-1G&gt;A variant currently does not serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "IKZF1 encodes a transcription factor involved in lymphocyte development. As a transcription factor, IKZF1 alters chromatin and regulates gene expression by recruiting histone deacetylases and chromatin remodeling ATPases to target genes (PMID: 10204490). IKZF1 is the target of lenalidomide-induced degradation in multiple myeloma and its degradation is a key component of the drug&#39;s activity in myeloma (PMID: 24292625). Loss-of-function alterations of IKZF1 are frequently found in B-cell acute lymphocytic leukemia.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/11 00:44:56",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "IKZF1",
      "transcript": "NM_006060.5",
      "cNomen": "c.716-1G>A",
      "type": "snp",
      "location": "intronic",
      "exon": 7,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11799,
      "chromosome": "7",
      "start": 55259485,
      "stop": 55259485,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "EGFR (HER1), epidermal growth factor receptor, is a tyrosine kinase receptor, which activates RAS/RAF/MEK and PI3K/AKT/mTOR pathways, leading to increased cell proliferation and growth (PMID: 24312144).<br />\nThe EGFR p.Pro848Leu missense variant affects the kinase domain of the EGFR protein (UniProt). Functional evidence suggests that this variant results in increased cell proliferation, phosphorylation and transformation, and may not confer sensitivity to tyrosine kinase inhibitors, in vitro (PMID: 29533785, 31314158, 22848293, 17877814).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the EGFR p.Pro848Leu variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of tyrosine kinase inhibitors.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:27",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "EGFR",
      "transcript": "NM_005228.3",
      "cNomen": "c.2543C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 21,
      "effect": "nonsynonymous",
      "pNomen": "p.P848L"
    },
    {
      "id": 11130,
      "chromosome": "7",
      "start": 81359097,
      "stop": 81359097,
      "classification": "Very high",
      "variantInfo": "The HGF c.866-2A&gt;T splice site variant is predicted to result in an altered protein product or absence of protein due to nonsense mediated decay.<br />\nA search by the Clinical Insight (Qiagen) platform indicates in this disease site, the HGF c.866-2A&gt;T variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "HGF, hepatocyte growth factor is an activating ligand of MET. HGF-activated Met signaling promotes MAPK signaling and plays a role in increased cell survival, motility and metastasis (PMID: 30513872, 24930887, 24865428, 22270953). Aberrant HGF expression HGF have been reported in several cancers (PMID: 30513872, 31512514).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/25 14:25:35",
      "evidences": [],
      "reference": "T",
      "alternative": "A",
      "gene": "HGF",
      "transcript": "NM_000601.5",
      "cNomen": "c.866-2A>T",
      "type": "snp",
      "location": "intronic",
      "exon": 8,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11794,
      "chromosome": "7",
      "start": 91603085,
      "stop": 91603085,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "AKAP9, A-kinase anchor protein 9, belongs to a family of A-kinase anchor proteins involved in centrosome duplication, cell cycle progression and maintenance of cell membrane integrity (PMID: 26441649, 26786868).<br />\nThe AKAP9 p.Lys39Argfs*17 frameshift variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants have been reported in gastric and colorectal cancers (PMID: 26786868), and gain-of-function AKAP9-BRAF fusions have been reported in thyroid and melanoma cancers (PMID: 15630448, 30776432).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the AKAP9 p.Lys39Argfs*17 variant does not currently serve as an inclusion eligibility criterion for clinical trials.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:27",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "AKAP9",
      "transcript": "NM_005751.4",
      "cNomen": "c.116delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 2,
      "effect": "frameshift",
      "pNomen": "p.K39Rfs*17"
    },
    {
      "id": 11536,
      "chromosome": "7",
      "start": 98530977,
      "stop": 98530989,
      "classification": "Very high",
      "variantInfo": "<br />\nThe p.Phe1323Leufs*14 frameshift variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in TRRAP are known to be oncogenic (PMID: 29653964, 20943076, 29936929, 31188495).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TRRAP p.Phe1323Leufs*14 variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "TRRAP is a common component of many histone acetyltransferase (HAT) complexes and interacts with different DNA-binding factors allowing recruitment of HAT complexes and histone acetylation at gene promoters. Deregulation of this gene may play a role in several types of cancer including glioblastoma multiforme (PMID: 31188495, 29936929, 20085741).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/11 01:21:04",
      "evidences": [],
      "reference": "CTTCACAATGGAC",
      "alternative": ".",
      "gene": "TRRAP",
      "transcript": "NM_001244580.1",
      "cNomen": "c.3969_3981delCACAATGGACCTT",
      "type": "deletion",
      "location": "exonic",
      "exon": 27,
      "effect": "frameshift",
      "pNomen": "p.F1323Lfs*14"
    },
    {
      "id": 11646,
      "chromosome": "7",
      "start": 124503403,
      "stop": 124503403,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "POT1 is a telomere binding protein that is a component of shelterin thereby regulating telomeres and chromosome stability (PMID: 29149597, 28393832, 30208292, 32232414). Germline loss-of-function mutations in POT1 are found in familial cutaneous melanoma, lymphoma and glioma (PMID: 24686849, 32283231, 25482530, 29693246). Somatic loss-of-function POT1 mutations are found in chronic lymphocytic leukemia (PMID: 23502782).<br />\nThe c.546&#43;1G&gt;A splice site variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in POT1 are known to be oncogenic (PMID: 29546066, 16839876).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the POT1 c.546&#43;1G&gt;A variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/19 18:28:59",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "POT1",
      "transcript": "NM_015450.2",
      "cNomen": "c.546+1G>A",
      "type": "snp",
      "location": "intronic",
      "exon": 8,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 12325,
      "chromosome": "7",
      "start": 140453134,
      "stop": 140453134,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "BRAF is a member of the Raf family of serine/threonine protein kinases, which signals through the MAP kinase pathway to regulate cell proliferation. BRAF mutations have been reported in a variety of cancer including colorectal, lung, thyroid and melanoma (PMID: 30122982, 29729495, 12970315, 24737949). The BRAF p.Lys601Glu missense variant occurs in the kinase domain (UniProt). Experimental studies suggest this variant is a gain-of-function alteration and results in activation of MAPK signaling and oncogenic transformation in vitro (PMID: 22798288, 28783719, 32059434, 29533785). Case report studies in other disease sites suggest this variant is predicted sensitive to MEK inhibitor (PMID: 23248257, 28344857) and there is conflicting evidence of responsiveness to BRAF inhibitors (PMID: 29320312, 22608338).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/05/17 20:53:53",
      "evidences": [],
      "reference": "T",
      "alternative": "C",
      "gene": "BRAF",
      "transcript": "NM_004333.4",
      "cNomen": "c.1801A>G",
      "type": "snp",
      "location": "exonic",
      "exon": 15,
      "effect": "nonsynonymous",
      "pNomen": "p.K601E"
    },
    {
      "id": 11393,
      "chromosome": "7",
      "start": 140453193,
      "stop": 140453193,
      "classification": "Very high",
      "variantInfo": "<br />\nThe BRAF p.Asn581Ser missense variant occurs in the kinase domain. Experimental studies suggest this variant is a gain-of-function alteration and results in activation of MAPK signaling and oncogenic transformation in vitro (PMID: 26498038, 28783719, 15035987).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the BRAF p.Asn581Ser variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MAPK inhibitors.<br />\n ",
      "reportAbstract": "BRAF is a member of the Raf family of serine/threonine protein kinases, which signals through the MAP kinase pathway to regulate cell proliferation (PMID: 24737949, 29540830, 15520807, 24202393). BRAF mutations have been reported in a variety of cancer including colorectal, lung, thyroid and melanoma (PMID: 30122982, 29729495, 12970315, 24737949). BRAF inhibitors, including vemurafenib and dabrafenib, are FDA-approved for the treatment of late-stage or unresectable melanoma.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/07/09 13:14:18",
      "evidences": [],
      "reference": "T",
      "alternative": "C",
      "gene": "BRAF",
      "transcript": "NM_004333.4",
      "cNomen": "c.1742A>G",
      "type": "snp",
      "location": "exonic",
      "exon": 15,
      "effect": "nonsynonymous",
      "pNomen": "p.N581S"
    },
    {
      "id": 12193,
      "chromosome": "7",
      "start": 148507497,
      "stop": 148507497,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "EZH2 is an epigenetic modifier involved in transcriptional repression (PMID: 24362326, 30112706). EZH2 alterations and overexpression have been reported in various solid and hematological malignancies (PMID: 30112706, 29289837, 29726819, 11389032, 16361539, 12374981, 14500907, 16330673, 24097870, 20081860, 21190999, 29726819).<br />\nThe EZH2 p.Gln653* nonsense variant is predicted to result in a truncated or absent protein. While this particular variant has not been reported in the literature, gain-of-function and loss-of-function variants in hematological malignancies are known to be oncogenic (PMID: 20081860, 21190999, 20601953, 20601954, 19749759). In other disease sites, mutations in EZH2 are responsive to EZH2 inhibitors (NCCN, FDA).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:31",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "EZH2",
      "transcript": "NM_004456.4",
      "cNomen": "c.1957C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 17,
      "effect": "stopgain",
      "pNomen": "p.Q653*"
    },
    {
      "id": 12355,
      "chromosome": "7",
      "start": 148511207,
      "stop": 148511207,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "EZH2 is an epigenetic modifier involved in transcriptional repression (PMID: 24362326, 30112706). EZH2 alterations and overexpression have been reported in various solid and hematological malignancies (PMID: 30112706, 29289837, 29726819, 11389032, 16361539, 12374981, 14500907, 16330673, 24097870, 20081860, 21190999, 29726819).<br />\nThe EZH2 p.Cys565* nonsense variant is predicted to result in a truncated or absent protein. While this particular variant has not been reported in the literature, gain-of-function and loss-of-function variants in hematological malignancies are known to be oncogenic (PMID: 20081860, 21190999, 20601953, 20601954, 19749759). In other disease sites, mutations in EZH2 are responsive to EZH2 inhibitors (NCCN, FDA).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/06/01 20:31:26",
      "evidences": [],
      "reference": "G",
      "alternative": "T",
      "gene": "EZH2",
      "transcript": "NM_004456.4",
      "cNomen": "c.1695C>A",
      "type": "snp",
      "location": "exonic",
      "exon": 15,
      "effect": "stopgain",
      "pNomen": "p.C565*"
    },
    {
      "id": 11800,
      "chromosome": "7",
      "start": 148543658,
      "stop": 148543658,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "EZH2 is an epigenetic modifier involved in transcriptional repression (PMID: 24362326, 30112706). EZH2 alterations and overexpression have been reported in various solid and hematological malignancies (PMID: 30112706, 29289837, 29726819, 11389032, 16361539, 12374981, 14500907, 16330673, 24097870, 20081860, 21190999, 29726819).<br />\nThe EZH2 p.Leu50Phefs*32 frameshift variant is predicted to result in a truncated or absent protein. While this particular variant has not been reported in the literature, gain-of-function and loss-of-function variants in hematological malignancies are known to be oncogenic (PMID: 20081860, 21190999, 20601953, 20601954, 19749759).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the EZH2 p.Leu50Phefs*32 variant does not currently serve as an inclusion eligibility criterion for clinical trials.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:27",
      "evidences": [],
      "reference": ".",
      "alternative": "A",
      "gene": "EZH2",
      "transcript": "NM_004456.4",
      "cNomen": "c.149dupT",
      "type": "insertion",
      "location": "exonic",
      "exon": 3,
      "effect": "frameshift",
      "pNomen": "p.L50Ffs*32"
    },
    {
      "id": 12326,
      "chromosome": "7",
      "start": 151845821,
      "stop": 151845821,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KMT2C, also referred to as MLL3, is a tumour suppressor and histone methyltransferase. KMT2C mutations have been reported in various solid and hematologic malignancies (PMID: 25794446, 11891048, 25537518, 25303977, 25151357, 28801450). The KMT2C p.Asp4398Thrfs*15 frameshift variant leads to a premature termination codon, which is predicted to result in a truncated or absent protein. While this variant has not been reported in the literature, loss-of-function variants in KMT2C are likely oncogenic (PMID: 23259788, 19433796, 30108106, 25537518).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/05/17 20:55:52",
      "evidences": [],
      "reference": "T",
      "alternative": ".",
      "gene": "KMT2C",
      "transcript": "NM_170606.2",
      "cNomen": "c.13191delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 52,
      "effect": "frameshift",
      "pNomen": "p.D4398Tfs*15"
    },
    {
      "id": 11129,
      "chromosome": "7",
      "start": 151851222,
      "stop": 151851222,
      "classification": "Very high",
      "variantInfo": "<br />\nThe KMT2C p.Ser4050* variant is a nonsense variant that leads to a premature termination codon, which is predicted to result in a truncated or absent protein. Due to the loss of multiple functional domains (UniProt.org), this variant is predicted to lead to a loss of KMT2C protein function (PMID: 23259788, 19433796, 30108106, 25537518).<br />\nA search by the Clinical Insight (Qiagen) platform indicates in this disease site, the KMT2C p.Ser4050* variant does not currently serves as an inclusion eligibility criterion for clinical trials.",
      "reportAbstract": "KMT2C, also referred to as MLL3, is a tumour suppressor and histone methyltransferase (PMID: 31128216). KMT2C mutations have been reported in various solid and hematologic malignancies (PMID: 25794446, 11891048, 25537518, 25303977, 25151357, 28801450).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/25 02:31:08",
      "evidences": [],
      "reference": "G",
      "alternative": "T",
      "gene": "KMT2C",
      "transcript": "NM_170606.2",
      "cNomen": "c.12149C>A",
      "type": "snp",
      "location": "exonic",
      "exon": 48,
      "effect": "stopgain",
      "pNomen": "p.S4050*"
    },
    {
      "id": 11697,
      "chromosome": "7",
      "start": 151864312,
      "stop": 151864312,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KMT2C, also referred to as MLL3, is a tumour suppressor and histone methyltransferase (PMID: 31128216). KMT2C mutations have been reported in various solid and hematologic malignancies (PMID: 25794446, 11891048, 25537518, 25303977, 25151357, 28801450).<br />\nThe KMT2C p.Arg3224Valfs*25 variant is a nonsense variant that leads to a premature termination codon, which is predicted to result in a truncated or absent protein. Due to the loss of multiple functional domains (UniProt.org), this variant is predicted to lead to a loss of KMT2C protein function (PMID: 23259788, 19433796, 30108106, 25537518).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the KMT2C p.Arg3224Valfs*25 variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/28 17:22:30",
      "evidences": [],
      "reference": "C",
      "alternative": ".",
      "gene": "KMT2C",
      "transcript": "NM_170606.2",
      "cNomen": "c.9669delG",
      "type": "deletion",
      "location": "exonic",
      "exon": 42,
      "effect": "frameshift",
      "pNomen": "p.R3224Vfs*25"
    },
    {
      "id": 12033,
      "chromosome": "7",
      "start": 151874614,
      "stop": 151874617,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KMT2C, also referred to as MLL3, is a tumour suppressor and histone methyltransferase (PMID: 31128216). KMT2C mutations have been reported in various solid and hematologic malignancies (PMID: 25794446, 11891048, 25537518, 25303977, 25151357, 28801450).<br />\nThe KMT2C p.Ser2641Leufs*5 frameshift variant leads to a premature termination codon, which is predicted to result in a truncated or absent protein. While this variant has not been reported in the literature, loss-of-function variants in KMT2C are likely oncogenic (PMID: 23259788, 19433796, 30108106, 25537518). The impact of this variant in this disease context is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/28 19:12:42",
      "evidences": [],
      "reference": "ATGA",
      "alternative": ".",
      "gene": "KMT2C",
      "transcript": "NM_170606.2",
      "cNomen": "c.7921_7924delTCAT",
      "type": "deletion",
      "location": "exonic",
      "exon": 38,
      "effect": "frameshift",
      "pNomen": "p.S2641Lfs*5"
    },
    {
      "id": 11801,
      "chromosome": "7",
      "start": 151879670,
      "stop": 151879670,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KMT2C, also referred to as MLL3, is a tumour suppressor and histone methyltransferase (PMID: 31128216). KMT2C mutations have been reported in various solid and hematologic malignancies (PMID: 25794446, 11891048, 25537518, 25303977, 25151357, 28801450).<br />\nThe KMT2C p.Gln1759* variant is a nonsense variant that leads to a premature termination codon, which is predicted to result in a truncated or absent protein. Due to the loss of multiple functional domains (UniProt.org), this variant is predicted to lead to a loss of KMT2C protein function (PMID: 23259788, 19433796, 30108106, 25537518).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the KMT2C p.Gln1759* variant does not currently serve as an inclusion eligibility criterion for clinical trials.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:23",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "KMT2C",
      "transcript": "NM_170606.2",
      "cNomen": "c.5275C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 36,
      "effect": "stopgain",
      "pNomen": "p.Q1759*"
    },
    {
      "id": 11550,
      "chromosome": "7",
      "start": 151932952,
      "stop": 151932952,
      "classification": "Very high",
      "variantInfo": "<br />\nThe KMT2C p.Arg907* variant is a nonsense variant that leads to a premature termination codon, which is predicted to result in a truncated or absent protein. Due to the loss of multiple functional domains (UniProt.org), this variant is predicted to lead to a loss of KMT2C protein function (PMID: 23259788, 19433796, 30108106, 25537518).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the KMT2C p.Arg907* variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "KMT2C, also referred to as MLL3, is a tumour suppressor and histone methyltransferase (PMID: 31128216). KMT2C mutations have been reported in various solid and hematologic malignancies (PMID: 25794446, 11891048, 25537518, 25303977, 25151357, 28801450).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/19 21:22:35",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "KMT2C",
      "transcript": "NM_170606.2",
      "cNomen": "c.2719C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 16,
      "effect": "stopgain",
      "pNomen": "p.R907*"
    },
    {
      "id": 11036,
      "chromosome": "7",
      "start": 151945168,
      "stop": 151945168,
      "classification": "Very high",
      "variantInfo": "The KMT2C p.Ser784* variant is a nonsense variant that leads to a premature termination codon, which is predicted to result in a truncated or absent protein. Due to the loss of multiple functional domains (UniProt.org), this variant is predicted to lead to a loss of KMT2C protein function.<br />\nA search by the Clinical Insight (Qiagen) platform indicates in this disease site, the KMT2C p.Ser784* variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "KMT2C, also referred to as MLL3, is a tumour suppressor and histone methyltransferase (PMID: 31128216). KMT2C mutations have been reported in various solid and hematologic malignancies (PMID: 25794446, 11891048, 25537518, 25303977, 25151357, 28801450).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/12 20:23:20",
      "evidences": [],
      "reference": "G",
      "alternative": "T",
      "gene": "KMT2C",
      "transcript": "NM_170606.2",
      "cNomen": "c.2351C>A",
      "type": "snp",
      "location": "exonic",
      "exon": 14,
      "effect": "nonsynonymous",
      "pNomen": "p.S784Y"
    },
    {
      "id": 11692,
      "chromosome": "7",
      "start": 151960216,
      "stop": 151960216,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KMT2C, also referred to as MLL3, is a tumour suppressor and histone methyltransferase (PMID: 31128216). KMT2C mutations have been reported in various solid and hematologic malignancies (PMID: 25794446, 11891048, 25537518, 25303977, 25151357, 28801450).<br />\nThe KMT2C c.1185-1G&gt;C variant is a splice site variant that may induce aberrant splicing resulting in a truncated protein and loss of function (PMID: 23259788, 19433796, 30108106, 25537518).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the KMT2C c.1185-1G&gt;C variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/28 17:09:21",
      "evidences": [],
      "reference": "C",
      "alternative": "G",
      "gene": "KMT2C",
      "transcript": "NM_170606.2",
      "cNomen": "c.1185-1G>C",
      "type": "snp",
      "location": "intronic",
      "exon": 9,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11549,
      "chromosome": "7",
      "start": 151970789,
      "stop": 151970789,
      "classification": "Very high",
      "variantInfo": "<br />\nThe KMT2C c.1012&#43;1G&gt;A variant is a splice site variant that may induce aberrant splicing resulting in a truncated protein and loss of function (PMID: 23259788, 19433796, 30108106, 25537518).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the KMT2C c.1012&#43;1G&gt;A variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "KMT2C, also referred to as MLL3, is a tumour suppressor and histone methyltransferase (PMID: 31128216). KMT2C mutations have been reported in various solid and hematologic malignancies (PMID: 25794446, 11891048, 25537518, 25303977, 25151357, 28801450).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/19 21:17:15",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "KMT2C",
      "transcript": "NM_170606.2",
      "cNomen": "c.1012+1G>A",
      "type": "snp",
      "location": "intronic",
      "exon": 7,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 12166,
      "chromosome": "7",
      "start": 152009030,
      "stop": 152009030,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KMT2C, also referred to as MLL3, is a tumour suppressor and histone methyltransferase (PMID: 31128216). KMT2C mutations have been reported in various solid and hematologic malignancies (PMID: 25794446, 11891048, 25537518, 25303977, 25151357, 28801450).<br />\nThe KMT2C p.Glu198* nonsense variant leads to a premature termination codon, which is predicted to result in a truncated or absent protein. While this variant has not been reported in the literature, loss-of-function variants in KMT2C are likely oncogenic (PMID: 23259788, 19433796, 30108106, 25537518).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:27",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "KMT2C",
      "transcript": "NM_170606.2",
      "cNomen": "c.592G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "stopgain",
      "pNomen": "p.E198*"
    },
    {
      "id": 11906,
      "chromosome": "8",
      "start": 31001132,
      "stop": 31001132,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "WRN possesses both DNA helicase and exonuclease activities and thus plays important roles in maintaining genomic stability (PMID: 27902925). Werner syndrome patients with inactivating WRN mutations are prone to cancer (PMID: 16723399, 16673358), inactivation of WRN has been found in multiple cancers (PMID: 25620975), and microsatellite unstable cancers have a dependency on active WRN, suggesting it to be a therapeutic target (PMID: 30971823).<br />\nThe WRN p.Ser1128Valfs*34 frameshift variant is expected to result in an absent or disrupted protein product. While this particular variant has not been functionally characterized in the literature, loss-of-function variants in WRN are known to be oncogenic (PMID: 28012115, 16723399, 25620975).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the WRN p.Ser1128Valfs*34 variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/21 17:13:27",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "WRN",
      "transcript": "NM_000553.4",
      "cNomen": "c.3382delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 28,
      "effect": "frameshift",
      "pNomen": "p.S1128Vfs*34"
    },
    {
      "id": 11725,
      "chromosome": "8",
      "start": 48710840,
      "stop": 48710840,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PRKDC is a serine/threonine protein kinase involved in genome maintenance by regulating the DNA damage control pathway (PMID: 14726021, 24680878). PRKDC alterations have been demonstrated in colorectal and prostate cancers (PMID: 26992638, 27856181).<br />\nThe p.Ile3472Metfs*9 frameshift variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in PRKDC are potentially predictive of sensitivity to immune checkpoint inhibitors (PMID: 32238472).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PRKDC p.Ile3472Metfs*9  variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/06 17:46:06",
      "evidences": [],
      "reference": "T",
      "alternative": ".",
      "gene": "PRKDC",
      "transcript": "NM_006904.6",
      "cNomen": "c.10416delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 73,
      "effect": "frameshift",
      "pNomen": "p.I3472Mfs*9"
    },
    {
      "id": 11903,
      "chromosome": "8",
      "start": 48746799,
      "stop": 48746800,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PRKDC is a serine/threonine protein kinase involved in genome maintenance by regulating the DNA damage control pathway (PMID: 14726021, 24680878). PRKDC alterations have been demonstrated in colorectal and prostate cancers (PMID: 26992638, 27856181).<br />\nThe p.Arg2704Alafs*10 frameshift variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in PRKDC are potentially predictive of sensitivity to immune checkpoint inhibitors (PMID: 32238472).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PRKDC p.Arg2704Alafs*10 variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/21 16:43:04",
      "evidences": [],
      "reference": "TT",
      "alternative": ".",
      "gene": "PRKDC",
      "transcript": "NM_006904.6",
      "cNomen": "c.8109_8110delAA",
      "type": "deletion",
      "location": "exonic",
      "exon": 59,
      "effect": "frameshift",
      "pNomen": "p.R2704Afs*10"
    },
    {
      "id": 11038,
      "chromosome": "8",
      "start": 48777325,
      "stop": 48777325,
      "classification": "Very high",
      "variantInfo": "The PRKDC c.5364-1G&gt;A variant is located within 2bp of intron-exon boundary and is predicted to result in aberrant splicing resulting in a truncated protein and loss of function.<br />\nA search by the Clinical Insight (Qiagen) platform indicates in this disease site, the PRKDC c.5364-1G&gt;A variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "reportAbstract": "PRKDC is a serine/threonine protein kinase involved in genome maintenance by regulating the DNA damage control pathway (PMID: 14726021, 24680878). PRKDC alterations have been demonstrated in colorectal and prostate cancers (PMID: 26992638, 27856181).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/12 20:42:54",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "PRKDC",
      "transcript": "NM_006904.6",
      "cNomen": "c.5364-1G>A",
      "type": "snp",
      "location": "intronic",
      "exon": 41,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 10998,
      "chromosome": "8",
      "start": 90960054,
      "stop": 90960054,
      "classification": "Very high",
      "variantInfo": "The NBN p.Ser638Pro variant is a missense variant located in the Mre11-binding domain which is predicted to result in altered function of the MRN complex and thus loss-of-function (PMID: 16790366, 18056440).  <br />\nGermline mutations of NBN are associated with Nijmegen breakage syndrome and predispose to cancer (PMID: 24349281, 22864661, 21923652,18593981,18056440). The NBN p.Ser638Pro variant has been reported in the germline context by 6 clinical laboratories as a variant of uncertain significance (ClinVar); this variant has been reported in population studies (MAF &#61; 0.003%; 6/230692 alleles; gnomAD).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the A NBN p.Ser638Pro variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.<br />\n ",
      "reportAbstract": "NBN is involved in genome maintenance through regulation of the DNA repair pathway (PMID: 15279770). Mutations and copy number alterations in NBN may lead to susceptibility to radiation and specific inhibitors related to DNA damage including PARP inhibitors (PMID:22396666, 25324139, 25415046, 24240112, 22983061).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/09 20:45:56",
      "evidences": [],
      "reference": "A",
      "alternative": "G",
      "gene": "NBN",
      "transcript": "NM_002485.4",
      "cNomen": "c.1912T>C",
      "type": "snp",
      "location": "exonic",
      "exon": 12,
      "effect": "nonsynonymous",
      "pNomen": "p.S638P"
    },
    {
      "id": 11632,
      "chromosome": "8",
      "start": 90990521,
      "stop": 90990521,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "NBN is involved in genome maintenance through regulation of the DNA repair pathway (PMID: 15279770). Mutations and copy number alterations in NBN may lead to susceptibility to radiation and specific inhibitors related to DNA damage including PARP inhibitors (PMID:22396666, 25324139, 25415046, 24240112, 22983061).<br />\nThe NBN p.Ile171Val variant is a missense variant located in the BRCT domain, however there is conflicting evidence regarding its functional impact on genomic instability (PMID: 24830725, 22131123). Germline mutations of NBN are associated with Nijmegen breakage syndrome and predispose to cancer (PMID: 24349281, 22864661, 21923652,18593981,18056440). The NBN p.Ile171Val variant has been reported in the germline context (ClinVar, PMID: 15338273, 17899368, 11325820).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the NBN p.Ile171Val variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/14 01:20:08",
      "evidences": [],
      "reference": "T",
      "alternative": "C",
      "gene": "NBN",
      "transcript": "NM_002485.4",
      "cNomen": "c.511A>G",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.I171V"
    },
    {
      "id": 11806,
      "chromosome": "8",
      "start": 103289349,
      "stop": 103289349,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "UBR5 (also known as EDD) is an E3 ubiquitin ligase involved in the degradation of proteins (PMID: 10030672, 21633985). Somatic mutations in UBR5 have been reported in mantle cell lymphoma and breast cancer (PMID: 23407552, 26464214, 27161491). Amplification and/or overexpression have been reported in breast and ovarian cancers (PMID: 28330927, 12902990, 18349819, 24379240).<br />\nThe UBR5 p.Glu2121Lysfs*28 frameshift variant is expected to result in an absent or disrupted protein product. This particular variant has been reported in colon cancers and several other cancers (PMID: 32733937, 20025491, COSMIC).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the UBR5 p.Glu2121Lysfs*28 variant does not currently serve as an inclusion eligibility criterion for clinical trials.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:23",
      "evidences": [],
      "reference": "T",
      "alternative": ".",
      "gene": "UBR5",
      "transcript": "NM_015902.5",
      "cNomen": "c.6360delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 45,
      "effect": "frameshift",
      "pNomen": "p.E2121Kfs*28"
    },
    {
      "id": 11587,
      "chromosome": "8",
      "start": 128750639,
      "stop": 128750639,
      "classification": "Very high",
      "variantInfo": "<br />\nThe MYC p.Ala59Val (also referred to as A44V in the literature) is a hotspot missense variant that lies within the Myc box 1 of the Myc protein (PMID: 24013231, 10706881). Functional studies suggest this is an activating variant as demonstrated by decreased turnover of MYC and increased transformation in vitro (PMID: 9927431, 24013231).<br />\nA search by the Watson for Genomics platform indicates in this disease site, both MYC variants currently serves as an inclusion eligibility criterion for Phase 1 or 2 clinical trials of BRD, AURKA, and CDK inhibitors.<br />\n ",
      "reportAbstract": "MYC is a transcription factor that regulates expression of genes involved in cell cycle progression, apoptosis, cellular transformation (PMID: 25038584, PMID: 32071436) and the immune system (PMID: 29514782). Amplification, overexpression, and rearrangement of MYC is commonly observed in solid and hematological tumors (PMID: 28587062, PMID: 32203465).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/27 22:49:44",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "MYC",
      "transcript": "NM_002467.4",
      "cNomen": "c.176C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "nonsynonymous",
      "pNomen": "p.A59V"
    },
    {
      "id": 11134,
      "chromosome": "9",
      "start": 5073770,
      "stop": 5073770,
      "classification": "Very high",
      "variantInfo": "<br />\nThe JAK2 p.Val617Phe missense variant is a gain-of-function alteration that results in increased kinase activity and leads to constitutive activation of the JAK/STAT signaling pathway (PMID: 17721432, 29355841, 12351625, 15793561, 21533163, 19543316, 28640953).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the JAK2 p.Val617Phe variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of JAK2 inhibitors.<br />\n ",
      "reportAbstract": "JAK2 is a is a non-receptor tyrosine kinase that activate the interferon-alpha/beta/gamma pathway and is a member of the JAK/STAT signaling pathway (PMID: 15575979, 30092288, 17208428). JAK2 mutations have been reported in both hematological and solid cancers (PMID: 30074114, 26151455, 29979407, 30003068, 16247455, 22209716, 22493978, 23406773).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/25 16:17:54",
      "evidences": [],
      "reference": "G",
      "alternative": "T",
      "gene": "JAK2",
      "transcript": "NM_004972.3",
      "cNomen": "c.1849G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 14,
      "effect": "nonsynonymous",
      "pNomen": "p.V617F"
    },
    {
      "id": 10925,
      "chromosome": "9",
      "start": 8389298,
      "stop": 8389298,
      "classification": "Uncertain",
      "variantInfo": "The PTPRD W1440* variant is a nonsense variant that leads to a premature termination codon, which is predicted to result in a truncated or absent protein.",
      "reportAbstract": "PTPRD is a tumour suppressor and receptor protein tyrosine phosphatase. Loss of function, either by deletion or inactivation, results in hyperactivation of STAT3 signaling (PMID: 24843164, 26267899, 22305495, 19478061).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/02/24 21:35:34",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "PTPRD",
      "transcript": "NM_002839.3",
      "cNomen": "c.4320G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 37,
      "effect": "stopgain",
      "pNomen": "p.W1440*"
    },
    {
      "id": 12265,
      "chromosome": "9",
      "start": 21971191,
      "stop": 21971207,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "The CDKN2A gene encodes multiple proteins, including the tumor suppressor p16INK4a (also known as Mts1), which plays a vital role in cell cycle G1 checkpoint regulation and is an inhibitor of Cdk4 activity. CDKN2A also encodes p14ARF, which regulates p53 by interacting with Mdm2 (PMID: 20565749, 7606716, 9529249). Because the CDKN2A and CDKN2B gene products encode proteins that act as tumor suppressors, deletion or loss of activity may result in deregulation of the p16INK4a/Cdk4/Cyclin/Rb and/or the Mdm2/p53 pathways, and altered regulation of the cell cycle (PMID:9484839, 9529249). The CDKN2A p.Val51Argfs*63 frameshift variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in CDKN2A are known to be oncogenic (PMID: 20340136, 9324288, 8603820). This variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials CDK4/6 inhibitor (CAPTUR; NCT03297606).  <br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/04/27 19:34:19",
      "evidences": [],
      "reference": "CTGCCCATCATCATGAC",
      "alternative": ".",
      "gene": "CDKN2A",
      "transcript": "NM_000077.4",
      "cNomen": "c.151_167delGTCATGATGATGGGCAG",
      "type": "deletion",
      "location": "exonic",
      "exon": 2,
      "effect": "frameshift",
      "pNomen": "p.V51Rfs*63"
    },
    {
      "id": 11779,
      "chromosome": "9",
      "start": 35074374,
      "stop": 35074374,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "FANCG is a tumor suppressor and DNA repair protein involved in genome maintenance by regulating the DNA damage control pathway (PMID: 27145721, 21118969, 32002546).<br />\n <br />\nThe FANCG p.Ala585Glyfs*20 frameshift variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in FANCG are known to be oncogenic (PMID: 16762635, 28440438).<br />\n <br />\nIn this disease site, the FANCG p.Ala585Glyfs*20 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/19 19:59:15",
      "evidences": [],
      "reference": ".",
      "alternative": "C",
      "gene": "FANCG",
      "transcript": "NM_004629.1",
      "cNomen": "c.1753dupG",
      "type": "insertion",
      "location": "exonic",
      "exon": 13,
      "effect": "frameshift",
      "pNomen": "p.A585Gfs*20"
    },
    {
      "id": 11905,
      "chromosome": "9",
      "start": 35075485,
      "stop": 35075485,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "FANCG is a tumor suppressor and DNA repair protein involved in genome maintenance by regulating the DNA damage control pathway (PMID: 27145721, 21118969, 32002546).<br />\nThe FANCG p.Val471Trpfs*47 frameshift variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in FANCG are known to be oncogenic (PMID: 16762635, 28440438).<br />\nIn this disease site, the FANCG p.Val471Trpfs*47 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/21 17:01:47",
      "evidences": [],
      "reference": "T",
      "alternative": ".",
      "gene": "FANCG",
      "transcript": "NM_004629.1",
      "cNomen": "c.1410delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 10,
      "effect": "frameshift",
      "pNomen": "p.V471Wfs*47"
    },
    {
      "id": 11975,
      "chromosome": "9",
      "start": 36882050,
      "stop": 36882050,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PAX5, paired box protein Pax-5, is a developmental transcription factor, which plays a role in B-cell development (PMID: 21970955, 10524622).<br />\nThe PAX5 p.A322Lfs*11 frameshift variant is predicted to result in an absent or disrupted protein product. Loss-of-function variants in PAX5 are known to be oncogenic (PMID: 17344859, 25855603). The impact of this variant in this disease context is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/15 01:04:53",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "PAX5",
      "transcript": "NM_016734.2",
      "cNomen": "c.963delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 8,
      "effect": "frameshift",
      "pNomen": "p.A322Lfs*11"
    },
    {
      "id": 11128,
      "chromosome": "9",
      "start": 127920568,
      "stop": 127920568,
      "classification": "Very high",
      "variantInfo": "<br />\nThe PPP6C p.Arg148* nonsense variant leads to a premature termination codon, which is predicted to result in a truncated or absent protein. While this particular variant has not been reported in the literature, truncating variants in PPP6C are known to be oncogenic (PMID: 23729733, 28658615, 26868000, 29758119). For these reasons, this variant has been classified as likely oncogenic.<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PPP6C p.Arg148* variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "PPP6C encodes a serine/threonine phosphatase involved in cell cycle progression and DNA double-strand break repair. Alterations in PPP6C have been reported in various cancer types (PMID: 25332711, 22395973, 21481188, 20463022, 24718460).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/25 00:56:36",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "PPP6C",
      "transcript": "NM_001123355.1",
      "cNomen": "c.442C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "stopgain",
      "pNomen": "p.R148*"
    },
    {
      "id": 11655,
      "chromosome": "9",
      "start": 135782168,
      "stop": 135782168,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TSC1, TSC complex subunit 1, is a tumor suppressor (PMID: 30562755) that forms a complex with TSC2 and inhibits mTOR pathway signaling, thus regulating cell growth and metabolism (PMID: 27226234). Somatic TSC1 mutations have been identified in various cancers, including renal cell carcinoma, mucosal melanoma, and breast cancer (PMID: 27226234, 30327302, 29185092, 28027327).<br />\nThe TSC1 p.Leu463* nonsense variant is predicted to result in an absent or disrupted protein product. While this variants has not been reported in the literature, loss-of-function variants in TSC1 are known to be oncogenic (PMID: 23485365, 20301399, 24529379). Germline TSC1 inactivating mutations cause tuberous sclerosis complex and the p.Leu463* variant has been previously reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TSC1 p.Leu463* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/20 19:17:48",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "TSC1",
      "transcript": "NM_000368.4",
      "cNomen": "c.1388delT",
      "type": "deletion",
      "location": "exonic",
      "exon": 14,
      "effect": "stopgain",
      "pNomen": "p.L463*"
    },
    {
      "id": 11586,
      "chromosome": "9",
      "start": 135785964,
      "stop": 135785964,
      "classification": "Very high",
      "variantInfo": "<br />\nThe TSC1 p.Arg420Glyfs*20 frameshift variant is predicted to result in an absent or disrupted protein product. While this variants has not been reported in the literature, loss-of-function variants in TSC1 are known to be oncogenic (PMID: 23485365, 20301399, 24529379). Germline TSC1 inactivating mutations cause tuberous sclerosis complex and the p.Arg420Glyfs*20 has been previously reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TSC1 p.Arg420Glyfs*20 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR inhibitors.<br />\n ",
      "reportAbstract": "TSC1, TSC complex subunit 1, is a tumor suppressor (PMID: 30562755) that forms a complex with TSC2 and inhibits mTOR pathway signaling, thus regulating cell growth and metabolism (PMID: 27226234). Somatic TSC1 mutations have been identified in various cancers, including renal cell carcinoma, mucosal melanoma, and breast cancer (PMID: 27226234, 30327302, 29185092, 28027327).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/27 22:39:06",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "TSC1",
      "transcript": "NM_000368.4",
      "cNomen": "c.1257delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 12,
      "effect": "frameshift",
      "pNomen": "p.R420Gfs*20"
    },
    {
      "id": 11654,
      "chromosome": "9",
      "start": 135786937,
      "stop": 135786937,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TSC1, TSC complex subunit 1, is a tumor suppressor (PMID: 30562755) that forms a complex with TSC2 and inhibits mTOR pathway signaling, thus regulating cell growth and metabolism (PMID: 27226234). Somatic TSC1 mutations have been identified in various cancers, including renal cell carcinoma, mucosal melanoma, and breast cancer (PMID: 27226234, 30327302, 29185092, 28027327).<br />\nThe TSC1 p.Pro311Leufs*7 frameshift variant is predicted to result in an absent or disrupted protein product. While this variants has not been reported in the literature, loss-of-function variants in TSC1 are known to be oncogenic (PMID: 23485365, 20301399, 24529379). Germline TSC1 inactivating mutations cause tuberous sclerosis complex and the p.Pro311Leufs*7 variant has not been previously reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TSC1 p.Pro311Leufs*7 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/20 19:17:31",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "TSC1",
      "transcript": "NM_000368.4",
      "cNomen": "c.932delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 10,
      "effect": "frameshift",
      "pNomen": "p.P311Lfs*7"
    },
    {
      "id": 12182,
      "chromosome": "10",
      "start": 88635782,
      "stop": 88635782,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "BMPR1A is a transmembrane serine/threonine kinase receptor involved in regulating growth and development through activation of the SMAD pathway (PMID: 16246179, 11057902).<br />\nThe BMPR1A p.Gln3* nonsense variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in BMPR1A are likely oncogenic (PMID: 11536076, 20843829). Pathogenic germline variants in BMPR1A have been associated with juvenile polyposis syndrome (PMID: 16246179, 31259752, 31949278, 15235019, 11536076). The p.Gln3* variant has not been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:31",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "BMPR1A",
      "transcript": "NM_004329.2",
      "cNomen": "c.7C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 3,
      "effect": "stopgain",
      "pNomen": "p.Q3*"
    },
    {
      "id": 12405,
      "chromosome": "10",
      "start": 89624271,
      "stop": 89624271,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "The PTEN p.Arg15Ser missense variant lies within the phosphatase tensin-type domain of the PTEN protein (UniProt.org). Experimental studies suggest this variant results in decreased phosphatase activity and impaired nuclear localization in vitro (PMID: 17942903, 25875300, 29706350). Germline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). The PTEN p.Arg15Ser variant has been reported in the germline context (ClinVar). PTEN mutations serve as an inclusion criterion for Phase 2 clinical trials of mTOR inhibitors (e.g. NCT03297606).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/07/06 18:22:53",
      "evidences": [],
      "reference": "A",
      "alternative": "T",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.45A>T",
      "type": "snp",
      "location": "exonic",
      "exon": 1,
      "effect": "nonsynonymous",
      "pNomen": "p.R15S"
    },
    {
      "id": 11989,
      "chromosome": "10",
      "start": 89624275,
      "stop": 89624275,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468). The PTEN p.Gln17* nonsense variant is predicted to result in a truncated or absent protein. While this variant has not been reported in the literature, loss-of-function variants in PTEN are likely oncogenic (PMID: 17218262, 11237521). Preclinical studies suggest PTEN mutations may predict sensitivity to mTOR/PI3K inhibitors (PMID: 22662154, 29636360, 27672108) or pan-RTK inhibitor (PMID: 31992589). Germline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). The PTEN p.Gln17* variant has been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/15 20:28:09",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.49C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 1,
      "effect": "stopgain",
      "pNomen": "p.Q17*"
    },
    {
      "id": 12266,
      "chromosome": "10",
      "start": 89653768,
      "stop": 89653785,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468). The PTEN c.80-14_83del is an intronic deletion variant that affects the acceptor splice site of exon 2 and is predicted to result in aberrant splicing and disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in PTEN are likely oncogenic (PMID: 17218262, 11237521). Preclinical studies suggest PTEN mutations may predict sensitivity to mTOR/PI3K inhibitors (PMID: 22662154, 29636360, 27672108) or pan-RTK inhibitor (PMID: 31992589). Germline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). This variant has not been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/04/27 19:52:34",
      "evidences": [],
      "reference": "ACTAAAGTACTCAGATAT",
      "alternative": ".",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.80-14_83delACTAAAGTACTCAGATAT",
      "type": "deletion",
      "location": "exonic",
      "exon": 2,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11745,
      "chromosome": "10",
      "start": 89653841,
      "stop": 89653841,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468).<br />\nThe PTEN p.Arg47Glyfs*7 frameshift variant lies within the phosphatase domain and is predicted to result in an absent or disrupted protein product. Inactivating variants result in loss of tumor suppressor function and aberrant activation of PI3K signaling, and promotion of cell growth, proliferation and survival (PMID: 12040186, 22473468, 17218262, 11237521). Germline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). The PTEN p.Arg47Glyfs*7 variant has not been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PTEN p.Arg47Glyfs*7 variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:18:05",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.139delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 2,
      "effect": "frameshift",
      "pNomen": "p.R47Gfs*7"
    },
    {
      "id": 12157,
      "chromosome": "10",
      "start": 89690801,
      "stop": 89690801,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468).<br />\nThe PTEN c.210-2A&gt;T splice site variant is located within 2bp of the intron-exon boundary and is predicted to result in aberrant splicing and disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in PTEN are likely oncogenic (PMID: 17218262, 11237521).<br />\nPreclinical studies suggest PTEN mutations may predict sensitivity to mTOR/PI3K inhibitors (PMID: 22662154, 29636360, 27672108) or pan-RTK inhibitor (PMID: 31992589). Germline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). The PTEN c.210-2A&gt;T variant has not been reported in the germline context (ClinVar).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:39",
      "evidences": [],
      "reference": "A",
      "alternative": "T",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.210-2A>T",
      "type": "snp",
      "location": "intronic",
      "exon": 4,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 12404,
      "chromosome": "10",
      "start": 89692790,
      "stop": 89692790,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468).<br />\nThe PTEN p.Asp92His missense variant lies within the phosphatase tensin-type domain of the PTEN protein (UniProt.org). Limited in vitro studies suggest this variant results in decreased phosphatase activity in vitro (PMID: 21828076). Germline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). The PTEN p.Asp92His variant has not been reported in the germline context (ClinVar). PTEN mutations serve as an inclusion criterion for Phase 2 clinical trials of mTOR inhibitors (e.g. NCT03297606).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/07/06 17:52:58",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.274G>C",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.D92H"
    },
    {
      "id": 11691,
      "chromosome": "10",
      "start": 89692904,
      "stop": 89692904,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468).<br />\n<br />\n<br />\nThe PTEN p.Arg130* nonsense variant lies within the catalytic domain and is predicted to result in an absent or disrupted protein product. Functional studies suggest this variant results in loss of tumor suppressor function in vitro and in vivo (PMID: 24721394, 32350270). Germline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). The PTEN p.Arg130* variant has been reported in the germline context (ClinVar).<br />\n<br />\n<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PTEN p.Arg130* variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/28 16:51:39",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.388C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "stopgain",
      "pNomen": "p.R130*"
    },
    {
      "id": 12035,
      "chromosome": "10",
      "start": 89692904,
      "stop": 89692904,
      "classification": "Very high",
      "variantInfo": "Preclinical studies of suggest this variant is responsive to ATR/mTOR/PI3K and MEK inhibitors in endometrial cancer (PMID: 26232337, 26469692).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PTEN p.Arg130Gly variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.",
      "reportAbstract": "PTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468).<br />\nThe PTEN p.Arg130Gly missense variant lies within the catalytic domain. Functional studies suggest this variant results in decreased phosphatase activity in vitro (PMID: 10866302, 11051241). Germline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). The PTEN p.Arg130Gly variant has been reported in the germline context as pathogenic (ClinVar).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/28 19:56:22",
      "evidences": [],
      "reference": "C",
      "alternative": "G",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.388C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.R130G"
    },
    {
      "id": 11656,
      "chromosome": "10",
      "start": 89692905,
      "stop": 89692905,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468).<br />\nThe PTEN p.Arg130Gln missense variant lies within the catalytic domain. Functional studies suggest this variant results in decreased phosphatase activity in vitro (PMID: 10866302, 17942903). Germline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). The PTEN p.Arg130Gln variant has been reported in the germline context as pathogenic (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PTEN p.Arg130Gln variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR or PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/20 19:22:27",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.389G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.R130Q"
    },
    {
      "id": 12227,
      "chromosome": "10",
      "start": 89692905,
      "stop": 89692905,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468).<br />\nThe PTEN p.Arg130Leu missense variant lies within the catalytic domain. Functional studies suggest this variant results in decreased phosphatase activity in vitro (PMID: 10866302, 25527629). Germline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). The PTEN p.Arg130Leu variant has been reported in the germline context (ClinVar). PTEN mutations serve as an inclusion criterion for Phase 2 clinical trials of mTOR inhibitors (e.g. NCT03297606).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/04/23 14:51:19",
      "evidences": [],
      "reference": "G",
      "alternative": "T",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.389G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.R130L"
    },
    {
      "id": 11565,
      "chromosome": "10",
      "start": 89692920,
      "stop": 89692920,
      "classification": "Very high",
      "variantInfo": "<br />\nThe PTEN p.Cys136Metfs*44 frameshift variant is predicted to result in an absent or disrupted protein product. Inactivating variants result in loss of tumor suppressor function and aberrant activation of PI3K signaling, and promotion of cell growth, proliferation and survival (PMID: 12040186, 22473468, 17218262, 11237521). Germline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). The PTEN p.Cys136Metfs*44 variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PTEN p.Cys136Metfs*44 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR or PARP inhibitors.<br />\n ",
      "reportAbstract": "PTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/24 02:16:45",
      "evidences": [],
      "reference": ".",
      "alternative": "A",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.405dupA",
      "type": "insertion",
      "location": "exonic",
      "exon": 5,
      "effect": "frameshift",
      "pNomen": "p.C136Mfs*44"
    },
    {
      "id": 11753,
      "chromosome": "10",
      "start": 89711876,
      "stop": 89711876,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468).<br />\nThe PTEN p.Gly165Glu missense variant lies within the phosphatase domain. Limited in vitro assays suggest this variant results in loss of phosphatase activity (PMID: 21828076). Germline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). This p.Gly165Glu variant may be associated with hereditary cancer (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PTEN p.Gly165Glu variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:26:19",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.494G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 6,
      "effect": "nonsynonymous",
      "pNomen": "p.G165E"
    },
    {
      "id": 11027,
      "chromosome": "10",
      "start": 89711900,
      "stop": 89711900,
      "classification": "Very high",
      "variantInfo": "The PTEN p.Arg173Pro missense variant lies within the phosphatase tensin-type domain. Functional studies suggest this variant results in decreased phosphatase activity in vitro (PMID: 10866302). Germline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). The PTEN p.Arg173Pro variant has been reported in the germline context by two clinical laboratories as likely pathogenic (ClinVar); this variant has not been reported in population studies (gnomAD).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PTEN p.Arg173Pro variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR or PARP inhibitors.",
      "reportAbstract": "PTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/10 21:59:23",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.518G>C",
      "type": "snp",
      "location": "exonic",
      "exon": 6,
      "effect": "nonsynonymous",
      "pNomen": "p.R173P"
    },
    {
      "id": 11754,
      "chromosome": "10",
      "start": 89711928,
      "stop": 89711928,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "<br />\nPTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468).<br />\nThe PTEN p.Lys183Argfs*16 frameshift variant lies within the phosphatase domain and is predicted to result in an absent or disrupted protein product. Inactivating variants result in loss of tumor suppressor function and aberrant activation of PI3K signaling, and promotion of cell growth, proliferation and survival (PMID: 12040186, 22473468, 17218262, 11237521). Germline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). This p.Lys183Argfs*16 variant may be associated with hereditary cancer (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PTEN p.Lys183Argfs*16 variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:26:58",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.548delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 6,
      "effect": "frameshift",
      "pNomen": "p.K183Rfs*16"
    },
    {
      "id": 11641,
      "chromosome": "10",
      "start": 89711993,
      "stop": 89711993,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468).<br />\nThe PTEN p.Pro204Leu missense variant lies within the phosphatase tensin-type domain. While this particular variant has not been reported in the literature, another missense mutation affecting the same codon has been identified as pathogenic (PMID: 11156408). Germline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). The PTEN p.Pro204Leu variant has not been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PTEN p.Pro204Leu variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR or PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/14 17:02:08",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.611C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 6,
      "effect": "nonsynonymous",
      "pNomen": "p.P204L"
    },
    {
      "id": 11642,
      "chromosome": "10",
      "start": 89717615,
      "stop": 89717615,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468).<br />\nThe PTEN p.Gln214* nonsense variant is predicted to result in an absent or disrupted protein product. Inactivating variants result in loss of tumor suppressor function and aberrant activation of PI3K signaling, and promotion of cell growth, proliferation and survival (PMID: 12040186, 22473468, 17218262, 11237521). Germline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). The PTEN p.Gln214* variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PTEN p.Gln214* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR or PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/14 17:04:31",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.640C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "stopgain",
      "pNomen": "p.Q214*"
    },
    {
      "id": 12138,
      "chromosome": "10",
      "start": 89717672,
      "stop": 89717672,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468). The PTEN p.Arg233* nonsense variant is predicted to result in a truncated or absent protein. Loss-of-function variants in PTEN are likely oncogenic (PMID: 17218262, 11237521). Functional studies suggest this variant results in loss of ability to suppress E2F1-mediated transcription and increased proliferation in vitro (PMID: 29108454, 29533785). Preclinical studies suggest PTEN mutations may predict sensitivity to mTOR/PI3K inhibitors (PMID: 22662154, 29636360, 27672108) or pan-RTK inhibitor (PMID: 31992589). Germline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). The PTEN p.Arg233* variant has been reported as pathogenic in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/02/22 21:42:20",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.697C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "stopgain",
      "pNomen": "p.R233*"
    },
    {
      "id": 11173,
      "chromosome": "10",
      "start": 89717770,
      "stop": 89717770,
      "classification": "Very high",
      "variantInfo": "The PTEN p.Lys267Argfs*9 frameshift variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, other C-terminal deletion mutants downstream of K267 are inactivating (PMID: 10468583). Germline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). The PTEN p.Lys267Argfs*9 variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PTEN p.Lys267Argfs*9 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR or PARP inhibitors.<br />\n ",
      "reportAbstract": "PTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/04/16 03:23:52",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.800delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 7,
      "effect": "frameshift",
      "pNomen": "p.K267Rfs*9"
    },
    {
      "id": 12188,
      "chromosome": "10",
      "start": 89720724,
      "stop": 89720755,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468).<br />\nThe PTEN p.Gly293Leufs*8 frameshift variant is predicted to result in an absent or disrupted protein product. Loss-of-function variants in PTEN are likely oncogenic (PMID: 17218262, 11237521). Preclinical studies suggest PTEN mutations may predict sensitivity to mTOR/PI3K inhibitors (PMID: 22662154, 29636360, 27672108) or pan-RTK inhibitor (PMID: 31992589).<br />\nGermline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). The PTEN p.Gly293Leufs*8 variant has not been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:39",
      "evidences": [],
      "reference": "ATGGAAGTCTATGTGATCAAGAAATCGATAGC",
      "alternative": ".",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.877_908delGGAAGTCTATGTGATCAAGAAATCGATAGCAT",
      "type": "deletion",
      "location": "exonic",
      "exon": 8,
      "effect": "frameshift",
      "pNomen": "p.G293Lfs*8"
    },
    {
      "id": 11746,
      "chromosome": "10",
      "start": 89720726,
      "stop": 89720726,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468).<br />\nThe PTEN p.Gly293* nonsense variant lies within the C2 domain and is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, other C-terminal deletion mutants downstream of K267 are inactivating (PMID: 10468583). Germline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). The PTEN p.Gly293* variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PTEN p.Gly293* variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:19:11",
      "evidences": [],
      "reference": "G",
      "alternative": "T",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.877G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "stopgain",
      "pNomen": "p.G293*"
    },
    {
      "id": 12389,
      "chromosome": "10",
      "start": 89720793,
      "stop": 89720793,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468).<br />\nThe PTEN p.Leu316Serfs*9 frameshift variant is predicted to result in an absent or disrupted protein product. Loss-of-function variants in PTEN are likely oncogenic (PMID: 17218262, 11237521). Preclinical studies suggest PTEN mutations may predict sensitivity to mTOR/PI3K inhibitors (PMID: 22662154, 29636360, 27672108) or pan-RTK inhibitor (PMID: 31992589).<br />\nGermline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). The PTEN p.Leu316Serfs*9 variant has not been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/06/25 18:31:43",
      "evidences": [],
      "reference": ".",
      "alternative": "T",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.945dupT",
      "type": "insertion",
      "location": "exonic",
      "exon": 8,
      "effect": "frameshift",
      "pNomen": "p.L316Sfs*9"
    },
    {
      "id": 11308,
      "chromosome": "10",
      "start": 89720799,
      "stop": 89720802,
      "classification": "Very high",
      "variantInfo": "<br />\nThe PTEN p.Thr319* nonsense variant is predicted to result in an absent or disrupted protein product. Inactivating variants result in loss of tumor suppressor function and aberrant activation of PI3K signaling, and promotion of cell growth, proliferation and survival (PMID: 12040186, 22473468, 17218262, 11237521). Germline pathogenic variants in PTEN are associated with PTEN Hamartoma Tumour Syndrome (PHTS), which encompasses a spectrum of clinical disorders including Cowden syndrome (PMID: 8673088). The PTEN p.Thr319* variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PTEN p.Thr319* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR or PARP inhibitors.<br />\n ",
      "reportAbstract": "PTEN is a tumor suppressor that is involved in cell growth, proliferation, and survival through the PI3K/AKT/MTOR pathway (PMID: 30562755, 12040186, 18794886, 18767981) and is frequently mutated in many cancers (PMID: 30142194, 9072974, 22473468).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/06/12 03:03:07",
      "evidences": [],
      "reference": "TACT",
      "alternative": ".",
      "gene": "PTEN",
      "transcript": "NM_000314.4",
      "cNomen": "c.955_958delACTT",
      "type": "deletion",
      "location": "exonic",
      "exon": 8,
      "effect": "stopgain",
      "pNomen": "p.T319*"
    },
    {
      "id": 12183,
      "chromosome": "10",
      "start": 90770509,
      "stop": 90770509,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "FAS (also referred to as FAS1, CD95, APO-1) encodes a death receptor that mediates apoptosis (PMID: 11739735, 12655293). FAS can also activate other downstream pathways including the NF-KB and JNK pathways (PMID: 8647190, 20505730, 22042271). Somatic FAS mutations and altered expression have been reported in non-Hodgkin lymphoma, colorectal and breast cancer (PMID: 9787134, 28766682, 28121628).<br />\nThe c.506-1G&gt;T splice site variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in FAS are known to be oncogenic (PMID: 10190897, 28521443, 11454987, 12204534).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:43",
      "evidences": [],
      "reference": "G",
      "alternative": "T",
      "gene": "FAS",
      "transcript": "NM_000043.4",
      "cNomen": "c.506-1G>T",
      "type": "snp",
      "location": "intronic",
      "exon": 6,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11368,
      "chromosome": "10",
      "start": 90774046,
      "stop": 90774046,
      "classification": "Very high",
      "variantInfo": "<br />\nThe p.Gln283* nonsense variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in FAS are known to be oncogenic (PMID: 10190897, 28521443, 11454987, 12204534).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the FAS p.Gln283* variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "FAS (also referred to as FAS1, CD95, APO-1) encodes a death receptor that mediates apoptosis (PMID: 11739735, 12655293). FAS can also activate other downstream pathways including the NF-KB and JNK pathways (PMID: 8647190, 20505730, 22042271). Somatic FAS mutations and altered expression have been reported in non-Hodgkin lymphoma, colorectal and breast cancer (PMID: 9787134, 28766682, 28121628). Germline mutations in FAS are associated with an autoimmune lymphoproliferative syndrome, a disorder associated with chronic lymphadenopathy and an increased risk of lymphoma development (PMID: 7540117, 11418480).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/06/29 17:51:20",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "FAS",
      "transcript": "NM_000043.4",
      "cNomen": "c.847C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 9,
      "effect": "stopgain",
      "pNomen": "p.Q283*"
    },
    {
      "id": 12390,
      "chromosome": "10",
      "start": 114925317,
      "stop": 114925317,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TCF7L2 (also known as TCF-4) is a transcription factor involved in cell proliferation and metabolism through regulation of the Wnt signaling pathway (PMID: 18177486, 22934027, 26955760, 18289012). Inactivating mutations in TCF7L2 have been reported in colorectal cancers with microsatellite instability (PMID: 10485457, 11876551, 18621708, 10919662). The TCF7L2 p.Lys468Serfs*23 frameshift variant is expected to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in TCF7L2 are likely oncogenic (PMID: 10919662, 16547505, 18599616, 10485457). Germline mutations in TCF7L2 have been weakly associated with colorectal cancer risk (PMID: 18398040, 18478343, 30026326). The TCF7L2 p.Lys468Serfs*23 has not been reported in the germline context (ClinVar).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/06/25 18:33:53",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "TCF7L2",
      "transcript": "NM_001146274.1",
      "cNomen": "c.1403delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 14,
      "effect": "frameshift",
      "pNomen": "p.K468Sfs*23"
    },
    {
      "id": 12224,
      "chromosome": "10",
      "start": 123247516,
      "stop": 123247516,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "FGFR2, fibroblast growth factor receptor 2, is a receptor tyrosine kinase and upon binding of the FGF ligand, results in the activation of downstream signaling pathways including the PI3K/AKT and MAPK pathways (PMID: 22508544, 20094046, 16597617). Activating mutations are found in 10 to 16% of endometrial cancer (PMID:1752574, 23636398).<br />\nThe FGFR2 p.Lys659Glu missense variant occurs within the kinase domain (UniProt). Experimental studies suggest this variant is a gain-of-function alteration that results in induced colony formation and transformation in vitro (PMID: 23786770, 19403560). In other disease sites, this variant is predicted responsive to pan-FGFR inhibitor (PMID: 31340094).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/25 01:48:52",
      "evidences": [],
      "reference": "T",
      "alternative": "C",
      "gene": "FGFR2",
      "transcript": "NM_000141.4",
      "cNomen": "c.1975A>G",
      "type": "snp",
      "location": "exonic",
      "exon": 14,
      "effect": "nonsynonymous",
      "pNomen": "p.K659E"
    },
    {
      "id": 11562,
      "chromosome": "10",
      "start": 123279677,
      "stop": 123279677,
      "classification": "Very high",
      "variantInfo": "<br />\nThe FGFR2 p.Ser252Trp missense variant occurs within the linker between the extracellular immunoglobulin domains of the FGFR2 gene, a region critical ligand contact region. This variant has been previously reported in endometrial carcinomas (PMID: 23636398, 17525745). Experimental studies suggest this variant is a gain-of-function alteration that results in altered ligand-binding specificities (PMID: 15282208, 17525745).<br />\nA search by the Watson for Genomics platform indicates in this disease site, FGFR2 p.Ser252Trp variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of FGFR2 inhibitors.<br />\n ",
      "reportAbstract": "FGFR2, fibroblast growth factor receptor 2, is a receptor tyrosine kinase and upon binding of the FGF ligand, results in the activation of downstream signaling pathways including the PI3K/AKT and MAPK pathways (PMID: 22508544, 20094046, 16597617). Activating mutations are found in 10 to 16% of endometrial cancer (PMID:1752574, 23636398).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/24 02:00:30",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "FGFR2",
      "transcript": "NM_000141.4",
      "cNomen": "c.755C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "nonsynonymous",
      "pNomen": "p.S252W"
    },
    {
      "id": 12395,
      "chromosome": "11",
      "start": 533874,
      "stop": 533874,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "HRAS is a member of the small GTPase family that upon activation by growth factors stimulates multiple downstream pathways such as RAF and PI3K to promote cell proliferation and survival (PMID: 21779504, 32241873).<br />\nThe HRAS p.Gln61Arg variant is a hotspot mutation that does not lie within any known functional domain (UniProt). Experimental studies suggest this variant results in decreased HRAS GTPase activity and increased cell proliferation in vitro (PMID: 3510078). Preclinical studies in other disease sites suggest this variant is predicted sensitive to farnesyltransferase or AKT inhibitors (PMID: 32636318, 32727882, 21289267), however the impact of this variant in this disease context remains unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/06/29 15:49:16",
      "evidences": [],
      "reference": "T",
      "alternative": "C",
      "gene": "HRAS",
      "transcript": "NM_005343.2",
      "cNomen": "c.182A>G",
      "type": "snp",
      "location": "exonic",
      "exon": 3,
      "effect": "nonsynonymous",
      "pNomen": "p.Q61R"
    },
    {
      "id": 11961,
      "chromosome": "11",
      "start": 534286,
      "stop": 534286,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "HRAS is a member of the small GTPase family that upon activation by growth factors stimulates multiple downstream pathways such as RAF and PI3K to promote cell proliferation and survival (PMID: 21779504, 32241873).<br />\nThe HRAS p.Gly13Arg variant is a hotspot mutation that lies within the GTP binding domain of the HRAS protein (UniProt). Experimental studies suggest this variant results in activation of MAPK and PI3K signaling and increased cell proliferation in vitro (PMID: 22683711, 21993244). Preclinical studies in other disease sites suggest this variant is predicted sensitive to farnesyltransferase or AKT inhibitors (PMID: 32636318, 32727882, 21289267), however the impact of this variant in this disease context remains unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/14 19:31:21",
      "evidences": [],
      "reference": "C",
      "alternative": "G",
      "gene": "HRAS",
      "transcript": "NM_005343.2",
      "cNomen": "c.37G>C",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "nonsynonymous",
      "pNomen": "p.G13R"
    },
    {
      "id": 11900,
      "chromosome": "11",
      "start": 44193237,
      "stop": 44193237,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "EXT2 encodes for a transmembrane glycoprotein involved in the biosynthesis of heparin sulphate. Germline mutation and functional loss of EXT2 are found in multiple osteochondromas and predispose to the development of chondrosarcoma (PMID: 7550340, 8782816, 24458248).<br />\nThe EXT2 p.Ile451Serfs*18 frameshift variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in EXT2 may be oncogenic (PMID: 24458248, 15796962, 10441575).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the EXT2 p.Ile451Serfs*18 variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/21 16:21:25",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "EXT2",
      "transcript": "NM_000401.3",
      "cNomen": "c.1350delG",
      "type": "deletion",
      "location": "exonic",
      "exon": 8,
      "effect": "frameshift",
      "pNomen": "p.I451Sfs*18"
    },
    {
      "id": 12262,
      "chromosome": "11",
      "start": 108117692,
      "stop": 108117692,
      "classification": "High",
      "variantInfo": "",
      "reportAbstract": "ATM is a tumor suppressor, a serine/threonine protein kinase involved in DNA damage and repair (PMID: 24003211). Somatic mutations in ATM have been identified in lymphoid malignancies and certain solid tumors (PMID: 12400598, 27413114).<br />\nThe ATM c.903T&gt;G variant affects a splice site and may result in an altered protein product or absence of protein due to nonsense mediated decay. Loss of ATM results in increased sensitivity to DNA damaging agents due to deficits in DNA repair pathways, and ATM loss-of-function variants may result in better response to checkpoint inhibitors (PMID: 32988960, 27413114, 29489427).<br />\nGermline ATM mutations are a defining feature of ataxia telangiectasia syndrome, a neurodegenerative, autosomal disorder that predisposes to various cancers (PMID: 10817650, 19781682, 21792198). The ATM c.903T&gt;G variant has been reported in the germline context by 3 clinical laboratories as likely benign (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/04/27 18:48:59",
      "evidences": [],
      "reference": "T",
      "alternative": "G",
      "gene": "ATM",
      "transcript": "NM_000051.3",
      "cNomen": "c.903T>G",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "synonymous",
      "pNomen": "p.G301="
    },
    {
      "id": 10995,
      "chromosome": "11",
      "start": 108168013,
      "stop": 108168013,
      "classification": "Very high",
      "variantInfo": "The ATM c.4910-1G&gt;A variant is a splice site variant and predicted to result in an altered protein product or absence of protein due to nonsense mediated decay. Loss of ATM results in increased sensitivity to DNA damaging agents due to deficits in DNA repair pathways, and ATM loss-of-function variants may result in better response to checkpoint inhibitors (PMID: 27413114, 29489427).<br />\nGermline ATM mutations are a defining feature of ataxia telangiectasia syndrome, a neurodegenerative, autosomal disorder that predisposes to various cancers (PMID: 10817650, 19781682, 21792198). The ATM c.4910-1G&gt;A variant has been reported in the germline context by 1 clinical laboratory as likely pathogenic (ClinVar); this variant has not been reported in population studies (gnomAD).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ATM c.4910-1G&gt;A variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.",
      "reportAbstract": "ATM is a tumor suppressor, a serine/threonine protein kinase involved in DNA damage and repair (PMID: 24003211). Somatic mutations in ATM have been identified in lymphoid malignancies and certain solid tumors (PMID: 12400598, 27413114).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:31",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "ATM",
      "transcript": "NM_000051.3",
      "cNomen": "c.4910-1G>A",
      "type": "snp",
      "location": "intronic",
      "exon": 33,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11578,
      "chromosome": "11",
      "start": 108201089,
      "stop": 108201089,
      "classification": "Very high",
      "variantInfo": "<br />\nThe p.Arg2486* nonsense variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in ATM are known to be oncogenic (PMID: 15928302, 16832357, 16998505). Pathogenic germline variants in ATM have been associated with susceptibility to breast cancer (PMID: 27112364, 21787400, 27595995, 29522266). This p.Arg2486* variant may be associated with hereditary cancer (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ATM p.Arg2486*<b>  </b>variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.<br />\n ",
      "reportAbstract": "ATM is a tumor suppressor and a serine/threonine protein kinase involved in DNA damage and repair (PMID: 24003211). Somatic mutations in ATM have been identified in lymphoid malignancies and certain solid tumors (PMID: 12400598, 27413114). ATM-mutant cancers are sensitive to DNA damaging agents due to deficits in DNA repair pathways, and ATM loss may result in better response to checkpoint inhibition in some cancers (PMID: 27413114, 29489427).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/27 21:59:02",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "ATM",
      "transcript": "NM_000051.3",
      "cNomen": "c.7456C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 50,
      "effect": "stopgain",
      "pNomen": "p.R2486*"
    },
    {
      "id": 11750,
      "chromosome": "11",
      "start": 108201105,
      "stop": 108201105,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ATM is a tumor suppressor and a serine/threonine protein kinase involved in DNA damage and repair (PMID: 24003211). Somatic mutations in ATM have been identified in lymphoid malignancies and certain solid tumors (PMID: 12400598, 27413114). ATM-mutant cancers are sensitive to DNA damaging agents due to deficits in DNA repair pathways, and ATM loss may result in better response to checkpoint inhibition in some cancers (PMID: 27413114, 29489427).<br />\nThe p.Trp2491* nonsense variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in ATM are known to be oncogenic (PMID: 15928302, 16832357, 16998505). Pathogenic germline variants in ATM have been associated with susceptibility to breast cancer (PMID: 27112364, 21787400, 27595995, 29522266). The ATM p.Trp2491* variant has not been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ATM p.Trp2491* variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:23:50",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "ATM",
      "transcript": "NM_000051.3",
      "cNomen": "c.7472G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 50,
      "effect": "stopgain",
      "pNomen": "p.W2491*"
    },
    {
      "id": 11796,
      "chromosome": "11",
      "start": 108224492,
      "stop": 108224492,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ATM is a tumor suppressor and a serine/threonine protein kinase involved in DNA damage and repair (PMID: 24003211). Somatic mutations in ATM have been identified in lymphoid malignancies and certain solid tumors (PMID: 12400598, 27413114). ATM-mutant cancers are sensitive to DNA damaging agents due to deficits in DNA repair pathways, and ATM loss may result in better response to checkpoint inhibition in some cancers (PMID: 27413114, 29489427).<br />\nThe c.8672-1G&gt;T splice site variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in ATM are known to be oncogenic (PMID: 15928302, 16832357, 16998505). Pathogenic germline variants in ATM have been associated with susceptibility to breast cancer (PMID: 27112364, 21787400, 27595995, 29522266). The ATM c.8672-1G&gt;T variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ATM c.8672-1G&gt;T variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:31",
      "evidences": [],
      "reference": "G",
      "alternative": "T",
      "gene": "ATM",
      "transcript": "NM_000051.3",
      "cNomen": "c.8672-1G>T",
      "type": "snp",
      "location": "intronic",
      "exon": 60,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11758,
      "chromosome": "11",
      "start": 108236087,
      "stop": 108236087,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ATM is a tumor suppressor and a serine/threonine protein kinase involved in DNA damage and repair (PMID: 24003211). Somatic mutations in ATM have been identified in lymphoid malignancies and certain solid tumors (PMID: 12400598, 27413114). ATM-mutant cancers are sensitive to DNA damaging agents due to deficits in DNA repair pathways, and ATM loss may result in better response to checkpoint inhibition in some cancers (PMID: 27413114, 29489427).<br />\nThe ATM p.Arg3008His missense variant is predicted to confer a loss of function as indicated by reduced ATM protein expression levels and deficient TP53 gene induction in vitro (PMID: 11756177, 23585524). Pathogenic germline variants in ATM have been associated with susceptibility to breast cancer (PMID: 27112364, 21787400, 27595995, 29522266). The ATM p.Arg3008His variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ATM p.Arg3008His variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:32:03",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "ATM",
      "transcript": "NM_000051.3",
      "cNomen": "c.9023G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 63,
      "effect": "nonsynonymous",
      "pNomen": "p.R3008H"
    },
    {
      "id": 12341,
      "chromosome": "11",
      "start": 118343057,
      "stop": 118343057,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KMT2A encodes a histone methyltransferase (also referred to as MLL1) and is altered by mutation or deletion in various solid tumors, and by chromosomal rearrangement in hematologic malignancies. Methylation of H3K4 leads to increased genome accessibility, recruitment of transcriptional complexes, and activation of gene expression (PMID: 25998713).<br />\nThe KMT2A p.Gln395* nonsense variant leads to a premature termination codon, which is predicted to result in a truncated or absent protein. While this particular variant has not been reported in the literature, loss-of-function variants in KMT2A may be oncogenic (PMID: 25998713). For these reasons, this variant has been classified as likely oncogenic.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/05/26 20:37:48",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "KMT2A",
      "transcript": "NM_001197104.1",
      "cNomen": "c.1183C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 3,
      "effect": "stopgain",
      "pNomen": "p.Q395*"
    },
    {
      "id": 11165,
      "chromosome": "11",
      "start": 118376179,
      "stop": 118376182,
      "classification": "Very high",
      "variantInfo": "The KMT2A p.Val3191Glyfs*23 frameshift variant leads to a premature termination codon, which is predicted to result in a truncated or absent protein. While this particular variant has not been reported in the literature, loss-of-function variants in KMT2A may be oncogenic (PMID: 25998713). For these reasons, this variant has been classified as likely oncogenic.<br />\nA search by the Watson for Genomics platform indicates in this disease site, the KMT2A p.Val3191Glyfs*23 variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "KMT2A encodes a histone methyltransferase (also referred to as MLL1) and is altered by mutation or deletion in various solid tumors, and by chromosomal rearrangement in hematologic malignancies. Methylation of H3K4 leads to increased genome accessibility, recruitment of transcriptional complexes, and activation of gene expression (PMID: 25998713).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/04/16 02:21:05",
      "evidences": [],
      "reference": "TTCA",
      "alternative": ".",
      "gene": "KMT2A",
      "transcript": "NM_001197104.1",
      "cNomen": "c.9572_9575delTTCA",
      "type": "deletion",
      "location": "exonic",
      "exon": 27,
      "effect": "frameshift",
      "pNomen": "p.V3191Gfs*23"
    },
    {
      "id": 12342,
      "chromosome": "11",
      "start": 118376768,
      "stop": 118376771,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KMT2A encodes a histone methyltransferase (also referred to as MLL1) and is altered by mutation or deletion in various solid tumors, and by chromosomal rearrangement in hematologic malignancies. Methylation of H3K4 leads to increased genome accessibility, recruitment of transcriptional complexes, and activation of gene expression (PMID: 25998713).<br />\nThe KMT2A p.Gln3390Argfs*33 frameshift variant leads to a premature termination codon, which is predicted to result in a truncated or absent protein. While this particular variant has not been reported in the literature, loss-of-function variants in KMT2A may be oncogenic (PMID: 25998713). For these reasons, this variant has been classified as likely oncogenic.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/05/26 20:40:57",
      "evidences": [],
      "reference": "AGCT",
      "alternative": ".",
      "gene": "KMT2A",
      "transcript": "NM_001197104.1",
      "cNomen": "c.10164_10167delTAGC",
      "type": "deletion",
      "location": "exonic",
      "exon": 27,
      "effect": "frameshift",
      "pNomen": "p.Q3390Rfs*33"
    },
    {
      "id": 12119,
      "chromosome": "12",
      "start": 25398281,
      "stop": 25398281,
      "classification": "Very high",
      "variantInfo": "CERVICAL: Preclinical evidence in other disease sites suggest this variant is predicted sensitive to MEK/PI3K inhibitor (PMID: 29067643, 26369631, 27104980, 33273059).",
      "reportAbstract": "KRAS is an oncogene and a member of the Ras family of membrane proteins that bind GDP/GTP and possess GTPase activity. RAS proteins are central mediators of RAF/MEK/ERK and PI3K/AKT signaling, critical for cell proliferation, survival and differentiation (PMID: 21993244, 23622131, 31988705). The KRAS gene is one of the most commonly mutated genes in human malignancies, with high incidences in pancreatic, colorectal, and lung cancers (PMID: 17520196, 22011285, 22016105).The KRAS p.Gly13Asp missense variant lies within a hotspot mutation region and affects the GTP-binding region of the KRAS protein (UniProt.org). This variant results in decreased KRAS GTPase activity and increased activation of downstream signaling and cell growth in vitro (PMID: 23455880, 26037647, 25705018, 20147967).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/02/18 20:25:47",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "KRAS",
      "transcript": "NM_033360.3",
      "cNomen": "c.38G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "nonsynonymous",
      "pNomen": "p.G13D"
    },
    {
      "id": 11931,
      "chromosome": "12",
      "start": 25398284,
      "stop": 25398284,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KRAS is an oncogene and a member of the Ras family of membrane proteins that bind GDP/GTP and possess GTPase activity. RAS proteins are central mediators of RAF/MEK/ERK and PI3K/AKT signaling, critical for cell proliferation, survival and differentiation (PMID: 21993244, 23622131, 31988705). The KRAS gene is one of the most commonly mutated genes in human malignancies, with high incidences in pancreatic, colorectal, and lung cancers (PMID: 17520196, 22011285, 22016105).<br />\nThe KRAS p.Gly12Ala variant is a hotspot mutation that lies within a GTP-binding region of the KRAS protein (UniProt.org). This variant results in decreased KRAS GTPase activity and increased activation of downstream signaling (PMID: 23455880, 26037647, 32079091). In other disease sites, activating variants in codons 12 are associated with poorer outcome in response to anti-EGFR therapies (PMID: 23182985, 23429431, 24024839).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the KRAS p.Gly12Ala variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MEK inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/14 19:32:07",
      "evidences": [],
      "reference": "C",
      "alternative": "G",
      "gene": "KRAS",
      "transcript": "NM_033360.3",
      "cNomen": "c.35G>C",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "nonsynonymous",
      "pNomen": "p.G12A"
    },
    {
      "id": 11963,
      "chromosome": "12",
      "start": 25398284,
      "stop": 25398284,
      "classification": "Very high",
      "variantInfo": "Preclinical studies suggest this variant is predicted sensitive to combined MEK and PI3K inhibitor (PMID: 29067643).",
      "reportAbstract": "KRAS is an oncogene and a member of the Ras family of membrane proteins that bind GDP/GTP and possess GTPase activity. RAS proteins are central mediators of RAF/MEK/ERK and PI3K/AKT signaling, critical for cell proliferation, survival and differentiation (PMID: 21993244, 23622131, 31988705). The KRAS gene is one of the most commonly mutated genes in human malignancies, with high incidences in pancreatic, colorectal, and lung cancers (PMID: 17520196, 22011285, 22016105).<br />\nThe KRAS p.Gly12Asp a hotspot mutation that lies within a GTP-binding region of the Kras protein (UniProt.org). This variant results in decreased Kras GTPase activity and increased activation of downstream signaling, leading to increased cell growth in a variety of lineages and tumour models (PMID: 20570890, 20147967, 11751631, 15093544, 19296721, 17349581, 26037647).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/14 19:55:04",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "KRAS",
      "transcript": "NM_033360.3",
      "cNomen": "c.35G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "nonsynonymous",
      "pNomen": "p.G12D"
    },
    {
      "id": 12043,
      "chromosome": "12",
      "start": 25398284,
      "stop": 25398284,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KRAS is an oncogene and a member of the Ras family of membrane proteins that bind GDP/GTP and possess GTPase activity. RAS proteins are central mediators of RAF/MEK/ERK and PI3K/AKT signaling, critical for cell proliferation, survival and differentiation (PMID: 21993244, 23622131, 31988705). The KRAS gene is one of the most commonly mutated genes in human malignancies, with high incidences in pancreatic, colorectal, and lung cancers (PMID: 17520196, 22011285, 22016105). The KRAS p.Gly12Val is a hotspot mutation that lies within a GTP-binding region of the Kras protein (UniProt.org). This variant results in decreased Kras GTPase activity and increased activation of downstream signaling, leading to increased cell growth in a variety of lineages and tumour models (PMID: 23455880, 26037647, 24642870, 29533785, 20516123, 25359494, 12957286). Preclinical evidence suggest this variant is predicted sensitive to MEK inhibitors (PMID: 29844129, 29067643, 27231576, 26125448).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/31 15:01:19",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "KRAS",
      "transcript": "NM_033360.3",
      "cNomen": "c.35G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "nonsynonymous",
      "pNomen": "p.G12V"
    },
    {
      "id": 11653,
      "chromosome": "12",
      "start": 25398285,
      "stop": 25398285,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KRAS is an oncogene and a member of the Ras family of membrane proteins that bind GDP/GTP and possess GTPase activity. RAS proteins are central mediators of RAF/MEK/ERK and PI3K/AKT signaling, critical for cell proliferation, survival and differentiation (PMID: 21993244, 23622131, 31988705). The KRAS gene is one of the most commonly mutated genes in human malignancies, with high incidences in pancreatic, colorectal, and lung cancers (PMID: 17520196, 22011285, 22016105).<br />\nThe KRAS p.Gly12Cys variant is a hotspot mutation that lies within a GTP-binding region of the KRAS protein (UniProt.org). This variant results in decreased KRAS GTPase activity and increased activation of downstream signaling, leading to increased cell growth in a variety of lineages and tumour models (PMID: 25705018, 26841430, 25705018, 16051643). In other disease sites, this variant is targetable by KRAS or MEK inhibitor therapies (PMID: 27068338, 31666701, 31658955).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the KRAS p.Gly12Cys variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MEK inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/20 19:09:31",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "KRAS",
      "transcript": "NM_033360.3",
      "cNomen": "c.34G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "nonsynonymous",
      "pNomen": "p.G12C"
    },
    {
      "id": 11811,
      "chromosome": "12",
      "start": 46231280,
      "stop": 46231280,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ARID2 is a member of the SWI/SNF chromatin remodeling complex and is involved in cell-cycle activation (PMID: 32303701, 29072391). Truncating, inactivating mutations have been described in hepatocellular carcinoma (PMID: 22095441, 28238438) and other cancer types (PMID: 23047306, 25790038, 29072391, 32303701).<br />\nThe c.1121-1G&gt;A splice site variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in ARID2 are known to be oncogenic (PMID: 15985610, 16847454).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ARID2 c.1121-1G&gt;A variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/25 21:43:36",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "ARID2",
      "transcript": "NM_152641.2",
      "cNomen": "c.1121-1G>A",
      "type": "snp",
      "location": "intronic",
      "exon": 10,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 12185,
      "chromosome": "12",
      "start": 49420204,
      "stop": 49420204,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KMT2D (also referred to as MLL2) is a histone-lysine methyltransferase involved in transcriptional regulation (PMID: 28669924). KMT2D alterations have been reported in follicular and diffuse large B cell lymphoma (PMID: 21804550, 21796119).<br />\nThe KMT2D p.Gly5182Alafs*61 frameshift variant is predicted to result in an absent or disrupted protein product. Loss-of-function variants in KMT2D are known to be oncogenic (PMID: 24633898, 24240169, 26366712). In case reports of other disease sites, loss of function variants in KMT2D are predicted sensitive to combined BTK and BCL2 inhibitor therapy (PMID: 30455436), however the impact of this variant in this disease context is uncertain.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:31",
      "evidences": [],
      "reference": "C",
      "alternative": ".",
      "gene": "KMT2D",
      "transcript": "NM_003482.3",
      "cNomen": "c.15545delG",
      "type": "deletion",
      "location": "exonic",
      "exon": 48,
      "effect": "frameshift",
      "pNomen": "p.G5182Afs*61"
    },
    {
      "id": 11763,
      "chromosome": "12",
      "start": 49423208,
      "stop": 49423208,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KMT2D (also referred to as MLL2) is a histone-lysine methyltransferase involved in transcriptional regulation (PMID: 28669924). KMT2D alterations have been reported in follicular and diffuse large B cell lymphoma (PMID: 21804550, 21796119).<br />\nThe KMT2D p.Pro4684Leufs*113 frameshift variant is predicted to result in a truncated or absent protein lacking the SET domain and thus loss of methyltransferase activity (PMID: 24240169).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the KMT2D p.Pro4684Leufs*113 variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:34:20",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "KMT2D",
      "transcript": "NM_003482.3",
      "cNomen": "c.14051delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 43,
      "effect": "frameshift",
      "pNomen": "p.P4684Lfs*113"
    },
    {
      "id": 11581,
      "chromosome": "12",
      "start": 49426706,
      "stop": 49426706,
      "classification": "Very high",
      "variantInfo": "<br />\nTwo deleterious variants were detected in KMT2D: the p.Gln3928* nonsense and the p.Glu987Alafs*73 frameshift variant is predicted to result in a truncated or absent protein lacking the SET domain and thus loss of methyltransferase activity (PMID: 24240169).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the KMT2D p.Gln3928* and p.Glu987Alafs*73 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "reportAbstract": "KMT2D (also referred to as MLL2) is a histone-lysine methyltransferase involved in transcriptional regulation (PMID: 28669924). KMT2D alterations have been reported in follicular and diffuse large B cell lymphoma (PMID: 21804550, 21796119).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/27 22:11:03",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "KMT2D",
      "transcript": "NM_003482.3",
      "cNomen": "c.11782C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 39,
      "effect": "stopgain",
      "pNomen": "p.Q3928*"
    },
    {
      "id": 11986,
      "chromosome": "12",
      "start": 49432195,
      "stop": 49432195,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KMT2D (also referred to as MLL2) is a histone-lysine methyltransferase involved in transcriptional regulation (PMID: 28669924). KMT2D alterations have been reported in follicular and diffuse large B cell lymphoma (PMID: 21804550, 21796119). The KMT2D p.Glu2982* nonsense variant is predicted to result in an absent or disrupted protein product. Loss-of-function variants in KMT2D are known to be oncogenic (PMID: 24633898, 24240169, 26366712). In case reports of other disease sites, loss of function variants in KMT2D are predicted sensitive to combined BTK and BCL2 inhibitor therapy (PMID: 30455436), however the impact of this variant in this disease context is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/15 19:57:09",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "KMT2D",
      "transcript": "NM_003482.3",
      "cNomen": "c.8944G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 34,
      "effect": "stopgain",
      "pNomen": "p.E2982*"
    },
    {
      "id": 12136,
      "chromosome": "12",
      "start": 49432738,
      "stop": 49432738,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KMT2D (also referred to as MLL2) is a histone-lysine methyltransferase involved in transcriptional regulation (PMID: 28669924). KMT2D alterations have been reported in follicular and diffuse large B cell lymphoma (PMID: 21804550, 21796119). The KMT2D p.Arg2801* nonsense variant is predicted to result in an absent or disrupted protein product. Loss-of-function variants in KMT2D are known to be oncogenic (PMID: 24633898, 24240169, 26366712). In case reports of other disease sites, loss of function variants in KMT2D are predicted sensitive to combined BTK and BCL2 inhibitor therapy (PMID: 30455436), however the impact of this variant in this disease context is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/02/22 21:17:57",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "KMT2D",
      "transcript": "NM_003482.3",
      "cNomen": "c.8401C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 34,
      "effect": "stopgain",
      "pNomen": "p.R2801*"
    },
    {
      "id": 11907,
      "chromosome": "12",
      "start": 49433650,
      "stop": 49433650,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KMT2D (also referred to as MLL2) is a histone-lysine methyltransferase involved in transcriptional regulation (PMID: 28669924). KMT2D alterations have been reported in follicular and diffuse large B cell lymphoma (PMID: 21804550, 21796119).<br />\nThe KMT2D p.Arg2635* nonsense variant is predicted to result in a truncated or absent protein lacking the SET domain and thus loss of methyltransferase activity (PMID: 24240169).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the KMT2D p.Arg2635* variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/21 17:19:02",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "KMT2D",
      "transcript": "NM_003482.3",
      "cNomen": "c.7903C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 31,
      "effect": "stopgain",
      "pNomen": "p.R2635*"
    },
    {
      "id": 11030,
      "chromosome": "12",
      "start": 49434289,
      "stop": 49434289,
      "classification": "Very high",
      "variantInfo": "The KMT2D p.Gln2422* variant is a nonsense variant that leads to a premature termination codon, which is predicted to result in a truncated or absent protein lacking the SET domain and thus loss of methyltransferase activity (PMID: 24240169).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the KMT2D p.Gln2422* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PARP inhibitors (NCT03297606, NCT03209401).<br />\n ",
      "reportAbstract": "KMT2D (also referred to as MLL2) is a histone-lysine methyltransferase involved in transcriptional regulation (PMID: 28669924). KMT2D alterations have been reported in follicular and diffuse large B cell lymphoma (PMID: 21804550, 21796119).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/11 20:08:19",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "KMT2D",
      "transcript": "NM_003482.3",
      "cNomen": "c.7264C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 31,
      "effect": "stopgain",
      "pNomen": "p.Q2422*"
    },
    {
      "id": 11693,
      "chromosome": "12",
      "start": 49435198,
      "stop": 49435198,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KMT2D (also referred to as MLL2) is a histone-lysine methyltransferase involved in transcriptional regulation (PMID: 28669924). KMT2D alterations have been reported in follicular and diffuse large B cell lymphoma (PMID: 21804550, 21796119).<br />\nThe KMT2D p.Ala2119Argfs*36 frameshift variant is predicted to result in a truncated or absent protein lacking the SET domain and thus loss of methyltransferase activity (PMID: 24240169).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the KMT2D p.Ala2119Argfs*36 variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/28 17:09:35",
      "evidences": [],
      "reference": ".",
      "alternative": "G",
      "gene": "KMT2D",
      "transcript": "NM_003482.3",
      "cNomen": "c.6354dupC",
      "type": "insertion",
      "location": "exonic",
      "exon": 31,
      "effect": "frameshift",
      "pNomen": "p.A2119Rfs*36"
    },
    {
      "id": 11764,
      "chromosome": "12",
      "start": 49443667,
      "stop": 49443667,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KMT2D (also referred to as MLL2) is a histone-lysine methyltransferase involved in transcriptional regulation (PMID: 28669924). KMT2D alterations have been reported in follicular and diffuse large B cell lymphoma (PMID: 21804550, 21796119).<br />\nThe KMT2D p.Gly1235Valfs*95 frameshift variant is predicted to result in a truncated or absent protein lacking the SET domain and thus loss of methyltransferase activity (PMID: 24240169).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the KMT2D p.Gly1235Valfs*95 variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:37:51",
      "evidences": [],
      "reference": "C",
      "alternative": ".",
      "gene": "KMT2D",
      "transcript": "NM_003482.3",
      "cNomen": "c.3704delG",
      "type": "deletion",
      "location": "exonic",
      "exon": 11,
      "effect": "frameshift",
      "pNomen": "p.G1235Vfs*95"
    },
    {
      "id": 11582,
      "chromosome": "12",
      "start": 49444389,
      "stop": 49444411,
      "classification": "Very high",
      "variantInfo": "<br />\nTwo deleterious variants were detected in KMT2D: the p.Gln3928* nonsense and the p.Glu987Alafs*73 frameshift variant is predicted to result in a truncated or absent protein lacking the SET domain and thus loss of methyltransferase activity (PMID: 24240169).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the KMT2D p.Gln3928* and p.Glu987Alafs*73 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "reportAbstract": "",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/27 22:11:21",
      "evidences": [],
      "reference": "CTCAGGGTCAGTGCAGTTAGCTT",
      "alternative": ".",
      "gene": "KMT2D",
      "transcript": "NM_003482.3",
      "cNomen": "c.2960_2982delAAGCTAACTGCACTGACCCTGAG",
      "type": "deletion",
      "location": "exonic",
      "exon": 11,
      "effect": "frameshift",
      "pNomen": "p.E987Afs*73"
    },
    {
      "id": 12186,
      "chromosome": "12",
      "start": 49445203,
      "stop": 49445203,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KMT2D (also referred to as MLL2) is a histone-lysine methyltransferase involved in transcriptional regulation (PMID: 28669924). KMT2D alterations have been reported in follicular and diffuse large B cell lymphoma (PMID: 21804550, 21796119).<br />\nThe KMT2D p.Arg755Glyfs*175 frameshift variant is predicted to result in an absent or disrupted protein product. Loss-of-function variants in KMT2D are known to be oncogenic (PMID: 24633898, 24240169, 26366712). In case reports of other disease sites, loss of function variants in KMT2D are predicted sensitive to combined BTK and BCL2 inhibitor therapy (PMID: 30455436), however the impact of this variant in this disease context is uncertain.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:36",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "KMT2D",
      "transcript": "NM_003482.3",
      "cNomen": "c.2263delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 10,
      "effect": "frameshift",
      "pNomen": "p.R755Gfs*175"
    },
    {
      "id": 11314,
      "chromosome": "12",
      "start": 49446794,
      "stop": 49446794,
      "classification": "Very high",
      "variantInfo": "<br />\nThe KMT2D p.Trp339* nonsense variant is predicted to result in a truncated or absent protein lacking the SET domain and thus loss of methyltransferase activity (PMID: 24240169).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the KMT2D p.Trp339* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "reportAbstract": "KMT2D (also referred to as MLL2) is a histone-lysine methyltransferase involved in transcriptional regulation (PMID: 28669924). KMT2D alterations have been reported in follicular and diffuse large B cell lymphoma (PMID: 21804550, 21796119).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/06/12 03:47:02",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "KMT2D",
      "transcript": "NM_003482.3",
      "cNomen": "c.1016G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "stopgain",
      "pNomen": "p.W339*"
    },
    {
      "id": 11971,
      "chromosome": "12",
      "start": 49448480,
      "stop": 49448480,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KMT2D (also referred to as MLL2) is a histone-lysine methyltransferase involved in transcriptional regulation (PMID: 28669924). KMT2D alterations have been reported in follicular and diffuse large B cell lymphoma (PMID: 21804550, 21796119).<br />\nThe KMT2D p.His77Glnfs*53 frameshift variant is predicted to result in an absent or disrupted protein product. Loss-of-function variants in KMT2D are known to be oncogenic (PMID: 24633898, 24240169, 26366712). In case reports of other disease sites, loss of function variants in KMT2D are predicted sensitive to combined BTK and BCL2 inhibitor therapy (PMID: 30455436), however the impact of this variant in this disease context is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/14 20:57:42",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "KMT2D",
      "transcript": "NM_003482.3",
      "cNomen": "c.231delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 3,
      "effect": "frameshift",
      "pNomen": "p.H77Qfs*53"
    },
    {
      "id": 11636,
      "chromosome": "12",
      "start": 121432118,
      "stop": 121432118,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "HNF1A is a transcription factor with tumor suppressor activity and plays a role in hepatocyte differentiation and glucose transport (PMID: 25233928, 26855178, 25076298). HNF1A inactivating mutations are associated with hepatic adenomas (PMID: 25076298) and may be associated with pancreatic tumorigenesis (PMID: 32154941).<br />\nThe HNF1A p.Pro291Glnfs*51 frameshift variant has been previously reported as a recurrent mutation associated with MSI-high CRC (PMID:12730871). This frameshift variant is predicted to result in the loss of the transactivation domain (PMID: 18003757, 12574234, 20132997).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the HNF1A p.Pro291Glnfs*51 variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/14 02:24:30",
      "evidences": [],
      "reference": "C",
      "alternative": ".",
      "gene": "HNF1A",
      "transcript": "NM_000545.5",
      "cNomen": "c.872delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 4,
      "effect": "frameshift",
      "pNomen": "p.P291Qfs*51"
    },
    {
      "id": 11657,
      "chromosome": "12",
      "start": 124829298,
      "stop": 124829298,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "NCOR2 is a nuclear hormone transcriptional co-repressor that is a member of the NCOR protein family (PMID: 20084085). NCOR2 represses transcription mainly by recruiting the histone deacetylase HDAC3 to DNA promoter regions (PMID: 20084085, 11509652).<br />\nThe p.Gly1520Alafs*22 frameshift variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in NOCR2 are predicted to be oncogenic (PMID: 20091860, 17694085, 27733359, 15729358).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the NCOR2 p.Gly1520Alafs*22 variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/20 19:29:45",
      "evidences": [],
      "reference": "C",
      "alternative": ".",
      "gene": "NCOR2",
      "transcript": "NM_006312.5",
      "cNomen": "c.4559delG",
      "type": "deletion",
      "location": "exonic",
      "exon": 34,
      "effect": "frameshift",
      "pNomen": "p.G1520Afs*22"
    },
    {
      "id": 12209,
      "chromosome": "12",
      "start": 133252337,
      "stop": 133252337,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "POLE encodes a DNA polymerase epsilon catalytic subunit that plays a role in genomic stability and is involved in DNA repair and replication (PMID: 31747945, 26822575, 29604063). Somatic variants in POLE have been identified frequently in colorectal and endometrial cancer (PMID: 29998005, 29072370, 26822575, 28795426, 30733993), and germline pathogenic variants in POLE have been associated with susceptibility to colorectal cancer (PMID: 23263490, 25370038, 26133394, 25860647). <br />\nThe POLE p.Gly364Arg variant results in substitution of a single amino acid in the POLE exonuclease domain. Variants affecting exonuclease domain function are frequently associated with high tumor mutational burden (PMID: 30733993, 29880869) and are likely to be oncogenic.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:27",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "POLE",
      "transcript": "NM_006231.3",
      "cNomen": "c.1090G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 11,
      "effect": "nonsynonymous",
      "pNomen": "p.G364R"
    },
    {
      "id": 11367,
      "chromosome": "13",
      "start": 32907420,
      "stop": 32907420,
      "classification": "Very high",
      "variantInfo": "<br />\nThe BRCA2 p.Ile605Asnfs*11 frameshift variant is predicted to result in a truncated or absent protein. Pathogenic germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410). The BRCA2 p.Ile605Asnfs*11 variant has been reported in the germline context by 23 clinical laboratories as pathogenic (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the BRCA2 p.Ile605Asnfs*11 variant currently serves as an inclusion eligibility criterion for FDA approved therapies and Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "reportAbstract": "BRCA2 is a tumour suppressor involved in DNA repair and maintenance of genomic stability (PMID: 27530658). Pathogenic germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/06/29 17:22:18",
      "evidences": [],
      "reference": ".",
      "alternative": "A",
      "gene": "BRCA2",
      "transcript": "NM_000059.3",
      "cNomen": "c.1813dupA",
      "type": "insertion",
      "location": "exonic",
      "exon": 10,
      "effect": "frameshift",
      "pNomen": "p.I605Nfs*11"
    },
    {
      "id": 11891,
      "chromosome": "13",
      "start": 32912051,
      "stop": 32912051,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "BRCA2 is a tumour suppressor involved in DNA repair and maintenance of genomic stability (PMID: 27530658). Pathogenic germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410).<br />\nThe BRCA2 p.Glu1187* nonsense variant is predicted to result in a truncated or absent protein. Pathogenic germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410). The BRCA2 p.Glu1187* variant has been reported in the germline context (PMID: 29681614).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the BRCA2 p.Glu1187* variant currently serves as an inclusion eligibility criterion for FDA approved therapies and Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/16 02:54:49",
      "evidences": [],
      "reference": "G",
      "alternative": "T",
      "gene": "BRCA2",
      "transcript": "NM_000059.3",
      "cNomen": "c.3559G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 11,
      "effect": "stopgain",
      "pNomen": "p.E1187*"
    },
    {
      "id": 12340,
      "chromosome": "13",
      "start": 32912905,
      "stop": 32912905,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "BRCA2 is a tumour suppressor involved in DNA repair and maintenance of genomic stability (PMID: 27530658). Pathogenic germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410). The BRCA2 p.Lys1472Argfs*7 frameshift variant is predicted to result in a truncated or absent protein. Results suggest this patient would be eligible for PARP inhibitor therapy.<br />\nPathogenic germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410). The BRCA2 p.Lys1472Argfs*7 variant has not been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/05/26 20:36:26",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "BRCA2",
      "transcript": "NM_000059.3",
      "cNomen": "c.4415delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 11,
      "effect": "frameshift",
      "pNomen": "p.K1472Rfs*7"
    },
    {
      "id": 11155,
      "chromosome": "13",
      "start": 32914645,
      "stop": 32914645,
      "classification": "Very high",
      "variantInfo": "<br />\nThe BRCA2 p.Ser2052Hisfs*18 variant is a frameshift variant that leads to a premature termination codon, which is predicted to result in a truncated or absent protein. Pathogenic germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410). The BRCA2 p.Ser2052Hisfs*18 variant has been reported in the germline context by 3 clinical laboratories as pathogenic (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the BRCA2 p.Ser2052Hisfs*18 variant currently serves as an inclusion eligibility criterion for FDA approved therapies and Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "reportAbstract": "BRCA2 is a tumour suppressor involved in DNA repair and maintenance of genomic stability (PMID: 27530658). Inactivating germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145676, 9145678, 10918303, 26928436) and increased susceptibility to additional cancer types (PMID: 24292448, 22516946).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/04/02 15:33:14",
      "evidences": [],
      "reference": "T",
      "alternative": ".",
      "gene": "BRCA2",
      "transcript": "NM_000059.3",
      "cNomen": "c.6154delT",
      "type": "deletion",
      "location": "exonic",
      "exon": 11,
      "effect": "frameshift",
      "pNomen": "p.S2052Hfs*18"
    },
    {
      "id": 11029,
      "chromosome": "13",
      "start": 32930673,
      "stop": 32930673,
      "classification": "Very high",
      "variantInfo": "BRCA2 is a tumour suppressor involved in DNA repair and maintenance of genomic stability (PMID: 27530658). The BRCA2 p.Thr2515Ile variant has been reported in breast cancer (COSMIC). This variant occurs in the helical domain and functional studies suggest this variant results in partial inactivation of BRCA2 in vitro (PMID: 29988080, 15695382).<br />\nPathogenic germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410). The BRCA2 p.Thr2515Ile variant has been reported in the germline context by 20 clinical laboratories as likely benign or benign (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the BRCA2 p.Thr2515Ile variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "reportAbstract": "BRCA2 is a tumour suppressor involved in DNA repair and maintenance of genomic stability (PMID: 27530658). Pathogenic germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/11 19:50:33",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "BRCA2",
      "transcript": "NM_000059.3",
      "cNomen": "c.7544C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 15,
      "effect": "nonsynonymous",
      "pNomen": "p.T2515I"
    },
    {
      "id": 11310,
      "chromosome": "13",
      "start": 32953886,
      "stop": 32953886,
      "classification": "Very high",
      "variantInfo": "<br />\nThe BRCA2 c.8954-1_8955delinsAA splice site variant is predicted to result in a truncated or absent protein. Pathogenic germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410). The BRCA2 c.8954-1_8955delinsAA variant has been reported in the germline context by 5 clinical laboratories as pathogenic (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the BRCA2 c.8954-1_8955delinsAA variant currently serves as an inclusion eligibility criterion for FDA approved therapies and Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "reportAbstract": "BRCA2 is a tumour suppressor involved in DNA repair and maintenance of genomic stability (PMID: 27530658). Pathogenic germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/06/12 03:21:26",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "BRCA2",
      "transcript": "NM_000059.3",
      "cNomen": "c.8954-1delG",
      "type": "deletion",
      "location": "intronic",
      "exon": 23,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11728,
      "chromosome": "13",
      "start": 48878062,
      "stop": 48878062,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "RB1 encodes the retinoblastoma protein (Rb), a tumor suppressor and negative regulator of the cell cycle (PMID: 15084261) and plays a role in cell differentiation, survival, senescence, epigenetic regulation, and genome stability (PMID: 21295686, 23359405). Inactivation of Rb has been associated with many human cancers including lung, breast, prostate and bladder cancers (PMID: 18650841, 19143056, 22237022, 12204530).<br />\nThe RB1 p.Arg7Glufs*58 frameshift variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in RB1 are known to be oncogenic (PMID: 21295686, 25621664, 30206110, 22293180). Pathogenic germline variants in RB1 have been associated with retinoblastoma which is associated with increased risk of secondary cancer development (PMID: 22293180, 19066271, 22205104). This variant has been reported in the germline context (PMID: 26925970, 16972022).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the RB1 p.Arg7Glufs*58 variant does not currently serves as an inclusion eligibility criterion for clinical trials.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:31",
      "evidences": [],
      "reference": "C",
      "alternative": ".",
      "gene": "RB1",
      "transcript": "NM_000321.2",
      "cNomen": "c.19delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 1,
      "effect": "frameshift",
      "pNomen": "p.R7Efs*58"
    },
    {
      "id": 11131,
      "chromosome": "13",
      "start": 48881530,
      "stop": 48881542,
      "classification": "Very high",
      "variantInfo": "<br />\nRB1 p.Asp85Glufs*22 frameshift variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in RB1 are known to be oncogenic (PMID: 21295686, 25621664, 30206110, 22293180). Pathogenic germline variants in RB1 have been associated with retinoblastoma which is associated with increased risk of secondary cancer development (PMID: 22293180, 19066271, 22205104).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the RB1 p.Asp85Glufs*22 variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "RB1 encodes the retinoblastoma protein (Rb), a tumor suppressor and negative regulator of the cell cycle (PMID: 15084261) and plays a role in cell differentiation, survival, senescence, epigenetic regulation, and genome stability (PMID: 21295686, 23359405). Inactivation of Rb has been associated with many human cancers including lung, breast, prostate and bladder cancers (PMID: 18650841, 19143056, 22237022, 12204530).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/25 14:26:30",
      "evidences": [],
      "reference": "GGATGGAGTATTG",
      "alternative": ".",
      "gene": "RB1",
      "transcript": "NM_000321.2",
      "cNomen": "c.252_264delGGATGGAGTATTG",
      "type": "deletion",
      "location": "exonic",
      "exon": 2,
      "effect": "frameshift",
      "pNomen": "p.D85Efs*22"
    },
    {
      "id": 11804,
      "chromosome": "13",
      "start": 48954321,
      "stop": 48954321,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "RB1 encodes the retinoblastoma protein (Rb), a tumor suppressor and negative regulator of the cell cycle (PMID: 15084261) and plays a role in cell differentiation, survival, senescence, epigenetic regulation, and genome stability (PMID: 21295686, 23359405). Inactivation of Rb has been associated with many human cancers including lung, breast, prostate and bladder cancers (PMID: 18650841, 19143056, 22237022, 12204530).<br />\nRB1 p.His483Ilefs*12 frameshift variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in RB1 are known to be oncogenic (PMID: 21295686, 25621664, 30206110, 22293180). Pathogenic germline variants in RB1 have been associated with retinoblastoma which is associated with increased risk of secondary cancer development (PMID: 22293180, 19066271, 22205104). The RB1 p.His483Ilefs*12 variant has not been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the RB1 p.His483Ilefs*12 variant does not currently serve as an inclusion eligibility criterion for clinical trials.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:31",
      "evidences": [],
      "reference": "T",
      "alternative": ".",
      "gene": "RB1",
      "transcript": "NM_000321.2",
      "cNomen": "c.1446delT",
      "type": "deletion",
      "location": "exonic",
      "exon": 16,
      "effect": "frameshift",
      "pNomen": "p.H483Ifs*12"
    },
    {
      "id": 12179,
      "chromosome": "13",
      "start": 49027168,
      "stop": 49027168,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "RB1 encodes the retinoblastoma protein (Rb), a tumor suppressor and negative regulator of the cell cycle (PMID: 15084261) and plays a role in cell differentiation, survival, senescence, epigenetic regulation, and genome stability (PMID: 21295686, 23359405). Inactivation of Rb has been associated with many human cancers including lung, breast, prostate and bladder cancers (PMID: 18650841, 19143056, 22237022, 12204530).<br />\nThe RB1 p.Arg579* nonsense variant is predicted to result in an absent or disrupted protein product. Loss-of-function variants in RB1 are known to be oncogenic (PMID: 21295686, 25621664, 30206110, 22293180). Pathogenic germline variants in RB1 have been associated with retinoblastoma which is associated with increased risk of secondary cancer development (PMID: 22293180, 19066271, 22205104). This variant has been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:39",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "RB1",
      "transcript": "NM_000321.2",
      "cNomen": "c.1735C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 18,
      "effect": "stopgain",
      "pNomen": "p.R579*"
    },
    {
      "id": 11904,
      "chromosome": "13",
      "start": 49030368,
      "stop": 49030368,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "RB1 encodes the retinoblastoma protein (Rb), a tumor suppressor and negative regulator of the cell cycle (PMID: 15084261) and plays a role in cell differentiation, survival, senescence, epigenetic regulation, and genome stability (PMID: 21295686, 23359405). Inactivation of Rb has been associated with many human cancers including lung, breast, prostate and bladder cancers (PMID: 18650841, 19143056, 22237022, 12204530).<br />\nThe RB1 p.Gly617Valfs*6 frameshift variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in RB1 are known to be oncogenic (PMID: 21295686, 25621664, 30206110, 22293180). Pathogenic germline variants in RB1 have been associated with retinoblastoma which is associated with increased risk of secondary cancer development (PMID: 22293180, 19066271, 22205104). This variant has been reported in the germline context (PMID: 26925970, 16972022).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the RB1 p.Gly617Valfs*6 variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/21 16:53:47",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "RB1",
      "transcript": "NM_000321.2",
      "cNomen": "c.1848delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 19,
      "effect": "frameshift",
      "pNomen": "p.G617Vfs*6"
    },
    {
      "id": 12356,
      "chromosome": "13",
      "start": 49037944,
      "stop": 49037944,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "RB1 encodes the retinoblastoma protein (Rb), a tumor suppressor and negative regulator of the cell cycle (PMID: 15084261) and plays a role in cell differentiation, survival, senescence, epigenetic regulation, and genome stability (PMID: 21295686, 23359405). Inactivation of Rb has been associated with many human cancers including lung, breast, prostate and bladder cancers (PMID: 18650841, 19143056, 22237022, 12204530).<br />\nThe RB1 p.Tyr728* nonsense variant is predicted to result in an absent or disrupted protein product. Loss-of-function variants in RB1 are known to be oncogenic (PMID: 21295686, 25621664, 30206110, 22293180). Pathogenic germline variants in RB1 have been associated with retinoblastoma which is associated with increased risk of secondary cancer development (PMID: 22293180, 19066271, 22205104). This variant has not been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/06/01 20:37:47",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "RB1",
      "transcript": "NM_000321.2",
      "cNomen": "c.2184C>A",
      "type": "snp",
      "location": "exonic",
      "exon": 21,
      "effect": "stopgain",
      "pNomen": "p.Y728*"
    },
    {
      "id": 11928,
      "chromosome": "14",
      "start": 35873699,
      "stop": 35873699,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "NFKBIA, NFKB inhibitor alpha, belongs to a family of transcription factors involved in cell adhesion, immune and proinflammatory responses, apoptosis, differentiation and growth (PMID: 11134170, 16724054, 24578542).<br />\nThe NFKBIA p.Glu51Glyfs*35 frameshift variant is predicted to result in a truncated or absent protein. While this variant has not been reported in the literature, loss-of-function variants in NFKBIA have been reported in several cancers and are likely oncogenic (PMID: 9572494, 27647909, 18412279, 16540234, 25215581, 12377412, 19507254, 21774728, 28098136).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the NFKBIA p.Glu51Glyfs*35 variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/14 19:32:07",
      "evidences": [],
      "reference": ".",
      "alternative": "C",
      "gene": "NFKBIA",
      "transcript": "NM_020529.2",
      "cNomen": "c.151dupG",
      "type": "insertion",
      "location": "exonic",
      "exon": 1,
      "effect": "frameshift",
      "pNomen": "p.E51Gfs*35"
    },
    {
      "id": 12038,
      "chromosome": "14",
      "start": 38060716,
      "stop": 38060716,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "FOXA1, a transcription factor, binds to core histones H3/H4 and exhibits pioneering activity by opening regions of condensed chromatin (PMID: 16909212). FOXA1 is frequently mutated in prostate and breast cancer (PMID: 25470049, 23000897, 22495314).<br />\nThe p.Gln425* nonsense variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in FOXA1 are known to be oncogenic (PMID: 24840332, 26544944, 25470049, 23000897, 22495314). The impact of this variant is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/30 00:26:30",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "FOXA1",
      "transcript": "NM_004496.3",
      "cNomen": "c.1273C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "stopgain",
      "pNomen": "p.Q425*"
    },
    {
      "id": 11852,
      "chromosome": "14",
      "start": 38060739,
      "stop": 38060743,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "FOXA1, a transcription factor, binds to core histones H3/H4 and exhibits pioneering activity by opening regions of condensed chromatin (PMID: 16909212); this allows for the recruitment of other transcription factors, including the androgen receptor (AR) and estrogen receptor (ER) (PMID: 21934649). FOXA1 has emerged as one of the most frequent recurrently mutated genes in hormone-dependent cancers including primary and metastatic castration-resistant prostate cancer (CRPC) and breast cancer (PMID: 25470049, 23000897,22495314). FOXA1 is also frequently mutated in urothelial bladder carcinoma and amplified in a number of other tumor types (PMID: 24476821). Somatic FOXA1 mutations predominantly map to the DNA-binding domain, suggesting that they function as loss-of-function alterations (PMID: 25470049, 23000897, 22495314).<br />\nThe p.Asp416Glnfs*140 frameshift variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in FOXA1 are known to be oncogenic (PMID: 24840332, 26544944).<br />\nIn this disease site, the FOXA1 p.Asp416Glnfs*140 does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/04 20:12:24",
      "evidences": [],
      "reference": "AAGTC",
      "alternative": ".",
      "gene": "FOXA1",
      "transcript": "NM_004496.3",
      "cNomen": "c.1246_1250delGACTT",
      "type": "deletion",
      "location": "exonic",
      "exon": 2,
      "effect": "frameshift",
      "pNomen": "p.D416Qfs*140"
    },
    {
      "id": 11534,
      "chromosome": "14",
      "start": 38060863,
      "stop": 38060900,
      "classification": "Very high",
      "variantInfo": "<br />\nThe p.Pro364Thrfs*38 frameshift variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in FOXA1 are known to be oncogenic (PMID: 24840332, 26544944).<br />\nA search by the OncoKB platform indicates in this disease site, the FOXA1 p.Pro364Thrfs*38 does not currently serve as an inclusion eligibility criterion for FDA-approved or NCCN-compendium listed treatments.<br />\n ",
      "reportAbstract": "FOXA1, a transcription factor, binds to core histones H3/H4 and exhibits pioneering activity by opening regions of condensed chromatin (PMID: 16909212); this allows for the recruitment of other transcription factors, including the androgen receptor (AR) and estrogen receptor (ER) (PMID: 21934649). FOXA1 has emerged as one of the most frequent recurrently mutated genes in hormone-dependent cancers including primary and metastatic castration-resistant prostate cancer (CRPC) and breast cancer (PMID: 25470049, 23000897,22495314). FOXA1 is also frequently mutated in urothelial bladder carcinoma and amplified in a number of other tumor types (PMID: 24476821). Somatic FOXA1 mutations predominantly map to the DNA-binding domain, suggesting that they function as loss-of-function alterations (PMID: 25470049, 23000897, 22495314).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/11 00:38:48",
      "evidences": [],
      "reference": "CCGGGTGAGAGGCGGGCACAGAGGCCAGCGCCCCGGGC",
      "alternative": ".",
      "gene": "FOXA1",
      "transcript": "NM_004496.3",
      "cNomen": "c.1089_1126del",
      "type": "deletion",
      "location": "exonic",
      "exon": 2,
      "effect": "frameshift",
      "pNomen": "p.P364Tfs*38"
    },
    {
      "id": 11633,
      "chromosome": "14",
      "start": 95560464,
      "stop": 95560464,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "DICER1 is a member of the RNase III family that plays a fundamental role in the biogenesis of miRNAs (PMID: 25883138). Loss-of-function variants in DICER1 have been observed in various tumor types and are considered a predictor of poor survival (PMID:19903759). Recurrent missense mutations affecting the RNase IIIb domain of DICER1 are common in nonepithelial ovarian tumors (granulosa-cell tumors) (PMID:22187960, 24136150).<br />\nThe p.Asp1709Asn variant is a hotspot mutation (PMID: 22187960, 23132766). This variant occurs in the RNase IIIb domain and functional studies suggest this variant results in reduced RNase IIIb activity, decreased miRNA processing and increased tumorigenic properties in vitro (PMID: 22187960, 23132766, 22546613, 26408257). Pathogenic germline mutations in DICER1 have been associated with an autosomal-dominant, tumor-predisposition disorder which commonly involves an increased risk of pleuropulmonary blastoma and Sertoli-Leydig cell tumors (PMID: 30715996, 29762508).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the DICER1 p.Asp1709Asn variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/14 02:16:23",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "DICER1",
      "transcript": "NM_177438.2",
      "cNomen": "c.5125G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 24,
      "effect": "nonsynonymous",
      "pNomen": "p.D1709N"
    },
    {
      "id": 11985,
      "chromosome": "14",
      "start": 95562839,
      "stop": 95562839,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "DICER1 is a member of the RNase III family that plays a fundamental role in the biogenesis of miRNAs (PMID: 25883138). Loss-of-function variants in DICER1 have been observed in various tumor types and are considered a predictor of poor survival (PMID: 19903759). Recurrent missense mutations affecting the RNase IIIb domain of DICER1 are common in nonepithelial ovarian tumors (granulosa-cell tumors) (PMID: 22187960, 24136150). The p.Ser1473* nonsense variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in DICER1 are likely oncogenic (PMID: 19903759, 20305640, 22133720, 21501861, 22353998, 21266384). The impact of this variant in this disease context is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/15 19:45:46",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "DICER1",
      "transcript": "NM_177438.2",
      "cNomen": "c.4418C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 23,
      "effect": "stopgain",
      "pNomen": "p.S1473*"
    },
    {
      "id": 11123,
      "chromosome": "14",
      "start": 105246551,
      "stop": 105246551,
      "classification": "Very high",
      "variantInfo": "<br />\nThe AKT1 p.Glu17Lys missense variant occurs in the N-terminal Pleckstrin homology domain and results in PI3K-independent activation of AKT1 and has been described in several types of cancer including breast cancer (PMID: 17611497, 9843996, 23888070, 23134728, 20440266, 23741320, 18256540, 21793738, 28489509, 19802009).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the AKT1 p.Glu17Lys variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of AKT inhibitors.<br />\n ",
      "reportAbstract": "AKT1 is an oncogenic serine/threonine protein kinase involved in cell survival through activation of the PI3K/AKT/MTOR pathway (PMID: 28557977). AKT1 is frequently activated in cancers, typically through activation of the PI3K pathway or by inactivation of PTEN (PMID: 28431241, 28489509, 26701849).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/24 19:30:40",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "AKT1",
      "transcript": "NM_001014432.1",
      "cNomen": "c.49G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 4,
      "effect": "nonsynonymous",
      "pNomen": "p.E17K"
    },
    {
      "id": 11983,
      "chromosome": "15",
      "start": 45007768,
      "stop": 45007768,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "B2M, beta-2-microglobulin, forms the light chain of the class I major histocompatibility complex (MHC) (PMID: 3312414, 8717519) and is required for antigen presentation during the immune response (PMID: 27433843). The B2M p.Ser72*nonsense variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in B2M are likely oncogenic (PMID: 25594174, 25294904, 22833104, 16730261, 22137796, 23784959, 9637706, 1898655). In other disease sites, preclinical studies suggest loss of function variants in B2M may be associated with sensitivity to immune checkpoint inhibitor (PMID: 31008436, 30559380), however the impact of this variant in this disease context is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/15 02:36:58",
      "evidences": [],
      "reference": "C",
      "alternative": "G",
      "gene": "B2M",
      "transcript": "NM_004048.2",
      "cNomen": "c.215C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "stopgain",
      "pNomen": "p.S72*"
    },
    {
      "id": 11312,
      "chromosome": "16",
      "start": 2098674,
      "stop": 2098674,
      "classification": "Very high",
      "variantInfo": "<br />\nThe TSC2 p.Gly20* nonsense variant is predicted to result in a truncated or absent protein. TSC2 loss-of-function mutations result in constitutive activation of the mTORC1 complex and responsiveness to MTOR inhibitors based on preclinical studies (PMID: 22923433, 26831717, 23158522). Germline pathogenic variants in TSC2 are known to cause tuberous sclerosis (PMID: 10205261). This variant has not been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TSC2 p.Gly20* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials for MTOR inhibitors.<br />\n ",
      "reportAbstract": "TSC2 is a tumor suppressing GTPase-activating protein involved in cell growth through regulation of the PI3K/AKT/MTOR pathway (PMID: 12869586, 12906785). Somatic TSC2 mutations have been identified in various cancers, including renal cell carcinoma, sarcoma, and breast cancer (PMID: 30303819, 28860410, 28027327).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/06/12 03:28:05",
      "evidences": [],
      "reference": "G",
      "alternative": "T",
      "gene": "TSC2",
      "transcript": "NM_000548.3",
      "cNomen": "c.58G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "stopgain",
      "pNomen": "p.G20*"
    },
    {
      "id": 11034,
      "chromosome": "16",
      "start": 2098752,
      "stop": 2098752,
      "classification": "Very high",
      "variantInfo": "The TSC2 p.Arg46* variant is a nonsense variant that leads to a premature termination codon, which is predicted to result in a truncated or absent protein. TSC2 loss-of-function mutations result in constitutive activation of the mTORC1 complex and responsiveness to MTOR inhibitors based on preclinical studies (PMID: 22923433, 26831717, 23158522). Germline pathogenic variants in TSC2 are known to cause tuberous sclerosis (PMID: 10205261). This variant has not been reported by clinical laboratories in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TSC2 p.Arg46* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials for MTOR inhibitors.<br />\n ",
      "reportAbstract": "TSC2 is a tumor suppressing GTPase-activating protein involved in cell growth through regulation of the PI3K/AKT/MTOR pathway (PMID: 12869586, 12906785). Somatic TSC2 mutations have been identified in various cancers, including renal cell carcinoma, sarcoma, and breast cancer (PMID: 30303819, 28860410, 28027327).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/12 19:10:48",
      "evidences": [],
      "reference": "A",
      "alternative": "T",
      "gene": "TSC2",
      "transcript": "NM_000548.3",
      "cNomen": "c.136A>T",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "stopgain",
      "pNomen": "p.R46*"
    },
    {
      "id": 11726,
      "chromosome": "16",
      "start": 2129160,
      "stop": 2129160,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TSC2 is a tumor suppressing GTPase-activating protein involved in cell growth through regulation of the PI3K/AKT/MTOR pathway (PMID: 12869586, 12906785). Somatic TSC2 mutations have been identified in various cancers, including renal cell carcinoma, sarcoma, and breast cancer (PMID: 30303819, 28860410, 28027327).<br />\n<br />\nThe TSC2 p.Arg1032* nonsense variant is predicted to result in an absent or disrupted protein product. TSC2 loss-of-function mutations result in constitutive activation of the mTORC1 complex and responsiveness to MTOR inhibitors based on preclinical studies (PMID: 22923433, 26831717, 23158522). Germline pathogenic variants in TSC2 are known to cause tuberous sclerosis (PMID: 10205261). This variant has been reported in the germline context (ClinVar).<br />\n<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TSC2 p.Arg1032* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of mTOR inhibitors.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:31",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "TSC2",
      "transcript": "NM_000548.3",
      "cNomen": "c.3094C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 27,
      "effect": "stopgain",
      "pNomen": "p.R1032*"
    },
    {
      "id": 11560,
      "chromosome": "16",
      "start": 3779057,
      "stop": 3779057,
      "classification": "Very high",
      "variantInfo": "<br />\nThe CREBBP p.Val1998* variant is a nonsense variant predicted to result in an altered protein product or nonsense mediated decay due to the introduction of a premature stop codon. Preclinical studies suggest inhibitors targeting EP300 result in suppressed growth of CREBBP-deficient tumours in vitro and vivo (PMID: 26603525).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the CREBBP p.Asp127Serfs*27 variant currently serves as an inclusion eligibility criterion for Phase 1 clinical trials of HDAC inhibitors.",
      "reportAbstract": "CREBBP is a histone acetyltransferase involved in transcriptional regulation and cell growth through activation of the RAS/RAF/MAPK pathway (PMID: 15156177, 8945521, 27979926). Somatic mutations of CREBBP have been found in leukemia, lymphoma and solid tumors including small-cell lung cancer, squamous carcinoma and bladder cancer (PMID: 24670651, 21796119, 21390130, 25151357).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/24 01:47:59",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "CREBBP",
      "transcript": "NM_004380.2",
      "cNomen": "c.5991delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 31,
      "effect": "stopgain",
      "pNomen": "p.V1998*"
    },
    {
      "id": 11719,
      "chromosome": "16",
      "start": 3779746,
      "stop": 3779746,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "CREBBP is a histone acetyltransferase involved in transcriptional regulation and cell growth through activation of the RAS/RAF/MAPK pathway (PMID: 15156177, 8945521, 27979926). Somatic mutations of CREBBP have been found in leukemia, lymphoma and solid tumors including small-cell lung cancer, squamous carcinoma and bladder cancer (PMID: 24670651, 21796119, 21390130, 25151357).<br />\nThe p.Arg1768Thrfs*198 frameshift variant is predicted to result in an absent or disrupted protein product. Preclinical studies suggest inhibitors targeting EP300 result in suppressed growth of CREBBP-deficient tumours in vitro and vivo (PMID: 26603525).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the CREBBP p.Arg1768Thrfs*198 variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/06 15:43:09",
      "evidences": [],
      "reference": ".",
      "alternative": "T",
      "gene": "CREBBP",
      "transcript": "NM_004380.2",
      "cNomen": "c.5301dupA",
      "type": "insertion",
      "location": "exonic",
      "exon": 31,
      "effect": "frameshift",
      "pNomen": "p.R1768Tfs*198"
    },
    {
      "id": 11967,
      "chromosome": "16",
      "start": 3807983,
      "stop": 3807983,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "CREBBP is a histone acetyltransferase involved in transcriptional regulation and cell growth through activation of the RAS/RAF/MAPK pathway (PMID: 15156177, 8945521, 27979926). Somatic mutations of CREBBP have been found in leukemia, lymphoma and solid tumors including small-cell lung cancer, squamous carcinoma and bladder cancer (PMID: 24670651, 21796119, 21390130, 25151357).<br />\nThe CREBBP p.Gln1146* nonsense variant is predicted to result in an altered protein product or nonsense mediated decay due to the introduction of a premature stop codon. Preclinical studies suggest inhibitors targeting EP300 result in suppressed growth of CREBBP-deficient tumours in vitro and vivo (PMID: 26603525).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/14 20:36:28",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "CREBBP",
      "transcript": "NM_004380.2",
      "cNomen": "c.3436C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 18,
      "effect": "stopgain",
      "pNomen": "p.Q1146*"
    },
    {
      "id": 11761,
      "chromosome": "16",
      "start": 3817720,
      "stop": 3817720,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "CREBBP is a histone acetyltransferase involved in transcriptional regulation and cell growth through activation of the RAS/RAF/MAPK pathway (PMID: 15156177, 8945521, 27979926). Somatic mutations of CREBBP have been found in leukemia, lymphoma and solid tumors including small-cell lung cancer, squamous carcinoma and bladder cancer (PMID: 24670651, 21796119, 21390130, 25151357).<br />\nThe p.Ile1084Asnfs*3 frameshift variant is predicted to result in an absent or disrupted protein product. Preclinical studies suggest inhibitors targeting EP300 result in suppressed growth of CREBBP-deficient tumours in vitro and vivo (PMID: 26603525).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the CREBBP p.Ile1084Asnfs*3 variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:33:38",
      "evidences": [],
      "reference": ".",
      "alternative": "T",
      "gene": "CREBBP",
      "transcript": "NM_004380.2",
      "cNomen": "c.3250_3250+1insA",
      "type": "insertion",
      "location": "intronic",
      "exon": 16,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 10996,
      "chromosome": "16",
      "start": 3900687,
      "stop": 3900718,
      "classification": "Very high",
      "variantInfo": "The CREBBP p.Asp127Serfs*27 variant is a frameshift variant predicted to result in an altered protein product or nonsense mediated decay due to the introduction of a premature stop codon. Preclinical studies suggest inhibitors targeting EP300 result in suppressed growth of CREBBP-deficient tumours in vitro and vivo (PMID: 26603525).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the CREBBP p.Asp127Serfs*27 variant currently serves as an inclusion eligibility criterion for Phase 1 clinical trials of HDAC inhibitors.<br />\n ",
      "reportAbstract": "CREBBP is a histone acetyltransferase involved in transcriptional regulation and cell growth through activation of the RAS/RAF/MAPK pathway (PMID: 15156177, 8945521, 27979926). Somatic mutations of CREBBP have been found in leukemia, lymphoma and solid tumors including small-cell lung cancer, squamous carcinoma and bladder cancer (PMID: 24670651, 21796119, 21390130, 25151357).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/09 20:18:30",
      "evidences": [],
      "reference": "CCTGTTTAGGCAGGCTGGGGGCTGAAGAATCT",
      "alternative": ".",
      "gene": "CREBBP",
      "transcript": "NM_004380.2",
      "cNomen": "c.378_409delAGATTCTTCAGCCCCCAGCCTGCCTAAACAGG",
      "type": "deletion",
      "location": "exonic",
      "exon": 2,
      "effect": "frameshift",
      "pNomen": "p.D127Sfs*27"
    },
    {
      "id": 12168,
      "chromosome": "16",
      "start": 23647357,
      "stop": 23647358,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PALB2, Partner and localizer of BRCA2, is a tumor suppressor involved in DNA double-strand break repair through homologous recombination (PMID: 24998779).<br />\nThe PALB2 p.Arg170Ilefs*14 frameshift variant is predicted to result in an absent or disrupted protein product. Functional assays suggest this variant results in loss-of-function as shown by impaired DNA binding and loss of RAD51 activation (PMID: 28158555). In other disease sites, inactivating variants in PALB2 are responsive to PARP inhibitors (NCCN.org).<br />\nPathogenic germline variants in PALB2 have been associated with hereditary breast cancer (PMID: 25099575, 17200668, 33193564, 31841383). The p.Arg170Ilefs*14 variant has been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:27",
      "evidences": [],
      "reference": "TC",
      "alternative": ".",
      "gene": "PALB2",
      "transcript": "NM_024675.3",
      "cNomen": "c.509_510delGA",
      "type": "deletion",
      "location": "exonic",
      "exon": 4,
      "effect": "frameshift",
      "pNomen": "p.R170Ifs*14"
    },
    {
      "id": 11559,
      "chromosome": "16",
      "start": 67644874,
      "stop": 67644874,
      "classification": "Very high",
      "variantInfo": "<br />\n <br />\nThe CTCF p.Gly48Valfs*14 variant is a frameshift variant predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in CTCF are known to be oncogenic (PMID: 25079317, 24130125, 23636398).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the CTCF p.Gly48Valfs*14 variant does not currently serves as an inclusion eligibility criterion for clinical trials.",
      "reportAbstract": "CTCF is a DNA-binding transcriptional repressor of numerous genes including MYC, TP53 (PMID: 8649389, 21465478) and plays a role in chromatin organization (PMID: 29307136). Loss-of-function CTCF variants have been identified in endometrial cancer, prostate cancer, Wilms tumor, and breast cancer (PMID: 24130125, 28648147, 23636398, 25079317).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/24 01:47:40",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "CTCF",
      "transcript": "NM_006565.3",
      "cNomen": "c.143delG",
      "type": "deletion",
      "location": "exonic",
      "exon": 3,
      "effect": "frameshift",
      "pNomen": "p.G48Vfs*14"
    },
    {
      "id": 11968,
      "chromosome": "16",
      "start": 67644928,
      "stop": 67644928,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "CTCF is a chromatin binding factor that is involved in transcriptional regulation by binding to CTCF is a DNA-binding transcriptional repressor of numerous genes including MYC, TP53 (PMID: 8649389, 21465478) and plays a role in chromatin organization (PMID: 29307136). Loss-of-function CTCF variants have been identified in endometrial cancer, prostate cancer, Wilms tumor, and breast cancer (PMID: 24130125, 28648147, 23636398, 25079317).<br />\nThe CTCF p.Gln65* nonsense variant is predicted to result in an absent or disrupted protein product. Loss-of-function variants in CTCF are known to be oncogenic (PMID: 25079317, 24130125, 23636398). The impact of this variant in this disease context is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/14 20:39:31",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "CTCF",
      "transcript": "NM_006565.3",
      "cNomen": "c.193C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 3,
      "effect": "stopgain",
      "pNomen": "p.Q65*"
    },
    {
      "id": 11652,
      "chromosome": "16",
      "start": 67645338,
      "stop": 67645338,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "CTCF is a DNA-binding transcriptional repressor of numerous genes including MYC, TP53 (PMID: 8649389, 21465478) and plays a role in chromatin organization (PMID: 29307136). Loss-of-function CTCF variants have been identified in endometrial cancer, prostate cancer, Wilms tumor, and breast cancer (PMID: 24130125, 28648147, 23636398, 25079317).<br />\nThe CTCF p.Thr204Asnfs*26 variant is a frameshift variant predicted to result in an absent or disrupted protein product. Loss-of-function variants in CTCF are known to be oncogenic (PMID: 25079317, 24130125, 23636398). The p.Thr204Asnfs*26 frameshift variant represents a hotspot mutation which results in a truncated CTCF protein lacking all zinc finger domains (PMID: 24130125). It is most commonly associated with endometrial carcinoma, CRC, and esophageal carcinoma (PMID: 24130125, 216330387, 29316436, 28052061). The p.Thr204Asnfs*26 variant has been associated with strand slippage mutations resulting in microsatellite instability (MSI)-positive endometrioid tumors (PMID: 24130125).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the CTCF p.Thr204Asnfs*26 variant does not currently serves as an inclusion eligibility criterion for clinical trials.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/20 19:03:32",
      "evidences": [],
      "reference": ".",
      "alternative": "A",
      "gene": "CTCF",
      "transcript": "NM_006565.3",
      "cNomen": "c.610dupA",
      "type": "insertion",
      "location": "exonic",
      "exon": 3,
      "effect": "frameshift",
      "pNomen": "p.T204Nfs*26"
    },
    {
      "id": 11635,
      "chromosome": "16",
      "start": 67645339,
      "stop": 67645339,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "CTCF is a DNA-binding transcriptional repressor of numerous genes including MYC, TP53 (PMID: 8649389, 21465478) and plays a role in chromatin organization (PMID: 29307136). Loss-of-function CTCF variants have been identified in endometrial cancer, prostate cancer, Wilms tumor, and breast cancer (PMID: 24130125, 28648147, 23636398, 25079317).<br />\nLoss-of-function variants in CTCF are known to be oncogenic (PMID: 25079317, 24130125, 23636398). The CTCF p.Thr204Glnfs*18 frameshift variant is a mutational hotspot and results in a truncated protein associated with MSI-positive endometrial cancer (PMID: 24130125).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the CTCF p.Thr204Glnfs*18 variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/14 02:17:39",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "CTCF",
      "transcript": "NM_006565.3",
      "cNomen": "c.610delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 3,
      "effect": "frameshift",
      "pNomen": "p.T204Qfs*18"
    },
    {
      "id": 12214,
      "chromosome": "16",
      "start": 67654646,
      "stop": 67654646,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "CTCF is a chromatin binding factor that is involved in transcriptional regulation by binding to CTCF is a DNA-binding transcriptional repressor of numerous genes including MYC, TP53 (PMID: 8649389, 21465478) and plays a role in chromatin organization (PMID: 29307136). Loss-of-function CTCF variants have been identified in endometrial cancer, prostate cancer, Wilms tumor, and breast cancer (PMID: 24130125, 28648147, 23636398, 25079317).<br />\n <br />\nThe CTCF p.Pro378Leu missense variant does not lie within any known functional domains of the CTCF protein (UniProt), however experimental studies suggest this variant results in loss-of-function of CTCF in vitro (PMID: 28319062). The impact of this variant in this disease context is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/25 00:27:51",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "CTCF",
      "transcript": "NM_006565.3",
      "cNomen": "c.1133C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 6,
      "effect": "nonsynonymous",
      "pNomen": "p.P378L"
    },
    {
      "id": 12226,
      "chromosome": "16",
      "start": 67655473,
      "stop": 67655474,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "CTCF is a chromatin binding factor that is involved in transcriptional regulation by binding to CTCF is a DNA-binding transcriptional repressor of numerous genes including MYC, TP53 (PMID: 8649389, 21465478) and plays a role in chromatin organization (PMID: 29307136). Loss-of-function CTCF variants have been identified in endometrial cancer, prostate cancer, Wilms tumor, and breast cancer (PMID: 24130125, 28648147, 23636398, 25079317).<br />\nThe CTCF p.Ile446Serfs*5 frameshift variant is predicted to result in an absent or disrupted protein product. Loss-of-function variants in CTCF are known to be oncogenic (PMID: 25079317, 24130125, 23636398). The impact of this variant in this disease context is uncertain.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/04/23 14:51:18",
      "evidences": [],
      "reference": "AT",
      "alternative": ".",
      "gene": "CTCF",
      "transcript": "NM_006565.3",
      "cNomen": "c.1337_1338delTA",
      "type": "deletion",
      "location": "exonic",
      "exon": 7,
      "effect": "frameshift",
      "pNomen": "p.I446Sfs*5"
    },
    {
      "id": 11762,
      "chromosome": "16",
      "start": 67660469,
      "stop": 67660469,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "CTCF is a chromatin binding factor that is involved in transcriptional regulation by binding to CTCF is a DNA-binding transcriptional repressor of numerous genes including MYC, TP53 (PMID: 8649389, 21465478) and plays a role in chromatin organization (PMID: 29307136). Loss-of-function CTCF variants have been identified in endometrial cancer, prostate cancer, Wilms tumor, and breast cancer (PMID: 24130125, 28648147, 23636398, 25079317).<br />\nThe CTCF p.Arg457* nonsense variant is predicted to result in an absent or disrupted protein product. Loss-of-function variants in CTCF are known to be oncogenic (PMID: 25079317, 24130125, 23636398).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the CTCF p.Arg457* variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:33:57",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "CTCF",
      "transcript": "NM_006565.3",
      "cNomen": "c.1369C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "stopgain",
      "pNomen": "p.R457*"
    },
    {
      "id": 12041,
      "chromosome": "17",
      "start": 7574003,
      "stop": 7574003,
      "classification": "Very high",
      "variantInfo": "In other gynecological disease sites, TP53 mutations are predicted sensitive to WEE1 inhibitor (PMID: 27998224, 32611648, 19887545, 27998224).<br />\nPathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Arg342* variant has not been reported in the germline context as pathogenic (ClinVar).",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The p.Arg342* nonsense variant leads to a premature termination codon, which is predicted to result in a truncated or absent protein (PMID: 16969106).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/30 00:53:12",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.1024C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 10,
      "effect": "stopgain",
      "pNomen": "p.R342*"
    },
    {
      "id": 12044,
      "chromosome": "17",
      "start": 7574003,
      "stop": 7574003,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). TP53 mutations are predicted sensitive to WEE1 inhibitor (PMID: 27998224, 32611648, 19887545, 27998224).<br />\nPathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Arg342Glufs*3 variant has been reported as pathogenic in the germline context (ClinVar).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/31 15:09:50",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.1024delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 10,
      "effect": "frameshift",
      "pNomen": "p.R342Efs*3"
    },
    {
      "id": 12034,
      "chromosome": "17",
      "start": 7574016,
      "stop": 7574016,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The p.Phe338Alafs*2 frameshift variant leads to a premature termination codon, which is predicted to result in a truncated or absent protein. An early phase trial study suggests endometrial cancer patients harboring TP53 mutations are predicted sensitive to WEE1 inhibitor (J Clin Oncol 38: 2020 (suppl; abstr 3624); NCT01748825, PMID: 19887545, 27998224, 32611648).<br />\nPathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Phe338Alafs*2 variant has not been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/28 19:35:16",
      "evidences": [],
      "reference": ".",
      "alternative": "CGCTCACGCC",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.1001_1010dupGGCGTGAGCG",
      "type": "insertion",
      "location": "exonic",
      "exon": 10,
      "effect": "frameshift",
      "pNomen": "p.F338Afs*2"
    },
    {
      "id": 11615,
      "chromosome": "17",
      "start": 7574018,
      "stop": 7574018,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Arg337Cys missense variant is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest the p.Arg337Cys variant results in loss transactivation activity (PMID: 19106109, 16007150, 11753428). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Arg337Cys variant has been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/08 18:50:24",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.1009C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 10,
      "effect": "nonsynonymous",
      "pNomen": "p.R337C"
    },
    {
      "id": 11893,
      "chromosome": "17",
      "start": 7574030,
      "stop": 7574030,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Arg333Valfs*12 variant has been reported in the germline context (PMID: 32577752).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Arg333Valfs*12 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/16 02:54:49",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.997delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 10,
      "effect": "frameshift",
      "pNomen": "p.R333Vfs*12"
    },
    {
      "id": 11396,
      "chromosome": "17",
      "start": 7576852,
      "stop": 7576852,
      "classification": "Very high",
      "variantInfo": "<br />\nThe c.993&#43;1G&gt;A splice site variant is predicted to result in an absent or disrupted protein product. Truncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The c.993&#43;1G&gt;A variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 c.993&#43;1G&gt;A variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/07/16 14:27:02",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.993+1G>A",
      "type": "snp",
      "location": "intronic",
      "exon": 9,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11311,
      "chromosome": "17",
      "start": 7576897,
      "stop": 7576897,
      "classification": "Very high",
      "variantInfo": "<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Gln317* variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Gln317* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/06/12 03:25:23",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.949C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 9,
      "effect": "stopgain",
      "pNomen": "p.Q317*"
    },
    {
      "id": 11387,
      "chromosome": "17",
      "start": 7576900,
      "stop": 7576901,
      "classification": "Very high",
      "variantInfo": "<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID: 11900253, 11753428, 16007150). The p.Gln317Alafs*19 frameshift variant is predicted to result in in an absent or disrupted protein product. Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Gln317Alafs*19 variant has not been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Gln317Alafs*19 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/07/09 11:03:30",
      "evidences": [],
      "reference": "GA",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.945_946delTC",
      "type": "deletion",
      "location": "exonic",
      "exon": 9,
      "effect": "frameshift",
      "pNomen": "p.Q317Afs*19"
    },
    {
      "id": 11533,
      "chromosome": "17",
      "start": 7576910,
      "stop": 7576910,
      "classification": "Very high",
      "variantInfo": "<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Ser313Alafs*32 variant (also referred to as has been reported in the germline context of breast cancer (29263802).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Arg209Lysfs*6 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/10 21:12:50",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.936delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 9,
      "effect": "frameshift",
      "pNomen": "p.S313Afs*32"
    },
    {
      "id": 11791,
      "chromosome": "17",
      "start": 7577018,
      "stop": 7577018,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nThe c.919&#43;1G&gt;C splice site variant is predicted to result in an absent or disrupted protein product. Truncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The c.919&#43;1G&gt;C variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 c.919&#43;1G&gt;C variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:31",
      "evidences": [],
      "reference": "C",
      "alternative": "G",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.919+1G>C",
      "type": "snp",
      "location": "intronic",
      "exon": 8,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11439,
      "chromosome": "17",
      "start": 7577022,
      "stop": 7577022,
      "classification": "Very high",
      "variantInfo": "<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID: 11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Arg306* nonsense variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Arg306* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/08/12 16:21:21",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.916C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "stopgain",
      "pNomen": "p.R306*"
    },
    {
      "id": 11724,
      "chromosome": "17",
      "start": 7577046,
      "stop": 7577046,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Glu298* variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Glu298* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/06 17:36:53",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.892G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "stopgain",
      "pNomen": "p.E298*"
    },
    {
      "id": 11718,
      "chromosome": "17",
      "start": 7577058,
      "stop": 7577058,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Glu294* variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Glu294* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/06 15:34:31",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.880G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "stopgain",
      "pNomen": "p.E294*"
    },
    {
      "id": 11438,
      "chromosome": "17",
      "start": 7577069,
      "stop": 7577092,
      "classification": "Very high",
      "variantInfo": "<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID: 11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Arg283_Arg290del in-frame deletion variant has not been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Arg283_Arg290del variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/08/12 16:14:08",
      "evidences": [],
      "reference": "CGGAGATTCTCTTCCTCTGTGCGC",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.846_869delGCGCACAGAGGAAGAGAATCTCCG",
      "type": "deletion",
      "location": "exonic",
      "exon": 8,
      "effect": "inframe",
      "pNomen": "p.R283_R290del"
    },
    {
      "id": 11313,
      "chromosome": "17",
      "start": 7577082,
      "stop": 7577082,
      "classification": "Very high",
      "variantInfo": "<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Glu286Lys missense variant is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest the p.Glu286Lys variant results in reduced transactivation activity (PMID: 20505364). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Glu286Lys variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Glu286Lys variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/06/12 03:42:50",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.856G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "nonsynonymous",
      "pNomen": "p.E286K"
    },
    {
      "id": 11649,
      "chromosome": "17",
      "start": 7577082,
      "stop": 7577082,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Glu286* nonsense variant has been reported in the germline context (PMID: 22878818).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Glu286* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/20 18:56:36",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.856G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "stopgain",
      "pNomen": "p.E286*"
    },
    {
      "id": 12167,
      "chromosome": "17",
      "start": 7577094,
      "stop": 7577094,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Arg282Trp missense variant is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest the p.Arg282Trp variant disrupts TP53 activity (PMID: 24857548, 31395785). Early phase clinical studies suggest patients with other gynecologic diseases harboring TP53 mutations are predicted sensitive to combined carboplatin and WEE1 inhibitor therapy (PMID: 27998224, 32611648).<br />\nPathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Arg282Trp variant has been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:36",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.844C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "nonsynonymous",
      "pNomen": "p.R282W"
    },
    {
      "id": 11132,
      "chromosome": "17",
      "start": 7577096,
      "stop": 7577096,
      "classification": "Very high",
      "variantInfo": "<br />\nThe TP53 p.Asp281Gl<b>y</b> is a missense variant result in loss of transactivation activity (PMID: 15077194, 23264849, 22114072). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Asp281Gly variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Asp281Gly variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/25 14:26:58",
      "evidences": [],
      "reference": "T",
      "alternative": "C",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.842A>G",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "nonsynonymous",
      "pNomen": "p.D281G"
    },
    {
      "id": 12061,
      "chromosome": "17",
      "start": 7577097,
      "stop": 7577097,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Asp281Asn missense variant occurs within the DNA binding domain of TP53 and is predicted to be non-functional (IARC TP53). Limited in vitro studies suggest the p.Asp281Asn variant results in loss transactivation activity (PMID: 11896595, 19850740). TP53 mutations are predicted sensitive to WEE1 inhibitor (PMID: 27998224, 32611648, 19887545, 27998224).<br />\nPathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Asp281Asn variant has not been reported as pathogenic in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/02/05 15:29:34",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.841G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "nonsynonymous",
      "pNomen": "p.D281N"
    },
    {
      "id": 12271,
      "chromosome": "17",
      "start": 7577099,
      "stop": 7577099,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC). Inactivation of TP53 results in increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). The TP53 p.Arg280Ile missense variant occurs within the DNA binding domain of TP53 and is predicted to be non-functional (IARC TP53). Limited in vitro assays in yeast suggest the p.Arg280Ile variant results in dominant-negative activity (PMID: 15825182). Other missense variants affecting the same Arg280 codon were shown to disrupt the normal activity of TP53 (PMID: 16322760, 18472962, 18524770, 21643018, 24763051). TP53 mutations are predicted sensitive to WEE1 inhibitors (PMID: 27998224, 32611648, 19887545, 27998224). Preclinical studies suggest another variant at the Arg280 codon is predicted sensitive to small molecule and cisplatin combination therapy in ovarian cancer (PMID: 27179933).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/04/27 20:26:42",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.839G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "nonsynonymous",
      "pNomen": "p.R280I"
    },
    {
      "id": 12151,
      "chromosome": "17",
      "start": 7577100,
      "stop": 7577100,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 results in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Arg280Gly missense variant occurs within the DNA binding domain of TP53 and is predicted to be non-functional (IARC TP53). Limited in vitro assays in yeast suggest the p.Arg280Gly variant results in dominant-negative activity (PMID: 15825182). Other missense variants affecting the same Arg280 codon were shown to disrupt the normal activity of TP53 (PMID: 16322760, 18472962, 18524770, 21643018, 24763051).<br />\nTP53 mutations are predicted sensitive to WEE1 inhibitors (PMID: 27998224, 32611648, 19887545, 27998224). Preclinical studies suggest another variant at the Arg280 codon is predicted sensitive to small molecule and cisplatin combination therapy in ovarian cancer (PMID: 27179933). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Arg280Gly variant has been reported in the germline context (ClinVar).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:36",
      "evidences": [],
      "reference": "T",
      "alternative": "C",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.838A>G",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "nonsynonymous",
      "pNomen": "p.R280G"
    },
    {
      "id": 11369,
      "chromosome": "17",
      "start": 7577102,
      "stop": 7577102,
      "classification": "Very high",
      "variantInfo": "<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Gly279Glu missense variant occurs within the DNA-binding domain and experimental studies suggest this variant results in reduced transactivation activity (PMID: 16508005, 11313981). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Gly279Glu variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Gly279Glu variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/06/29 18:00:15",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.836G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "nonsynonymous",
      "pNomen": "p.G279E"
    },
    {
      "id": 11713,
      "chromosome": "17",
      "start": 7577105,
      "stop": 7577105,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Pro278Arg missense variant occurs in the DNA binding domain and is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest other variants at this codon position results in loss transactivation activity (PMID: 24076587, 22989750, 11867759). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Pro278Arg variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Pro278Arg variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/05 21:00:37",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.833C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "nonsynonymous",
      "pNomen": "p.P278R"
    },
    {
      "id": 12269,
      "chromosome": "17",
      "start": 7577120,
      "stop": 7577120,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).The TP53 p.Arg273His hotspot variant (PMID: 24651012) occurs within the DNA-binding domain of the protein and results in a loss transactivation of downstream target genes (PMID: 31395785, 14743206) and increased tumorigenic growth in vitro (PMID: 22114072, 32002804). TP53 variants in gynecological cancers are predicted sensitive to WEE1 inhibitors (PMID: 27998224, J Clin Oncol 38: 2020 (suppl; abstr 3624); NCT01748825). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Arg273His variant has been reported in the germline context as pathogenic (ClinVar).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/04/27 20:07:16",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.818G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "nonsynonymous",
      "pNomen": "p.R273H"
    },
    {
      "id": 12140,
      "chromosome": "17",
      "start": 7577121,
      "stop": 7577121,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC). The TP53 p.Arg273Cys hotspot variant (PMID: 24868540, 27149842) within the DNA-binding domain of the protein and results in a loss-of-function (PMID: 23863845, 24677579, 23612969). Preclinical evidence suggest this variant in ovarian cancer is responsive to WEE1 inhibitors (PMID: 27998224). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Arg273Cys variant has been reported in the germline context as pathogenic/likely pathogenic (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/02/22 21:58:56",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.817C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "nonsynonymous",
      "pNomen": "p.R273C"
    },
    {
      "id": 11164,
      "chromosome": "17",
      "start": 7577129,
      "stop": 7577129,
      "classification": "Very high",
      "variantInfo": "The TP53 p.Phe270Ser is a missense variant and is predicted to be transcriptionally non-functional (IARC TP53). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Phe270Ser variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Phe270Ser variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/04/16 02:20:39",
      "evidences": [],
      "reference": "A",
      "alternative": "G",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.809T>C",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "nonsynonymous",
      "pNomen": "p.F270S"
    },
    {
      "id": 11388,
      "chromosome": "17",
      "start": 7577141,
      "stop": 7577141,
      "classification": "Very high",
      "variantInfo": "<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). The TP53 p.Gly266Val missense variant is located in the DNA binding domain and is predicted to be transcriptionally non-functional (IARC TP53). Another variant at this codon position has been reported to result in reduced transactivation activity in vitro (PMID: 20505364). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Gly266Val variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Gly266Val variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/07/09 11:34:51",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.797G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "nonsynonymous",
      "pNomen": "p.G266V"
    },
    {
      "id": 11876,
      "chromosome": "17",
      "start": 7577141,
      "stop": 7577141,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). The TP53 p.Gly266Glu missense variant is located in the DNA binding domain and is predicted to be transcriptionally non-functional (IARC TP53). Another variant at this codon position has been reported to result in reduced transactivation activity in vitro (PMID: 20505364). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Gly266Glu variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Gly266Glu variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:30:14",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.797G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "nonsynonymous",
      "pNomen": "p.G266E"
    },
    {
      "id": 11892,
      "chromosome": "17",
      "start": 7577144,
      "stop": 7577146,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID: 11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Leu265del in-frame deletion variant has not been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Leu265del variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/16 02:54:49",
      "evidences": [],
      "reference": "AGT",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.792_794delACT",
      "type": "deletion",
      "location": "exonic",
      "exon": 8,
      "effect": "inframe",
      "pNomen": "p.L265del"
    },
    {
      "id": 12158,
      "chromosome": "17",
      "start": 7577152,
      "stop": 7577152,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Asn263Ilefs*82 variant has been reported in the germline context (ClinVar).<br />\nEarly phase clinical studies suggest ovarian cancer patients harboring TP53 mutations are predicted sensitive to combined carboplatin and WEE1 inhibitor therapy (PMID: 27998224, 32611648).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:36",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.786delT",
      "type": "deletion",
      "location": "exonic",
      "exon": 8,
      "effect": "frameshift",
      "pNomen": "p.N263Ifs*82"
    },
    {
      "id": 12392,
      "chromosome": "17",
      "start": 7577498,
      "stop": 7577498,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC). The c.782&#43;1G&gt;A splice site variant is predicted to result in an altered protein product or absence of protein due to nonsense mediated decay. Truncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID: 11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). TP53 variants in gynecological cancer are predicted sensitive to WEE1 inhibitors (PMID: 27998224, J Clin Oncol 38: 2020 (suppl; abstr 3624); NCT01748825). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The c.782&#43;1G&gt;A variant has been reported as pathogenic in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/06/25 19:03:40",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.782+1G>A",
      "type": "snp",
      "location": "intronic",
      "exon": 7,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11127,
      "chromosome": "17",
      "start": 7577509,
      "stop": 7577509,
      "classification": "Very high",
      "variantInfo": "<br />\nThe TP53 p.Leu257dup is an in-frame duplication variant located within the DNA binding domain. Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Leu257dup variant has not been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Leu257dup variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/24 20:19:10",
      "evidences": [],
      "reference": ".",
      "alternative": "CAG",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.769_771dupCTG",
      "type": "insertion",
      "location": "exonic",
      "exon": 7,
      "effect": "inframe",
      "pNomen": "p.L257dup"
    },
    {
      "id": 11366,
      "chromosome": "17",
      "start": 7577518,
      "stop": 7577523,
      "classification": "Very high",
      "variantInfo": "<br />\nThe p.Thr253_Ile254del variant results in a loss of 2 residues within the DNA-binding domain. Truncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID: 11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Thr253_Ile254del variant has not been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Thr253_Ile254del variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/06/29 17:14:58",
      "evidences": [],
      "reference": "TGATGG",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.758_763delCCATCA",
      "type": "deletion",
      "location": "exonic",
      "exon": 7,
      "effect": "inframe",
      "pNomen": "p.T253_I254del"
    },
    {
      "id": 11929,
      "chromosome": "17",
      "start": 7577520,
      "stop": 7577520,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Ile254Thr missense variant is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest the p.Ile254Thr variant results in decreased transactivation activity (PMID: 25584008). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Ile254Thr variant has not been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Ile254Thr variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/14 19:32:07",
      "evidences": [],
      "reference": "A",
      "alternative": "G",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.761T>C",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "nonsynonymous",
      "pNomen": "p.I254T"
    },
    {
      "id": 11178,
      "chromosome": "17",
      "start": 7577538,
      "stop": 7577538,
      "classification": "Very high",
      "variantInfo": "The TP53 p.Arg248Gln is a hotspot missense variant that lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). Functional studies suggest that the p.Arg248Gln variant results in a loss of DNA binding leading to resistance to apoptosis, loss of cell cycle control, and increased tumorigenesis in vivo (PMID: 23538418, 16861262, 31395785, 30107178). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Arg248Gln variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Arg248Gln variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/04/16 04:45:37",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.743G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "nonsynonymous",
      "pNomen": "p.R248Q"
    },
    {
      "id": 10999,
      "chromosome": "17",
      "start": 7577539,
      "stop": 7577539,
      "classification": "Very high",
      "variantInfo": "The TP53 p.Arg248Trp variant lies in the DNA binding domain of TP53 and is most prevalent in colorectal and breast cancer (COSMIC). Functional studies suggest this variant results in disruption of TP53 activity (PMID: 17606709, 21343334, 23172776). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Arg248Trp variant has been reported in the germline context by 36 clinical laboratories as pathogenic (including by the ClinGen TP53 Variant Curation Expert Panel; ClinVar); this variant is rare in population studies (MAF &lt; 0.001%; 1/251476 alleles; gnomAD).<br />\nA search by the Watson for Genomics platform indicates in this disease site, TP53 p.Arg248Trp variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 encodes for a tumour suppressor protein involved in cell cycle control. TP53 is a transcription factor that regulates a large number of genes involved in cell cycle arrest, apoptosis, senescence, DNA repair, and metabolism. TP53 is the most frequently altered gene in cancer (COSMIC).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/09 21:02:07",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.742C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "nonsynonymous",
      "pNomen": "p.R248W"
    },
    {
      "id": 12126,
      "chromosome": "17",
      "start": 7577543,
      "stop": 7577564,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The p.Asn239Lysfs*99 frameshift variant leads to a premature termination codon, which is predicted to result in a truncated protein (PMID: 16969106). Preclinical evidence suggest this variant in ovarian cancer is responsive to WEE1 inhibitors (PMID: 27998224).<br />\nPathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Asn239Lysfs*99 variant has not been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/02/22 20:05:38",
      "evidences": [],
      "reference": "CATGCCGCCCATGCAGGAACTG",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.717_738delCAGTTCCTGCATGGGCGGCATG",
      "type": "deletion",
      "location": "exonic",
      "exon": 7,
      "effect": "frameshift",
      "pNomen": "p.N239Kfs*99"
    },
    {
      "id": 12345,
      "chromosome": "17",
      "start": 7577547,
      "stop": 7577547,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Gly245Asp missense variant is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest that codon Gly245 variants such as p.Gly245Asp variant results in disrupted transactivation activity and gain of function properties (PMID: 22214764, 29269868, 25634208, 27533082). TP53 variants in gynecological cancer are predicted sensitive to WEE1 inhibitors (PMID: 27998224, J Clin Oncol 38: 2020 (suppl; abstr 3624); NCT01748825).<br />\nPathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Gly245Asp variant has been reported as pathogenic/likely pathogenic in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/06/25 18:26:25",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.734G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "nonsynonymous",
      "pNomen": "p.G245D"
    },
    {
      "id": 12042,
      "chromosome": "17",
      "start": 7577548,
      "stop": 7577548,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Gly245Ser missense variant is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest the p.Gly245Ser variant results in loss transactivation activity (PMID: 20212049, 23538418, 17417775). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Gly245Ser variant has been reported as pathogenic in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/31 14:49:25",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.733G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "nonsynonymous",
      "pNomen": "p.G245S"
    },
    {
      "id": 12191,
      "chromosome": "17",
      "start": 7577558,
      "stop": 7577558,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The p.Cys242Alafs*5 frameshift variant is predicted to result in an absent or disrupted protein product. TP53 variants in ovarian cancer are predicted sensitive to WEE1 inhibitors (PMID: 27998224).<br />\nPathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Cys242Alafs*5 variant has not been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:39",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.723delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 7,
      "effect": "frameshift",
      "pNomen": "p.C242Afs*5"
    },
    {
      "id": 12153,
      "chromosome": "17",
      "start": 7577559,
      "stop": 7577559,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Ser241Phe missense variant is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest the p.Ser241Phe variant results in disrupted TP53 activity (PMID: 19225112, 26585234, 21383700). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Ser241Phe variant has been reported in the germline context (ClinVar).<br />\nEarly phase clinical studies suggest ovarian cancer patients harboring TP53 mutations are predicted sensitive to combined carboplatin and WEE1 inhibitor therapy (PMID: 27998224, 32611648).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:39",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.722C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "nonsynonymous",
      "pNomen": "p.S241F"
    },
    {
      "id": 10919,
      "chromosome": "17",
      "start": 7577560,
      "stop": 7577560,
      "classification": "Very high",
      "variantInfo": "Truncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID: 11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). This variant has not been previously reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 S241Pfs*6 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (COSMIC).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/02/24 20:44:43",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.721delT",
      "type": "deletion",
      "location": "exonic",
      "exon": 7,
      "effect": "frameshift",
      "pNomen": "p.S241Pfs*6"
    },
    {
      "id": 11372,
      "chromosome": "17",
      "start": 7577565,
      "stop": 7577565,
      "classification": "Very high",
      "variantInfo": "<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). The TP53 p.Asn239Ser missense variant is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest the p.Asn239Ser variant results in loss transactivation activity (PMID: 22553460). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Asn239Ser variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Asn239Ser variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/07/06 15:17:27",
      "evidences": [],
      "reference": "T",
      "alternative": "C",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.716A>G",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "nonsynonymous",
      "pNomen": "p.N239S"
    },
    {
      "id": 11771,
      "chromosome": "17",
      "start": 7577568,
      "stop": 7577568,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Cys238Tyr missense variant is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest the p.Cys238Tyr variant results in loss transactivation activity (PMID: 21343334). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Cys238Tyr variant has been reported as likely pathogenic in the germline context (ClinVar).<br />\nPreclinical evidence suggests TP53 mutations are associated with responsiveness to Adavosertib in case reports of endometrial carcinoma (J Clin Oncol 38: 2020 (suppl; abstr 3624); NCT01748825).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 19:47:45",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.713G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "nonsynonymous",
      "pNomen": "p.C238Y"
    },
    {
      "id": 10917,
      "chromosome": "17",
      "start": 7577570,
      "stop": 7577570,
      "classification": "Very high",
      "variantInfo": "The M237I is a missense variant that occurs within the DNA binding domain of TP53. Functional studies suggest this variant results in a loss-of-function (PMID: 12826609, 21343334, 17606709). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The M237I variant has been previously reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 M237I variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials.",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/02/24 20:31:10",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.711G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "nonsynonymous",
      "pNomen": "p.M237I"
    },
    {
      "id": 11890,
      "chromosome": "17",
      "start": 7577581,
      "stop": 7577581,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Tyr234His missense variant is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest the p.Tyr234His variant results in loss of transactivation activity (PMID: 10871862, 27533082). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Tyr234His variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Tyr234His variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/16 02:54:49",
      "evidences": [],
      "reference": "A",
      "alternative": "G",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.700T>C",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "nonsynonymous",
      "pNomen": "p.Y234H"
    },
    {
      "id": 12354,
      "chromosome": "17",
      "start": 7578190,
      "stop": 7578190,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC). Inactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Tyr220Cys missense variant is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest the p.Tyr220Cys variant results in loss of transactivation activity (PMID: 20128691, 21343334, 17015838, 12826609, 16861262, 23630318). Clinical studies suggest TP53 variants in ovarian cancer are predicted sensitive to WEE1 inhibitors (PMID: 27998224). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Tyr220Cys variant has been reported as pathogenic in the germline context (ClinVar).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/06/01 20:27:31",
      "evidences": [],
      "reference": "T",
      "alternative": "C",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.659A>G",
      "type": "snp",
      "location": "exonic",
      "exon": 6,
      "effect": "nonsynonymous",
      "pNomen": "p.Y220C"
    },
    {
      "id": 11748,
      "chromosome": "17",
      "start": 7578203,
      "stop": 7578203,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Val216Met missense variant lies within the DNA-binding domain and is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest the p.Val216Met variant results in disrupted TP53 activity in vitro (PMID: 21232794, 28369373, 20505364). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Val216Met variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Val216Met variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:21:45",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.646G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 6,
      "effect": "nonsynonymous",
      "pNomen": "p.V216M"
    },
    {
      "id": 11177,
      "chromosome": "17",
      "start": 7578211,
      "stop": 7578211,
      "classification": "Very high",
      "variantInfo": "The TP53 p.Arg213Leu is a missense variant and is predicted to be transcriptionally non-functional (IARC TP53). Functional studies suggest that the p.Arg213Leu variant results in loss of TP53 transactivation activity (PMID: 21514416). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Arg213Leu variant has not been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Arg213Leu variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/04/16 04:29:37",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.638G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 6,
      "effect": "nonsynonymous",
      "pNomen": "p.R213L"
    },
    {
      "id": 11551,
      "chromosome": "17",
      "start": 7578212,
      "stop": 7578212,
      "classification": "Very high",
      "variantInfo": "<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID: 11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Arg306* nonsense variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Arg213* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/19 21:25:23",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.637C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 6,
      "effect": "stopgain",
      "pNomen": "p.R213*"
    },
    {
      "id": 11115,
      "chromosome": "17",
      "start": 7578222,
      "stop": 7578223,
      "classification": "Very high",
      "variantInfo": "Truncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Arg209Lysfs*6 variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Arg209Lysfs*6 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/24 14:16:46",
      "evidences": [],
      "reference": "TC",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.626_627delGA",
      "type": "deletion",
      "location": "exonic",
      "exon": 6,
      "effect": "frameshift",
      "pNomen": "p.R209Kfs*6"
    },
    {
      "id": 11039,
      "chromosome": "17",
      "start": 7578263,
      "stop": 7578263,
      "classification": "Very high",
      "variantInfo": "The TP53 p.Arg196* variant is a nonsense variant that leads to a premature termination codon, which is predicted to result in a truncated or absent protein. Truncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID: 11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). This variant has been previously reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Arg196* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials for WEE1 kinase inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/12 20:47:18",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.586C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 6,
      "effect": "stopgain",
      "pNomen": "p.R196*"
    },
    {
      "id": 11121,
      "chromosome": "17",
      "start": 7578268,
      "stop": 7578268,
      "classification": "Very high",
      "variantInfo": "<br />\nThe TP53 p.Leu194Arg is a missense variant that occurs within the DNA-binding domain and is predicted to be transcriptionally non-functional (IARC TP53). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Ser127Phe variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the T TP53 p.Leu194Arg variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/24 18:18:30",
      "evidences": [],
      "reference": "A",
      "alternative": "C",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.581T>G",
      "type": "snp",
      "location": "exonic",
      "exon": 6,
      "effect": "nonsynonymous",
      "pNomen": "p.L194R"
    },
    {
      "id": 12263,
      "chromosome": "17",
      "start": 7578271,
      "stop": 7578271,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). The TP53 p.His193Arg missense variant is predicted to be transcriptionally non-functional (IARC TP53). Although this variant has not been functionally characterized, experimental studies show that this and another variant at this codon results in disrupted transactivation activity (PMID: 25584008, 9627118, 21763698). TP53 variants in gynecological cancer are predicted sensitive to WEE1 inhibitors (PMID: 27998224, J Clin Oncol 38: 2020 (suppl; abstr 3624); NCT01748825).<br />\nPathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.His193Arg variant has been reported as likely pathogenic in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/04/27 19:08:33",
      "evidences": [],
      "reference": "T",
      "alternative": "C",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.578A>G",
      "type": "snp",
      "location": "exonic",
      "exon": 6,
      "effect": "nonsynonymous",
      "pNomen": "p.H193R"
    },
    {
      "id": 11715,
      "chromosome": "17",
      "start": 7578290,
      "stop": 7578290,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The c.560-1G&gt;A variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 c.560-1G&gt;A variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/05 21:18:17",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.560-1G>A",
      "type": "snp",
      "location": "intronic",
      "exon": 6,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11813,
      "chromosome": "17",
      "start": 7578370,
      "stop": 7578370,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The c.559&#43;1G&gt;A variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 c.559&#43;1G&gt;A variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/25 21:48:37",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.559+1G>A",
      "type": "snp",
      "location": "intronic",
      "exon": 5,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 12407,
      "chromosome": "17",
      "start": 7578382,
      "stop": 7578382,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC). Truncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The p.Ser183* nonsense variant is predicted to result in an absent or disrupted protein product. Clinical studies suggest TP53 variants in ovarian cancer are predicted sensitive to WEE1 inhibitors (PMID: 27998224).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/07/06 18:29:48",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.548C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "stopgain",
      "pNomen": "p.S183*"
    },
    {
      "id": 12196,
      "chromosome": "17",
      "start": 7578384,
      "stop": 7578401,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). The p.Pro177_Cys182del in-frame deletion variant occurs in the DNA binding domain of the TP53 protein. TP53 mutations in gynecologic diseases are predicted sensitive to WEE1 inhibitors (PMID: 27998224, 32611648, 19887545).<br />\nPathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Pro177_Cys182del variant has not been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:39",
      "evidences": [],
      "reference": "GCAGCGCTCATGGTGGGG",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.529_546delCCCCACCATGAGCGCTGC",
      "type": "deletion",
      "location": "exonic",
      "exon": 5,
      "effect": "inframe",
      "pNomen": "p.P177_C182del"
    },
    {
      "id": 11881,
      "chromosome": "17",
      "start": 7578394,
      "stop": 7578423,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Met169_His179delinsIle variant has not been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Met169_His179delinsIle variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 17:05:04",
      "evidences": [],
      "reference": "TGGTGGGGGCAGCGCCTCACAACCTCCGTC",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.507_536delGACGGAGGTTGTGAGGCGCTGCCCCCACCA",
      "type": "deletion",
      "location": "exonic",
      "exon": 5,
      "effect": "inframe",
      "pNomen": "p.M169_H179delinsI"
    },
    {
      "id": 11940,
      "chromosome": "17",
      "start": 7578395,
      "stop": 7578395,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.His179Asn missense variant occurs within the DNA binding domain of TP53 and is predicted to be partially functional (IARC TP53). Functional evidence suggests this variant results in disruption of TP53 activity (PMID: 10778859, 19462533, 27813088, 9290701, 8633021, 10616528). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.His179Asn variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.His179Asn variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/14 19:32:07",
      "evidences": [],
      "reference": "G",
      "alternative": "T",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.535C>A",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.H179N"
    },
    {
      "id": 12045,
      "chromosome": "17",
      "start": 7578395,
      "stop": 7578395,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.His179Asp missense variant occurs within the DNA binding domain of TP53 and is predicted to be partially functional (IARC TP53). Another variant at this codon position has been reported to result in disruption of TP53 activity (PMID: 22427690, 26585234, 16778209). TP53 mutations are predicted sensitive to WEE1 inhibitor (PMID: 27998224, 32611648, 19887545, 27998224).<br />\nPathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.His179Asp variant has not been reported in the germline context (ClinVar).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/31 15:36:02",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.535C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.H179D"
    },
    {
      "id": 11925,
      "chromosome": "17",
      "start": 7578406,
      "stop": 7578406,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Arg175His missense variant is a recurrent hotspot variant within the DNA-binding domain of TP53 (PMID: 22713868, 17401432, 24651012, COSMIC) and is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest the p.Arg175His variant results in disruption of TP53 protein function in addition to being a gain-of-function (PMID: 10713666, 22114072, 19881536, 14743206, 31395785, 8510927, 17401432, 27589690, 8633021, 10519380). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Arg175His variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Arg175His variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/14 19:32:07",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.524G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.R175H"
    },
    {
      "id": 11613,
      "chromosome": "17",
      "start": 7578416,
      "stop": 7578416,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Val172Phe missense variant is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest the p.Val172Phe variant induces cisplatin resistance by inhibiting TP53-dependent transactivation by increasing the binding of MDM4 to P53 (PMID: 26876197). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Val172Phe variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Val172Phe variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/08 18:40:46",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.514G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.V172F"
    },
    {
      "id": 11722,
      "chromosome": "17",
      "start": 7578427,
      "stop": 7578427,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.His168Arg missense variant is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest the p.His168Arg variant results in disrupted transactivation activity (PMID: 18996393, 12826609<i>).</i> Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.His168Arg variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.His168Arg variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/06 16:06:12",
      "evidences": [],
      "reference": "T",
      "alternative": "C",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.503A>G",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.H168R"
    },
    {
      "id": 12192,
      "chromosome": "17",
      "start": 7578427,
      "stop": 7578427,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.His168Pro missense variant is predicted to be transcriptionally non-functional (IARC TP53). Although this variant has not been functionally characterized, experimental studies show that another variant at this codon results in disrupted transactivation activity (PMID: 18996393, 12826609). TP53 variants in ovarian cancer are predicted sensitive to WEE1 inhibitors (PMID: 27998224).<br />\nPathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.His168Pro variant has not been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:39",
      "evidences": [],
      "reference": "T",
      "alternative": "G",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.503A>C",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.H168P"
    },
    {
      "id": 11962,
      "chromosome": "17",
      "start": 7578461,
      "stop": 7578461,
      "classification": "Very high",
      "variantInfo": "Early phase clinical studies suggest ovarian cancer patients harboring TP53 mutations are predicted sensitive to combined carboplatin and WEE1 inhibitor therapy (PMID: 27998224, 32611648).",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Val157Phe missense variant is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest the p.Val157Phe variant results in loss transactivation activity (PMID: 22710932, 16778209, 15037740, 21561095). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Val157Phe variant has been reported in the germline context (ClinVar).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/14 19:36:00",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.469G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.V157F"
    },
    {
      "id": 12323,
      "chromosome": "17",
      "start": 7578475,
      "stop": 7578475,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC). Truncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The p.Pro152Argfs*18 frameshift variant is predicted to result in an absent or disrupted protein product. Clinical studies suggest TP53 variants in ovarian cancer are predicted sensitive to WEE1 inhibitors (PMID: 27998224). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Pro152Argfs*18 variant has been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/05/17 20:25:24",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.455delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 5,
      "effect": "frameshift",
      "pNomen": "p.P152Rfs*18"
    },
    {
      "id": 11531,
      "chromosome": "17",
      "start": 7578479,
      "stop": 7578479,
      "classification": "Very high",
      "variantInfo": "<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Pro151Ala missense variant is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest the p.Pro151Ala variant results in loss transactivation activity (PMID: 20407015). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Pro151Ala variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Pro151Ala variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/10 20:42:27",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.451C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.P151A"
    },
    {
      "id": 12282,
      "chromosome": "17",
      "start": 7578479,
      "stop": 7578479,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Pro151Ser missense variant is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest the p.Pro151Ser variant results in loss of transactivation activity and tumor growth (PMID: 21903770, 23625637, 21343334). TP53 variants in gynecological cancer are predicted sensitive to WEE1 inhibitors (PMID: 27998224, J Clin Oncol 38: 2020 (suppl; abstr 3624); NCT01748825).<br />\nPathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Pro151Ser variant has been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/05/17 20:25:24",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.451C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.P151S"
    },
    {
      "id": 10910,
      "chromosome": "17",
      "start": 7578486,
      "stop": 7578487,
      "classification": "Very high",
      "variantInfo": "Truncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID: 11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The D148Vfs*32 variant has not been reported in the germline context (ClinVar).<br />\n                                                                                                                                  <br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 D148Vfs*32 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials (NCT Number: NCT02465060, NCT03579316, NCT01827384, NCT02095132, NCT02354547).",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/02/24 19:33:08",
      "evidences": [],
      "reference": "AT",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.443_444delAT",
      "type": "deletion",
      "location": "exonic",
      "exon": 5,
      "effect": "frameshift",
      "pNomen": "p.D148Vfs*32"
    },
    {
      "id": 12211,
      "chromosome": "17",
      "start": 7578508,
      "stop": 7578508,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\n <br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Cys141Tyr missense variant is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest the p.Cys141Tyr variant results in loss transactivation activity (PMID: 12725534, 20128691, 12826609, 16861262, 21343334, 24256616).<br />\n <br />\nPathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Cys141Tyr variant has been reported as pathogenic in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:43:18",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.422G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.C141Y"
    },
    {
      "id": 11648,
      "chromosome": "17",
      "start": 7578525,
      "stop": 7578525,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). The TP53 p.Cys135Trp missense variant is predicted to be partially functional (IARC TP53). Experimental studies suggest that other variants at this codon position are pathogenic (PMID: 19626115, 22847613, 8336941,16492679). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Cys135Trp variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Cys135Trp variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/19 20:20:07",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.405C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.C135W"
    },
    {
      "id": 11383,
      "chromosome": "17",
      "start": 7578526,
      "stop": 7578526,
      "classification": "Very high",
      "variantInfo": "<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). The TP53 p.Cys135Tyr missense variant is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest the p.Cys135Tyr variant represses miRNA expression in vitro (PMID: 19626115, 22847613). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Cys135Tyr variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Cys135Tyr variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/07/09 03:45:31",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.404G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.C135Y"
    },
    {
      "id": 11386,
      "chromosome": "17",
      "start": 7578535,
      "stop": 7578535,
      "classification": "Very high",
      "variantInfo": "<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). The TP53 p.Lys132Arg missense variant occurs in the DNA-binding domain and is predicted to be transcriptionally non-functional (IARC TP53). Experimental studies suggest the p.Lys132Arg variant results in a dominant negative effect on wildtype TP53 based on a yeast functional assay (PMID: 16861262). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Lys132Arg variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Lys132Arg variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/07/09 10:43:54",
      "evidences": [],
      "reference": "T",
      "alternative": "C",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.395A>G",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.K132R"
    },
    {
      "id": 11118,
      "chromosome": "17",
      "start": 7578550,
      "stop": 7578550,
      "classification": "Very high",
      "variantInfo": "The TP53 p.Ser127Phe is a missense variant and is predicted to be transcriptionally non-functional (IARC TP53). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Ser127Phe variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Ser127Phe variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/24 17:21:09",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.380C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.S127F"
    },
    {
      "id": 12216,
      "chromosome": "17",
      "start": 7578552,
      "stop": 7578552,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The p.Tyr126* nonsense variant is predicted to result in an absent or disrupted protein product. Clinical studies suggest TP53 variants in ovarian cancer are predicted sensitive to WEE1 inhibitors (PMID: 27998224).<br />\nPathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Tyr126* variant has been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/25 00:45:36",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.378C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "stopgain",
      "pNomen": "p.Y126*"
    },
    {
      "id": 11175,
      "chromosome": "17",
      "start": 7579316,
      "stop": 7579316,
      "classification": "Very high",
      "variantInfo": "Truncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID: 11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Cys124Leufs*25 frameshift variant has not been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Cys124Leufs*25 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/04/16 03:59:09",
      "evidences": [],
      "reference": ".",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.370dupT",
      "type": "insertion",
      "location": "exonic",
      "exon": 4,
      "effect": "frameshift",
      "pNomen": "p.C124Lfs*25"
    },
    {
      "id": 12180,
      "chromosome": "17",
      "start": 7579358,
      "stop": 7579358,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The TP53 p.Arg110Pro missense variant occurs within the DNA binding domain of TP53 and is predicted to be non-functional (IARC TP53). In vitro studies suggest the p.Arg110Pro variant disrupts TP53 activity (PMID: 24076587, 21445056). TP53 mutations in gynecologic diseases are predicted sensitive to WEE1 inhibitors (PMID: 27998224, 32611648, 19887545).<br />\nPathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Arg110Pro variant has been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:39",
      "evidences": [],
      "reference": "C",
      "alternative": "G",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.329G>C",
      "type": "snp",
      "location": "exonic",
      "exon": 4,
      "effect": "nonsynonymous",
      "pNomen": "p.R110P"
    },
    {
      "id": 12122,
      "chromosome": "17",
      "start": 7579394,
      "stop": 7579394,
      "classification": "Very high",
      "variantInfo": "Preclinical evidence suggest this variant in ovarian cancer is responsive to WEE1 inhibitors (PMID: 27998224).",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397).<br />\nPathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Pro98Leufs*25 variant has been reported in the germline context (PMID: 27374712, 30709381).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/02/22 19:25:54",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.293delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 4,
      "effect": "frameshift",
      "pNomen": "p.P98Lfs*25"
    },
    {
      "id": 10920,
      "chromosome": "17",
      "start": 7579402,
      "stop": 7579415,
      "classification": "Very high",
      "variantInfo": "Truncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID: 11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). This variant has not been previously reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 W91Ffs*53 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (COSMIC).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/02/24 20:58:05",
      "evidences": [],
      "reference": "AGATGACAGGGGCC",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.272_285delGGCCCCTGTCATCT",
      "type": "deletion",
      "location": "exonic",
      "exon": 4,
      "effect": "frameshift",
      "pNomen": "p.W91Ffs*53"
    },
    {
      "id": 12212,
      "chromosome": "17",
      "start": 7579408,
      "stop": 7579460,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The p.Ala76Valfs*55 frameshift variant is predicted to result in an absent or disrupted protein product. TP53 variants in ovarian cancer are predicted sensitive to WEE1 inhibitors (PMID: 27998224).<br />\nPathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Ala76Valfs*55 variant has not been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:47:16",
      "evidences": [],
      "reference": "CAGGGGCCAGGAGGGGGCTGGTGCAGGGGCCGCCGGTGTAGGAGCTGCTGGTG",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.227_279del",
      "type": "deletion",
      "location": "exonic",
      "exon": 4,
      "effect": "frameshift",
      "pNomen": "p.A76Vfs*55"
    },
    {
      "id": 11569,
      "chromosome": "17",
      "start": 7579409,
      "stop": 7579410,
      "classification": "Very high",
      "variantInfo": "<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID: 11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Leu93Valfs*55 frameshift variant has been reported in the germline context (PMID: 29752822).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Leu93Valfs*55 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/24 03:00:58",
      "evidences": [],
      "reference": "AG",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.277_278delCT",
      "type": "deletion",
      "location": "exonic",
      "exon": 4,
      "effect": "frameshift",
      "pNomen": "p.L93Vfs*55"
    },
    {
      "id": 11032,
      "chromosome": "17",
      "start": 7579418,
      "stop": 7579418,
      "classification": "Very high",
      "variantInfo": "The TP53 p.Ser90Alafs*33 variant is a nonsense variant that leads to a premature termination codon, which is predicted to result in a truncated or absent protein. Truncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID: 11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). This variant has been previously reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Ser90Alafs*33 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials for WEE1 kinase inhibitors.",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/12 18:58:56",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.269C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 4,
      "effect": "nonsynonymous",
      "pNomen": "p.S90C"
    },
    {
      "id": 11033,
      "chromosome": "17",
      "start": 7579420,
      "stop": 7579420,
      "classification": "Very high",
      "variantInfo": "The TP53 p.Ser90Alafs*33 variant is a nonsense variant that leads to a premature termination codon, which is predicted to result in a truncated or absent protein. Truncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID: 11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). This variant has been previously reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Ser90Alafs*33 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials for WEE1 kinase inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/12 18:59:19",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.267delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 4,
      "effect": "frameshift",
      "pNomen": "p.S90Pfs*33"
    },
    {
      "id": 11060,
      "chromosome": "17",
      "start": 7579470,
      "stop": 7579470,
      "classification": "Very high",
      "variantInfo": "Truncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p<b>.</b>Val73Argfs*76 frameshift variant has been reported in the germline context (ClinVar).  <br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p<b>.</b>Val73Argfs*76 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/18 02:26:23",
      "evidences": [],
      "reference": ".",
      "alternative": "G",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.216dupC",
      "type": "insertion",
      "location": "exonic",
      "exon": 4,
      "effect": "frameshift",
      "pNomen": "p.V73Rfs*76"
    },
    {
      "id": 11932,
      "chromosome": "17",
      "start": 7579489,
      "stop": 7579492,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Arg65Serfs*57 variant has not been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Arg65Serfs*57 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of WEE1 inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/14 19:32:07",
      "evidences": [],
      "reference": "CATT",
      "alternative": ".",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.195_198delAATG",
      "type": "deletion",
      "location": "exonic",
      "exon": 4,
      "effect": "frameshift",
      "pNomen": "p.R65Sfs*57"
    },
    {
      "id": 12213,
      "chromosome": "17",
      "start": 7579521,
      "stop": 7579521,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nTruncating mutations, which disrupt the DNA-binding domain or oligodimerization domain of the protein are predicted to be inactivating (PMID:11900253, 11753428, 16007150). Inactivation of TP53 can confer cells additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance (PMID:11156366, 19691397). The p.Glu56* nonsense variant is predicted to result in an absent or disrupted protein product. Clinical studies suggest TP53 variants in ovarian cancer are predicted sensitive to WEE1 inhibitors (PMID: 27998224).<br />\nPathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Glu56* variant has not been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 21:03:27",
      "evidences": [],
      "reference": ".",
      "alternative": "A",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.165dupT",
      "type": "insertion",
      "location": "exonic",
      "exon": 4,
      "effect": "stopgain",
      "pNomen": "p.E56*"
    },
    {
      "id": 11899,
      "chromosome": "17",
      "start": 7579848,
      "stop": 7579848,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "TP53 is a transcription factor involved in cell growth and survival through regulation of apoptosis and cell cycle pathways. TP53 is the most frequently altered gene in cancer (PMID: 30224644; COSMIC).<br />\nInactivation of TP53 result in increased proliferation, evasion of apoptosis, and chemoresistance (PMID: 11156366, 19691397). The TP53 p.Leu22Gln missense variant is predicted to be partially functional (IARC TP53). Experimental studies suggest the p.Leu22Gln variant results in reduced transactivation activity (PMID: 26578795, 7926727), with greater phenotypes observed when mutated with additional TP53 mutations (PMID: 31506076, 22427690, 15654339). Pathogenic germline variants in TP53 have been associated with Li-Fraumeni syndrome (PMID: 2259385, 8118819, 12619118). The p.Leu22Gln variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the TP53 p.Leu22Gln variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/16 02:54:31",
      "evidences": [],
      "reference": "A",
      "alternative": "T",
      "gene": "TP53",
      "transcript": "NM_000546.5",
      "cNomen": "c.65T>A",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "nonsynonymous",
      "pNomen": "p.L22Q"
    },
    {
      "id": 12343,
      "chromosome": "17",
      "start": 12016662,
      "stop": 12016662,
      "classification": "Very high",
      "variantInfo": "The MAP2K4 p.Cys266* nonsense variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in MAP2K4 are known to be oncogenic and may be sensitive to MEK inhibitors (PMID: 21896780, 29795445, 21896780).<br />\nA search by the Clinical Insight (QCI) platform indicates in this disease site, the MAP2K4 p.Cys266* variant currently serves as an inclusion eligibility criterion for Phase 1/Phase 2 clinical trials of RAF/MEK inhibitors.",
      "reportAbstract": "MAP2K4 is a serine/threonine protein kinase involved in cell growth and survival through activation of the RAS/RAF/MAPK pathway (PMID:18572308). MAP2K4 has been implicated across many different cancer types (PMID: 20610622, 17057737, 25019290, 10554023, 12438272).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/05/26 20:42:23",
      "evidences": [],
      "reference": "T",
      "alternative": "A",
      "gene": "MAP2K4",
      "transcript": "NM_003010.3",
      "cNomen": "c.798T>A",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "stopgain",
      "pNomen": "p.C266*"
    },
    {
      "id": 12344,
      "chromosome": "17",
      "start": 12044563,
      "stop": 12044566,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "MAP2K4 is a serine/threonine protein kinase involved in cell growth and survival through activation of the RAS/RAF/MAPK pathway (PMID:18572308). MAP2K4 has been implicated across many different cancer types (PMID: 20610622, 17057737, 25019290, 10554023, 12438272). The MAP2K4 p.Tyr397Serfs*15 frameshift variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in MAP2K4 are known to be oncogenic and may be sensitive to MEK inhibitors (PMID: 21896780, 29795445, 21896780).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/05/26 20:42:44",
      "evidences": [],
      "reference": "ATGT",
      "alternative": ".",
      "gene": "MAP2K4",
      "transcript": "NM_003010.3",
      "cNomen": "c.1190_1193delATGT",
      "type": "deletion",
      "location": "exonic",
      "exon": 11,
      "effect": "frameshift",
      "pNomen": "p.Y397Sfs*15"
    },
    {
      "id": 11167,
      "chromosome": "17",
      "start": 17119709,
      "stop": 17119709,
      "classification": "Very high",
      "variantInfo": "The FLCN p.His429Thrfs*39 frameshift variant lies in the C-terminal folliculin domain of the protein and is predicted to result in a truncated or absent protein. Pathogenic germline mutations in FLCN are responsible for Birt-Hogg-Dube syndrome, and predisposition toward development of some types of cancer, particularly renal cancer (PMID:20392993, 23740406). The p.His429Thrfs*39 variant has been reported in the germline context (ClinVar).<br />\nA search by the Clinical Insight (Qiagen) platform indicates in this disease site, the FLCN p.His429Thrfs*39 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR inhibitors.<br />\n ",
      "reportAbstract": "FLCN encodes the protein folliculin, a tumor suppressor with roles in energy and nutrient sensing that negatively regulates AMPK signaling and the mTOR pathway (PMID:17028174, 19850877, 24762438, 24763318). Inactivating mutations of FLCN may confer sensitivity to mTOR and mTORC1/2 inhibitors (PMID:17028174, 24762438, 24763318, 24782981).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/04/16 02:41:19",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "FLCN",
      "transcript": "NM_144997.5",
      "cNomen": "c.1285delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 11,
      "effect": "frameshift",
      "pNomen": "p.H429Tfs*39"
    },
    {
      "id": 11927,
      "chromosome": "17",
      "start": 29509567,
      "stop": 29509567,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "NF1 is a tumor suppressing RAS GTPase-related protein involved in cell proliferation and survival through negative regulation of the RAS/RAF/MAPK pathway (PMID: 22898602).<br />\nThe NF1 p.Glu258* nonsense variant is predicted to result in a truncated or absent protein. While this variant has not been reported in the literature, loss-of-function variants in NF1 are likely oncogenic (PMID: 19573811, 26345759, 8563751, 24576830, 10543400). Pathogenic germline variants in NF1 have been associated with juvenile myelomonocytic leukemia (PMID: 8302341, 9639526, 10979983, 18172006). The NF1 p.Glu258* variant has not been previously reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the p.Glu258* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MAPK inhibitors.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/14 19:32:07",
      "evidences": [],
      "reference": "G",
      "alternative": "T",
      "gene": "NF1",
      "transcript": "NM_000267.3",
      "cNomen": "c.772G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 8,
      "effect": "stopgain",
      "pNomen": "p.E258*"
    },
    {
      "id": 10924,
      "chromosome": "17",
      "start": 29528086,
      "stop": 29528086,
      "classification": "Very high",
      "variantInfo": "The NF1 S365* variant is a nonsense variant that leads to a premature termination codon, which is predicted to result in a truncated or absent protein. Pathogenic germline variants in NF1 have been associated with juvenile myelomonocytic leukemia (PMID: 8302341, 9639526, 10979983, 18172006). The NF1 S365* variant has not been previously reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the NF1 S365* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials.",
      "reportAbstract": "NF1 is a tumor suppressing RAS GTPase-related protein involved in cell proliferation and survival through negative regulation of the RAS/RAF/MAPK pathway (PMID: 22898602, 1946382). Loss-of-function mutations and loss of protein expression cause NF1 inactivation and result in hyperactivation of the RAS pathway (PMID: 2121370, 2121371, 8417346, 12509763).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/02/24 21:34:35",
      "evidences": [],
      "reference": "C",
      "alternative": "G",
      "gene": "NF1",
      "transcript": "NM_000267.3",
      "cNomen": "c.1094C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 10,
      "effect": "stopgain",
      "pNomen": "p.S365*"
    },
    {
      "id": 11766,
      "chromosome": "17",
      "start": 29550473,
      "stop": 29550473,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "NF1 is a tumor suppressing RAS GTPase-related protein involved in cell proliferation and survival through negative regulation of the RAS/RAF/MAPK pathway (PMID: 22898602).<br />\nThe NF1 p.Tyr580Thrfs*6 frameshift variant is predicted to result in a truncated or absent protein. While this variant has not been reported in the literature, loss-of-function variants in NF1 are likely oncogenic (PMID: 19573811, 26345759, 8563751, 24576830, 10543400). Pathogenic germline variants in NF1 have been associated with juvenile myelomonocytic leukemia (PMID: 8302341, 9639526, 10979983, 18172006). The NF1 p.Tyr580Thrfs*6 variant has not been previously reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the p.Tyr580Thrfs*6 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MAPK inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:45:24",
      "evidences": [],
      "reference": "T",
      "alternative": ".",
      "gene": "NF1",
      "transcript": "NM_000267.3",
      "cNomen": "c.1738delT",
      "type": "deletion",
      "location": "exonic",
      "exon": 16,
      "effect": "frameshift",
      "pNomen": "p.Y580Tfs*6"
    },
    {
      "id": 11765,
      "chromosome": "17",
      "start": 29553477,
      "stop": 29553477,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "NF1 is a tumor suppressing RAS GTPase-related protein involved in cell proliferation and survival through negative regulation of the RAS/RAF/MAPK pathway (PMID: 22898602).<br />\nThe NF1 p.Ile679Aspfs*21 frameshift variant is predicted to result in a truncated or absent protein. While this variant has not been reported in the literature, loss-of-function variants in NF1 are likely oncogenic (PMID: 19573811, 26345759, 8563751, 24576830, 10543400). Pathogenic germline variants in NF1 have been associated with juvenile myelomonocytic leukemia (PMID: 8302341, 9639526, 10979983, 18172006). The NF1 p.Ile679Aspfs*21 variant has been previously reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the p.Ile679Aspfs*21 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MAPK inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:44:35",
      "evidences": [],
      "reference": ".",
      "alternative": "C",
      "gene": "NF1",
      "transcript": "NM_000267.3",
      "cNomen": "c.2033dupC",
      "type": "insertion",
      "location": "exonic",
      "exon": 18,
      "effect": "frameshift",
      "pNomen": "p.I679Dfs*21"
    },
    {
      "id": 11170,
      "chromosome": "17",
      "start": 29553615,
      "stop": 29553615,
      "classification": "Very high",
      "variantInfo": "The NF1 p.Val723Trpfs*25 frameshift variant is predicted to result in a truncated or absent protein. Pathogenic germline variants in NF1 have been associated with juvenile myelomonocytic leukemia (PMID: 8302341, 9639526, 10979983, 18172006). The NF1 p.Val723Trpfs*25 variant has not been previously reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the p.Val723Trpfs*25 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MAPK inhibitors.<br />\n ",
      "reportAbstract": "NF1 is a tumor suppressing RAS GTPase-related protein involved in cell proliferation and survival through negative regulation of the RAS/RAF/MAPK pathway (PMID: 22898602, 1946382). Loss-of-function mutations and loss of protein expression cause NF1 inactivation and result in hyperactivation of the RAS pathway (PMID: 2121370, 2121371, 8417346, 12509763).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/04/16 03:05:47",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "NF1",
      "transcript": "NM_000267.3",
      "cNomen": "c.2167delG",
      "type": "deletion",
      "location": "exonic",
      "exon": 18,
      "effect": "frameshift",
      "pNomen": "p.V723Wfs*25"
    },
    {
      "id": 11987,
      "chromosome": "17",
      "start": 29562746,
      "stop": 29562746,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "NF1 is a tumor suppressing RAS GTPase-related protein involved in cell proliferation and survival through negative regulation of the RAS/RAF/MAPK pathway (PMID: 22898602). The NF1 p.Arg1276* nonsense variant is predicted to result in a truncated or absent protein. While this variant has not been reported in the literature, loss-of-function variants in NF1 are likely oncogenic (PMID: 19573811, 26345759, 8563751, 24576830, 10543400). This variant is predicted sensitive to an AKT inhibitor in a case report of cervical cancer (PMID: 28489509). Pathogenic germline variants in NF1 have been associated with juvenile myelomonocytic leukemia (PMID: 8302341, 9639526, 10979983, 18172006). The NF1 p.Arg1276* variant has been previously reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/15 20:18:32",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "NF1",
      "transcript": "NM_000267.3",
      "cNomen": "c.3826C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 28,
      "effect": "stopgain",
      "pNomen": "p.R1276*"
    },
    {
      "id": 11988,
      "chromosome": "17",
      "start": 29654575,
      "stop": 29654575,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "NF1 is a tumor suppressing RAS GTPase-related protein involved in cell proliferation and survival through negative regulation of the RAS/RAF/MAPK pathway (PMID: 22898602). The NF1 p.Ser1755* nonsense variant is predicted to result in a truncated or absent protein. While this variant has not been reported in the literature, loss-of-function variants in NF1 are likely oncogenic (PMID: 19573811, 26345759, 8563751, 24576830, 10543400). This variant is predicted sensitive to an AKT inhibitor in a case report of cervical cancer (PMID: 28489509). Pathogenic germline variants in NF1 have been associated with juvenile myelomonocytic leukemia (PMID: 8302341, 9639526, 10979983, 18172006). The NF1 p.Arg1755* variant has not been previously reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/15 20:19:08",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "NF1",
      "transcript": "NM_000267.3",
      "cNomen": "c.5264C>A",
      "type": "snp",
      "location": "exonic",
      "exon": 37,
      "effect": "stopgain",
      "pNomen": "p.S1755*"
    },
    {
      "id": 12406,
      "chromosome": "17",
      "start": 29661899,
      "stop": 29661899,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "NF1 is a tumor suppressing RAS GTPase-related protein involved in cell proliferation and survival through negative regulation of the RAS/RAF/MAPK pathway (PMID: 22898602). The NF1 p.Trp1931* nonsense variant is predicted to result in a truncated or absent protein. While this variant has not been reported in the literature, loss-of-function variants in NF1 are likely oncogenic (PMID: 19573811, 26345759, 8563751, 24576830, 10543400). This variant is predicted sensitive to an AKT inhibitor in a case report of cervical cancer (PMID: 28489509). Pathogenic germline variants in NF1 have been associated with juvenile myelomonocytic leukemia (PMID: 8302341, 9639526, 10979983, 18172006). The NF1 p.Trp1931* variant has been previously reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/07/06 18:28:04",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "NF1",
      "transcript": "NM_000267.3",
      "cNomen": "c.5793G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 39,
      "effect": "stopgain",
      "pNomen": "p.W1931*"
    },
    {
      "id": 11063,
      "chromosome": "17",
      "start": 29684326,
      "stop": 29684326,
      "classification": "Very high",
      "variantInfo": "Loss-of-function variants in NF1 are known to be oncogenic (PMID: 19573811, 8563751, 7542586, 7655472, 24576830, 12509763, 14722914). The NF1 p.Arg2616* nonsense variant is expected to result in an absent or disrupted protein product. Pathogenic germline variants in NF1 cause neurofibromatosis type I (PMID: 10712197, 23913538). The p.Arg2616* variant has been reported as pathogenic in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the NF1 p.Arg2616* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MAPK inhibitors.<br />\n ",
      "reportAbstract": "NF1 is a tumor suppressing RAS GTPase-related protein involved in cell proliferation and survival through negative regulation of the RAS/RAF/MAPK pathway (PMID:22898602).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/18 03:31:48",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "NF1",
      "transcript": "NM_000267.3",
      "cNomen": "c.7846C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 53,
      "effect": "stopgain",
      "pNomen": "p.R2616*"
    },
    {
      "id": 11117,
      "chromosome": "17",
      "start": 33430520,
      "stop": 33430520,
      "classification": "Very high",
      "variantInfo": "<br />\nThe RAD51D p.Ser207Leu is a missense variant that has been functionally demonstrated to destabilize the RAD51DXRCC2 binding, impair HR, and respond to PARP inhibitor in vitro (PMID: 28646019). Germline mutations of RAD51D are associated with an increased risk of developing breast and ovarian cancer (PMID: 30111881, 30165555, 31341520, 21822267, 23372765, 1903388, 15170666). The RAD51D p.Ser207Leu variant has been reported in the germline context (PMID: 28646019, ClinVar).<br />\nA search by the Clinical Insight (Qiagen) platform indicates in this disease site, the RAD51D p.Ser207Leu variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "reportAbstract": "RAD51D is a DNA repair protein involved in genome maintenance through regulation of the homologous recombination (HR) pathway (PMID: 23149936, 15109494, 11283264, 21205838, 15781618). Loss-of-function mutations cause RAD51D inactivation mutation and impairs HR by disrupting the RAD51D-XRCC2 interaction and has been associated with sensitivity to PARP inhibitors (PMID: 28646019, 29255180, 30099541).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/24 15:43:59",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "RAD51D",
      "transcript": "NM_002878.3",
      "cNomen": "c.620C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "nonsynonymous",
      "pNomen": "p.S207L"
    },
    {
      "id": 11315,
      "chromosome": "17",
      "start": 37646973,
      "stop": 37646973,
      "classification": "Very high",
      "variantInfo": "The CDK12 p.Lys700Argfs*53 frameshift variant is predicted to result in a truncated or absent protein. Inactivating mutations of CDK12 result in defects in DNA repair pathways AND lead to genomic instability, and subsequent sensitization of cells to cisplatin and PARP inhibitors in vitro (PMID: 25712099, 24554720).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the CDK12 p.Lys700Argfs*53 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials for PARP or ATR inhibitors.<br />\n ",
      "reportAbstract": "CDK12 encodes Cyclin-dependent kinase 12, a serine/threonine kinase involved in transcription elongation and termination, and regulation of RNA splicing (PMID:16537916, 20952539, 24478330). CDK12 is involved in transcriptional regulation of DNA damage-response genes (PMID: 22012619) and inactivation of CDK12 may be associated with increased sensitivity to DNA damage agents (PMID: 24554720, 25712099). Inactivating CDK12 mutations have been frequently reported in metastatic prostate and serous ovarian cancers (PMID: 28843286, 26787835, 21720365).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/06/12 04:15:46",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "CDK12",
      "transcript": "NM_016507.3",
      "cNomen": "c.2099delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 3,
      "effect": "frameshift",
      "pNomen": "p.K700Rfs*53"
    },
    {
      "id": 12217,
      "chromosome": "17",
      "start": 37879658,
      "stop": 37879658,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ERBB2 (HER2) is a receptor tyrosine kinase that activates the MAPK and PI3K/AKT/MTOR pathways (PMID: 22239438, 12853564, 17471238). ERBB2 is altered by amplification and/or overexpression most frequently in breast, esophagogastric and endometrial cancers (PMID: 19536107, 24656976, 17471238, 31019892, 31650186, 32161378). Activation of ERBB2-mediated signaling results in cellular proliferation, migration, and differentiation (PMID: 18045542, 21965336, 23630663). Overexpression of ERBB2 is predicted to be sensitive to targeted therapies (PMID: 24799465, 17311002, 21353324, 16775247, 20728210).<br />\nThe ERRB2 p.Arg678Gln missense variant occurs in the juxtamembrane domain of the ERBB2 protein (PMID: 30449325). Some preclinical studies have suggested that this recurrent alteration does not alter ERBB2 activity, while others have reported that the p.Arg678Gln variant is associated with increased proliferation, survival, and anchorage-independent growth in vitro and in vivo (PMID: 23220880, 24971884, 29533785, 31046123, 30449325).<br />\nA search by the Qiagen Clinical Insight platform indicates in this disease site, the ERRB2 p.Arg678Gln variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of pan-ErbB inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/25 01:14:51",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "ERBB2",
      "transcript": "NM_004448.3",
      "cNomen": "c.2033G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 17,
      "effect": "nonsynonymous",
      "pNomen": "p.R678Q"
    },
    {
      "id": 11658,
      "chromosome": "17",
      "start": 37879903,
      "stop": 37879903,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ERBB2 (HER2) is a receptor tyrosine kinase that activates the MAPK and PI3K/AKT/MTOR pathways (PMID: 22239438, 12853564, 17471238). ERBB2 is altered by amplification and/or overexpression most frequently in breast, esophagogastric and endometrial cancers (PMID: 19536107, 24656976, 17471238, 31019892, 31650186, 32161378). Activation of ERBB2-mediated signaling results in cellular proliferation, migration, and differentiation (PMID: 18045542, 21965336, 23630663). Overexpression of ERBB2 is predicted to be sensitive to targeted therapies (PMID: 24799465, 17311002, 21353324, 16775247, 20728210).<br />\nThe ERRB2 p.Thr733Ile missense variant occurs in the kinase domain of the ERBB2 protein (Uniprot). Experimental studies suggests this variant is associated with weak transformation activity (PMID: 18413839, 29533785).<br />\nA search by the Qiagen Clinical Insight platform indicates in this disease site, the ERRB2 p.Thr733Ile variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of TKI inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/20 19:37:24",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "ERBB2",
      "transcript": "NM_004448.3",
      "cNomen": "c.2198C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 18,
      "effect": "nonsynonymous",
      "pNomen": "p.T733I"
    },
    {
      "id": 11376,
      "chromosome": "17",
      "start": 37881329,
      "stop": 37881329,
      "classification": "Very high",
      "variantInfo": "The ERRB2 p.Leu841Val missense variant occurs in the kinase domain of the ERBB2 protein (Uniprot). Experimental studies suggests this variant is a gain-of-function alteration and results in increased cell proliferation in vitro (PMID: 29533785, 29967253).<br />\nA search by the Qiagen Clinical Insight platform indicates in this disease site, the ERRB2 p.Leu841Val variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of TKI inhibitors.<br />\n ",
      "reportAbstract": "ERBB2 (HER2) is a receptor tyrosine kinase that activates the MAPK and PI3K/AKT/MTOR pathways (PMID: 22239438, 12853564, 17471238). ERBB2 is altered by amplification and/or overexpression most frequently in breast, esophagogastric and endometrial cancers (PMID: 19536107, 24656976, 17471238, 31019892, 31650186, 32161378). Activation of ERBB2-mediated signaling results in cellular proliferation, migration, and differentiation (PMID: 18045542, 21965336, 23630663). Overexpression of ERBB2 is predicted to be sensitive to targeted therapies (PMID: 24799465, 17311002, 21353324, 16775247, 20728210).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/07/08 17:40:31",
      "evidences": [],
      "reference": "C",
      "alternative": "G",
      "gene": "ERBB2",
      "transcript": "NM_004448.3",
      "cNomen": "c.2521C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 21,
      "effect": "nonsynonymous",
      "pNomen": "p.L841V"
    },
    {
      "id": 11808,
      "chromosome": "17",
      "start": 41197708,
      "stop": 41197708,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "BRCA1 is a tumour suppressor responsible for DNA repair and maintenance of genomic stability (PMID: 22193408, 28976962). Inactivating germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145676, 9145678, 10918303, 26928436) and increased susceptibility to additional cancer types (PMID: 24292448, 22516946).<br />\nThe BRCA1 p.His1860Profs*20 frameshift variant is predicted to result in a truncated or absent protein. Pathogenic germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410). The BRCA1 p.His1860Profs*20 variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the BRCA1 p.His1860Profs*20 variant currently serves as an inclusion eligibility criterion for FDA approved therapies and Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/25 21:16:31",
      "evidences": [],
      "reference": ".",
      "alternative": "G",
      "gene": "BRCA1",
      "transcript": "NM_007294.3",
      "cNomen": "c.5578dupC",
      "type": "insertion",
      "location": "exonic",
      "exon": 23,
      "effect": "frameshift",
      "pNomen": "p.H1860Pfs*20"
    },
    {
      "id": 11717,
      "chromosome": "17",
      "start": 41197790,
      "stop": 41197790,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "BRCA1 is a tumour suppressor responsible for DNA repair and maintenance of genomic stability (PMID: 22193408, 28976962). Inactivating germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145676, 9145678, 10918303, 26928436) and increased susceptibility to additional cancer types (PMID: 24292448, 22516946).<br />\nThe BRCA1 p.Val1833Met missense variant results in loss of BRCA1 function as demonstrated by reduced homologous recombination and BRCA1 transcriptional activity in vitro (PMID: 18992264, 20516115, 30257991). Pathogenic germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410). The BRCA1 p.Val1833Met variant has been reported in the germline context (ClinVar).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/05 21:30:13",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "BRCA1",
      "transcript": "NM_007294.3",
      "cNomen": "c.5497G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 23,
      "effect": "nonsynonymous",
      "pNomen": "p.V1833M"
    },
    {
      "id": 12353,
      "chromosome": "17",
      "start": 41209079,
      "stop": 41209079,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "The BRCA1 p.Gln1756Profs*74 frameshift variant is predicted to result in a truncated or absent protein. Pathogenic germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410). The BRCA1 p.Gln1756Profs*74 variant (also referred to as 5382insC and 5385insC in the literature) has been reported in somatic (acquired) high-grade serous cancer (COSMIC, cBioPortal) and as a recurrent founder mutation in germline (inherited) ovarian and breast cancer (PMID: 15994883, 9042909, 22430266, 22185575; ClinVar). Results suggest this patient would be eligible for PARP inhibitor therapy.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/06/01 20:27:05",
      "evidences": [],
      "reference": ".",
      "alternative": "G",
      "gene": "BRCA1",
      "transcript": "NM_007294.3",
      "cNomen": "c.5266dupC",
      "type": "insertion",
      "location": "exonic",
      "exon": 19,
      "effect": "frameshift",
      "pNomen": "p.Q1756Pfs*74"
    },
    {
      "id": 11723,
      "chromosome": "17",
      "start": 41215899,
      "stop": 41215902,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "BRCA1 is a tumour suppressor responsible for DNA repair and maintenance of genomic stability (PMID: 22193408, 28976962). Inactivating germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145676, 9145678, 10918303, 26928436) and increased susceptibility to additional cancer types (PMID: 24292448, 22516946).<br />\nThe BRCA1 p.Val1714Alafs*5 frameshift variant is predicted to result in a truncated or absent protein. Pathogenic germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410). The BRCA1 p.Val1714Alafs*5 variant has not been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the BRCA1 p.Val1714Alafs*5 variant currently serves as an inclusion eligibility criterion for FDA approved therapies and Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/06 17:21:20",
      "evidences": [],
      "reference": "CTAA",
      "alternative": ".",
      "gene": "BRCA1",
      "transcript": "NM_007294.3",
      "cNomen": "c.5141_5144delTTAG",
      "type": "deletion",
      "location": "exonic",
      "exon": 17,
      "effect": "frameshift",
      "pNomen": "p.V1714Afs*5"
    },
    {
      "id": 11568,
      "chromosome": "17",
      "start": 41215969,
      "stop": 41215969,
      "classification": "Very high",
      "variantInfo": "<br />\nThe BRCA1 c.5075-1G&gt;C splice site variant is predicted to result in a truncated or absent protein. Pathogenic germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410). The BRCA1 c.5075-1G&gt;C has not been reported in somatic (acquired) high-grade serous cancer (COSMIC) but has been reported in germline (inherited) ovarian and breast cancer (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the BRCA1 c.5075-1G&gt;C variant currently serves as an inclusion eligibility criterion for FDA approved therapies and Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "reportAbstract": "BRCA1 is a tumour suppressor responsible for DNA repair and maintenance of genomic stability (PMID: 22193408, 28976962). Inactivating germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145676, 9145678, 10918303, 26928436) and increased susceptibility to additional cancer types (PMID: 24292448, 22516946).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/24 02:57:54",
      "evidences": [],
      "reference": "C",
      "alternative": "G",
      "gene": "BRCA1",
      "transcript": "NM_007294.3",
      "cNomen": "c.5075-1G>C",
      "type": "snp",
      "location": "intronic",
      "exon": 17,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11179,
      "chromosome": "17",
      "start": 41222949,
      "stop": 41222967,
      "classification": "Very high",
      "variantInfo": "The BRCA1 p.Ser1655Tyrfs*16 frameshift variant is predicted to result in a truncated or absent protein. Pathogenic germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410). The BRCA1 p.Ser1655Tyrfs*16 variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the BRCA1 p.Ser1655Tyrfs*16 variant currently serves as an inclusion eligibility criterion for FDA approved therapies and Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "reportAbstract": "BRCA1 is a tumour suppressor responsible for DNA repair and maintenance of genomic stability (PMID: 22193408, 28976962). Inactivating germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145676, 9145678, 10918303, 26928436) and increased susceptibility to additional cancer types (PMID: 24292448, 22516946).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/04/16 04:46:21",
      "evidences": [],
      "reference": "TCTTCTGGGGTCAGGCCAG",
      "alternative": ".",
      "gene": "BRCA1",
      "transcript": "NM_007294.3",
      "cNomen": "c.4964_4982delCTGGCCTGACCCCAGAAGA",
      "type": "deletion",
      "location": "exonic",
      "exon": 15,
      "effect": "frameshift",
      "pNomen": "p.S1655Yfs*16"
    },
    {
      "id": 11870,
      "chromosome": "17",
      "start": 41244549,
      "stop": 41244549,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "BRCA1 is a tumour suppressor responsible for DNA repair and maintenance of genomic stability (PMID: 22193408, 28976962). Inactivating germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145676, 9145678, 10918303, 26928436) and increased susceptibility to additional cancer types (PMID: 24292448, 22516946).<br />\nThe BRCA1 p.Glu1000Glyfs*24 frameshift variant is predicted to result in a truncated or absent protein. Pathogenic germline mutations in BRCA1/2 genes are associated with increased risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410). The BRCA1 p p.Glu1000Glyfs*24 variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the BRCA1 p.Glu1000Glyfs*24 variant currently serves as an inclusion eligibility criterion for FDA approved therapies and Phase 2 clinical trials of PARP inhibitors.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:23",
      "evidences": [],
      "reference": "T",
      "alternative": ".",
      "gene": "BRCA1",
      "transcript": "NM_007294.3",
      "cNomen": "c.2999delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 10,
      "effect": "frameshift",
      "pNomen": "p.E1000Gfs*24"
    },
    {
      "id": 11566,
      "chromosome": "17",
      "start": 41245279,
      "stop": 41245279,
      "classification": "Very high",
      "variantInfo": "<br />\nThe BRCA1 p.Val757Phefs*8 frameshift variant is predicted to result in a truncated or absent protein. Pathogenic germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410). The BRCA1 p.Val757Phefs*8 has been reported in somatic (acquired) high-grade serous cancer (COSMIC) and as a germline (inherited) ovarian and breast cancer (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the BRCA1 p.Val757Phefs*8 variant currently serves as an inclusion eligibility criterion for FDA approved therapies and Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "reportAbstract": "BRCA1 is a tumour suppressor responsible for DNA repair and maintenance of genomic stability (PMID: 22193408, 28976962). Inactivating germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145676, 9145678, 10918303, 26928436) and increased susceptibility to additional cancer types (PMID: 24292448, 22516946).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/24 02:45:17",
      "evidences": [],
      "reference": "C",
      "alternative": ".",
      "gene": "BRCA1",
      "transcript": "NM_007294.3",
      "cNomen": "c.2269delG",
      "type": "deletion",
      "location": "exonic",
      "exon": 10,
      "effect": "frameshift",
      "pNomen": "p.V757Ffs*8"
    },
    {
      "id": 11798,
      "chromosome": "17",
      "start": 41245587,
      "stop": 41245587,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "BRCA1 is a tumour suppressor responsible for DNA repair and maintenance of genomic stability (PMID: 22193408, 28976962). Inactivating germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145676, 9145678, 10918303, 26928436) and increased susceptibility to additional cancer types (PMID: 24292448, 22516946).<br />\nThe BRCA1 p.Lys654Serfs*47 frameshift variant is predicted to result in a truncated or absent protein. Pathogenic germline mutations in BRCA1/2 genes are associated with increased risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410). The BRCA1 p.Lys654Serfs*47 has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the BRCA1 p.Lys654Serfs*47 variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:23",
      "evidences": [],
      "reference": "T",
      "alternative": ".",
      "gene": "BRCA1",
      "transcript": "NM_007294.3",
      "cNomen": "c.1961delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 10,
      "effect": "frameshift",
      "pNomen": "p.K654Sfs*47"
    },
    {
      "id": 11908,
      "chromosome": "17",
      "start": 41246331,
      "stop": 41246331,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "BRCA1 is a tumour suppressor responsible for DNA repair and maintenance of genomic stability (PMID: 22193408, 28976962). Inactivating germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145676, 9145678, 10918303, 26928436) and increased susceptibility to additional cancer types (PMID: 24292448, 22516946).<br />\nThe BRCA1 p.Asn406Metfs*4 frameshift variant is predicted to result in a truncated or absent protein. Pathogenic germline mutations in BRCA1/2 genes are associated with increased risk for breast and/or ovarian cancer (PMID: 9145678, 16950820) and increased susceptibility to additional cancer types (PMID: 12097290, 12569143, 25356972, 17301269, 18445692, 20587410). The BRCA1 p.Asn406Metfs*4 variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the BRCA1 p.Asn406Metfs*4 variant currently serves as an inclusion eligibility criterion for FDA approved therapies and Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/21 17:23:09",
      "evidences": [],
      "reference": "T",
      "alternative": ".",
      "gene": "BRCA1",
      "transcript": "NM_007294.3",
      "cNomen": "c.1217delA",
      "type": "deletion",
      "location": "exonic",
      "exon": 10,
      "effect": "frameshift",
      "pNomen": "p.N406Mfs*4"
    },
    {
      "id": 10911,
      "chromosome": "17",
      "start": 41276045,
      "stop": 41276046,
      "classification": "Very high",
      "variantInfo": "The BRCA1 E23Vfs*17 variant is a frameshift variant that leads to a premature termination codon, which is predicted to result in a truncated or absent protein. The BRCA1 E23Vfs*17 variant has been reported in the germline context by 35 clinical laboratories as pathogenic (ClinVar); this variant has been reported in population studies (MAF&#61;0.02%; gnomAD).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the BRCA1 E23Vfs*17 variant currently serves as an inclusion eligibility criterion for FDA approved therapies (PMID: 30948273, 30345884, 27908594, 27002934) and Phase 2 clinical trials (NCT Number: NCT03150810, NCT02660034, NCT03330405, NCT02286687, NCT03565991, NCT02921919, NCT03875313, NCT01989546, NCT04158336, NCT02997176, NCT03968406, NCT01827384, NCT02723864, NCT01434316).",
      "reportAbstract": "BRCA1 is a tumour suppressor responsible for DNA repair and maintenance of genomic stability (PMID: 22193408, 28976962). Inactivating germline mutations in BRCA1/2 genes are associated with increase the risk for breast and/or ovarian cancer (PMID: 9145676, 9145678, 10918303, 26928436) and increased susceptibility to additional cancer types (PMID: 24292448, 22516946).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/02/24 19:34:22",
      "evidences": [],
      "reference": "CT",
      "alternative": ".",
      "gene": "BRCA1",
      "transcript": "NM_007294.3",
      "cNomen": "c.68_69delAG",
      "type": "deletion",
      "location": "exonic",
      "exon": 2,
      "effect": "frameshift",
      "pNomen": "p.E23Vfs*17"
    },
    {
      "id": 12149,
      "chromosome": "17",
      "start": 47696404,
      "stop": 47696404,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "SPOP is an adaptor protein that is a component of an E3 ubiquitin-protein ligase complex that mediates ubiquitination, thereby regulating proteasomal degradation (PMID: 25274033, 28805822, 28805820, 19818708). Somatic mutations of SPOP have been found in prostate and endometrial cancer (PMID: 21307934, 22610119, 22722839, 20668451, 23104009). Loss-of-function mutations that affect conserved residues of the MATH domain important for substrate recognition have been identified (PMID: 23216165, 22610119, 25766326, 19818708, 18218622, 25766326, 25351530).<br />\nThe SPOP p.Asp140Gly missense variant occurs within the conserved MATH domain of the SPOP protein (PMID: 18218622, 19818708). Functional studies suggest this variant results in disruption of SPOP activity in vitro (PMID: 25766326, 31911863, 25766326).<br />\nPreclinical studies suggest SPOP mutations in endometrial cancer cell lines may be responsive to bromodomain inhibitors (PMID: 28805821).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:36",
      "evidences": [],
      "reference": "T",
      "alternative": "C",
      "gene": "SPOP",
      "transcript": "NM_001007226.1",
      "cNomen": "c.419A>G",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "nonsynonymous",
      "pNomen": "p.D140G"
    },
    {
      "id": 11694,
      "chromosome": "17",
      "start": 47696461,
      "stop": 47696461,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "SPOP is an adaptor protein that is a component of an E3 ubiquitin-protein ligase complex that mediates ubiquitination, thereby regulating proteasomal degradation (PMID: 25274033, 28805822, 28805820, 19818708). Somatic mutations of SPOP have been found in prostate and endometrial cancer (PMID: 21307934, 22610119, 22722839, 20668451, 23104009). Loss-of-function mutations that affect conserved residues of the MATH domain important for substrate recognition have been identified (PMID: 23216165, 22610119, 25766326, 19818708, 18218622, 25766326, 25351530).<br />\n<br />\nThe SPOP p.Arg121Gln missense variant occurs within the conserved MATH domain of the SPOP protein (PMID: 18218622, 19818708). Functional assays suggest this variant results in disruption of SPOP activity in vitro (PMID: 25766326).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the SPOP p.Arg121Gln variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/28 17:11:10",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "SPOP",
      "transcript": "NM_001007226.1",
      "cNomen": "c.362G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "nonsynonymous",
      "pNomen": "p.R121Q"
    },
    {
      "id": 11869,
      "chromosome": "17",
      "start": 47696599,
      "stop": 47696599,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "SPOP is an adaptor protein that is a component of an E3 ubiquitin-protein ligase complex that mediates ubiquitination, thereby regulating proteasomal degradation (PMID: 25274033, 28805822, 28805820, 19818708). Somatic mutations of SPOP have been found in prostate and endometrial cancer (PMID: 21307934, 22610119, 22722839, 20668451, 23104009). Loss-of-function mutations that affect conserved residues of the MATH domain important for substrate recognition have been identified (PMID: 23216165, 22610119, 25766326, 19818708, 18218622, 25766326, 25351530).<br />\nThe SPOP p.Met117Val missense variant occurs within the conserved MATH domain of the SPOP protein (PMID: 18218622, 19818708). Functional studies suggest this variant results in disruption of SPOP activity in vitro (PMID: 25766326, 31911863).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the SPOP p.Met117Val variant does not currently serve as an inclusion eligibility criterion for clinical trials.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:31",
      "evidences": [],
      "reference": "T",
      "alternative": "C",
      "gene": "SPOP",
      "transcript": "NM_001007226.1",
      "cNomen": "c.349A>G",
      "type": "snp",
      "location": "exonic",
      "exon": 6,
      "effect": "nonsynonymous",
      "pNomen": "p.M117V"
    },
    {
      "id": 11812,
      "chromosome": "17",
      "start": 47699369,
      "stop": 47699369,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "SPOP is an adaptor protein that is a component of an E3 ubiquitin-protein ligase complex that mediates ubiquitination, thereby regulating proteasomal degradation (PMID: 25274033, 28805822, 28805820, 19818708). Somatic mutations of SPOP have been found in prostate and endometrial cancer (PMID: 21307934, 22610119, 22722839, 20668451, 23104009). Loss-of-function mutations that affect conserved residues of the MATH domain important for substrate recognition have been identified (PMID: 23216165, 22610119, 25766326, 19818708, 18218622, 25766326, 25351530).<br />\nThe SPOP p.Glu47Lys missense variant occurs within the conserved MATH domain of the SPOP protein (PMID: 18218622, 19818708). Functional assays suggest this variant results in disruption of SPOP activity in vitro (PMID: 25766326).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the SPOP p.Glu47Lys variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/25 21:46:09",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "SPOP",
      "transcript": "NM_001007226.1",
      "cNomen": "c.139G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.E47K"
    },
    {
      "id": 11977,
      "chromosome": "17",
      "start": 56435161,
      "stop": 56435161,
      "classification": "Very high",
      "variantInfo": "Preclinical studies in other disease sites suggest loss of function variants in RNF43 is predicted sensitive to WNT inhibitors (PMID: 26257057, 23847203, 26023187).",
      "reportAbstract": "RNF43 encodes a E3 ubiquitin ligase and tumor suppressor involved in the Wnt/beta-catenin signaling pathway (PMID: 22895187, 25825523, 23096461). RNF43 targets Frizzled receptors for degradation resulting in negative regulation of Wnt signaling (PMID: 25460271, 22895187, 23847203). RNF43 mutations are associated with several tumor types and are frequent in colorectal and endometrial cancer (PMID: 25460271, 25344691, 32092099, 32008206, 29756208).<br />\nThe RNF43 p.Gly659Valfs*41 frameshift variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in RNF43 are known to be oncogenic (PMID: 23096461, 25344691, 23847203).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/15 01:51:25",
      "evidences": [],
      "reference": "C",
      "alternative": ".",
      "gene": "RNF43",
      "transcript": "NM_017763.5",
      "cNomen": "c.1976delG",
      "type": "deletion",
      "location": "exonic",
      "exon": 9,
      "effect": "frameshift",
      "pNomen": "p.G659Vfs*41"
    },
    {
      "id": 11877,
      "chromosome": "17",
      "start": 59821824,
      "stop": 59821824,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "BRIP1 is a member of the RecQ DEAH helicase family and is involved in DNA repair. DEAH helicases participate in pre-messenger RNA splicing and ribosome biogenesis (PMID: 20168331). BRIP1 interacts with the BRCT motif-containing domain of BRCA1 (PMID: 17033622, 11301010). BRIP1 has been shown to be mutated in hereditary breast (PMID: 11301010, 17033622), ovarian (PMID: 21964575, 26315354) and prostate (PMID: 19127258) cancers as well as the Fanconi anemia (PMID: 24348213, 16493006).<br />\nThe BRIP1 p.Tyr742* nonsense variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in BRIP1 are known to be oncogenic (PMID: 16153896, 24040146, 17033622, 21964575, 18628483). Pathogenic germline variants in BRIP1 have been associated with Increased risk of ovarian cancer (PMID:26315354, 21964575). The p.Tyr742* variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the BRIP1 p.Tyr742* variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP1 inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:37:37",
      "evidences": [],
      "reference": ".",
      "alternative": "TAC",
      "gene": "BRIP1",
      "transcript": "NM_032043.2",
      "cNomen": "c.2223_2225dupGTA",
      "type": "insertion",
      "location": "exonic",
      "exon": 15,
      "effect": "stopgain",
      "pNomen": "p.Y742*"
    },
    {
      "id": 12152,
      "chromosome": "17",
      "start": 59934505,
      "stop": 59934508,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "BRIP1 is a member of the RecQ DEAH helicase family and is involved in DNA repair. DEAH helicases participate in pre-messenger RNA splicing and ribosome biogenesis (PMID: 20168331). BRIP1 interacts with the BRCT motif-containing domain of BRCA1 (PMID: 17033622, 11301010). BRIP1 has been shown to be mutated in hereditary breast (PMID: 11301010, 17033622), ovarian (PMID: 21964575, 26315354) and prostate (PMID: 19127258) cancers as well as the Fanconi anemia (PMID: 24348213, 16493006).<br />\nThe BRIP1 p.Asn97Metfs*3 frameshift variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in BRIP1 are known to be oncogenic (PMID: 16153896, 24040146, 17033622, 21964575, 18628483). Pathogenic germline variants in BRIP1 have been associated with increased risk of ovarian cancer (PMID:26315354, 21964575). The p.Asn97Metfs*3 variant has been reported in the germline context (ClinVar).<br />\nClinical studies in other tumor types suggest that inactivating mutations in BRIP1 may be responsive to PARP inhibitors (PMID: 32343890, 32086346); however, the impact of this variant in this disease site on patient management is currently unknown.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:27",
      "evidences": [],
      "reference": "TTGT",
      "alternative": ".",
      "gene": "BRIP1",
      "transcript": "NM_032043.2",
      "cNomen": "c.290_293delACAA",
      "type": "deletion",
      "location": "exonic",
      "exon": 4,
      "effect": "frameshift",
      "pNomen": "p.N97Mfs*3"
    },
    {
      "id": 11714,
      "chromosome": "17",
      "start": 59934594,
      "stop": 59934594,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "BRIP1 is a member of the RecQ DEAH helicase family and is involved in DNA repair. DEAH helicases participate in pre-messenger RNA splicing and ribosome biogenesis (PMID: 20168331). BRIP1 interacts with the BRCT motif-containing domain of BRCA1 (PMID: 17033622, 11301010). BRIP1 has been shown to be mutated in hereditary breast (PMID: 11301010, 17033622), ovarian (PMID: 21964575, 26315354) and prostate (PMID: 19127258) cancers as well as the Fanconi anemia (PMID: 24348213, 16493006).<br />\nThe c.206-2A&gt;G variant is a splice site variant and is predicted to result in an altered protein product or absence of protein due to nonsense mediated decay. While this particular variant has not been reported in the literature, loss-of-function variants in BRIP1 are known to be oncogenic (PMID: 16153896, 24040146, 17033622, 21964575, 18628483). Pathogenic germline variants in BRIP1 have been associated with Increased risk of ovarian cancer (PMID:26315354, 21964575). The c.206-2A&gt;G variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the BRIP1 c.206-2A&gt;G variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP1 inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/05 21:16:20",
      "evidences": [],
      "reference": "T",
      "alternative": "C",
      "gene": "BRIP1",
      "transcript": "NM_032043.2",
      "cNomen": "c.206-2A>G",
      "type": "snp",
      "location": "intronic",
      "exon": 4,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11166,
      "chromosome": "18",
      "start": 50918223,
      "stop": 50918223,
      "classification": "Very high",
      "variantInfo": "The DCC p.Trp885* variant is a nonsense variant that leads to a premature termination codon, which is predicted to result in a truncated or absent protein. While this particular variant has not been reported in the literature, inactivation of DCC via allelic loss or reduced expression may play a role in the pathogenesis of gynecological carcinoma (PMID: 10646905, 20054719, 9021725, 10682668, 7514150). For these reasons, this variant has been classified as likely oncogenic.<br />\nA search by the Watson for Genomics platform indicates in this disease site, the DCC p.Trp885* variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "DCC gene encodes a neural cell adhesion-like transmembrane protein and is implicated as a putative tumour suppressor in colorectal cancer (PMID: 22158121, 9796814, 7553661, 9484816).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/04/16 02:21:28",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "DCC",
      "transcript": "NM_005215.3",
      "cNomen": "c.2654G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 17,
      "effect": "stopgain",
      "pNomen": "p.W885*"
    },
    {
      "id": 12210,
      "chromosome": "19",
      "start": 1218423,
      "stop": 1218423,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "STK11, serine/threonine kinase 11 (also known as Lkb1), is a tumour suppressor (PMID: 30562755) involved in cellular metabolism via regulation of AMPK and the mTOR pathway (PMID: 15261145, 26398719, 26877140). Inactivating mutations of STK11 are most frequently reported in lung and cervical cancer (PMID: 18948947, 21532627, 24390348, 29191602) and may be associated with resistance to immune checkpoint blockade (PMID: 30626603).<br />\n <br />\nThe STK11 p.Gln100* nonsense variant is predicted to result in a truncated or absent protein. Inactivation of STK11 results in reduced cell cycle control (PMID: 20541700, 15261145). Preclinical studies in endometrial cancer suggest this variant is predicted to be responsive to PI3K or MTOR inhibitors (PMID: 24322983, 20142330).<br />\n <br />\nInactivating germline mutations in STK11 are associated with Peutz-Jeghers syndrome, an autosomal dominant disorder associated with increased susceptibility to various cancers (PMID: 10362809, 23415580, 9425897, 27241107). The STK11 p.Gln100* variant has been previously reported in the germline context (PMID: 10408777).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:18",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "STK11",
      "transcript": "NM_000455.4",
      "cNomen": "c.298C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "stopgain",
      "pNomen": "p.Q100*"
    },
    {
      "id": 11305,
      "chromosome": "19",
      "start": 1220484,
      "stop": 1220488,
      "classification": "Very high",
      "variantInfo": "<br />\nThe STK11 p.Ser193Profs*71 frameshift variant is predicted to result in a truncated or absent protein. Inactivation of STK11 results in reduced cell cycle control (PMID: 20541700, 15261145). Inactivating germline mutations in STK11 are associated with Peutz-Jeghers syndrome, an autosomal dominant disorder associated with increased susceptibility to various cancers (PMID: 10362809, 23415580, 9425897, 27241107). The STK11 p.Ser193Profs*71 variant has not been previously reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the STK11 p.Ser193Profs*71 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR inhibitors.<br />\n ",
      "reportAbstract": "STK11, serine/threonine kinase 11 (also known as Lkb1), is a tumour suppressor (PMID: 30562755) involved in cellular metabolism via regulation of AMPK and the mTOR pathway (PMID: 15261145, 26398719, 26877140). Inactivating mutations of STK11 are most frequently reported in lung and cervical cancer (PMID: 18948947, 21532627, 24390348, 29191602) and may be associated with resistance to immune checkpoint blockade (PMID: 30626603).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/06/12 02:24:37",
      "evidences": [],
      "reference": "TCCGA",
      "alternative": ".",
      "gene": "STK11",
      "transcript": "NM_000455.4",
      "cNomen": "c.577_581delTCCGA",
      "type": "deletion",
      "location": "exonic",
      "exon": 4,
      "effect": "frameshift",
      "pNomen": "p.S193Pfs*71"
    },
    {
      "id": 11035,
      "chromosome": "19",
      "start": 10610405,
      "stop": 10610405,
      "classification": "Very high",
      "variantInfo": "The KEAP1 p.Ser102Leu missense variant occurs within the BTB domain of the KEAP1 protein. Limited in vitro studies suggest this variant may result in decreased activity of KEAP1 (PMID: 27478040).<br />\nA search by the Clinical Insight (Qiagen) platform indicates in this disease site, the KEAP1 p.Ser102Leu variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of glutaminase inhibitors (NCT03872427).<br />\n ",
      "reportAbstract": "KEAP1 is an adapter protein involved in the antioxidant response to oxidative stress (PMID, 28441057, 29499228). KEAP1 loss-of-function mutations have been identified in several tumor types, including lung and liver cancers (PMID: 24142871, 27263465, 29615460).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/12 20:03:40",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "KEAP1",
      "transcript": "NM_012289.3",
      "cNomen": "c.305C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "nonsynonymous",
      "pNomen": "p.S102L"
    },
    {
      "id": 11116,
      "chromosome": "19",
      "start": 10610444,
      "stop": 10610453,
      "classification": "Very high",
      "variantInfo": "Truncating mutations are predicted to result in the inactivation of KEAP1-dependent inhibition of NFE2L2 and potential resistance to chemotherapy and radiation (PMID: 17020408, 18555005, 18316592, 20534738).<br />\nA search by the Clinical Insight (Qiagen) platform indicates in this disease site, the KEAP1 p.Gln86Argfs*68 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of glutaminase inhibitor.<br />\n ",
      "reportAbstract": "KEAP1 is an adapter protein involved in the antioxidant response to oxidative stress (PMID: 28601065, 28441057, 29499228). Mutations in KEAP1 disrupt KEAP1-dependent regulation of NFE2L2 (also referred to as NRF2), a master regulator of oxidative stress response (PMID: 24142871). KEAP1 loss-of-function variants have been reported as oncogenic most often in the context of lung cancer (PMID: 17020408, 24142871, 24322982).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/24 14:35:10",
      "evidences": [],
      "reference": "GGTGCATCCT",
      "alternative": ".",
      "gene": "KEAP1",
      "transcript": "NM_012289.3",
      "cNomen": "c.257_266delAGGATGCACC",
      "type": "deletion",
      "location": "exonic",
      "exon": 2,
      "effect": "frameshift",
      "pNomen": "p.Q86Rfs*68"
    },
    {
      "id": 11792,
      "chromosome": "19",
      "start": 11100063,
      "stop": 11100063,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "SMARCA4 is a member of the SWI/SNF family, which regulates transcription through chromatin remodeling (PMID: 27413115, 18301784). Mutations in SMARCA4 are found in a variety of cancer types including rhabdoid tumors, lymphoma, medulloblastoma, lung, pancreas, ovarian, and colon cancers (PMID: 29892061, 18437052, 19234488, 25060813, 23143597, 22722829, 22832583, 22820256, 24658001, 24658004, 24658002).<br />\nThe SMARCA4 p.Arg397* nonsense variant is predicted to result in an absent or disrupted protein product. While this variant has not been functionally characterized, loss-of-function variants in SMARCA4 are known to be oncogenic (PMID: 25060813, 24658004, 24658001, 18301784, 24658002). Pathogenic germline variants in SMARCA4 have been associated with pediatric atypical teratoid/rhabdoid tumors and small cell carcinoma of the ovaries, hypercalcemic type (SCCOHT) (PMID: 20137775, 25060813, 24658002, 24658004, 24658001). The p.Arg397* variant has been reported in the germline context (ClinVar, PMID: 32382648).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the SMARCA4 p.Arg397* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of EZH2 inhibitors.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:27",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "SMARCA4",
      "transcript": "NM_001128849.1",
      "cNomen": "c.1189C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "stopgain",
      "pNomen": "p.R397*"
    },
    {
      "id": 11570,
      "chromosome": "19",
      "start": 13054605,
      "stop": 13054607,
      "classification": "Very high",
      "variantInfo": "<br />\nThe CALR p.Glu381del deletion variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in ovarian cancer, loss-of-function variants in CALR are known to be oncogenic in myeloproliferative neoplasms (PMID: 26951227, 26817954, 26668133, 24325356).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the CALR p.Glu381del variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "CALR encodes calreticulin (also known as calregulin/CRP55/CRT), a calcium-binding chaperone protein that plays a role in calcium homeostasis, immune response, cell adhesion and migration, and cell signaling (PMID: 19940256, 28470469, 22959412). CALR mutations have been described in myeloproliferative neoplasms, including essential thrombocytothemia and myelofibrosis (PMID: 24365789, 28470469).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/24 03:06:37",
      "evidences": [],
      "reference": "GAG",
      "alternative": ".",
      "gene": "CALR",
      "transcript": "NM_004343.3",
      "cNomen": "c.1142_1144delAGG",
      "type": "deletion",
      "location": "exonic",
      "exon": 9,
      "effect": "inframe",
      "pNomen": "p.E381del"
    },
    {
      "id": 11405,
      "chromosome": "19",
      "start": 13054659,
      "stop": 13054659,
      "classification": "Uncertain",
      "variantInfo": "<br />\nThe CALR p.Glu396* nonsense variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in ovarian cancer, loss-of-function variants in CALR are known to be oncogenic in myeloproliferative neoplasms (PMID: 26951227, 26817954, 26668133, 24325356).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the CALR p.Glu396* variant does not currently serve as an inclusion eligibility criterion for clinical trials.",
      "reportAbstract": "CALR encodes calreticulin (also known as calregulin/CRP55/CRT), a calcium-binding chaperone protein that plays a role in calcium homeostasis, immune response, cell adhesion and migration, and cell signaling (PMID: 19940256, 28470469, 22959412). CALR mutations have been described in myeloproliferative neoplasms, including essential thrombocytothemia and myelofibrosis (PMID: 24365789, 28470469).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/07/22 01:44:22",
      "evidences": [],
      "reference": "G",
      "alternative": "T",
      "gene": "CALR",
      "transcript": "NM_004343.3",
      "cNomen": "c.1186G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 9,
      "effect": "stopgain",
      "pNomen": "p.E396*"
    },
    {
      "id": 11122,
      "chromosome": "19",
      "start": 45868165,
      "stop": 45868165,
      "classification": "Very high",
      "variantInfo": "<br />\nThe ERCC2 p.Tyr175* nonsense variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in ERCC2 are likely oncogenic (PMID: 27004399, 27504877). Germline mutations of ERCC2 are associated with xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome, and associated with an increased risk of certain cancers (PMID: 19809470, 27504877, 20651612). The ERCC2 p.Tyr175* variant has not been reported in the germline context (ClinVar). <br />\nA search by the Clinical Insight (QCI) platform indicates in this disease site, the ERCC2 p.Tyr175* variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PARP inhibitors.",
      "reportAbstract": "ERCC2, a DNA helicase involved in the nucleotide excision repair (NER) pathway (PMID: 24086042, 27004399). Somatic ERCC2 mutations occur frequently in invasive bladder cancer and have been associated with response to cisplatin-based chemotherapy and checkpoint inhibition (PMID: 24476821, 25096233, 29489427).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/24 18:59:55",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "ERCC2",
      "transcript": "NM_000400.3",
      "cNomen": "c.525C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "stopgain",
      "pNomen": "p.Y175*"
    },
    {
      "id": 11807,
      "chromosome": "19",
      "start": 50919867,
      "stop": 50919867,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "POLD1 is part of the DNA polymerase delta complex, which mediates DNA replication and repair (PMID: 27320729, 30625304).<br />\nThe POLD1 p.Asp1013Thrfs*58 frameshift variant is predicted to result in a truncated or absent protein. Germline mutations of POLD1 are associated with susceptibility to colorectal and endometrial cancers, and increased risk for breast cancer (PMID: 23263490, 26133394, 24838932, 23263490, 26133394, 28306219, 24501277, 15113441, 25023197). The POLD1 p.Asp1013Thrfs*58 variant has been reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the POLD1 p.Asp1013Thrfs*58 variant does not currently serve as an inclusion eligibility criterion for clinical trials.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:27",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "POLD1",
      "transcript": "NM_001308632.1",
      "cNomen": "c.3037delG",
      "type": "deletion",
      "location": "exonic",
      "exon": 23,
      "effect": "frameshift",
      "pNomen": "p.D1013Tfs*58"
    },
    {
      "id": 11631,
      "chromosome": "19",
      "start": 52715971,
      "stop": 52715971,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PPP2R1A codes protein phosphatase 2A (PP2A) a serine/threonine phosphatase involved in cell growth and division (PMID: 11171037, 23454242). PPP2R1A is frequently mutated in uterine serous and endometrial cancer (PMID: 23454242, 22888282, 31214504, 21435433).<br />\n <br />\nLoss-of-function variants in PPP2R1A are known to be oncogenic (PMID: 2153055, 22262169, 21791616, 27485451, 16166293, 17632053). Experimental studies suggest the PPP2R1A p.Pro179Arg missense variant results in impaired binding to the PP2A catalytic subunit, disruption of holoenzyme formation and enzymatic activity, to promote endometrial cancer progression (PMID: 31142515). <br />\n <br />\nA search by the Watson for Genomics platform indicates in this disease site, the PPP2R1A p.Pro179Arg variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/13 18:19:50",
      "evidences": [],
      "reference": "C",
      "alternative": "G",
      "gene": "PPP2R1A",
      "transcript": "NM_014225.5",
      "cNomen": "c.536C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.P179R"
    },
    {
      "id": 11778,
      "chromosome": "19",
      "start": 52715983,
      "stop": 52715983,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PPP2R1A codes protein phosphatase 2A (PP2A) a serine/threonine phosphatase involved in cell growth and division (PMID: 11171037, 23454242). PPP2R1A is frequently mutated in uterine serous and endometrial cancer (PMID: 23454242, 22888282, 31214504, 21435433).<br />\nLoss-of-function variants in PPP2R1A are known to be oncogenic (PMID: 2153055, 22262169, 21791616, 27485451, 16166293, 17632053). Experimental studies suggest the PPP2R1A p.Arg183Gln missense variant results in impaired binding to the PP2A catalytic subunit and promotes proliferation in vitro and in vivo (PMID: 27485451).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PPP2R1A p.Arg183Gln variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/19 19:44:53",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "PPP2R1A",
      "transcript": "NM_014225.5",
      "cNomen": "c.548G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 5,
      "effect": "nonsynonymous",
      "pNomen": "p.R183Q"
    },
    {
      "id": 11524,
      "chromosome": "19",
      "start": 52716323,
      "stop": 52716323,
      "classification": "Very high",
      "variantInfo": "<br />\nLoss-of-function variants in PPP2R1A are known to be oncogenic (PMID: 2153055, 22262169, 21791616, 27485451, 16166293, 17632053). The PPP2R1A p.Ser256Phe missense results in decreased binding to PP2A subunits and increased tumorigenic properties in vitro and in vivo (PMID: 27485451, 27272709, 31142515).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PPP2R1A p.Ser256Phe variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "PPP2R1A codes protein phosphatase 2A (PP2A) a serine/threonine phosphatase involved in cell growth and division (PMID: 11171037, 23454242). PPP2R1A is frequently mutated in uterine serous and endometrial cancer (PMID: 23454242, 22888282, 31214504, 21435433).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/09 19:00:15",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "PPP2R1A",
      "transcript": "NM_014225.5",
      "cNomen": "c.767C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 6,
      "effect": "nonsynonymous",
      "pNomen": "p.S256F"
    },
    {
      "id": 11395,
      "chromosome": "19",
      "start": 52716325,
      "stop": 52716325,
      "classification": "Very high",
      "variantInfo": "<br />\nLoss-of-function variants in PPP2R1A are known to be oncogenic (PMID: 2153055, 22262169, 21791616, 27485451, 16166293, 17632053). The PPP2R1A p.Trp257Gly missense variant results in decreased binding to PP2A subunits and increased tumorigenic properties in vitro and in vivo (PMID: 27485451, 27272709).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PPP2R1A p.Trp257Gly variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "PPP2R1A codes protein phosphatase 2A (PP2A) a serine/threonine phosphatase involved in cell growth and division (PMID: 11171037, 23454242). PPP2R1A is frequently mutated in uterine serous and endometrial cancer (PMID: 23454242, 22888282, 31214504, 21435433).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/07/16 14:26:09",
      "evidences": [],
      "reference": "T",
      "alternative": "G",
      "gene": "PPP2R1A",
      "transcript": "NM_014225.5",
      "cNomen": "c.769T>G",
      "type": "snp",
      "location": "exonic",
      "exon": 6,
      "effect": "nonsynonymous",
      "pNomen": "p.W257G"
    },
    {
      "id": 11180,
      "chromosome": "19",
      "start": 52723448,
      "stop": 52723448,
      "classification": "Very high",
      "variantInfo": "The PPP2R1A p.Glu437* nonsense variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in PPP2R1A are known to be oncogenic (PMID: 2153055, 22262169, 21791616, 27485451, 16166293, 17632053).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PPP2R1A <b>p.Glu437* </b>variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "PPP2R1A codes protein phosphatase 2A (PP2A) a serine/threonine phosphatase involved in cell growth and division (PMID: 11171037, 23454242). PPP2R1A is frequently mutated in uterine serous and endometrial cancer (PMID: 23454242, 22888282, 31214504, 21435433).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/04/16 05:07:37",
      "evidences": [],
      "reference": "G",
      "alternative": "T",
      "gene": "PPP2R1A",
      "transcript": "NM_014225.5",
      "cNomen": "c.1309G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 11,
      "effect": "stopgain",
      "pNomen": "p.E437*"
    },
    {
      "id": 11133,
      "chromosome": "20",
      "start": 31022288,
      "stop": 31022288,
      "classification": "Very high",
      "variantInfo": "<br />\n <br />\nThe ASXL1 p.Tyr591* nonsense variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in ASXL1 are known to be oncogenic (PMID: 24216483, 22897849, 26095772, 29113963, 24218140, 24255920).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ASXL1 p.Tyr591* variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "ASXL1 is involved in recruitment of epigenetic and transc, riptional regulators at genomic loci to regulate transcription (PMID: 23736028). ASXL1 inactivating variants have been reported most frequently in myeloid malignancies (PMID: 19388938, 26771811, 23736028, 19861679, 24216483, 25426837, 26429975).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/25 16:16:43",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "ASXL1",
      "transcript": "NM_015338.5",
      "cNomen": "c.1773C>A",
      "type": "snp",
      "location": "exonic",
      "exon": 13,
      "effect": "stopgain",
      "pNomen": "p.Y591*"
    },
    {
      "id": 11990,
      "chromosome": "20",
      "start": 40743943,
      "stop": 40743943,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "PTPRT encodes a tyrosine phosphatase involved in cell adhesion, and acts as a tumor suppressor by dephosphorylating proteins involved in cell proliferation, migration, growth, and survival (PMID: 17360477, 20133777, 21517784). The PTEN p.Arg1018* nonsense variant is predicted to result in a truncated or absent protein. While this variant has not been reported in the literature, loss-of-function variants in PTPRT are likely oncogenic (PMID: 15155950, 20133777, 21517784). The impact of this variant in this disease context is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/15 20:31:14",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "PTPRT",
      "transcript": "NM_133170.3",
      "cNomen": "c.3052C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 23,
      "effect": "stopgain",
      "pNomen": "p.R1018*"
    },
    {
      "id": 11136,
      "chromosome": "21",
      "start": 44514777,
      "stop": 44514777,
      "classification": "Very high",
      "variantInfo": "<br />\nThe U2AF1 p.Gln157Pro variant is a hotspot mutation (PMID: 28986033) that lies within the C3H1-type zinc finger domain of the U2AF1 protein (UniProt.org). The p.Gln157Pro variant is a gain of function alteration as indicated by increased exon skipping and aberrant splicing of U2AF1 target genes in vitro (PMID: 25267526, 25311244).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PHF6 p.Lys21Glnfs*11 variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "U2AF1 is a subunit splicing factor that functions in 3&#39; splice site recognition and pre-mRNA splicing (PMID: 15231733, 2531895). U2AF1 activating variants are most frequently reported in hematological malignancies (PMID: 23645565, 22678168, 24498085, 30138727, 29991672).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/25 16:19:11",
      "evidences": [],
      "reference": "T",
      "alternative": "G",
      "gene": "U2AF1",
      "transcript": "NM_001025203.1",
      "cNomen": "c.470A>C",
      "type": "snp",
      "location": "exonic",
      "exon": 6,
      "effect": "nonsynonymous",
      "pNomen": "p.Q157P"
    },
    {
      "id": 11889,
      "chromosome": "22",
      "start": 22127162,
      "stop": 22127162,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "MAPK1 (also referred to as ERK2) is a serine/threonine kinase involved in cell proliferation, differentiation and transcription through the RAS/RAF/MAPK pathway (PMID: 22450690, 22569528, 17496922). MAPK1 alterations and dysregulation have been reported in head and neck, cervical and ovarian cancers (PMID: 25631445, 21720365, 23820584, 12937136).<br />\nThe MAPK1 p.Glu322Asp missense variant lies within the protein kinase domain of the MAPK1 protein (Uniprot). Although this variant has not been functionally characterized, in vitro functional evidence shows that variants at this codon are activating and results in resistance to Raf/Mek inhibitors (PMID: 16273204, 27760319).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the MAPK1 p.Glu322Asp variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of ERK inhibitors.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/16 02:54:49",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "MAPK1",
      "transcript": "NM_002745.4",
      "cNomen": "c.966G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "nonsynonymous",
      "pNomen": "p.E322D"
    },
    {
      "id": 12143,
      "chromosome": "22",
      "start": 22127164,
      "stop": 22127164,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "MAPK1 (also referred to as ERK2) is a serine/threonine kinase involved in cell proliferation, differentiation and transcription through the RAS/RAF/MAPK pathway (PMID: 22450690, 22569528, 17496922). MAPK1 alterations and dysregulation have been reported in head and neck, cervical and ovarian cancers (PMID: 25631445, 21720365, 23820584, 12937136).<br />\nThe MAPK1 p.Glu322Lys missense variant lies within the protein kinase domain of the MAPK1 protein (Uniprot). In vitro functional evidence suggests this variant is activating and results in resistance to Raf/Mek inhibitors (PMID: 16273204, 27760319). A clinical study suggests this variant is predicted sensitive to EGFR inhibitor in a patient with oral cavity squamous cell carcinoma (PMID: 26181029).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:36",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "MAPK1",
      "transcript": "NM_002745.4",
      "cNomen": "c.964G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 7,
      "effect": "nonsynonymous",
      "pNomen": "p.E322K"
    },
    {
      "id": 11028,
      "chromosome": "22",
      "start": 29090054,
      "stop": 29090054,
      "classification": "Very high",
      "variantInfo": "The CHEK2 p.Thr476Met variant has not been previously reported in ovarian cancer (COSMIC). The variant occurs within the kinase domain and functional studies suggest this variant results in a loss of CHEK2 kinase activity in vitro (PMID: 22114986). Germline mutations in CHEK2 have been associated with an increased risk of breast, prostate, and colon cancers (PMID: 21701879, 12533788, 17106448). The CHEK2 p.Thr476Met variant has been reported in the germline context with conflicting classifications (ClinVar).<br />\nA search by the Clinical Insight (Qiagen) platform indicates in this disease site, the CHEK2 p.Thr476Met variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "reportAbstract": "CHEK2 is a serine/threonine protein kinase involved in cell cycle control and DNA damage and repair (PMID: 25404613, 28553140). CHEK2 alterations are found in a range of cancers including glioblastoma, breast, ovarian, prostate, colorectal, gastric, thyroid, and lung cancer (PMID: 23296741, 24713400, 25583358, 12052256, 15125777).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/11 14:50:12",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "CHEK2",
      "transcript": "NM_007194.3",
      "cNomen": "c.1427C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 13,
      "effect": "nonsynonymous",
      "pNomen": "p.T476M"
    },
    {
      "id": 11061,
      "chromosome": "22",
      "start": 29090061,
      "stop": 29090061,
      "classification": "Very high",
      "variantInfo": "The p.Arg474Cys missense variant occurs within the protein kinase domain (UniProt). This variant has not been previously reported in ovarian cancer (COSMIC). Limited in vitro studies suggest this variant results in a loss-of-function alteration (PMID: 27900359, 30851065). Germline mutations in CHEK2 have been associated with an increased risk of breast, prostate, and colon cancers (PMID: 21701879, 12533788, 17106448). The CHEK2 p.Arg474Cys variant has been reported in the germline context with conflicting classifications (ClinVar).<br />\nA search by the Clinical Insight (Qiagen) platform indicates in this disease site, the CHEK2 p.Arg474Cys variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of PARP inhibitors.<br />\n ",
      "reportAbstract": "CHEK2 is a serine/threonine protein kinase involved in cell cycle control and DNA damage and repair (PMID: 25404613, 28553140). CHEK2 alterations are found in a range of cancers including glioblastoma, breast, ovarian, prostate, colorectal, gastric, thyroid, and lung cancer (PMID: 23296741, 24713400, 25583358, 12052256, 15125777).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/18 02:46:18",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "CHEK2",
      "transcript": "NM_007194.3",
      "cNomen": "c.1420C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 13,
      "effect": "nonsynonymous",
      "pNomen": "p.R474C"
    },
    {
      "id": 11875,
      "chromosome": "22",
      "start": 29130652,
      "stop": 29130652,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "CHEK2 is a serine/threonine protein kinase involved in cell cycle control and DNA damage and repair (PMID: 25404613, 28553140). CHEK2 alterations are found in a range of cancers including glioblastoma, breast, ovarian, prostate, colorectal, gastric, thyroid, and lung cancer (PMID: 23296741, 24713400, 25583358, 12052256, 15125777).<br />\nThe p.Gln20* nonsense variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in CHEK2 are known to be oncogenic (PMID: 19401704, 27464310, 28779002). Germline mutations in CHEK2 have been associated with an increased risk of breast, prostate, and colon cancers (PMID: 21701879, 12533788, 17106448). The CHEK2 p.Gln20* variant has been reported in the germline context in individuals affected with breast and ovarian cancer (PMID: 26023681, 27039729; ClinVar).<br />\nA search by the Watson for Genomics (IBM) platform indicates in this disease site, the CHEK2 p.Gln20* variant currently serves as an inclusion eligibility criterion for Phase 3 clinical trials of PARP inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:28:27",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "CHEK2",
      "transcript": "NM_007194.3",
      "cNomen": "c.58C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 2,
      "effect": "stopgain",
      "pNomen": "p.Q20*"
    },
    {
      "id": 11530,
      "chromosome": "22",
      "start": 30032783,
      "stop": 30032783,
      "classification": "Very high",
      "variantInfo": "<br />\nThe NF2 p.Leu54Serfs*32 frameshift variant is predicted to result in a truncated or absent protein. While this particular variant has not been reported in the literature, loss-of-function variants in NF2 are known to be oncogenic (PMID: 19545378, 8755919, 22825583, 9643284). Pathogenic germline variants in NF2 by mutation or deletion results in the autosomal dominant tumor syndrome Neurofibromatosis Type 2, which is associated with the development of benign central nervous system (CNS) tumors such as vestibular schwannomas (PMID: 7911002). The NF2 p.Leu54Serfs*32 variant has not been previously reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the NF2 p.Leu54Serfs*32 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR inhibitors.<br />\n ",
      "reportAbstract": "NF1 is a scaffolding protein that is expressed predominantly in nervous tissues (PMID: 25893302). NF2 is important in indirectly linking actin-transmembrane receptors and intracellular effectors to modulate signaling pathways controlling cell proliferation and survival. These include downstream signaling pathways of receptor tyrosine kinases (RTKs), cell adhesion, small GTPases, mTOR, PI3K/Akt and Hippo pathways (PMID: 20491622).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/10 20:35:33",
      "evidences": [],
      "reference": ".",
      "alternative": "G",
      "gene": "NF2",
      "transcript": "NM_000268.3",
      "cNomen": "c.158_159insG",
      "type": "insertion",
      "location": "exonic",
      "exon": 2,
      "effect": "frameshift",
      "pNomen": "p.L54Sfs*32"
    },
    {
      "id": 11810,
      "chromosome": "22",
      "start": 30064415,
      "stop": 30064431,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "NF2 is a scaffolding protein that is expressed predominantly in nervous tissues (PMID: 25893302). NF2 is important in indirectly linking actin-transmembrane receptors and intracellular effectors to modulate signaling pathways controlling cell proliferation and survival. These include downstream signaling pathways of receptor tyrosine kinases (RTKs), cell adhesion, small GTPases, mTOR, PI3K/Akt and Hippo pathways (PMID: 20491622).<br />\nThe NF2 p.Glu327Alafs*18 frameshift variant is predicted to result in a truncated or absent protein. While this particular variant has not been reported in the literature, loss-of-function variants in NF2 are known to be oncogenic (PMID: 19545378, 8755919, 22825583, 9643284). Pathogenic germline variants in NF2 by mutation or deletion results in the autosomal dominant tumor syndrome Neurofibromatosis Type 2, which is associated with the development of benign central nervous system (CNS) tumors such as vestibular schwannomas (PMID: 7911002). The NF2 p.Glu327Alafs*18 variant has not been previously reported in the germline context (ClinVar).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the NF2 p.Glu327Alafs*18 variant currently serves as an inclusion eligibility criterion for Phase 2 clinical trials of MTOR inhibitors.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/25 21:26:28",
      "evidences": [],
      "reference": "GAGGAGAAGGCTAGAAA",
      "alternative": ".",
      "gene": "NF2",
      "transcript": "NM_000268.3",
      "cNomen": "c.980_996delAGGAGAAGGCTAGAAAG",
      "type": "deletion",
      "location": "exonic",
      "exon": 10,
      "effect": "frameshift",
      "pNomen": "p.E327Afs*18"
    },
    {
      "id": 12120,
      "chromosome": "22",
      "start": 41522045,
      "stop": 41522045,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "EP300 is a transcriptional co-activator that activates transcription by opening chromatin at gene promoters, recruiting transcriptional machinery and acting as a co-factor to recruit transcription factors (PMID: 15186775, 24480624, 11050151, 23474763, 15691758). Somatic mutations in EP300 are found in leukemia, lymphoma and solid tumors including small-cell lung cancer, cervical cancer and bladder cancer (PMID: 21390126, 22941188, 24390348, 21822268).<br />\nThe EP300 c.906&#43;1G&gt;T splice site variant is predicted is predicted to result in an altered protein product or absence of protein due to nonsense mediated decay. While this particular variant has not been reported in the literature, loss-of-function variants in EP300 are known to be oncogenic (PMID: 10700188, 15156177, 12402157, 12237408).<br />\n <br />\nA search by the Qiagen Clinical Insights platform indicates in this disease site, the EP300 c.906&#43;1G&gt;T variant currently serves as an inclusion eligibility criterion for clinical trials of p300/CBP inhibitors (NCT03568656).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/02/18 20:33:52",
      "evidences": [],
      "reference": "G",
      "alternative": "T",
      "gene": "EP300",
      "transcript": "NM_001429.3",
      "cNomen": "c.906+1G>T",
      "type": "snp",
      "location": "intronic",
      "exon": 3,
      "effect": null,
      "pNomen": null
    },
    {
      "id": 11647,
      "chromosome": "22",
      "start": 41542790,
      "stop": 41542790,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "EP300 is a transcriptional co-activator that activates transcription by opening chromatin at gene promoters, recruiting transcriptional machinery and acting as a co-factor to recruit transcription factors (PMID: 15186775, 24480624, 11050151, 23474763, 15691758). Somatic mutations in EP300 are found in leukemia, lymphoma and solid tumors including small-cell lung cancer, cervical cancer and bladder cancer (PMID: 21390126, 22941188, 24390348, 21822268).<br />\nThe p.Gln701* nonsense variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in EP300 are known to be oncogenic (PMID: 10700188, 15156177, 12402157, 12237408).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the EP300 p.Gln701* variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/10/19 20:07:07",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "EP300",
      "transcript": "NM_001429.3",
      "cNomen": "c.2101C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 11,
      "effect": "stopgain",
      "pNomen": "p.Q701*"
    },
    {
      "id": 11789,
      "chromosome": "22",
      "start": 41573104,
      "stop": 41573104,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "EP300 is a transcriptional co-activator that activates transcription by opening chromatin at gene promoters, recruiting transcriptional machinery and acting as a co-factor to recruit transcription factors (PMID: 15186775, 24480624, 11050151, 23474763, 15691758). Somatic mutations in EP300 are found in leukemia, lymphoma and solid tumors including small-cell lung cancer, cervical cancer and bladder cancer (PMID: 21390126, 22941188, 24390348, 21822268).<br />\nThe EP300 p.Gln1797* nonsense variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in EP300 are known to be oncogenic (PMID: 10700188, 15156177, 12402157, 12237408).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the EP300 p.Gln1797* variant does not currently serve as an inclusion eligibility criterion for clinical trials.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:27",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "EP300",
      "transcript": "NM_001429.3",
      "cNomen": "c.5389C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 31,
      "effect": "stopgain",
      "pNomen": "p.Q1797*"
    },
    {
      "id": 11529,
      "chromosome": "X",
      "start": 39913197,
      "stop": 39913197,
      "classification": "Very high",
      "variantInfo": "<br />\nThe p.Glu1640* nonsense variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in BCOR are known to be oncogenic (PMID: 26847029, 25550361, 22237022, 22012066, 24047651).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the BCOR p.Glu1640* variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "BCOR is a chromatin regulatory protein that functions in epigenetic repressive complexes and binds the transcriptional repressor BCL6 (PMID: 27505670, 29337181). Depletion of BCOR results in loss of Polycomb protein binding at target genes, which is critical for maintaining repressed chromatin (PMID: 9337181). Somatic BCOR truncating mutations have also been identified in retinoblastoma and hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (PMID: 22237022, 22012066, 24047651, 25550361).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/09/10 20:26:43",
      "evidences": [],
      "reference": "C",
      "alternative": "A",
      "gene": "BCOR",
      "transcript": "NM_001123385.1",
      "cNomen": "c.4918G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 14,
      "effect": "stopgain",
      "pNomen": "p.E1640*"
    },
    {
      "id": 12037,
      "chromosome": "X",
      "start": 39932085,
      "stop": 39932085,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "BCOR is a chromatin regulatory protein that functions in epigenetic repressive complexes and binds the transcriptional repressor BCL6 (PMID: 27505670, 29337181). Depletion of BCOR results in loss of Polycomb protein binding at target genes, which is critical for maintaining repressed chromatin (PMID: 9337181). Somatic BCOR truncating mutations have also been identified in retinoblastoma and hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (PMID: 22237022, 22012066, 24047651, 25550361).<br />\nThe p.Lys839Serfs*17 frameshift variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in BCOR are known to be oncogenic (PMID: 26847029, 25550361, 22237022, 22012066, 24047651). The impact of this variant is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/28 20:06:41",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "BCOR",
      "transcript": "NM_001123385.1",
      "cNomen": "c.2514delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 4,
      "effect": "frameshift",
      "pNomen": "p.K839Sfs*17"
    },
    {
      "id": 11793,
      "chromosome": "X",
      "start": 41055857,
      "stop": 41055857,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "USP9X is a deubiquitinase in the TGF-beta/BMP signaling pathway involved in regulation of protein turnover (PMID: 19135894, 27462448). Inactivation of USP9X is found in pancreatic ductal adenocarcinoma (PMID: 22699621), and somatic mutations have been reported in breast cancer (PMID: 27161491).<br />\nThe USP9X p.Glu1367* nonsense variant is predicted to result in an absent or disrupted protein product. This particular variant has not been reported in the literature.<br />\nA search by the Watson for Genomics platform indicates in this disease site, the USP9X p.Glu1367* variant does not currently serve as an inclusion eligibility criterion for clinical trials.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:27",
      "evidences": [],
      "reference": "G",
      "alternative": "T",
      "gene": "USP9X",
      "transcript": "NM_001039590.2",
      "cNomen": "c.4099G>T",
      "type": "snp",
      "location": "exonic",
      "exon": 28,
      "effect": "stopgain",
      "pNomen": "p.E1367*"
    },
    {
      "id": 12142,
      "chromosome": "X",
      "start": 44896921,
      "stop": 44896921,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KDM6A encodes a chromatin-modifying enzyme that mediates transcriptional co-activation (PMID: 17761849, 30753822). Germline deletions and point mutations in KDM6A cause Kabuki syndrome (PMID: 22197486, 22840376, 22901312, 23076834). Alterations in KDM6A have been reported in a number of human malignancies including multiple myeloma and esophageal squamous cell carcinoma, medulloblastoma, bladder cancer, and endometrial adenocarcinoma (PMID: 30753822, 22832583, 24476821, 21822268, 25092538, 25225064). Loss of KDM6A may confer sensitivity to EZH2 inhibitors (PMID: 28228601).<br />\nThe p.Tyr215Ilefs*2 frameshift variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in KDM6A are known to be oncogenic (PMID: 28228601, 19330029, 24633898, 25225064).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:27",
      "evidences": [],
      "reference": ".",
      "alternative": "A",
      "gene": "KDM6A",
      "transcript": "NM_021140.3",
      "cNomen": "c.642dupA",
      "type": "insertion",
      "location": "exonic",
      "exon": 8,
      "effect": "frameshift",
      "pNomen": "p.Y215Ifs*2"
    },
    {
      "id": 11930,
      "chromosome": "X",
      "start": 44923012,
      "stop": 44923013,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KDM6A encodes a chromatin-modifying enzyme that mediates transcriptional co-activation (PMID: 17761849, 30753822). Germline deletions and point mutations in KDM6A cause Kabuki syndrome (PMID: 22197486, 22840376, 22901312, 23076834). Alterations in KDM6A have been reported in a number of human malignancies including multiple myeloma and esophageal squamous cell carcinoma, medulloblastoma, bladder cancer, and endometrial adenocarcinoma (PMID: 30753822, 22832583, 24476821, 21822268, 25092538, 25225064). Loss of KDM6A may confer sensitivity to EZH2 inhibitors (PMID: 28228601).<br />\nThe p.Thr625Glnfs*13 frameshift variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in KDM6A are known to be oncogenic (PMID: 28228601, 19330029, 24633898, 25225064).<br />\nA search indicates in this disease site, the KDM6A p.Thr625Glnfs*13 variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/14 19:32:07",
      "evidences": [],
      "reference": "AC",
      "alternative": ".",
      "gene": "KDM6A",
      "transcript": "NM_021140.3",
      "cNomen": "c.1873_1874delAC",
      "type": "deletion",
      "location": "exonic",
      "exon": 16,
      "effect": "frameshift",
      "pNomen": "p.T625Qfs*13"
    },
    {
      "id": 11880,
      "chromosome": "X",
      "start": 44949124,
      "stop": 44949124,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "KDM6A encodes a chromatin-modifying enzyme that mediates transcriptional co-activation (PMID: 17761849, 30753822). Germline deletions and point mutations in KDM6A cause Kabuki syndrome (PMID: 22197486, 22840376, 22901312, 23076834). Alterations in KDM6A have been reported in a number of human malignancies including multiple myeloma and esophageal squamous cell carcinoma, medulloblastoma, bladder cancer, and endometrial adenocarcinoma (PMID: 30753822, 22832583, 24476821, 21822268, 25092538, 25225064). Loss of KDM6A may confer sensitivity to EZH2 inhibitors (PMID: 28228601).<br />\nThe p.Gln1229* nonsense variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in KDM6A are known to be oncogenic (PMID: 28228601, 19330029, 24633898, 25225064).<br />\nA search indicates in this disease site, the KDM6A p.Gln1229* variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 17:03:14",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "KDM6A",
      "transcript": "NM_021140.3",
      "cNomen": "c.3685C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 25,
      "effect": "stopgain",
      "pNomen": "p.Q1229*"
    },
    {
      "id": 12131,
      "chromosome": "X",
      "start": 63412648,
      "stop": 63412648,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "<br />\nAMER1 encodes for a tumor suppressor and inhibits Wnt/beta-catenin signaling (PMID: 17925383, 17510365, 21498506). The AMER1 p.Phe173Leufs*36 frameshift variant is predicted to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in AMER1 are known to be likely oncogenic (PMID: 26071483, 19416806, 20956941, 21498506).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/02/22 20:26:42",
      "evidences": [],
      "reference": "A",
      "alternative": ".",
      "gene": "AMER1",
      "transcript": "NM_152424.3",
      "cNomen": "c.519delT",
      "type": "deletion",
      "location": "exonic",
      "exon": 2,
      "effect": "frameshift",
      "pNomen": "p.F173Lfs*36"
    },
    {
      "id": 12181,
      "chromosome": "X",
      "start": 66941680,
      "stop": 66941680,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "AR, androgen receptor, is a transcription factor that belongs to the nuclear hormone receptor family that is activated by binding of androgenic hormones (PMID: 24909511). Mutations in AR are frequently observed in prostate cancer (PMID: 26566796, 24384911, 22722839).<br />\nThe AR p.Arg775His (also known as Arg773His) missense variant lies within the C-terminal ligand binding domain (LBD) of the AR protein (Uniprot.org). Experimental assays suggest this variant disrupts the androgen binding activity of the AR protein (PMID: 1609793). In other disease sites, AR mutations are predicted sensitive to androgen receptor therapy (NCCN).<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:43",
      "evidences": [],
      "reference": "G",
      "alternative": "A",
      "gene": "AR",
      "transcript": "NM_000044.3",
      "cNomen": "c.2324G>A",
      "type": "snp",
      "location": "exonic",
      "exon": 6,
      "effect": "nonsynonymous",
      "pNomen": "p.R775H"
    },
    {
      "id": 11982,
      "chromosome": "X",
      "start": 76776372,
      "stop": 76776372,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ATRX is part of the SWI/SNF family of chromatin remodeling proteins and plays a role in DNA repair and telomere length (PMID: 14990586, 22829774). ATRX loss and mutations have been identified most frequently in central nervous tumours (PMID: 23249563, 26936505, 21719641, 22286061, 30081149, 24148618). The ATRX p.Ser2365* nonsense variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in ATRX are known to be oncogenic (PMID: 29535300, 14990586, 22829774, 21719641, 22286061). In other disease sites, preclinical studies suggest loss of function variants in ATRX are associated with sensitivity to mTOR/PARP/WEE1 inhibitors (PMID: 26853339, 31806540, 31551363, 26513298), however the impact of this variant in this disease context is currently unknown.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/01/15 02:31:12",
      "evidences": [],
      "reference": "G",
      "alternative": "C",
      "gene": "ATRX",
      "transcript": "NM_000489.4",
      "cNomen": "c.7094C>G",
      "type": "snp",
      "location": "exonic",
      "exon": 34,
      "effect": "stopgain",
      "pNomen": "p.S2365*"
    },
    {
      "id": 11797,
      "chromosome": "X",
      "start": 76777820,
      "stop": 76777820,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "ATRX is part of the SWI/SNF family of chromatin remodeling proteins and plays a role in DNA repair and telomere length (PMID: 14990586, 22829774). ATRX loss and mutations have been identified most frequently in central nervous tumours (PMID: 23249563, 26936505, 21719641, 22286061, 30081149, 24148618)<br />\nThe ATRX p.Pro2299Leufs*21 frameshift variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in ATRX are known to be oncogenic (PMID: 29535300, 14990586, 22829774, 21719641, 22286061).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the ATRX p.Pro2299Leufs*21 variant does not currently serve as an inclusion eligibility criterion for clinical trials.",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/12/10 16:49:31",
      "evidences": [],
      "reference": "G",
      "alternative": ".",
      "gene": "ATRX",
      "transcript": "NM_000489.4",
      "cNomen": "c.6896delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 32,
      "effect": "frameshift",
      "pNomen": "p.P2299Lfs*21"
    },
    {
      "id": 12145,
      "chromosome": "X",
      "start": 123215311,
      "stop": 123215311,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "STAG2 is part of the cohesion complex, which is involved in regulation of spindle formation and cohesion of sister chromatids in meiosis and mitosis (PMID: 12034751, 24854081). Inactivating mutations in STAG2 have been reported in various solid and hematological malignancies (PMID: 22668012, 29954776, 27207471, 23955599, 25223734, 24270882, 24335498, 24121792, 25501392).<br />\nThe STAG2 p.Arg953* variant has previously been reported in endometrial cancer (COSMIC) and is a nonsense variant that leads to a premature termination codon, which is predicted to result in a truncated or absent protein. Loss-of-function variants in STAG2 are likely oncogenic (PMID: 22417201, 21852505, 24121789, 25010205, 26871722).<br />\nIn myelodysplastic syndrome, STAG2 mutations are associated with poor prognosis (NCCN, PMID: 25006131).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2021/03/24 20:34:36",
      "evidences": [],
      "reference": "C",
      "alternative": "T",
      "gene": "STAG2",
      "transcript": "NM_001042749.2",
      "cNomen": "c.2857C>T",
      "type": "snp",
      "location": "exonic",
      "exon": 28,
      "effect": "stopgain",
      "pNomen": "p.R953*"
    },
    {
      "id": 11759,
      "chromosome": "X",
      "start": 129190011,
      "stop": 129190011,
      "classification": "Very high",
      "variantInfo": "",
      "reportAbstract": "BCORL1 is a transcriptional repressor involved in histone deacetylase activity (PMID: 17379597). Somatic BCORL1 mutations have been observed in hematological malignancies, astrocytomas and intracranial germ cell tumors (PMID: 30618304, 21989985, 24047651, 24896186, 27470916, 27425854).   <br />\nThe BCORL1 p.Pro1681Glnfs*20 frameshift variant is predicted to result in an absent or disrupted protein product. While this variant has not been reported in the literature, loss-of-function variants in BCORL1 are likely oncogenic (PMID: 22210327, 21989985).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the BCORL1 p.Pro1681Glnfs*20 variant does not currently serves as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/11/17 00:32:48",
      "evidences": [],
      "reference": "C",
      "alternative": ".",
      "gene": "BCORL1",
      "transcript": "NM_021946.4",
      "cNomen": "c.5042delC",
      "type": "deletion",
      "location": "exonic",
      "exon": 12,
      "effect": "frameshift",
      "pNomen": "p.P1681Qfs*20"
    },
    {
      "id": 11135,
      "chromosome": "X",
      "start": 133511706,
      "stop": 133511709,
      "classification": "Very high",
      "variantInfo": "<br />\nThe PHF6 p.Lys21Glnfs*11 frameshift variant is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in PHF6 are known to be oncogenic (PMID: 20228800, 21030981, 21736506, 22928734, 22417203).<br />\nA search by the Watson for Genomics platform indicates in this disease site, the PHF6 p.Lys21Glnfs*11 variant does not currently serve as an inclusion eligibility criterion for clinical trials.<br />\n ",
      "reportAbstract": "PHF6 is involved in chromatin organization and plays a role in cell-cycle regulation via suppression of ribosomal RNA transcription (PMID: 12415272, 23229552). PHF6 inactivating variants have been reported most frequently in hematological malignancies (PMID:12415272, 20228800, 20806366, 21030981, 23229552, 26103525).",
      "lastUpdatedBy": "nicole.park",
      "lastUpdatedOn": "2020/03/25 16:18:33",
      "evidences": [],
      "reference": "GTAA",
      "alternative": ".",
      "gene": "PHF6",
      "transcript": "NM_032458.2",
      "cNomen": "c.61_64delAAGT",
      "type": "deletion",
      "location": "exonic",
      "exon": 2,
      "effect": "frameshift",
      "pNomen": "p.K21Qfs*11"
    }
  ],
  "structuralVariants": null
}